
CANCER INCIDENCE IN MASSACHUSETTS 2010 – 2014:

CITY AND TOWN SUPPLEMENT

Office of Data Management and Outcomes Assessment

Massachusetts Department of Public Health

January 2019



CANCER INCIDENCE IN MASSACHUSETTS 2010 – 2014:

CITY AND TOWN SUPPLEMENT

Charlie Baker, Governor
Karyn Polito, Lieutenant Governor
Marylou Sudders, Secretary of Health and Human Services
Monica Bharel, Commissioner of Public Health
Abigail Averbach, Assistant Commissioner and Director,
Office of Population Health

Natalie Nguyen Durham, Director, Office of Data Management and
Outcomes Assessment
Susan T. Gershman, Director, Massachusetts Cancer Registry
Massachusetts Department of Public Health

January 2019

ACKNOWLEDGMENTS

This report was prepared by Susan T. Gershman, Director, Massachusetts Cancer Registry, and Massachusetts Cancer Registry staff and consultants. Special thanks are extended to the following: Richard Knowlton and Annie MacMillan for their diligent work in the preparation of this report, Steve Pankowicz formerly of the Mass CHIP Program for his time and his excellent work in creating a program for formatting the tables in the report, staff of the Massachusetts Cancer Registry for their editing and data processing efforts, and Gail Merriam and the staff of the Comprehensive Cancer Control Program for updating the section on Cancer Control Initiatives and Publications.

Massachusetts Cancer Registry Staff

Susan T. Gershman, MS, MPH, PhD, CTR, <i>Director</i>	
Nancy Donovan, MA, CTR, <i>Cancer Registrar/</i>	Jayne Nussdorfer, CTR, <i>Cancer Registrar</i>
<i>Quality Assurance Coordinator</i>	Barbara J. Rhodes, CMA, CTR, <i>Cancer</i>
Richard Knowlton, MS, <i>Epidemiologist</i>	<i>Registrar/Death Clearance Coordinator</i>
Ann MacMillan, MPH, <i>Epidemiologist</i>	Pamela Shuttle, CTR, RHIT, <i>Cancer Registrar/Non-</i>
Mary Mroszczyk, CTR, <i>Geocoding/ Special</i>	<i>Hospital Reporting Coordinator</i>
<i>Projects Coordinator</i>	Hung Tran, <i>Software Developer</i>
Jeremiah Nesser, <i>Technical Assistant to Non-</i>	
<i>Hospital Reporting</i>	

Massachusetts Cancer Registry Advisory Committee

Lindsay Frazier, MD, ScM (<i>Chair</i>)	
Martie Carnie, Community Representative	Larissa Nekhlyudov, MD, MPH
Anita Christie, RN, MHA, CPHQ	Al Ozonoff, MA, PhD
Deborah Dillon, MD	Sigalle Reiss, MPH, RS/REHS
Joanna Haas, MD	Paul C. Shroy, MD, MPH
Joseph Jacobson, MD	Ingrid Stendhal, CTR
Nancy Keating, MD, MPH	Susan Sturgeon, DrPH, MPH
Carol Lowenstein, CTR, MBA	Jan Sullivan, MS
Gail Merriam, MSW, MPH	Michelle A. Williams, MS, SM, ScD

The data in this report are intended for public use and may be reproduced without permission. Proper acknowledgement of the source is requested.

For further information, please contact the following:

Massachusetts Cancer Registry.....	(617) 624-5642
Research and Epidemiology.....	(617) 624-5642
Occupational Health Surveillance.....	(617) 624-5632
Bureau of Environmental Health.....	(617) 624-5757
Cancer Prevention and Control Initiative.....	(617) 624-5479
Massachusetts Department of Public Health website.....	www.mass.gov/dph

We acknowledge the Centers for Disease Control and Prevention for its support of the staff and the printing and distribution of this report under cooperative agreement 5 NU58 DP006271-02-00 awarded to the Massachusetts Cancer Registry at the Massachusetts Department of Public Health. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention.

CONTENTS

	<u>Page</u>
INTRODUCTION AND METHODS	
Introduction	1
Content	1
Comparison with Previous Reports	1
Methods	2
Data Sources	2
Presentation of Data	3
Observed and Expected Case Counts	3
Standardized Incidence Ratios	4
Statistical Significance and Interpretation of SIRs	4
Example of Calculation of an SIR and Its Significance	5
Notes about Data Interpretation	6
Data Limitations	6
Border Areas and Neighboring States	7
Cases Diagnosed in Non-Hospital Settings	7
City/Town Misassignment	7
Small Numbers of Cases	7
TABLES	
Observed and Expected Counts, with Standardized Incidence Ratios, by Sex, for 351 Cities and Towns, 2009 - 2014	10
APPENDICES	
APPENDIX I	
International Classification of Diseases for Oncology (Third Edition) Codes Used for This Report	362
APPENDIX II	
Selected Resources for Information on Cancer	365
APPENDIX III	
Massachusetts Department of Public Health (MDPH) Cancer Prevention and Control Initiatives	366
REFERENCES	367

INTRODUCTION

Content

The purpose of this report is to provide an estimate of cancer incidence for each of the 351 cities and towns of Massachusetts for the five-year time period 2010 through 2014. For each city and town, Standardized Incidence Ratios (SIRs) are presented for twenty-three types of invasive cancer and for all invasive cancer types combined. These ratios compare the cancer incidence experience of each city or town with the cancer experience of the state as a whole. The method involves comparing the number of cases that were observed for a city or town to the number of cases that would be expected if the city or town had the same cancer rates as the state as whole. The report is organized into the following sections:

METHODS provides a detailed explanation of the data collection, data processing, and statistical techniques employed in this report.

TABLES present data for selected types of cancer by city/town and sex.

APPENDIX I provides a listing of *International Classification of Diseases for Oncology* codes used in the preparation of this report.

APPENDIX II provides selected resources for information on cancer.

APPENDIX III describes the Massachusetts Department of Public Health's current cancer control initiatives, and provides links to bureaus within the department that address some aspect of cancer. Links to resources for publications are also provided.

Comparison with Previous Reports

This report updates previous annual reports published by the Massachusetts Cancer Registry (MCR). It is available on line at <http://www.mass.gov/dph/mcr>. For questions about the report, contact the MCR at:

Massachusetts Cancer Registry
Office of Data Management and Outcomes Assessment
Office of Population Health
Massachusetts Department of Public Health
250 Washington Street, 6th floor
Boston, MA 02108-4619
telephone 617-624-5642; fax 617-624-5695

The preceding report, *Cancer Incidence in Massachusetts 2009-2013: City and Town Supplement*, included data for diagnosis years 2009 through 2013. This report contains data for the diagnosis years 2010 through 2014. There have been no changes in this report's format from the previous report.

METHODS

Data Sources

Cancer Incidence

The MCR collects reports of newly diagnosed cancer cases from health care facilities and practitioners throughout Massachusetts. Facilities that reported the 2010-2014 diagnoses that comprise this report include 69 Massachusetts acute care hospitals, 20 independent laboratories, 10 surgical centers, 5 radiation/oncology centers, 10 medical practice associations, 4 endoscopy centers, and approximately 500 private practice physicians. The MCR signed the modified National Data Exchange Agreement on March 28, 2013. This is a single agreement that allows participating states to exchange data on cases diagnosed or treated in other areas. Together with states participating in the agreement, and states with individual agreements, the MCR now has reciprocal reporting agreements with 42 states and with the District of Columbia, the Virgin Islands, Puerto Rico and Guam to obtain data on Massachusetts residents diagnosed out of state. Currently the MCR collects information on *in situ* and invasive cancers and benign tumors of the brain and associated tissues. The MCR does not collect information on basal and squamous cell carcinomas of the skin.

The MCR also collects information from reporting hospitals on cases diagnosed and treated in staff physician offices when this information is available. Not all hospitals report this type of case, however, some hospitals report such cases as if the patients had been diagnosed and treated by the hospital directly. Collecting these types of data makes the MCR's overall case ascertainment more complete. Some cancer types that may be reported to the MCR in this manner are melanoma, prostate, colon/rectum, and oral cancers.

In addition, the MCR identifies previously unreported cancer cases through review of death certificate data to further improve case completeness. This process is referred to as death clearance and identifies cancers mentioned on death certificates that were not previously reported to the MCR. In some instances, the MCR obtains additional information on these cases through follow-up activities with hospitals, nursing homes, hospice residences, and physicians' offices. In other instances, a cancer-related cause of death recorded on a Massachusetts death certificate is the only source of information for a cancer case. Thus these "death certificate only" cancer diagnoses are poorly documented and have not been confirmed by review of clinical and pathological information. Such cases are included in this report, but they comprise less than 3% of all cancer cases.

All case reports that provided the basis for this report were coded following the *International Classification of Diseases for Oncology, Third Edition* (ICD-O-3), which was implemented in North America with cases diagnosed as of January 1, 2001. (1) Please see Appendix A for the classification of cancers by ICD-O3 codes.

Each year, the North American Association of Central Cancer Registries (NAACCR) reviews cancer registry data for quality, completeness, and timeliness. For 2010-2014, the MCR's annual case count was estimated by NAACCR to be more than 95% complete for each year. The MCR has achieved the gold standard for this certification element as well as for six other certification elements for each case year since 1997.

The Massachusetts cancer cases presented in this report are primary cases of cancer diagnosed among Massachusetts residents during 2010-2014 and reported to the MCR as of June 14, 2018. These data include some additional cases diagnosed in 2009-2013 that were not counted in the

previous report, *Cancer Incidence in Massachusetts 2009-2013: City and Town Supplement*. The lag time between this report and the annual statewide report of 2010-2014 cancer cases is due to the fact that data for this city and town report needed to be cleaned for accuracy of residence within Massachusetts. The statewide report presented data at the state level and did not require such accuracy of city and town of residence. The numbers presented in this report may change slightly in future reports, reflecting late reported cases or corrections based on subsequent details from the reporting facilities. Such changes might result in slight differences in numbers and rates in future reports of MCR data, reflecting the nature of population-based cancer registries that receive case reports on an ongoing basis.

Massachusetts cancer cases presented in this report are primary cases of cancer diagnosed among Massachusetts residents during 2010-2014. The Massachusetts data presented include invasive cancers only (except cancer of the urinary bladder, where *in situ* cancers are also included). Invasive cancers have spread beyond the layer of cells where they started and have the potential to spread to other parts of the body. *In situ* cancers are neoplasms diagnosed at the earliest stage, before they have spread, when they are limited to a small number of cells and have not invaded the organ itself. Typically, published incidence rates do not combine invasive and *in situ* cancers due to differences in the biologic significance, survival prognosis and types of treatment of the tumors. Cancer of the urinary bladder is the only exception, due to the specific nature of the diagnostic techniques and treatment patterns.

Presentation of Data

Each city and town in Massachusetts is listed alphabetically in the **TABLES** section. The observed number of cases, the expected number of cases, the standardized incidence ratios, and 95% confidence intervals are presented for twenty-three main types of cancer and for all cancer types combined. The “all cancers combined” category includes the twenty-three main types presented in this report and other malignant neoplasms. This category is meant to provide a summary of the total cancer experience in a community. As different cancers have different causes, this category does not reflect any specific risk factor that may be important for this community.

Observed and Expected Case Counts

The *observed* case count (**Obs**) for a particular type of cancer in a city/town is the actual number of newly diagnosed cases among residents of that city/town for a given time period.

A city/town’s *expected* case count (**Exp**) for a certain type of cancer for this time period is a calculated number based on that city/town’s population distribution² (by sex and among eighteen age groups) for the time period 2010-2014, and the corresponding statewide average annual age-specific incidence rates. The source of the city and town population data for the 2010-2014 period was the US Census American Community Survey (ACS), an ongoing national survey that provides demographic estimates on a yearly basis.²

Standardized Incidence Ratios

A Standardized Incidence Ratio (SIR) is an indirect method of adjustment for age and sex that describes in numerical terms how a city/town's cancer experience in a given time period compares with that of the state as a whole.

- An SIR of *exactly 100* indicates that a city/town's incidence of a certain type of cancer is *equal to that expected* based on statewide average age-specific incidence rates.
- An SIR of *more than 100* indicates that a city/town's incidence of a certain type of cancer is *higher than expected* for that type of cancer based on statewide average annual age-specific incidence rates. For example, an SIR of 105 indicates that a city/town's cancer incidence is 5% higher than expected based on statewide average annual age-specific incidence rates.
- An SIR of *less than 100* indicates that a city/town's incidence of a certain type of cancer is *lower than expected* based on statewide average age-specific incidence rates. For example, an SIR of 85 indicates that a city/town's cancer incidence is 15% lower than expected based on statewide average annual age-specific incidence rates.

Statistical Significance and Interpretation of SIRs

The interpretation of the SIR depends on both how large it is and how stable it is. Stability in this context refers to how much the SIR changes when there are small increases or decreases in the observed or expected number of cases. Two SIRs may have the same size but not the same stability. For example, an SIR of 150 may represent 6 observed cases and 4 expected cases, or 600 observed cases and 400 expected cases. Both represent a 50 percent excess of observed cases. However, in the first instance, one or two fewer cases would change the SIR a great deal, whereas in the second instance, even if there were several fewer cases, the SIR would only change minimally. When the observed and expected numbers of cases are relatively small, their ratio is easily affected by one or two cases. Conversely, when the observed and expected numbers of cases are relatively large, the value of the SIR is stable.

A 95 percent confidence interval (CI) has been presented for each SIR in this report (when the observed number of cases is at least 5), to indicate if the observed number of cases is significantly different from the expected number, or if the difference is most likely due to chance. A confidence interval is a range of values around a measurement that indicates the precision of the measurement. In this report, the 95% confidence interval is the range of estimated SIR values that has a 95% probability of including the true SIR for a specific city or town. If the 95% confidence interval range *does not* include the value 100.0, then the number of observed cases is significantly different from the expected number of cases. "Significantly different" means there is at most a 5% chance that the difference between the number of observed and expected cancer cases is due solely to chance alone. If the confidence interval does contain the value 100.0, there is no significant difference between the observed and expected numbers. Statistically, the width of the interval reflects the size of the population and the number of events; smaller populations and smaller observed numbers of cases yield less precise estimates that have wider confidence intervals. Wide confidence intervals indicate instability, meaning that small changes in the observed or expected number of cases would change the SIR a great deal.

Examples:

- SIR = 137.0; 95% CI (101.6 - 180.6) – the confidence interval does not include 100.0 and the interval is above 100.0, indicating that the number of observed cases is *statistically significantly higher* than the expected number.
- SIR = 71.0; 95% CI (56.2 – 88.4) – the confidence interval does not include 100.0 and the interval is below 100.0, indicating that the number of observed cases is *statistically significantly lower* than the expected number.
- SIR = 108.8 95% CI (71.0-159.4) – the confidence interval DOES include 100.0 indicating that the number of observed cases is *NOT statistically significantly different* from what is expected, and the difference is likely due to chance. When the interval includes 100.0, then the true SIR may be 100.0.

Example of Calculation of an SIR and Its Significance

$$\text{SIR} = \frac{\text{OBSERVED CASES}}{\text{EXPECTED CASES}} \times 100$$

The following example illustrates the method of calculation for a hypothetical town for one type of cancer and one sex for the years 2007-2011:

Age Group	<u>Town X</u> Population (A)	<u>State</u> Age-Specific Incidence Rate (B)	<u>Town X</u> Expected Cases (C) = (A) x (B)	<u>Town X</u> Observed Cases (D)
00-04	74,657	0.0001	7.47	11
05-09	134,957	0.0002	26.99	25
10-14	54,463	0.0005	27.23	30
15-19	25,136	0.0015	37.70	40
20-24	17,012	0.0018	30.62	30
UP TO				
85+	6,337	0.0010	6.34	8
Total:			136.35	144

$$\text{SIR} = \frac{\text{Observed Cases}}{\text{Expected Cases}} \times 100 = \frac{(\text{column D total})}{(\text{column C total})} \times 100 = \frac{144}{136.35} \times 100 \approx 106$$

Thus the SIR for this type of cancer in Town X is 106, indicating that the incidence of this cancer in Town X is 6% higher than the corresponding statewide average incidence for this cancer. However, the range for the 95% confidence interval (89.1-124.3) (calculation not shown) indicates that the true value may be as low as 89.1 or as high as 124.3. Also, since the range

includes the value 100, it means that the observed number of cases is *not statistically significantly higher or lower* than what is expected.

Whenever the number of observed cases is less than five, the corresponding SIR is neither calculated nor tested for statistical significance. This is indicated with an (nc) (“not calculated”). However, the number of observed and expected cases is shown in these circumstances.

Notes about Data Interpretation

The SIR is a useful indication of the disease categories that have relatively high or low rates for a given community. These statistics, however, should be used with care. Such statistics provide a starting point for further research and investigation into a possible health problem, but they do not by themselves confirm or deny the existence of a particular health problem. Many factors unrelated to disease causation may contribute to an elevated SIR, including demographic factors, changes in diagnostic techniques, and changes in data collection or recording methods over time, as well as the natural variation in disease occurrence.

When reviewing the data tables, it is important to keep in mind that an SIR compares the observed cancer incidence in a particular community with the expected incidence based on statewide average annual age-specific incidence rates. This means that *valid comparisons can only be made between a community and the state as a whole. SIRs for different cities and towns CANNOT and SHOULD NOT be compared to each other.* (Comparisons between two communities would be valid only if there were no differences in the age and sex distributions of the two communities’ populations.)

Another point to keep in mind when reviewing these data is the large number of statistical tests being performed in this report. For each of the 351 cities and towns, we evaluate 18 types of cancer that can occur in both males and females, 3 types that occur only in females and 2 types that occur only in males, resulting in 41 gender/cancer categories. This results in 14,391 possible calculations (351 cities and towns x 41 gender cancer categories). Note that gender/cancer categories with less than 5 observed cases are not evaluated for statistical significance, so the actual numbers of tests is slightly lower than 14,391. This is important for the reader because when multiple significance tests are performed, some will result in a significant finding due to chance alone. Based on the number of calculations in this report, we expect 720 significant findings to be due to chance alone. Half of these would be significant excesses (360) and half would be significant deficits (360). There are statistical techniques that can be used to reduce this number, however use of these techniques leads to the opposite problem – true significant differences that may be missed. We choose to err on the side of caution and identify more significant results, knowing that some will be due to chance alone.

Data Limitations

It should be emphasized that apparent increases or decreases in cancer incidence over time might reflect changes in diagnostic methods or case reporting rather than true changes in cancer incidence. Four other limitations must be considered when interpreting cancer incidence data for Massachusetts cities and towns: under-reporting in areas close to neighboring states; under-reporting for cancers that may not be diagnosed in hospitals; cases being assigned to incorrect cities/towns; and standardized incidence ratios based on small numbers of cases.

Border Areas and Neighboring States

Some areas of Massachusetts appear to have low cancer incidence, but this may be due to loss of Massachusetts resident cases who are diagnosed in neighboring or other states and not reported to the MCR. The MCR has reciprocal reporting agreements with 42 states and with the District of Columbia, the Virgin Islands, Puerto Rico, and Guam.

Cases Diagnosed in Non-Hospital Settings

During the time period covered by this report, the MCR's primary information source for most newly diagnosed cases of cancer was hospitals. In addition the MCR collected information from reporting hospitals on cases diagnosed and treated in staff physician offices, when this information was available. Other reporting sources include dermatologists and dermatopathology laboratories, urologists' offices and a general laboratory. Some types of cancer in this report may be under-reported because they are diagnosed primarily by private physicians, private laboratories, health maintenance organizations, radiotherapy centers that escape identification systems used by hospitals. The most common types of cancer diagnosed or treated outside of the hospital include melanoma and prostate cancer. The exact extent of this under-reporting has not been determined, but cases included in this report represent the great majority of cases statewide and provide an essential basis for evaluating statewide cancer incidence patterns.

City/Town Misassignment

In accordance with standard central cancer registry procedures, each case reported to the MCR ideally should be assigned to the city/town in which the patient lived at the time of diagnosis, based on the address provided by the reporting hospital. In practice, however, a patient may provide the hospital with his/her mailing address (e.g., a post office box located outside the patient's city/town of residence); a business address; a temporary address (e.g., the patient is staying with a relative while receiving treatment and reports the relative's address as his/her own); or a locality or post office name (e.g., "Chestnut Hill" rather than "Boston," "Brookline," or "Newton"). In addition, if a patient has moved since being diagnosed, the hospital may report the patient's current address. Because of the large number of cases reported to the MCR, and because data are reported to the MCR via electronic media, most city/town case assignments are performed by an automated computer process. This simplified matching process may misassign some cases based on the reported locality name. When MCR staff become aware of such misassignments, they manually correct the errors. Furthermore, in order to minimize such errors, cases from fifty geographic localities prone to city/town misassignment are reviewed manually.

Small Numbers of Cases

Standardized incidence ratios based on small numbers of cases result in estimates that are very unstable. This situation is common when the population of a city or town is small or if the particular cancer type is rare. SIRs and statistical significance are not calculated when the number of observed cases for a specific category is less than five. In these instances, the observed and expected cases are presented in the tables for qualitative comparison only.

This page intentionally left blank.

TABLES

Abington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	13.6	95.8	(51.0-163.9)	Male	11	9.4	116.5	(58.1-208.5)
Female	7	5.6	125.2	(50.1-257.9)	Female	10	8.6	116.2	(55.7-213.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	3.0	nc	(nc-nc)	Male	6	3.0	198.9	(72.6-432.9)
Female	4	2.8	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.5	nc	(nc-nc)	Male	1	8.4	nc	(nc-nc)
Female	62	68.8	90.1	(69.1-115.5)	Female	4	8.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.4	nc	(nc-nc)	Male	5	7.6	65.6	(21.1-153.1)
<u>Colon / Rectum</u>					Female	6	3.6	167.0	(61.0-363.5)
Male	21	15.7	133.4	(82.6-203.9)	<u>Ovary</u>				
Female	22	16.6	132.3	(82.9-200.3)	Female	4	5.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.9	129.3	(41.7-301.7)	Male	8	5.1	155.9	(67.1-307.3)
Female	0	1.1	nc	(nc-nc)	Female	4	5.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	51	49.7	102.6	(76.4-134.9)
Female	3	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	3.5	nc	(nc-nc)
Male	17	8.7	195.2	(113.7-312.6)	Female	5	2.3	220.3	(71.0-514.2)
Female	7	5.3	131.6	(52.7-271.2)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.3	nc	(nc-nc)
Male	4	2.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	6	0.7	801.6	(292.7-1744.8)	Male	4	4.2	nc	(nc-nc)
<u>Leukemia</u>					Female	12	13.6	88.0	(45.4-153.7)
Male	3	5.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	4.9	143.0	(57.3-294.6)	Female	17	16.0	106.5	(62.0-170.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	5.5	109.2	(39.9-237.6)	Male	222	193.1	114.9	(100.3-131.1)
Female	2	2.0	nc	(nc-nc)	Female	245	225.3	108.7	(95.6-123.2)
<u>Lung and Bronchus</u>									
Male	39	25.1	155.4	(110.5-212.4)					
Female	38	29.6	128.2	(90.7-176.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Acton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	19.5	97.3	(58.6-152.0)	Male	15	13.8	108.7	(60.8-179.2)
Female	5	7.3	68.1	(22.0-159.0)	Female	16	11.3	141.5	(80.8-229.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	4.4	157.5	(63.1-324.6)	Male	4	4.4	nc	(nc-nc)
Female	2	3.7	nc	(nc-nc)	Female	5	3.5	142.0	(45.8-331.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.7	nc	(nc-nc)	Male	16	12.4	129.1	(73.7-209.6)
Female	114	94.7	120.3	(99.3-144.6)	Female	12	10.9	109.7	(56.6-191.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.3	nc	(nc-nc)	Male	13	11.3	114.6	(60.9-195.9)
<u>Colon / Rectum</u>					Female	5	4.8	104.7	(33.8-244.4)
Male	19	23.9	79.5	(47.8-124.1)	<u>Ovary</u>				
Female	22	22.9	95.9	(60.1-145.2)	Female	10	8.0	125.6	(60.1-231.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	5.5	126.8	(50.8-261.3)	Male	6	7.5	80.5	(29.4-175.1)
Female	4	1.4	nc	(nc-nc)	Female	7	7.5	93.2	(37.3-192.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.7	nc	(nc-nc)	Male	79	69.4	113.8	(90.1-141.8)
Female	1	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	5.1	nc	(nc-nc)
Male	4	12.8	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
Female	9	7.2	125.8	(57.4-238.9)	<u>Testis</u>				
<u>Larynx</u>					Male	0	3.2	nc	(nc-nc)
Male	3	3.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.0	nc	(nc-nc)	Male	6	6.4	94.4	(34.5-205.5)
<u>Leukemia</u>					Female	17	18.1	93.8	(54.6-150.1)
Male	5	8.6	58.2	(18.7-135.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	6.3	159.1	(76.2-292.6)	Female	16	20.8	76.8	(43.9-124.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	8.1	nc	(nc-nc)	Male	236	279.3	84.5	(74.0-96.0)
Female	3	2.5	nc	(nc-nc)	Female	319	302.4	105.5	(94.2-117.7)
<u>Lung and Bronchus</u>									
Male	15	35.6	42.2	(23.6-69.6)					
Female	31	39.5	78.4	(53.3-111.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Acushnet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	12.2	172.4	(106.7-263.6)	Male	6	7.7	78.1	(28.5-169.9)
Female	3	4.5	nc	(nc-nc)	Female	5	5.9	84.6	(27.3-197.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.3	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)	Female	4	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	9	6.9	130.3	(59.5-247.4)
Female	46	48.9	94.1	(68.9-125.5)	Female	8	6.2	128.3	(55.2-252.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.5	nc	(nc-nc)	Male	2	5.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	2.6	nc	(nc-nc)
Male	16	13.1	122.4	(69.9-198.9)	<u>Ovary</u>				
Female	13	13.1	99.3	(52.8-169.9)	Female	3	4.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.1	nc	(nc-nc)	Male	5	4.3	115.8	(37.3-270.2)
Female	0	0.9	nc	(nc-nc)	Female	5	4.6	108.2	(34.9-252.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.9	nc	(nc-nc)	Male	39	36.6	106.5	(75.7-145.6)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.9	nc	(nc-nc)
Male	7	6.7	105.2	(42.1-216.7)	Female	1	1.8	nc	(nc-nc)
Female	3	3.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.6	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.6	nc	(nc-nc)	Male	0	3.1	nc	(nc-nc)
<u>Leukemia</u>					Female	7	8.4	83.3	(33.4-171.7)
Male	3	4.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	3.5	228.3	(98.3-449.8)	Female	9	10.8	83.0	(37.9-157.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.1	nc	(nc-nc)	Male	173	154.7	111.8	(95.8-129.8)
Female	1	1.5	nc	(nc-nc)	Female	153	164.9	92.8	(78.7-108.7)
<u>Lung and Bronchus</u>									
Male	28	21.1	132.7	(88.2-191.8)					
Female	22	23.9	91.9	(57.6-139.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	9.5	105.6	(50.6-194.2)	Male	3	5.9	nc	(nc-nc)
Female	3	3.9	nc	(nc-nc)	Female	5	5.1	98.3	(31.7-229.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.8	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
Female	4	1.6	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	5.4	130.8	(52.4-269.5)
Female	34	41.9	81.2	(56.2-113.5)	Female	7	5.4	130.3	(52.2-268.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.3	nc	(nc-nc)	Male	5	4.5	111.5	(35.9-260.1)
<u>Colon / Rectum</u>					Female	0	2.2	nc	(nc-nc)
Male	9	10.2	88.2	(40.3-167.5)	<u>Ovary</u>				
Female	10	11.3	88.4	(42.3-162.6)	Female	3	3.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.4	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	4	3.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.7	nc	(nc-nc)	Male	30	30.3	98.9	(66.7-141.2)
Female	2	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.3	nc	(nc-nc)
Male	4	5.2	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
Female	4	3.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.2	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	7	7.2	97.6	(39.1-201.2)
Male	5	3.8	131.2	(42.3-306.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.0	nc	(nc-nc)	Female	7	9.3	75.4	(30.2-155.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.3	nc	(nc-nc)	Male	129	122.3	105.5	(88.1-125.3)
Female	0	1.3	nc	(nc-nc)	Female	130	142.0	91.6	(76.5-108.7)
<u>Lung and Bronchus</u>									
Male	24	16.8	143.2	(91.7-213.1)					
Female	25	20.9	119.9	(77.6-177.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Agawam

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	35	31.8	110.0	(76.6-152.9)	Male	21	20.4	103.1	(63.8-157.6)
Female	10	13.9	72.1	(34.5-132.6)	Female	15	17.7	84.5	(47.3-139.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	6.2	nc	(nc-nc)	Male	11	6.6	166.3	(82.9-297.6)
Female	5	5.6	90.0	(29.0-210.0)	Female	7	6.2	112.8	(45.2-232.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.1	nc	(nc-nc)	Male	24	18.3	131.3	(84.1-195.3)
Female	142	141.7	100.2	(84.4-118.1)	Female	17	18.8	90.3	(52.6-144.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	4.5	155.8	(62.4-321.0)	Male	23	15.5	148.0	(93.8-222.1)
<u>Colon / Rectum</u>					Female	13	7.8	166.1	(88.4-284.0)
Male	43	34.5	124.6	(90.1-167.8)	<u>Ovary</u>				
Female	34	40.6	83.8	(58.0-117.1)	Female	8	12.4	64.6	(27.8-127.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	8.4	nc	(nc-nc)	Male	10	11.5	86.9	(41.6-159.8)
Female	2	2.6	nc	(nc-nc)	Female	17	14.3	119.0	(69.3-190.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.3	nc	(nc-nc)	Male	88	104.3	84.4	(67.7-104.0)
Female	2	2.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	9	7.7	116.5	(53.2-221.1)
Male	27	18.1	149.1	(98.3-217.0)	Female	5	5.5	90.2	(29.1-210.6)
Female	6	11.4	52.6	(19.2-114.4)	<u>Testis</u>				
<u>Larynx</u>					Male	1	4.0	nc	(nc-nc)
Male	7	4.9	142.6	(57.1-293.7)	<u>Thyroid</u>				
Female	1	1.6	nc	(nc-nc)	Male	5	8.0	62.3	(20.1-145.4)
<u>Leukemia</u>					Female	18	24.3	74.0	(43.8-116.9)
Male	11	13.0	84.9	(42.3-151.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	10.8	83.0	(37.9-157.6)	Female	24	31.6	76.0	(48.7-113.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	13	11.4	113.7	(60.5-194.5)	Male	448	418.2	107.1	(97.4-117.5)
Female	5	4.4	113.1	(36.4-263.9)	Female	473	489.5	96.6	(88.1-105.7)
<u>Lung and Bronchus</u>									
Male	82	57.2	143.4	(114.0-178.0)					
Female	88	69.8	126.0	(101.1-155.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Alford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	3	3.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	3.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.4	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	12.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	7	10.5	66.9	(26.8-137.9)
<u>Lung and Bronchus</u>									
Male	0	1.8	nc	(nc-nc)					
Female	0	1.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Amesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	14.3	126.3	(74.8-199.6)	Male	8	10.3	77.9	(33.5-153.5)
Female	10	5.8	171.9	(82.3-316.2)	Female	5	8.8	56.7	(18.3-132.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.3	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
Female	6	2.7	219.1	(80.0-476.8)	Female	0	2.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	12	9.1	131.4	(67.8-229.5)
Female	76	72.2	105.3	(83.0-131.8)	Female	10	8.6	117.0	(56.0-215.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.6	nc	(nc-nc)	Male	9	8.5	106.4	(48.5-201.9)
<u>Colon / Rectum</u>					Female	3	3.7	nc	(nc-nc)
Male	19	17.1	111.3	(67.0-173.8)	<u>Ovary</u>				
Female	20	17.7	113.1	(69.1-174.7)	Female	6	6.1	98.9	(36.1-215.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	4.1	nc	(nc-nc)	Male	8	5.5	145.2	(62.5-286.2)
Female	2	1.1	nc	(nc-nc)	Female	7	5.9	118.7	(47.5-244.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.4	nc	(nc-nc)	Male	71	52.8	134.5	(105.0-169.6)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	3.7	nc	(nc-nc)
Male	5	9.6	52.3	(16.9-122.1)	Female	1	2.4	nc	(nc-nc)
Female	5	5.5	90.3	(29.1-210.6)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.6	nc	(nc-nc)
Male	1	2.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	6	4.8	125.1	(45.7-272.3)
<u>Leukemia</u>					Female	18	14.0	128.3	(76.0-202.7)
Male	9	6.4	140.2	(64.0-266.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	4.9	164.8	(71.0-324.8)	Female	13	16.0	81.4	(43.3-139.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	6.0	115.7	(46.4-238.5)	Male	238	207.9	114.5	(100.4-130.0)
Female	2	2.0	nc	(nc-nc)	Female	247	233.5	105.8	(93.0-119.8)
<u>Lung and Bronchus</u>									
Male	31	26.4	117.4	(79.8-166.7)					
Female	40	31.0	128.9	(92.1-175.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Amherst

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	18.3	81.9	(45.8-135.0)	Male	13	12.1	107.7	(57.3-184.2)
Female	2	7.2	nc	(nc-nc)	Female	14	11.4	122.5	(66.9-205.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	5.1	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
Female	2	4.5	nc	(nc-nc)	Female	1	3.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	6	11.8	50.9	(18.6-110.8)
Female	77	76.5	100.7	(79.4-125.8)	Female	13	10.7	121.6	(64.7-208.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.7	nc	(nc-nc)	Male	9	8.7	103.5	(47.3-196.6)
<u>Colon / Rectum</u>					Female	3	4.4	nc	(nc-nc)
Male	14	19.6	71.3	(39.0-119.7)	<u>Ovary</u>				
Female	27	20.9	129.2	(85.1-188.0)	Female	9	7.4	122.3	(55.8-232.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	4.6	nc	(nc-nc)	Male	9	6.4	139.8	(63.8-265.5)
Female	0	1.4	nc	(nc-nc)	Female	7	7.1	98.3	(39.4-202.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	4.0	nc	(nc-nc)	Male	42	55.7	75.4	(54.3-101.9)
Female	0	4.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	4.4	nc	(nc-nc)
Male	5	10.1	49.7	(16.0-116.0)	Female	1	2.9	nc	(nc-nc)
Female	7	6.3	110.9	(44.4-228.5)	<u>Testis</u>				
<u>Larynx</u>					Male	1	7.0	nc	(nc-nc)
Male	2	2.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	7	5.7	123.7	(49.5-254.8)
<u>Leukemia</u>					Female	3	20.3	nc	(nc-nc)
Male	9	9.2	98.0	(44.7-186.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	7.0	nc	(nc-nc)	Female	13	17.3	75.2	(40.0-128.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	6.5	nc	(nc-nc)	Male	169	250.0	67.6	(57.8-78.6)
Female	0	2.5	nc	(nc-nc)	Female	219	278.6	78.6	(68.5-89.7)
<u>Lung and Bronchus</u>									
Male	14	32.6	43.0	(23.5-72.2)					
Female	17	37.3	45.6	(26.5-73.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	25	35.1	71.3	(46.1-105.3)	Male	26	22.6	115.0	(75.1-168.5)
Female	9	12.3	73.1	(33.4-138.8)	Female	28	18.1	155.1	(103.0-224.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	7.0	114.6	(49.3-225.8)	Male	7	7.4	94.3	(37.8-194.3)
Female	5	5.9	84.6	(27.3-197.5)	Female	12	5.8	207.3	(107.0-362.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.2	nc	(nc-nc)	Male	29	20.4	142.3	(95.3-204.4)
Female	158	150.2	105.2	(89.4-122.9)	Female	18	17.9	100.4	(59.4-158.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	5.0	nc	(nc-nc)	Male	16	17.5	91.2	(52.1-148.2)
<u>Colon / Rectum</u>					Female	2	7.7	nc	(nc-nc)
Male	31	38.7	80.1	(54.4-113.7)	<u>Ovary</u>				
Female	39	37.3	104.6	(74.4-143.1)	Female	12	12.7	94.2	(48.6-164.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	9.4	96.0	(43.8-182.2)	Male	13	12.7	102.4	(54.5-175.1)
Female	7	2.4	286.2	(114.7-589.8)	Female	13	12.6	103.3	(54.9-176.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.5	nc	(nc-nc)	Male	107	116.6	91.8	(75.2-110.9)
Female	3	2.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	8.6	58.3	(18.8-136.1)
Male	19	20.4	93.0	(55.9-145.2)	Female	4	5.0	nc	(nc-nc)
Female	12	11.6	103.4	(53.4-180.7)	<u>Testis</u>				
<u>Larynx</u>					Male	8	4.3	188.2	(81.0-370.8)
Male	3	5.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.6	nc	(nc-nc)	Male	14	9.1	153.4	(83.8-257.3)
<u>Leukemia</u>					Female	42	28.0	150.0	(108.1-202.8)
Male	18	14.4	124.8	(73.9-197.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	10.4	106.3	(53.0-190.1)	Female	25	33.4	74.9	(48.4-110.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	12.8	62.4	(26.9-122.9)	Male	421	466.2	90.3	(81.9-99.4)
Female	2	4.1	nc	(nc-nc)	Female	476	488.4	97.5	(88.9-106.6)
<u>Lung and Bronchus</u>									
Male	40	63.4	63.1	(45.0-85.9)					
Female	40	66.2	60.5	(43.2-82.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Aquinnah

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	3	1.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.3	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	4	4.9	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	0	0.4	nc	(nc-nc)					
Female	0	0.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Arlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	47	45.7	102.9	(75.6-136.8)	Male	27	29.4	91.9	(60.5-133.7)
Female	17	18.4	92.5	(53.8-148.0)	Female	24	25.5	94.1	(60.3-140.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	9.0	100.3	(45.8-190.4)	Male	11	9.3	118.1	(58.9-211.4)
Female	9	7.9	114.0	(52.0-216.4)	Female	5	8.4	59.6	(19.2-139.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.6	nc	(nc-nc)	Male	19	26.5	71.8	(43.2-112.2)
Female	209	201.8	103.6	(90.0-118.6)	Female	32	25.8	123.9	(84.7-174.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	7.0	71.3	(23.0-166.4)	Male	18	21.6	83.5	(49.5-132.0)
<u>Colon / Rectum</u>					Female	14	10.9	129.0	(70.5-216.4)
Male	44	50.3	87.4	(63.5-117.4)	<u>Ovary</u>				
Female	52	55.0	94.6	(70.7-124.1)	Female	17	17.4	97.5	(56.8-156.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	11.5	95.6	(47.6-171.0)	Male	18	16.3	110.4	(65.4-174.4)
Female	3	3.6	nc	(nc-nc)	Female	16	18.9	84.5	(48.3-137.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	3.5	nc	(nc-nc)	Male	136	136.6	99.6	(83.5-117.8)
Female	6	2.9	207.3	(75.7-451.1)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	11.1	90.0	(43.1-165.5)
Male	27	25.5	105.9	(69.8-154.1)	Female	7	7.5	93.3	(37.4-192.2)
Female	11	15.9	69.0	(34.4-123.5)	<u>Testis</u>				
<u>Larynx</u>					Male	7	6.7	105.2	(42.2-216.8)
Male	5	6.7	74.8	(24.1-174.6)	<u>Thyroid</u>				
Female	3	2.2	nc	(nc-nc)	Male	13	12.0	108.3	(57.6-185.2)
<u>Leukemia</u>					Female	38	37.8	100.6	(71.2-138.1)
Male	18	18.8	95.7	(56.7-151.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	12	15.0	80.2	(41.4-140.1)	Female	46	44.7	103.0	(75.4-137.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	15	15.7	95.7	(53.5-157.9)	Male	558	585.9	95.2	(87.5-103.5)
Female	4	6.0	nc	(nc-nc)	Female	677	682.8	99.2	(91.8-106.9)
<u>Lung and Bronchus</u>									
Male	73	79.7	91.6	(71.8-115.2)					
Female	91	93.7	97.1	(78.2-119.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashburnham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.0	100.0	(32.2-233.3)	Male	2	3.7	nc	(nc-nc)
Female	0	2.0	nc	(nc-nc)	Female	4	3.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.2	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	19	28.0	67.9	(40.9-106.1)	Female	1	3.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.3	nc	(nc-nc)
Male	4	6.2	nc	(nc-nc)	<u>Ovary</u>				
Female	7	6.0	116.5	(46.7-240.0)	Female	3	2.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.6	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	21	21.2	98.9	(61.2-151.2)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.3	nc	(nc-nc)
Male	2	3.7	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.8	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<u>Leukemia</u>					Female	4	5.3	nc	(nc-nc)
Male	6	2.3	261.7	(95.5-569.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	1.7	nc	(nc-nc)	Female	4	6.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.3	nc	(nc-nc)	Male	71	77.8	91.3	(71.3-115.1)
Female	0	0.7	nc	(nc-nc)	Female	64	86.1	74.3	(57.2-94.9)
<u>Lung and Bronchus</u>									
Male	7	9.6	72.7	(29.1-149.8)					
Female	4	11.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	3.3	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.7	nc	(nc-nc)	Male	3	0.7	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	13	14.7	88.4	(47.0-151.2)	Female	0	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.5	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	0.8	nc	(nc-nc)
Male	4	3.9	nc	(nc-nc)	<u>Ovary</u>				
Female	2	3.6	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.9	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	8	11.3	70.9	(30.5-139.7)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.8	nc	(nc-nc)
Male	0	2.0	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	2	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.7	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.0	nc	(nc-nc)	Female	1	3.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.3	nc	(nc-nc)	Male	41	45.6	90.0	(64.6-122.1)
Female	2	0.4	nc	(nc-nc)	Female	42	47.4	88.7	(63.9-119.9)
<u>Lung and Bronchus</u>									
Male	3	6.0	nc	(nc-nc)					
Female	3	6.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.5	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	6	9.6	62.7	(22.9-136.4)	Female	0	1.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<u>Ovary</u>				
Female	3	2.4	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	6.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.6	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.6	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.7	nc	(nc-nc)	Male	18	23.2	77.7	(46.0-122.9)
Female	0	0.3	nc	(nc-nc)	Female	20	31.3	63.8	(39.0-98.6)
<u>Lung and Bronchus</u>									
Male	2	2.8	nc	(nc-nc)					
Female	2	4.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	16.1	112.1	(66.4-177.2)	Male	6	10.9	54.8	(20.0-119.3)
Female	4	6.1	nc	(nc-nc)	Female	3	9.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.4	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	Female	2	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	8	9.8	81.5	(35.1-160.6)
Female	62	73.7	84.1	(64.5-107.9)	Female	6	8.9	67.3	(24.6-146.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.6	nc	(nc-nc)	Male	5	8.8	57.1	(18.4-133.2)
<u>Colon / Rectum</u>					Female	5	3.8	130.5	(42.1-304.6)
Male	11	18.6	59.3	(29.5-106.1)	<u>Ovary</u>				
Female	21	18.2	115.5	(71.5-176.6)	Female	7	6.3	111.5	(44.7-229.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	4.4	225.9	(108.2-415.5)	Male	3	6.1	nc	(nc-nc)
Female	4	1.2	nc	(nc-nc)	Female	6	6.2	96.3	(35.2-209.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.3	nc	(nc-nc)	Male	40	56.1	71.3	(51.0-97.2)
Female	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	4.0	148.2	(54.1-322.6)
Male	5	10.0	49.9	(16.1-116.5)	Female	3	2.5	nc	(nc-nc)
Female	1	5.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.4	nc	(nc-nc)
Male	1	2.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	3	4.7	nc	(nc-nc)
<u>Leukemia</u>					Female	21	14.0	150.2	(93.0-229.7)
Male	2	6.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	5.2	116.1	(42.4-252.7)	Female	15	16.8	89.1	(49.8-146.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	6.3	79.3	(25.6-185.1)	Male	168	223.0	75.3	(64.4-87.6)
Female	3	2.1	nc	(nc-nc)	Female	224	241.5	92.8	(81.0-105.7)
<u>Lung and Bronchus</u>									
Male	24	29.1	82.3	(52.7-122.5)					
Female	41	32.5	126.1	(90.5-171.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Athol

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	14.6	123.4	(73.1-195.1)	Male	6	9.3	64.4	(23.5-140.1)
Female	3	4.4	nc	(nc-nc)	Female	3	6.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.8	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
Female	0	2.0	nc	(nc-nc)	Female	0	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	2	8.2	nc	(nc-nc)
Female	44	49.7	88.5	(64.3-118.8)	Female	5	6.3	79.9	(25.7-186.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.7	nc	(nc-nc)	Male	7	7.1	99.2	(39.7-204.4)
<u>Colon / Rectum</u>					Female	3	2.7	nc	(nc-nc)
Male	17	15.4	110.6	(64.4-177.1)	<u>Ovary</u>				
Female	14	13.0	107.3	(58.6-180.1)	Female	1	4.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.9	nc	(nc-nc)	Male	4	5.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	5	4.5	110.0	(35.5-256.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.0	nc	(nc-nc)	Male	26	48.1	54.1	(35.3-79.3)
Female	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.5	nc	(nc-nc)
Male	10	8.2	122.5	(58.7-225.3)	Female	1	1.8	nc	(nc-nc)
Female	4	3.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.7	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.5	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
<u>Leukemia</u>					Female	11	9.1	121.2	(60.4-217.0)
Male	2	5.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	3.6	139.5	(45.0-325.6)	Female	20	11.4	175.6	(107.2-271.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	5.4	nc	(nc-nc)	Male	167	191.2	87.3	(74.6-101.6)
Female	2	1.5	nc	(nc-nc)	Female	174	166.7	104.4	(89.4-121.1)
<u>Lung and Bronchus</u>									
Male	37	26.8	138.2	(97.3-190.5)					
Female	32	23.0	138.9	(95.0-196.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Attleboro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	41	42.0	97.6	(70.1-132.5)	Male	27	27.9	96.7	(63.7-140.7)
Female	17	15.1	112.9	(65.8-180.8)	Female	23	22.3	103.3	(65.4-154.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	8.9	78.7	(31.5-162.2)	Male	6	8.9	67.6	(24.7-147.1)
Female	7	7.2	97.5	(39.1-201.0)	Female	7	7.0	99.9	(40.0-205.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.5	nc	(nc-nc)	Male	13	25.1	51.8	(27.6-88.7)
Female	184	179.4	102.5	(88.3-118.5)	Female	17	21.8	78.1	(45.5-125.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	6.3	79.8	(25.7-186.3)	Male	21	21.3	98.6	(61.0-150.7)
<u>Colon / Rectum</u>					Female	12	9.3	128.9	(66.5-225.1)
Male	55	47.2	116.5	(87.8-151.7)	<u>Ovary</u>				
Female	46	45.0	102.3	(74.9-136.5)	Female	22	15.4	143.2	(89.7-216.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	11.1	116.8	(62.1-199.8)	Male	21	15.3	137.4	(85.0-210.1)
Female	5	3.0	168.2	(54.2-392.5)	Female	17	15.2	111.5	(64.9-178.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	7	3.6	191.9	(76.9-395.3)	Male	142	136.1	104.3	(87.9-123.0)
Female	2	2.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	10.4	48.2	(15.5-112.5)
Male	17	25.0	68.0	(39.6-108.8)	Female	8	6.1	131.6	(56.7-259.4)
Female	12	14.0	85.6	(44.2-149.6)	<u>Testis</u>				
<u>Larynx</u>					Male	10	6.9	145.0	(69.4-266.7)
Male	10	6.5	153.8	(73.6-282.8)	<u>Thyroid</u>				
Female	3	2.0	nc	(nc-nc)	Male	10	12.0	83.2	(39.8-153.0)
<u>Leukemia</u>					Female	24	35.1	68.3	(43.8-101.6)
Male	15	17.9	83.9	(46.9-138.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	12.8	62.5	(26.9-123.3)	Female	48	40.0	120.1	(88.6-159.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	15.3	72.1	(35.9-128.9)	Male	571	563.2	101.4	(93.2-110.1)
Female	11	5.1	216.2	(107.8-386.8)	Female	614	591.6	103.8	(95.7-112.3)
<u>Lung and Bronchus</u>									
Male	99	75.6	131.0	(106.5-159.5)					
Female	78	80.5	96.9	(76.6-120.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Auburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	19.4	139.2	(91.7-202.6)	Male	15	12.0	124.7	(69.8-205.8)
Female	11	8.0	137.0	(68.3-245.2)	Female	11	10.3	106.9	(53.3-191.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.5	nc	(nc-nc)	Male	5	3.9	127.3	(41.0-297.1)
Female	4	3.2	nc	(nc-nc)	Female	8	3.6	221.7	(95.4-436.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	11	10.9	101.3	(50.5-181.2)
Female	83	83.5	99.5	(79.2-123.3)	Female	13	11.0	118.3	(62.9-202.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.6	nc	(nc-nc)	Male	11	8.8	124.7	(62.2-223.1)
<u>Colon / Rectum</u>					Female	1	4.6	nc	(nc-nc)
Male	20	20.8	96.2	(58.7-148.5)	<u>Ovary</u>				
Female	20	23.6	84.8	(51.8-130.9)	Female	7	7.2	96.7	(38.7-199.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	4.9	123.1	(44.9-267.9)	Male	6	6.9	87.6	(32.0-190.6)
Female	1	1.6	nc	(nc-nc)	Female	6	8.3	72.5	(26.5-157.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.2	nc	(nc-nc)	Male	56	58.7	95.4	(72.1-123.9)
Female	3	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.6	nc	(nc-nc)
Male	10	10.5	95.6	(45.7-175.7)	Female	4	3.2	nc	(nc-nc)
Female	5	6.6	75.2	(24.2-175.6)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.1	nc	(nc-nc)
Male	8	2.8	281.8	(121.4-555.4)	<u>Thyroid</u>				
Female	0	1.0	nc	(nc-nc)	Male	5	4.6	109.6	(35.3-255.7)
<u>Leukemia</u>					Female	13	14.2	91.6	(48.7-156.6)
Male	7	7.6	92.1	(36.9-189.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	6.2	96.3	(35.2-209.7)	Female	22	18.4	119.4	(74.8-180.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	6.4	108.7	(43.5-224.0)	Male	266	244.4	108.8	(96.1-122.7)
Female	0	2.5	nc	(nc-nc)	Female	282	285.8	98.7	(87.5-110.9)
<u>Lung and Bronchus</u>									
Male	37	34.2	108.0	(76.1-148.9)					
Female	39	40.8	95.6	(68.0-130.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Avon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	5.2	171.8	(78.4-326.2)	Male	5	3.2	154.1	(49.7-359.6)
Female	1	2.0	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	8	2.9	273.4	(117.7-538.7)
Female	26	21.8	119.5	(78.1-175.1)	Female	3	2.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.7	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.2	nc	(nc-nc)
Male	5	5.6	88.9	(28.7-207.6)	<u>Ovary</u>				
Female	5	5.6	88.8	(28.6-207.1)	Female	3	1.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.4	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.4	nc	(nc-nc)	Male	9	16.9	53.4	(24.4-101.4)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.2	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.6	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	3	3.7	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.6	nc	(nc-nc)	Female	2	5.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	1.8	275.0	(88.6-641.7)	Male	78	67.4	115.8	(91.5-144.5)
Female	0	0.7	nc	(nc-nc)	Female	74	73.6	100.6	(79.0-126.3)
<u>Lung and Bronchus</u>									
Male	12	9.2	130.8	(67.5-228.5)					
Female	14	10.9	128.6	(70.2-215.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ayer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	6.6	105.5	(42.2-217.3)	Male	1	4.7	nc	(nc-nc)
Female	4	2.5	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.5	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	4.2	nc	(nc-nc)
Female	35	29.9	117.2	(81.6-163.0)	Female	4	3.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.1	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.5	nc	(nc-nc)
Male	6	7.7	78.3	(28.6-170.5)	<u>Ovary</u>				
Female	11	7.6	145.0	(72.3-259.6)	Female	3	2.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	1.8	325.3	(118.8-708.0)	Male	4	2.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	4	2.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	20	22.2	90.1	(55.0-139.1)
Female	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.7	nc	(nc-nc)
Male	2	4.2	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	4	2.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.2	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
<u>Leukemia</u>					Female	4	6.3	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	2.1	nc	(nc-nc)	Female	12	6.2	192.3	(99.3-336.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.6	nc	(nc-nc)	Male	87	93.0	93.5	(74.9-115.4)
Female	1	0.8	nc	(nc-nc)	Female	121	98.8	122.5	(101.6-146.4)
<u>Lung and Bronchus</u>									
Male	18	12.4	145.1	(86.0-229.4)					
Female	19	13.5	140.3	(84.4-219.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Barnstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	98	68.4	143.3	(116.3-174.6)	Male	60	41.1	145.9	(111.4-187.8)
Female	28	23.4	119.7	(79.5-172.9)	Female	44	28.9	152.3	(110.7-204.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	14	11.4	122.7	(67.0-205.9)	Male	9	13.4	66.9	(30.5-127.0)
Female	10	9.2	108.6	(52.0-199.8)	Female	13	10.5	124.4	(66.2-212.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	2.3	nc	(nc-nc)	Male	46	36.6	125.6	(91.9-167.5)
Female	312	242.9	128.4	(114.6-143.5)	Female	43	31.4	136.8	(99.0-184.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	7.1	113.3	(48.8-223.3)	Male	32	29.8	107.2	(73.3-151.4)
<u>Colon / Rectum</u>					Female	16	13.1	121.9	(69.6-197.9)
Male	59	69.5	84.9	(64.6-109.6)	<u>Ovary</u>				
Female	60	64.8	92.6	(70.6-119.1)	Female	21	21.0	99.9	(61.8-152.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	21	17.2	122.4	(75.7-187.1)	Male	31	23.9	129.6	(88.1-184.0)
Female	4	4.6	nc	(nc-nc)	Female	19	23.5	80.9	(48.7-126.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	3.9	nc	(nc-nc)	Male	236	209.4	112.7	(98.8-128.0)
Female	0	3.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	18	16.0	112.4	(66.6-177.7)
Male	32	35.1	91.1	(62.3-128.6)	Female	10	8.8	113.5	(54.3-208.8)
Female	19	19.8	95.8	(57.7-149.7)	<u>Testis</u>				
<u>Larynx</u>					Male	7	6.2	113.8	(45.6-234.5)
Male	6	9.9	60.5	(22.1-131.7)	<u>Thyroid</u>				
Female	0	2.8	nc	(nc-nc)	Male	10	14.2	70.2	(33.6-129.1)
<u>Leukemia</u>					Female	28	38.3	73.2	(48.6-105.8)
Male	30	26.0	115.6	(77.9-165.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	27	17.6	153.3	(101.0-223.1)	Female	43	56.0	76.8	(55.6-103.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	27	22.6	119.3	(78.6-173.5)	Male	919	846.8	108.5	(101.6-115.8)
Female	6	7.6	79.1	(28.9-172.1)	Female	885	826.5	107.1	(100.1-114.4)
<u>Lung and Bronchus</u>									
Male	91	121.6	74.8	(60.3-91.9)					
Female	111	124.7	89.0	(73.2-107.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Barre

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	5.0	120.4	(44.0-262.1)	Male	3	3.4	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	Female	4	2.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	17	23.4	72.7	(42.3-116.3)	Female	0	2.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.2	nc	(nc-nc)
Male	10	5.8	172.6	(82.6-317.4)	<u>Ovary</u>				
Female	2	6.2	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.4	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	16	18.0	89.0	(50.8-144.5)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.3	nc	(nc-nc)
Male	2	3.1	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.8	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	1	4.2	nc	(nc-nc)
Male	0	2.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	1.7	nc	(nc-nc)	Female	7	5.2	133.6	(53.5-275.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.9	nc	(nc-nc)	Male	60	69.9	85.8	(65.5-110.5)
Female	0	0.7	nc	(nc-nc)	Female	61	77.6	78.6	(60.1-101.0)
<u>Lung and Bronchus</u>									
Male	7	8.9	78.6	(31.5-162.0)					
Female	6	10.5	57.3	(20.9-124.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Becket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	3.2	158.5	(51.1-369.8)	Male	1	1.9	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	9	10.4	86.4	(39.4-164.1)	Female	2	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	5	3.1	159.2	(51.3-371.5)	<u>Ovary</u>				
Female	2	2.5	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	0.8	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	9.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.7	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.7	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.7	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.0	nc	(nc-nc)	Male	33	38.1	86.7	(59.7-121.8)
Female	0	0.3	nc	(nc-nc)	Female	27	33.9	79.7	(52.5-115.9)
<u>Lung and Bronchus</u>									
Male	5	5.6	88.5	(28.5-206.6)					
Female	5	5.0	100.9	(32.5-235.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	18.0	100.2	(59.3-158.3)	Male	14	10.8	129.0	(70.5-216.5)
Female	5	6.0	83.5	(26.9-194.9)	Female	4	7.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.1	159.8	(51.5-372.9)	Male	5	3.5	144.7	(46.6-337.8)
Female	0	2.5	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	15	9.7	155.3	(86.8-256.1)
Female	67	62.9	106.5	(82.5-135.2)	Female	9	8.2	110.1	(50.2-208.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.0	nc	(nc-nc)	Male	8	7.4	107.8	(46.4-212.4)
<u>Colon / Rectum</u>					Female	4	3.4	nc	(nc-nc)
Male	15	18.7	80.4	(45.0-132.6)	<u>Ovary</u>				
Female	15	17.7	84.9	(47.5-140.1)	Female	1	5.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	4.2	nc	(nc-nc)	Male	8	6.1	130.4	(56.2-257.0)
Female	2	1.1	nc	(nc-nc)	Female	7	6.1	114.8	(46.0-236.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.1	nc	(nc-nc)	Male	58	45.9	126.3	(95.9-163.3)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	4.2	142.5	(52.0-310.2)
Male	8	8.8	90.5	(39.0-178.3)	Female	4	2.4	nc	(nc-nc)
Female	2	5.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.9	nc	(nc-nc)
Male	1	2.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	1	3.9	nc	(nc-nc)
<u>Leukemia</u>					Female	11	11.0	100.1	(49.9-179.0)
Male	10	7.0	142.5	(68.2-262.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	4.8	147.3	(59.0-303.5)	Female	6	13.6	44.2	(16.1-96.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	5.6	nc	(nc-nc)	Male	226	212.5	106.4	(92.9-121.2)
Female	1	1.9	nc	(nc-nc)	Female	187	214.8	87.1	(75.0-100.5)
<u>Lung and Bronchus</u>									
Male	28	30.9	90.7	(60.2-131.1)					
Female	26	30.6	84.9	(55.5-124.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Belchertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	14.5	68.8	(32.9-126.5)	Male	6	10.0	60.1	(21.9-130.8)
Female	3	4.5	nc	(nc-nc)	Female	6	7.3	82.1	(30.0-178.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	3.2	189.8	(69.3-413.1)	Male	5	3.2	155.2	(50.0-362.2)
Female	1	2.4	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	9	8.9	101.3	(46.2-192.3)
Female	71	61.2	116.0	(90.6-146.3)	Female	15	6.9	217.6	(121.7-358.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.2	nc	(nc-nc)	Male	7	8.2	85.6	(34.3-176.4)
<u>Colon / Rectum</u>					Female	5	3.0	165.3	(53.3-385.7)
Male	15	16.7	89.8	(50.2-148.1)	<u>Ovary</u>				
Female	19	13.8	138.0	(83.1-215.5)	Female	5	5.1	97.7	(31.5-227.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	4.2	nc	(nc-nc)	Male	4	5.6	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	6	4.5	132.2	(48.3-287.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	48	54.5	88.0	(64.9-116.7)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	3.7	162.1	(59.2-352.7)
Male	8	9.3	85.8	(36.9-169.1)	Female	5	1.8	271.7	(87.6-634.1)
Female	2	4.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.0	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	4.3	nc	(nc-nc)
<u>Leukemia</u>					Female	9	12.1	74.2	(33.9-140.9)
Male	6	6.2	96.8	(35.3-210.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.9	nc	(nc-nc)	Female	20	13.9	144.2	(88.1-222.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	6.0	nc	(nc-nc)	Male	164	207.5	79.0	(67.4-92.1)
Female	2	1.6	nc	(nc-nc)	Female	209	192.7	108.5	(94.3-124.2)
<u>Lung and Bronchus</u>									
Male	14	27.7	50.6	(27.6-84.9)					
Female	20	25.0	80.1	(48.9-123.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bellingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	14.4	76.5	(38.1-136.9)	Male	10	10.2	98.1	(47.0-180.5)
Female	3	5.8	nc	(nc-nc)	Female	9	8.7	102.9	(47.0-195.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.2	nc	(nc-nc)	Male	6	3.2	184.9	(67.5-402.4)
Female	4	2.8	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	19	9.1	209.3	(125.9-326.8)
Female	69	71.5	96.4	(75.0-122.1)	Female	12	8.4	142.2	(73.4-248.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.5	nc	(nc-nc)	Male	7	8.4	83.5	(33.5-172.1)
<u>Colon / Rectum</u>					Female	2	3.6	nc	(nc-nc)
Male	21	17.1	122.5	(75.8-187.3)	<u>Ovary</u>				
Female	20	16.9	118.3	(72.2-182.7)	Female	3	6.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	4.1	169.0	(67.7-348.2)	Male	6	5.5	108.9	(39.8-237.1)
Female	2	1.2	nc	(nc-nc)	Female	8	5.9	136.5	(58.8-269.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.3	nc	(nc-nc)	Male	73	52.7	138.5	(108.5-174.1)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	3.7	135.0	(43.5-315.0)
Male	8	9.5	84.3	(36.3-166.2)	Female	1	2.3	nc	(nc-nc)
Female	5	5.6	89.9	(29.0-209.9)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.5	nc	(nc-nc)
Male	1	2.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	4	4.6	nc	(nc-nc)
<u>Leukemia</u>					Female	16	13.9	114.9	(65.6-186.6)
Male	5	6.3	79.5	(25.6-185.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	4.9	nc	(nc-nc)	Female	17	16.3	104.4	(60.8-167.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	6.0	99.4	(36.3-216.4)	Male	246	207.3	118.7	(104.3-134.5)
Female	0	2.0	nc	(nc-nc)	Female	211	232.1	90.9	(79.1-104.1)
<u>Lung and Bronchus</u>									
Male	31	26.7	116.3	(79.0-165.0)					
Female	22	31.4	70.0	(43.9-106.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Belmont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	28.2	78.1	(48.9-118.3)	Male	16	17.5	91.5	(52.3-148.6)
Female	3	10.1	nc	(nc-nc)	Female	6	13.9	43.2	(15.8-94.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.2	114.7	(41.9-249.6)	Male	4	5.6	nc	(nc-nc)
Female	4	4.5	nc	(nc-nc)	Female	4	4.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	1.0	nc	(nc-nc)	Male	18	15.8	113.9	(67.5-180.0)
Female	125	111.3	112.3	(93.4-133.8)	Female	8	14.1	56.7	(24.4-111.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.8	nc	(nc-nc)	Male	5	12.6	39.7	(12.8-92.6)
<u>Colon / Rectum</u>					Female	6	5.9	101.6	(37.1-221.0)
Male	21	30.0	69.9	(43.2-106.8)	<u>Ovary</u>				
Female	23	29.8	77.3	(49.0-115.9)	Female	13	9.5	136.2	(72.5-233.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	7.0	71.7	(23.1-167.3)	Male	12	9.9	121.5	(62.7-212.2)
Female	6	2.0	307.6	(112.3-669.6)	Female	11	10.3	107.0	(53.3-191.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.9	nc	(nc-nc)	Male	76	82.7	91.9	(72.4-115.1)
Female	1	1.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	6.7	74.5	(24.0-173.9)
Male	12	15.0	79.9	(41.2-139.6)	Female	7	4.0	173.7	(69.6-358.0)
Female	3	8.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	6	3.5	173.1	(63.2-376.7)
Male	2	4.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.2	nc	(nc-nc)	Male	8	6.7	119.1	(51.3-234.6)
<u>Leukemia</u>					Female	20	20.8	96.2	(58.7-148.5)
Male	4	11.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	8.2	60.7	(19.5-141.6)	Female	26	24.5	106.3	(69.4-155.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	9.2	nc	(nc-nc)	Male	289	352.1	82.1	(72.9-92.1)
Female	3	3.3	nc	(nc-nc)	Female	334	375.3	89.0	(79.7-99.1)
<u>Lung and Bronchus</u>									
Male	33	49.0	67.4	(46.4-94.7)					
Female	35	52.3	67.0	(46.6-93.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Berkley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	6.6	nc	(nc-nc)	Male	5	4.4	114.0	(36.7-266.0)
Female	0	1.5	nc	(nc-nc)	Female	6	2.8	216.4	(79.0-471.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.4	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.9	nc	(nc-nc)
Female	27	23.3	116.1	(76.5-168.9)	Female	6	2.4	247.0	(90.2-537.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.9	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.1	nc	(nc-nc)
Male	10	7.2	138.2	(66.1-254.1)	<u>Ovary</u>				
Female	6	4.8	124.6	(45.5-271.2)	Female	0	1.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.8	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	18	22.1	81.5	(48.3-128.8)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.6	nc	(nc-nc)
Male	3	4.0	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.9	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
<u>Leukemia</u>					Female	5	5.1	97.6	(31.4-227.7)
Male	3	2.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	1.4	nc	(nc-nc)	Female	9	5.1	178.2	(81.3-338.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.5	nc	(nc-nc)	Male	73	89.3	81.8	(64.1-102.8)
Female	0	0.6	nc	(nc-nc)	Female	88	70.7	124.6	(99.9-153.5)
<u>Lung and Bronchus</u>									
Male	11	12.4	88.8	(44.3-158.9)					
Female	9	8.5	105.6	(48.2-200.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Berlin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	4.2	nc	(nc-nc)	Male	6	2.5	238.1	(87.0-518.3)
Female	2	1.2	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
Female	12	13.8	87.2	(45.0-152.3)	Female	1	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.7	nc	(nc-nc)
Male	3	4.4	nc	(nc-nc)	<u>Ovary</u>				
Female	2	3.4	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	1.0	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.3	nc	(nc-nc)	Male	10	12.3	81.3	(38.9-149.6)
Female	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.0	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.5	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	4	2.3	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.9	nc	(nc-nc)	Female	5	3.1	160.5	(51.7-374.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.3	nc	(nc-nc)	Male	55	51.4	106.9	(80.5-139.2)
Female	0	0.4	nc	(nc-nc)	Female	39	44.6	87.4	(62.1-119.4)
<u>Lung and Bronchus</u>									
Male	8	7.2	111.7	(48.1-220.2)					
Female	5	6.3	79.4	(25.6-185.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bernardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	3.7	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	4	1.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	1.9	257.8	(83.1-601.7)
Female	10	12.1	82.5	(39.5-151.7)	Female	3	1.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.6	nc	(nc-nc)
Male	2	3.8	nc	(nc-nc)	<u>Ovary</u>				
Female	2	3.0	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	0.9	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	14	10.6	131.9	(72.1-221.3)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	0.9	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.9	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.8	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.1	nc	(nc-nc)	Male	40	43.9	91.1	(65.1-124.0)
Female	1	0.4	nc	(nc-nc)	Female	36	40.0	89.9	(63.0-124.5)
<u>Lung and Bronchus</u>									
Male	6	6.3	95.5	(34.9-207.9)					
Female	4	5.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Beverly

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	52	42.5	122.3	(91.3-160.4)	Male	40	26.8	149.1	(106.5-203.0)
Female	22	16.4	134.3	(84.1-203.3)	Female	31	22.8	136.0	(92.4-193.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	13	8.1	159.6	(84.9-272.9)	Male	10	8.6	116.9	(56.0-215.0)
Female	6	7.2	83.1	(30.4-181.0)	Female	6	7.5	80.2	(29.3-174.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	1.4	nc	(nc-nc)	Male	24	24.0	99.8	(63.9-148.5)
Female	180	180.9	99.5	(85.5-115.2)	Female	19	23.0	82.6	(49.7-128.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	6.0	83.3	(26.8-194.3)	Male	29	20.0	145.1	(97.2-208.5)
<u>Colon / Rectum</u>					Female	12	9.7	123.1	(63.5-215.1)
Male	33	45.7	72.2	(49.7-101.4)	<u>Ovary</u>				
Female	49	48.1	101.8	(75.3-134.6)	Female	15	15.7	95.3	(53.3-157.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	10.8	110.8	(57.2-193.5)	Male	17	15.1	112.8	(65.7-180.6)
Female	5	3.3	153.8	(49.6-358.9)	Female	17	16.9	100.5	(58.5-161.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	3.3	nc	(nc-nc)	Male	158	130.8	120.8	(102.7-141.1)
Female	0	3.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	10.2	nc	(nc-nc)
Male	28	23.3	120.3	(79.9-173.8)	Female	4	6.6	nc	(nc-nc)
Female	18	14.3	126.0	(74.6-199.1)	<u>Testis</u>				
<u>Larynx</u>					Male	8	5.8	136.9	(58.9-269.7)
Male	9	6.2	144.7	(66.1-274.8)	<u>Thyroid</u>				
Female	3	2.1	nc	(nc-nc)	Male	12	10.6	113.2	(58.4-197.8)
<u>Leukemia</u>					Female	30	33.9	88.4	(59.7-126.2)
Male	27	17.2	156.7	(103.2-228.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	20	13.3	150.5	(91.9-232.4)	Female	38	40.7	93.4	(66.1-128.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	14	14.6	95.7	(52.3-160.5)	Male	636	544.3	116.8	(107.9-126.3)
Female	9	5.4	168.1	(76.7-319.2)	Female	653	611.7	106.7	(98.7-115.3)
<u>Lung and Bronchus</u>									
Male	85	74.7	113.7	(90.8-140.6)					
Female	89	85.1	104.6	(84.0-128.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Billerica

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	56	40.2	139.2	(105.2-180.8)	Male	28	27.2	102.9	(68.3-148.7)
Female	15	13.6	110.5	(61.8-182.2)	Female	23	20.7	111.2	(70.5-166.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	13	8.6	151.7	(80.7-259.5)	Male	11	8.7	125.8	(62.7-225.1)
Female	5	6.7	75.2	(24.2-175.5)	Female	6	6.4	94.2	(34.4-205.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.5	nc	(nc-nc)	Male	23	24.4	94.1	(59.6-141.2)
Female	177	168.0	105.3	(90.4-122.1)	Female	19	19.9	95.5	(57.5-149.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	5.9	84.3	(27.2-196.7)	Male	18	21.6	83.4	(49.4-131.9)
<u>Colon / Rectum</u>					Female	10	8.5	117.6	(56.3-216.3)
Male	38	46.4	81.9	(58.0-112.5)	<u>Ovary</u>				
Female	57	40.6	140.5	(106.4-182.1)	Female	12	14.1	84.8	(43.8-148.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	11.1	90.2	(43.2-165.9)	Male	13	14.9	87.5	(46.5-149.6)
Female	2	2.7	nc	(nc-nc)	Female	9	13.9	64.9	(29.6-123.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	3.5	171.1	(62.5-372.5)	Male	130	139.4	93.2	(77.9-110.7)
Female	1	2.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	9	10.1	89.4	(40.8-169.8)
Male	29	24.9	116.3	(77.9-167.1)	Female	8	5.5	146.3	(63.0-288.3)
Female	8	12.9	61.9	(26.6-121.9)	<u>Testis</u>				
<u>Larynx</u>					Male	5	6.6	76.0	(24.5-177.4)
Male	2	6.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.8	nc	(nc-nc)	Male	15	12.0	125.0	(69.9-206.1)
<u>Leukemia</u>					Female	35	33.2	105.4	(73.4-146.6)
Male	28	17.0	164.3	(109.1-237.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	19	11.5	164.6	(99.1-257.1)	Female	39	37.1	105.1	(74.7-143.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	12	15.4	78.1	(40.3-136.5)	Male	567	555.5	102.1	(93.8-110.8)
Female	2	4.6	nc	(nc-nc)	Female	593	545.6	108.7	(100.1-117.8)
<u>Lung and Bronchus</u>									
Male	79	72.7	108.7	(86.0-135.5)					
Female	106	73.4	144.3	(118.2-174.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Blackstone

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	7.2	153.1	(76.3-274.0)	Male	6	5.2	115.4	(42.2-251.3)
Female	4	3.0	nc	(nc-nc)	Female	6	4.8	124.1	(45.3-270.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.7	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.3	nc	(nc-nc)	Male	4	4.6	nc	(nc-nc)
Female	28	39.7	70.5	(46.8-101.9)	Female	3	4.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.4	nc	(nc-nc)	Male	2	4.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	2.0	nc	(nc-nc)
Male	9	8.8	102.2	(46.7-194.1)	<u>Ovary</u>				
Female	7	9.6	72.8	(29.2-150.0)	Female	5	3.3	149.4	(48.2-348.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	2.1	286.9	(104.8-624.5)	Male	1	2.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.7	nc	(nc-nc)	Male	26	26.3	98.8	(64.5-144.8)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.9	nc	(nc-nc)
Male	2	4.9	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	4	2.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.3	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
<u>Leukemia</u>					Female	3	7.9	nc	(nc-nc)
Male	4	3.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	2.6	229.8	(83.9-500.2)	Female	7	8.7	80.1	(32.1-165.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.1	nc	(nc-nc)	Male	117	105.0	111.5	(92.2-133.6)
Female	0	1.0	nc	(nc-nc)	Female	111	126.7	87.6	(72.1-105.5)
<u>Lung and Bronchus</u>									
Male	18	13.3	135.5	(80.2-214.1)					
Female	11	16.0	68.7	(34.2-122.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Blandford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.3	nc	(nc-nc)	Male	3	0.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	4	5.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.2	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<u>Ovary</u>				
Female	2	1.2	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	6	5.4	112.1	(40.9-244.0)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.3	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.0	nc	(nc-nc)
Male	2	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	19	19.3	98.6	(59.3-154.0)
Female	0	0.1	nc	(nc-nc)	Female	17	17.0	99.7	(58.1-159.7)
<u>Lung and Bronchus</u>									
Male	2	2.4	nc	(nc-nc)					
Female	2	2.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bolton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	4.8	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	3.0	168.7	(54.4-393.7)
Female	28	19.4	144.6	(96.1-209.0)	Female	1	2.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.9	nc	(nc-nc)
Male	5	5.7	87.4	(28.2-203.8)	<u>Ovary</u>				
Female	5	3.9	128.8	(41.5-300.6)	Female	3	1.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.3	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	21	16.6	126.5	(78.3-193.4)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.2	nc	(nc-nc)
Male	3	3.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.7	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	4	4.1	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.1	nc	(nc-nc)	Female	8	4.3	186.7	(80.4-367.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.9	nc	(nc-nc)	Male	58	67.0	86.6	(65.7-111.9)
Female	0	0.5	nc	(nc-nc)	Female	60	57.8	103.9	(79.3-133.7)
<u>Lung and Bronchus</u>									
Male	2	8.8	nc	(nc-nc)					
Female	5	7.0	71.8	(23.1-167.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	338	462.6	73.1	(65.5-81.3)	Male	249	315.3	79.0	(69.5-89.4)
Female	143	181.6	78.8	(66.4-92.8)	Female	205	290.5	70.6	(61.2-80.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	74	109.4	67.6	(53.1-84.9)	Male	107	96.7	110.7	(90.7-133.8)
Female	71	93.2	76.1	(59.5-96.1)	Female	124	83.6	148.3	(123.3-176.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	15	16.4	91.7	(51.3-151.2)	Male	265	285.3	92.9	(82.0-104.8)
Female	1909	2115.3	90.2	(86.2-94.4)	Female	252	267.3	94.3	(83.0-106.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	88	83.2	105.8	(84.8-130.3)	Male	265	232.9	113.8	(100.5-128.3)
<u>Colon / Rectum</u>					Female	107	111.7	95.8	(78.5-115.7)
Male	557	519.1	107.3	(98.6-116.6)	<u>Ovary</u>				
Female	581	542.1	107.2	(98.6-116.3)	Female	187	185.7	100.7	(86.8-116.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	122	120.9	100.9	(83.8-120.5)	Male	163	167.1	97.5	(83.1-113.7)
Female	32	35.6	89.8	(61.4-126.7)	Female	176	184.2	95.5	(81.9-110.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	58	58.4	99.4	(75.4-128.5)	Male	1787	1465.8	121.9	(116.3-127.7)
Female	32	51.5	62.2	(42.5-87.8)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	173	114.2	151.5	(129.8-175.9)
Male	235	274.4	85.6	(75.0-97.3)	Female	118	73.9	159.8	(132.2-191.3)
Female	170	167.4	101.6	(86.9-118.0)	<u>Testis</u>				
<u>Larynx</u>					Male	102	119.3	85.5	(69.7-103.8)
Male	90	70.3	128.0	(102.9-157.3)	<u>Thyroid</u>				
Female	17	22.6	75.3	(43.9-120.6)	Male	149	145.5	102.4	(86.6-120.2)
<u>Leukemia</u>					Female	451	490.0	92.0	(83.7-100.9)
Male	174	206.6	84.2	(72.2-97.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	145	162.3	89.3	(75.4-105.1)	Female	435	464.2	93.7	(85.1-102.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	257	165.8	155.0	(136.6-175.1)	Male	6570	6276.4	104.7	(102.2-107.2)
Female	95	60.9	155.9	(126.1-190.6)	Female	6789	7191.1	94.4	(92.2-96.7)
<u>Lung and Bronchus</u>									
Male	874	820.0	106.6	(99.6-113.9)					
Female	875	953.2	91.8	(85.8-98.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bourne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	38	29.7	127.9	(90.5-175.6)	Male	25	17.6	142.1	(91.9-209.8)
Female	9	10.9	82.7	(37.7-156.9)	Female	14	13.0	108.0	(59.0-181.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	4.9	nc	(nc-nc)	Male	9	5.8	154.4	(70.4-293.1)
Female	2	4.1	nc	(nc-nc)	Female	4	4.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	13	15.8	82.2	(43.7-140.5)
Female	87	107.0	81.3	(65.1-100.3)	Female	8	14.4	55.5	(23.9-109.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.1	nc	(nc-nc)	Male	16	12.5	128.5	(73.4-208.6)
<u>Colon / Rectum</u>					Female	6	6.0	100.7	(36.8-219.2)
Male	26	30.0	86.5	(56.5-126.8)	<u>Ovary</u>				
Female	28	30.8	91.0	(60.5-131.5)	Female	12	9.4	128.2	(66.2-224.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	7.3	165.0	(85.2-288.2)	Male	8	10.2	78.2	(33.7-154.0)
Female	4	2.1	nc	(nc-nc)	Female	9	11.1	81.1	(37.0-154.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.7	nc	(nc-nc)	Male	85	86.2	98.6	(78.8-122.0)
Female	0	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	6.9	101.3	(40.6-208.7)
Male	10	14.8	67.7	(32.4-124.5)	Female	5	4.2	118.8	(38.3-277.3)
Female	8	8.8	91.0	(39.2-179.3)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.7	nc	(nc-nc)
Male	10	4.2	237.1	(113.5-436.0)	<u>Thyroid</u>				
Female	4	1.3	nc	(nc-nc)	Male	4	6.0	nc	(nc-nc)
<u>Leukemia</u>					Female	21	16.5	127.0	(78.6-194.1)
Male	5	11.2	44.7	(14.4-104.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	8.1	61.5	(19.8-143.5)	Female	22	24.2	91.0	(57.0-137.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	9.5	73.4	(29.4-151.3)	Male	369	359.9	102.5	(92.3-113.6)
Female	2	3.4	nc	(nc-nc)	Female	335	372.3	90.0	(80.6-100.2)
<u>Lung and Bronchus</u>									
Male	58	52.1	111.3	(84.5-143.9)					
Female	61	56.1	108.7	(83.1-139.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	4.7	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
Female	22	20.4	107.6	(67.4-163.0)	Female	2	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.0	nc	(nc-nc)
Male	5	5.7	87.8	(28.3-204.9)	<u>Ovary</u>				
Female	6	4.3	138.1	(50.4-300.5)	Female	0	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.4	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	3	1.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	15	18.2	82.2	(46.0-135.6)
Female	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.2	nc	(nc-nc)
Male	2	3.2	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.7	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	4	4.2	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	1.2	nc	(nc-nc)	Female	4	4.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.0	nc	(nc-nc)	Male	61	69.0	88.4	(67.6-113.5)
Female	0	0.5	nc	(nc-nc)	Female	68	62.5	108.8	(84.5-137.9)
<u>Lung and Bronchus</u>									
Male	7	8.7	80.5	(32.3-165.9)					
Female	9	7.8	116.0	(52.9-220.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	9.4	63.6	(23.2-138.4)	Male	13	6.3	206.6	(109.9-353.3)
Female	1	3.0	nc	(nc-nc)	Female	9	4.3	206.9	(94.4-392.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.9	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	3	1.4	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.6	89.3	(28.8-208.5)
Female	43	37.0	116.3	(84.1-156.6)	Female	3	4.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.2	nc	(nc-nc)	Male	2	5.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.9	nc	(nc-nc)
Male	2	10.5	nc	(nc-nc)	<u>Ovary</u>				
Female	7	8.8	79.3	(31.8-163.3)	Female	2	3.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	2.6	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	4	3.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	43	33.3	129.0	(93.3-173.8)
Female	2	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.4	nc	(nc-nc)
Male	3	5.7	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.1	nc	(nc-nc)
Male	2	1.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
<u>Leukemia</u>					Female	9	6.6	137.3	(62.6-260.6)
Male	5	3.8	130.0	(41.9-303.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.5	nc	(nc-nc)	Female	6	8.5	70.6	(25.8-153.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	3.7	nc	(nc-nc)	Male	109	129.3	84.3	(69.2-101.7)
Female	0	1.1	nc	(nc-nc)	Female	119	119.6	99.5	(82.4-119.1)
<u>Lung and Bronchus</u>									
Male	9	17.6	51.1	(23.3-96.9)					
Female	10	16.6	60.3	(28.9-110.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	5.4	110.7	(40.4-240.9)	Male	3	3.4	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	8	2.3	353.6	(152.3-696.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	4	1.1	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
Female	27	18.5	146.0	(96.2-212.5)	Female	0	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.0	nc	(nc-nc)
Male	3	6.0	nc	(nc-nc)	<u>Ovary</u>				
Female	6	4.8	125.9	(46.0-274.1)	Female	2	1.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.4	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	15	16.6	90.5	(50.6-149.2)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.3	nc	(nc-nc)
Male	2	3.0	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.6	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
<u>Leukemia</u>					Female	4	3.5	nc	(nc-nc)
Male	1	2.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.3	nc	(nc-nc)	Female	3	4.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.9	nc	(nc-nc)	Male	55	69.5	79.1	(59.6-103.0)
Female	0	0.5	nc	(nc-nc)	Female	68	60.7	112.0	(87.0-142.0)
<u>Lung and Bronchus</u>									
Male	2	9.5	nc	(nc-nc)					
Female	5	8.1	62.0	(20.0-144.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	46	39.7	115.9	(84.9-154.6)	Male	28	24.9	112.4	(74.7-162.4)
Female	22	16.3	134.8	(84.4-204.1)	Female	22	21.1	104.4	(65.4-158.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	7.5	nc	(nc-nc)	Male	6	7.9	75.7	(27.6-164.8)
Female	6	6.7	89.4	(32.6-194.5)	Female	3	7.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.3	nc	(nc-nc)	Male	23	22.4	102.8	(65.2-154.3)
Female	195	165.9	117.5	(101.6-135.2)	Female	19	22.1	86.0	(51.8-134.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	5.5	128.2	(51.3-264.1)	Male	21	18.1	115.8	(71.7-177.0)
<u>Colon / Rectum</u>					Female	11	9.1	120.2	(59.9-215.1)
Male	52	42.5	122.2	(91.3-160.3)	<u>Ovary</u>				
Female	60	47.8	125.4	(95.7-161.5)	Female	16	14.5	110.4	(63.0-179.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	9.9	131.4	(69.9-224.7)	Male	15	14.0	107.4	(60.0-177.1)
Female	3	3.1	nc	(nc-nc)	Female	19	16.8	113.1	(68.0-176.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	2.9	170.0	(54.8-396.8)	Male	131	116.3	112.6	(94.2-133.7)
Female	5	2.5	200.6	(64.6-468.1)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	9.5	84.3	(36.3-166.2)
Male	22	21.3	103.4	(64.8-156.5)	Female	6	6.6	91.5	(33.4-199.2)
Female	13	13.5	96.6	(51.4-165.2)	<u>Testis</u>				
<u>Larynx</u>					Male	6	5.2	114.6	(41.9-249.5)
Male	3	5.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	6	1.9	319.5	(116.7-695.5)	Male	8	9.7	82.7	(35.6-163.0)
<u>Leukemia</u>					Female	38	29.7	128.0	(90.6-175.7)
Male	13	16.1	80.6	(42.9-137.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	19	13.0	146.0	(87.9-228.0)	Female	42	36.2	116.1	(83.7-157.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	13	13.4	97.2	(51.7-166.3)	Male	517	499.2	103.6	(94.8-112.9)
Female	5	5.1	97.5	(31.4-227.6)	Female	655	576.4	113.6	(105.1-122.7)
<u>Lung and Bronchus</u>									
Male	58	69.0	84.0	(63.8-108.6)					
Female	89	82.3	108.2	(86.9-133.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brewster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	18.5	97.4	(57.7-153.9)	Male	17	10.7	159.2	(92.7-255.0)
Female	6	7.0	86.2	(31.5-187.7)	Female	10	7.8	128.3	(61.4-235.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.8	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)	Female	1	3.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.6	nc	(nc-nc)	Male	13	9.5	137.4	(73.1-234.9)
Female	93	66.5	139.8	(112.9-171.3)	Female	16	9.0	177.5	(101.4-288.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.7	nc	(nc-nc)	Male	6	7.5	80.3	(29.3-174.7)
<u>Colon / Rectum</u>					Female	3	3.7	nc	(nc-nc)
Male	12	18.1	66.4	(34.3-116.0)	<u>Ovary</u>				
Female	18	18.9	95.5	(56.5-150.9)	Female	6	5.8	102.7	(37.5-223.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	4.5	nc	(nc-nc)	Male	5	6.3	80.0	(25.8-186.6)
Female	1	1.4	nc	(nc-nc)	Female	3	7.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	61	54.4	112.2	(85.8-144.1)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	4.2	nc	(nc-nc)
Male	4	9.0	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
Female	6	5.6	107.8	(39.4-234.6)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.1	nc	(nc-nc)
Male	2	2.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	0	3.3	nc	(nc-nc)
<u>Leukemia</u>					Female	7	9.0	77.7	(31.1-160.0)
Male	9	6.6	135.7	(61.9-257.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	5.0	140.4	(56.3-289.3)	Female	13	15.7	82.8	(44.0-141.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	5.8	103.2	(37.7-224.6)	Male	211	220.9	95.5	(83.1-109.3)
Female	0	2.2	nc	(nc-nc)	Female	237	232.0	102.1	(89.5-116.0)
<u>Lung and Bronchus</u>									
Male	33	33.3	99.2	(68.3-139.4)					
Female	25	36.5	68.4	(44.3-101.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	25	26.3	95.2	(61.6-140.5)	Male	13	17.2	75.5	(40.2-129.1)
Female	13	7.6	172.0	(91.5-294.2)	Female	19	11.6	164.1	(98.8-256.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	5.6	126.1	(50.5-259.8)	Male	3	5.5	nc	(nc-nc)
Female	7	3.8	184.9	(74.1-381.0)	Female	2	3.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	8	15.8	50.7	(21.8-100.0)
Female	79	90.7	87.1	(69.0-108.5)	Female	12	11.1	107.7	(55.6-188.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	3.1	nc	(nc-nc)	Male	14	13.2	105.8	(57.8-177.6)
<u>Colon / Rectum</u>					Female	5	4.7	105.3	(33.9-245.7)
Male	29	29.6	97.9	(65.5-140.6)	<u>Ovary</u>				
Female	17	22.4	75.8	(44.1-121.4)	Female	9	7.9	114.3	(52.2-217.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	6.9	nc	(nc-nc)	Male	10	9.5	105.0	(50.3-193.0)
Female	0	1.5	nc	(nc-nc)	Female	8	7.7	103.8	(44.7-204.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.5	nc	(nc-nc)	Male	79	84.1	94.0	(74.4-117.1)
Female	0	1.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	6.4	77.8	(25.1-181.6)
Male	10	15.4	64.9	(31.1-119.4)	Female	3	3.1	nc	(nc-nc)
Female	8	7.0	113.9	(49.0-224.4)	<u>Testis</u>				
<u>Larynx</u>					Male	0	4.6	nc	(nc-nc)
Male	3	4.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.0	nc	(nc-nc)	Male	11	7.4	148.3	(73.9-265.3)
<u>Leukemia</u>					Female	30	18.5	162.4	(109.5-231.8)
Male	6	11.2	53.4	(19.5-116.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	6.5	nc	(nc-nc)	Female	19	20.6	92.4	(55.6-144.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	15	9.4	160.3	(89.6-264.4)	Male	318	349.7	90.9	(81.2-101.5)
Female	3	2.6	nc	(nc-nc)	Female	295	300.4	98.2	(87.3-110.1)
<u>Lung and Bronchus</u>									
Male	45	45.9	98.0	(71.5-131.2)					
Female	33	40.1	82.3	(56.6-115.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brimfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	3.7	nc	(nc-nc)	Male	0	2.7	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
Female	18	17.7	101.7	(60.3-160.8)	Female	4	2.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.9	nc	(nc-nc)
Male	3	4.4	nc	(nc-nc)	<u>Ovary</u>				
Female	1	4.1	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.1	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.3	nc	(nc-nc)	Male	9	14.8	60.6	(27.7-115.1)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.0	nc	(nc-nc)
Male	7	2.5	281.1	(112.6-579.2)	Female	1	0.5	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.5	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	2	3.2	nc	(nc-nc)
Male	3	1.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.1	nc	(nc-nc)	Female	2	4.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.6	nc	(nc-nc)	Male	51	55.0	92.7	(69.1-121.9)
Female	0	0.5	nc	(nc-nc)	Female	38	56.0	67.8	(48.0-93.1)
<u>Lung and Bronchus</u>									
Male	7	7.2	97.0	(38.9-199.9)					
Female	4	7.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brockton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	80	83.9	95.3	(75.6-118.7)	Male	24	54.8	43.8	(28.0-65.2)
Female	36	31.8	113.2	(79.3-156.8)	Female	30	46.4	64.7	(43.7-92.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	17	17.9	94.8	(55.2-151.7)	Male	11	17.5	62.9	(31.4-112.6)
Female	20	15.3	130.4	(79.6-201.4)	Female	18	14.6	123.5	(73.2-195.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	2.9	nc	(nc-nc)	Male	48	49.5	96.9	(71.4-128.5)
Female	317	366.7	86.5	(77.2-96.5)	Female	38	45.5	83.5	(59.1-114.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	25	13.0	191.8	(124.1-283.2)	Male	38	41.7	91.2	(64.5-125.1)
<u>Colon / Rectum</u>					Female	23	19.2	119.7	(75.9-179.6)
Male	113	92.8	121.7	(100.3-146.4)	<u>Ovary</u>				
Female	96	94.3	101.8	(82.5-124.4)	Female	44	31.5	139.6	(101.4-187.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	21	22.1	95.2	(58.9-145.6)	Male	35	30.4	115.2	(80.2-160.2)
Female	6	6.3	95.8	(35.0-208.5)	Female	47	32.3	145.5	(106.9-193.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	7.3	82.1	(30.0-178.8)	Male	260	271.1	95.9	(84.6-108.3)
Female	7	6.3	110.5	(44.3-227.6)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	31	20.5	151.0	(102.6-214.3)
Male	60	48.7	123.2	(94.0-158.6)	Female	12	12.8	94.1	(48.6-164.3)
Female	23	29.1	79.1	(50.1-118.7)	<u>Testis</u>				
<u>Larynx</u>					Male	12	13.3	90.0	(46.5-157.3)
Male	18	12.9	139.9	(82.9-221.1)	<u>Thyroid</u>				
Female	4	4.0	nc	(nc-nc)	Male	26	22.9	113.6	(74.2-166.4)
<u>Leukemia</u>					Female	86	73.0	117.8	(94.2-145.5)
Male	30	36.0	83.3	(56.2-118.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	17	27.3	62.4	(36.3-99.8)	Female	79	80.7	97.9	(77.5-122.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	46	30.5	151.1	(110.6-201.5)	Male	1161	1116.0	104.0	(98.1-110.2)
Female	13	10.5	123.6	(65.8-211.4)	Female	1251	1227.0	102.0	(96.4-107.8)
<u>Lung and Bronchus</u>									
Male	177	149.3	118.5	(101.7-137.3)					
Female	195	168.4	115.8	(100.1-133.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	4.3	116.9	(37.7-272.8)	Male	1	2.8	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
Female	14	15.3	91.6	(50.0-153.7)	Female	5	2.0	252.6	(81.4-589.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	0.8	nc	(nc-nc)
Male	4	4.5	nc	(nc-nc)	<u>Ovary</u>				
Female	5	4.1	123.2	(39.7-287.5)	Female	1	1.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.2	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	11	14.7	75.1	(37.4-134.3)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.0	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	4	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	4	2.7	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.1	nc	(nc-nc)	Female	4	3.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.6	nc	(nc-nc)	Male	46	57.0	80.7	(59.0-107.6)
Female	2	0.5	nc	(nc-nc)	Female	63	52.0	121.2	(93.2-155.1)
<u>Lung and Bronchus</u>									
Male	8	7.9	101.5	(43.7-199.9)					
Female	13	7.6	171.9	(91.5-294.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brookline

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	50	53.0	94.4	(70.0-124.4)	Male	49	34.0	144.3	(106.8-190.8)
Female	18	23.2	77.7	(46.0-122.8)	Female	37	32.9	112.5	(79.2-155.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	10.7	84.5	(38.5-160.3)	Male	12	10.8	110.9	(57.2-193.8)
Female	14	10.5	133.0	(72.7-223.2)	Female	8	10.5	76.4	(32.9-150.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.8	nc	(nc-nc)	Male	35	30.5	114.6	(79.8-159.4)
Female	228	247.9	92.0	(80.4-104.7)	Female	38	32.5	117.0	(82.8-160.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	8.8	nc	(nc-nc)	Male	28	24.9	112.6	(74.8-162.8)
<u>Colon / Rectum</u>					Female	7	13.5	51.7	(20.7-106.6)
Male	33	56.2	58.8	(40.4-82.5)	<u>Ovary</u>				
Female	41	67.0	61.2	(43.9-83.1)	Female	32	21.9	146.3	(100.1-206.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	13.7	36.4	(11.7-85.1)	Male	23	18.9	122.0	(77.3-183.0)
Female	2	4.6	nc	(nc-nc)	Female	27	23.8	113.4	(74.7-165.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	7	4.7	150.1	(60.1-309.2)	Male	159	170.4	93.3	(79.4-109.0)
Female	5	5.0	99.6	(32.1-232.4)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	11	12.7	86.3	(43.0-154.4)
Male	36	29.6	121.4	(85.0-168.1)	Female	6	9.1	65.8	(24.0-143.3)
Female	15	20.1	74.8	(41.8-123.3)	<u>Testis</u>				
<u>Larynx</u>					Male	11	8.9	123.3	(61.5-220.6)
Male	3	8.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	2.8	nc	(nc-nc)	Male	14	13.9	101.1	(55.2-169.6)
<u>Leukemia</u>					Female	50	50.5	99.1	(73.6-130.7)
Male	30	21.7	138.1	(93.1-197.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	29	19.4	149.9	(100.3-215.2)	Female	45	55.8	80.6	(58.8-107.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	18.2	54.8	(26.2-100.8)	Male	629	692.6	90.8	(83.9-98.2)
Female	5	7.5	66.8	(21.5-155.8)	Female	759	857.8	88.5	(82.3-95.0)
<u>Lung and Bronchus</u>									
Male	57	95.2	59.9	(45.3-77.6)					
Female	77	120.4	64.0	(50.5-80.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Buckland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.3	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	3	1.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	7	11.3	61.8	(24.8-127.4)	Female	0	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.6	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	<u>Ovary</u>				
Female	4	2.9	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	7.8	90.1	(36.1-185.7)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.8	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.8	nc	(nc-nc)	Female	0	2.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.8	nc	(nc-nc)	Male	25	30.5	82.1	(53.1-121.2)
Female	0	0.4	nc	(nc-nc)	Female	31	37.9	81.7	(55.5-116.0)
<u>Lung and Bronchus</u>									
Male	1	4.1	nc	(nc-nc)					
Female	8	5.7	140.9	(60.7-277.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Burlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	31.5	63.4	(38.7-98.0)	Male	18	19.2	93.5	(55.4-147.8)
Female	6	10.6	56.4	(20.6-122.8)	Female	13	14.1	91.9	(48.9-157.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	5.6	142.3	(61.3-280.5)	Male	7	6.1	114.0	(45.7-235.0)
Female	5	4.5	110.4	(35.6-257.6)	Female	4	4.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	23	17.2	134.1	(85.0-201.2)
Female	132	116.4	113.4	(94.9-134.5)	Female	14	14.6	96.0	(52.5-161.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.8	nc	(nc-nc)	Male	10	13.3	75.0	(35.9-138.0)
<u>Colon / Rectum</u>					Female	5	6.1	81.8	(26.4-190.8)
Male	26	32.7	79.6	(52.0-116.6)	<u>Ovary</u>				
Female	26	30.5	85.4	(55.7-125.1)	Female	8	9.9	80.8	(34.8-159.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	7.6	nc	(nc-nc)	Male	18	10.8	166.8	(98.8-263.6)
Female	0	2.1	nc	(nc-nc)	Female	7	10.7	65.3	(26.2-134.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.2	nc	(nc-nc)	Male	89	85.5	104.0	(83.6-128.0)
Female	2	1.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	7.4	nc	(nc-nc)
Male	17	15.9	106.7	(62.1-170.9)	Female	3	4.1	nc	(nc-nc)
Female	5	9.3	53.7	(17.3-125.2)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.9	nc	(nc-nc)
Male	2	4.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.3	nc	(nc-nc)	Male	10	7.1	141.0	(67.5-259.4)
<u>Leukemia</u>					Female	28	20.9	134.0	(89.0-193.6)
Male	16	12.3	129.6	(74.0-210.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	8.4	59.7	(19.2-139.3)	Female	32	25.5	125.4	(85.8-177.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	9.9	100.8	(48.3-185.4)	Male	366	381.0	96.1	(86.5-106.4)
Female	3	3.4	nc	(nc-nc)	Female	383	391.3	97.9	(88.3-108.2)
<u>Lung and Bronchus</u>									
Male	41	54.8	74.8	(53.7-101.5)					
Female	55	57.2	96.2	(72.5-125.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Cambridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	47	74.3	63.3	(46.5-84.1)	Male	51	50.5	101.0	(75.2-132.8)
Female	13	29.9	43.5	(23.1-74.3)	Female	46	48.0	95.9	(70.2-127.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	25	17.9	139.6	(90.3-206.1)	Male	17	15.2	111.8	(65.1-179.0)
Female	14	15.1	92.5	(50.5-155.2)	Female	10	13.7	72.9	(34.9-134.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	2.6	nc	(nc-nc)	Male	42	45.7	91.8	(66.2-124.1)
Female	318	339.2	93.7	(83.7-104.6)	Female	45	43.8	102.6	(74.9-137.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	13.6	51.6	(20.7-106.3)	Male	42	35.9	117.0	(84.3-158.2)
<u>Colon / Rectum</u>					Female	16	18.2	87.9	(50.2-142.7)
Male	67	81.0	82.7	(64.1-105.1)	<u>Ovary</u>				
Female	67	87.1	76.9	(59.6-97.7)	Female	29	30.2	96.0	(64.3-137.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	16	19.1	83.8	(47.9-136.1)	Male	32	26.4	121.1	(82.8-171.0)
Female	5	6.0	83.8	(27.0-195.6)	Female	25	30.4	82.4	(53.3-121.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	8	10.7	74.8	(32.2-147.4)	Male	253	231.9	109.1	(96.1-123.4)
Female	4	9.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	12	18.1	66.3	(34.2-115.8)
Male	31	43.0	72.1	(49.0-102.4)	Female	8	11.9	67.0	(28.9-132.0)
Female	17	27.1	62.7	(36.5-100.4)	<u>Testis</u>				
<u>Larynx</u>					Male	19	22.5	84.4	(50.8-131.8)
Male	4	11.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	3.7	nc	(nc-nc)	Male	27	23.6	114.4	(75.3-166.4)
<u>Leukemia</u>					Female	85	81.0	104.9	(83.8-129.7)
Male	28	33.2	84.3	(56.0-121.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	16	26.4	60.5	(34.6-98.3)	Female	65	75.8	85.8	(66.2-109.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	16	25.5	62.8	(35.9-102.0)	Male	914	1001.6	91.3	(85.4-97.4)
Female	10	10.0	100.0	(47.9-184.0)	Female	981	1170.7	83.8	(78.6-89.2)
<u>Lung and Bronchus</u>									
Male	109	131.9	82.6	(67.9-99.7)					
Female	107	157.5	67.9	(55.7-82.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Canton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	26.4	87.2	(55.2-130.8)	Male	20	16.4	122.2	(74.6-188.8)
Female	7	9.8	71.2	(28.5-146.7)	Female	14	12.8	109.0	(59.5-182.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	4.8	103.7	(33.4-242.1)	Male	10	5.3	189.0	(90.5-347.5)
Female	6	4.1	145.0	(52.9-315.5)	Female	5	4.4	113.7	(36.7-265.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.9	nc	(nc-nc)	Male	12	14.7	81.7	(42.2-142.7)
Female	106	104.3	101.6	(83.2-122.9)	Female	17	13.4	126.9	(73.9-203.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	3.4	nc	(nc-nc)	Male	11	11.8	93.5	(46.6-167.3)
<u>Colon / Rectum</u>					Female	8	5.6	143.4	(61.8-282.7)
Male	35	27.7	126.5	(88.1-175.9)	<u>Ovary</u>				
Female	30	28.3	105.9	(71.4-151.2)	Female	6	8.9	67.1	(24.5-146.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	6.6	136.7	(62.4-259.5)	Male	8	9.3	86.1	(37.1-169.6)
Female	1	1.9	nc	(nc-nc)	Female	9	10.0	89.6	(40.9-170.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.8	nc	(nc-nc)	Male	85	78.3	108.5	(86.7-134.2)
Female	1	1.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	6.3	95.6	(34.9-208.0)
Male	9	14.0	64.1	(29.3-121.8)	Female	3	3.8	nc	(nc-nc)
Female	5	8.4	59.4	(19.1-138.5)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.0	nc	(nc-nc)
Male	2	3.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.2	nc	(nc-nc)	Male	11	6.1	179.0	(89.2-320.3)
<u>Leukemia</u>					Female	35	18.4	190.1	(132.4-264.3)
Male	18	10.4	172.4	(102.1-272.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	7.8	64.2	(20.7-149.8)	Female	27	22.9	118.0	(77.8-171.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	8.7	nc	(nc-nc)	Male	357	330.0	108.2	(97.2-120.0)
Female	0	3.1	nc	(nc-nc)	Female	373	355.1	105.0	(94.6-116.3)
<u>Lung and Bronchus</u>									
Male	51	46.6	109.3	(81.4-143.8)					
Female	52	51.5	100.9	(75.4-132.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Carlisle

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	6.4	nc	(nc-nc)	Male	7	4.1	169.5	(67.9-349.2)
Female	1	2.1	nc	(nc-nc)	Female	7	2.9	239.9	(96.1-494.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.2	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
Female	21	25.2	83.2	(51.5-127.2)	Female	5	3.0	164.7	(53.1-384.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	0	3.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.3	nc	(nc-nc)
Male	4	7.0	nc	(nc-nc)	<u>Ovary</u>				
Female	3	6.4	nc	(nc-nc)	Female	4	2.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.8	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	24	22.6	106.4	(68.1-158.3)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.6	nc	(nc-nc)
Male	1	3.8	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	0	2.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.5	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
<u>Leukemia</u>					Female	5	4.2	119.8	(38.6-279.5)
Male	5	2.5	198.3	(63.9-462.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.7	nc	(nc-nc)	Female	9	5.6	159.6	(72.8-303.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.5	nc	(nc-nc)	Male	67	86.2	77.7	(60.2-98.7)
Female	1	0.7	nc	(nc-nc)	Female	73	81.9	89.2	(69.9-112.1)
<u>Lung and Bronchus</u>									
Male	6	12.0	49.9	(18.2-108.7)					
Female	3	11.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Carver

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	13.6	110.0	(61.5-181.4)	Male	10	8.6	116.3	(55.7-214.0)
Female	8	5.3	151.6	(65.3-298.7)	Female	10	7.1	141.6	(67.8-260.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.5	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	0	2.3	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	3	7.7	nc	(nc-nc)
Female	42	59.8	70.3	(50.7-95.0)	Female	12	7.4	162.4	(83.8-283.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.9	nc	(nc-nc)	Male	6	6.4	94.2	(34.4-205.1)
<u>Colon / Rectum</u>					Female	2	3.1	nc	(nc-nc)
Male	14	14.5	96.7	(52.8-162.2)	<u>Ovary</u>				
Female	11	15.2	72.5	(36.1-129.7)	Female	3	5.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	3.5	199.8	(80.1-411.7)	Male	5	4.9	102.0	(32.9-238.0)
Female	0	1.0	nc	(nc-nc)	Female	1	5.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.9	nc	(nc-nc)	Male	38	43.1	88.1	(62.3-120.9)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.3	nc	(nc-nc)
Male	4	7.5	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
Female	8	4.7	171.5	(73.9-338.0)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.6	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
<u>Leukemia</u>					Female	6	10.0	60.1	(22.0-130.9)
Male	3	5.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	4.1	121.1	(39.0-282.6)	Female	14	13.7	102.0	(55.7-171.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	4.7	nc	(nc-nc)	Male	165	175.1	94.2	(80.4-109.8)
Female	3	1.8	nc	(nc-nc)	Female	181	197.1	91.8	(78.9-106.2)
<u>Lung and Bronchus</u>									
Male	33	24.2	136.4	(93.9-191.6)					
Female	41	27.8	147.7	(105.9-200.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Charlemont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.9	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	10	6.6	151.4	(72.5-278.4)	Female	1	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.2	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.4	nc	(nc-nc)
Male	3	2.0	nc	(nc-nc)	<u>Ovary</u>				
Female	2	1.7	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.5	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	5.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	0.5	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.1	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	4	1.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.6	nc	(nc-nc)	Male	23	23.5	97.7	(61.9-146.6)
Female	0	0.2	nc	(nc-nc)	Female	28	22.2	126.2	(83.8-182.4)
<u>Lung and Bronchus</u>									
Male	3	3.4	nc	(nc-nc)					
Female	2	3.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Charlton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	13.0	123.4	(70.5-200.3)	Male	4	8.7	nc	(nc-nc)
Female	7	4.0	174.7	(70.0-359.9)	Female	6	6.6	90.9	(33.2-197.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	2.7	223.7	(81.7-486.8)	Male	2	2.8	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	4	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	11	7.8	140.8	(70.2-251.9)
Female	53	54.1	98.0	(73.4-128.2)	Female	6	6.2	97.3	(35.5-211.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.9	nc	(nc-nc)	Male	3	6.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	2.7	nc	(nc-nc)
Male	9	15.0	60.0	(27.4-113.9)	<u>Ovary</u>				
Female	15	12.7	118.4	(66.2-195.3)	Female	2	4.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.5	nc	(nc-nc)	Male	7	4.8	146.5	(58.7-301.9)
Female	0	0.8	nc	(nc-nc)	Female	5	4.2	120.4	(38.8-280.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.1	nc	(nc-nc)	Male	23	42.9	53.6	(34.0-80.4)
Female	2	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.2	nc	(nc-nc)
Male	10	7.8	127.7	(61.2-235.0)	Female	0	1.7	nc	(nc-nc)
Female	3	4.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.9	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	3	0.6	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
<u>Leukemia</u>					Female	16	10.8	147.6	(84.3-239.8)
Male	4	5.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.5	nc	(nc-nc)	Female	11	12.2	90.3	(45.0-161.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	4.8	nc	(nc-nc)	Male	140	175.3	79.9	(67.2-94.2)
Female	0	1.5	nc	(nc-nc)	Female	181	170.8	105.9	(91.1-122.6)
<u>Lung and Bronchus</u>									
Male	21	22.9	91.6	(56.7-140.1)					
Female	25	21.1	118.5	(76.7-175.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chatham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	14.4	104.5	(58.4-172.3)	Male	21	8.0	261.2	(161.6-399.2)
Female	10	4.7	211.4	(101.2-388.8)	Female	14	5.0	281.6	(153.8-472.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.0	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	4	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	8	7.2	111.2	(47.9-219.1)
Female	43	42.4	101.5	(73.5-136.8)	Female	7	6.0	117.6	(47.1-242.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	7	5.4	128.5	(51.5-264.8)
<u>Colon / Rectum</u>					Female	1	2.4	nc	(nc-nc)
Male	16	13.8	115.6	(66.0-187.8)	<u>Ovary</u>				
Female	14	12.6	110.9	(60.6-186.0)	Female	3	3.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.4	nc	(nc-nc)	Male	7	4.8	145.2	(58.2-299.2)
Female	0	0.9	nc	(nc-nc)	Female	6	4.8	125.0	(45.7-272.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	44	39.3	111.8	(81.3-150.1)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.3	nc	(nc-nc)
Male	6	6.6	91.1	(33.3-198.3)	Female	1	1.7	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.6	nc	(nc-nc)
Male	0	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	2	5.4	nc	(nc-nc)
Male	9	5.1	178.0	(81.2-337.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.3	nc	(nc-nc)	Female	11	9.9	111.4	(55.5-199.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	4.3	nc	(nc-nc)	Male	183	165.2	110.8	(95.3-128.1)
Female	2	1.4	nc	(nc-nc)	Female	169	151.4	111.6	(95.4-129.8)
<u>Lung and Bronchus</u>									
Male	22	25.1	87.6	(54.9-132.6)					
Female	24	24.7	97.3	(62.3-144.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chelmsford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	51	39.6	128.7	(95.8-169.2)	Male	20	25.4	78.6	(48.0-121.4)
Female	16	15.3	104.7	(59.8-170.0)	Female	20	20.4	98.2	(59.9-151.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	7.6	144.8	(72.2-259.1)	Male	8	8.2	97.8	(42.1-192.7)
Female	8	6.5	123.8	(53.3-244.0)	Female	11	7.0	157.8	(78.6-282.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.4	nc	(nc-nc)	Male	27	22.6	119.2	(78.6-173.5)
Female	177	170.6	103.8	(89.0-120.2)	Female	16	21.2	75.5	(43.1-122.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	5.4	110.3	(40.3-240.2)	Male	21	19.0	110.5	(68.4-169.0)
<u>Colon / Rectum</u>					Female	8	8.9	89.5	(38.5-176.4)
Male	40	43.1	92.7	(66.2-126.3)	<u>Ovary</u>				
Female	44	43.9	100.2	(72.8-134.6)	Female	22	14.5	151.6	(95.0-229.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	10.2	58.7	(21.4-127.7)	Male	18	14.2	126.8	(75.1-200.4)
Female	4	3.0	nc	(nc-nc)	Female	18	15.5	116.5	(69.0-184.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.8	nc	(nc-nc)	Male	126	122.8	102.6	(85.5-122.2)
Female	3	2.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	9.6	nc	(nc-nc)
Male	19	22.2	85.6	(51.5-133.8)	Female	4	5.9	nc	(nc-nc)
Female	12	13.5	88.8	(45.8-155.1)	<u>Testis</u>				
<u>Larynx</u>					Male	5	5.1	98.5	(31.8-229.9)
Male	4	6.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	2.0	nc	(nc-nc)	Male	13	10.1	128.9	(68.6-220.4)
<u>Leukemia</u>					Female	29	29.6	97.8	(65.5-140.5)
Male	17	15.9	106.6	(62.1-170.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	25	11.9	210.0	(135.9-310.1)	Female	50	38.0	131.4	(97.6-173.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	14.0	57.2	(24.6-112.8)	Male	513	512.2	100.2	(91.7-109.2)
Female	2	5.0	nc	(nc-nc)	Female	613	567.8	108.0	(99.6-116.9)
<u>Lung and Bronchus</u>									
Male	64	71.0	90.1	(69.4-115.0)					
Female	79	82.4	95.9	(75.9-119.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chelsea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	22.1	63.2	(34.5-106.1)	Male	8	16.4	48.9	(21.1-96.4)
Female	10	8.5	117.0	(56.0-215.2)	Female	10	14.4	69.5	(33.3-127.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	6.2	112.2	(45.0-231.2)	Male	5	4.9	102.4	(33.0-238.9)
Female	6	4.9	122.6	(44.8-266.8)	Female	4	4.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	13	14.9	87.2	(46.4-149.1)
Female	96	104.1	92.2	(74.7-112.6)	Female	16	12.9	124.0	(70.8-201.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	4.5	155.5	(62.3-320.4)	Male	7	12.4	56.5	(22.6-116.4)
<u>Colon / Rectum</u>					Female	8	5.4	147.0	(63.3-289.7)
Male	32	27.1	118.0	(80.7-166.6)	<u>Ovary</u>				
Female	17	26.5	64.2	(37.4-102.8)	Female	5	9.0	55.6	(17.9-129.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	6.0	83.5	(26.9-195.0)	Male	9	8.3	108.6	(49.6-206.2)
Female	0	1.7	nc	(nc-nc)	Female	15	8.8	169.6	(94.9-279.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	3.2	nc	(nc-nc)	Male	51	72.2	70.6	(52.6-92.8)
Female	1	2.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	12	5.7	209.4	(108.1-365.8)
Male	6	14.8	40.6	(14.8-88.3)	Female	4	3.6	nc	(nc-nc)
Female	11	8.1	135.5	(67.5-242.4)	<u>Testis</u>				
<u>Larynx</u>					Male	4	6.9	nc	(nc-nc)
Male	4	3.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.1	nc	(nc-nc)	Male	7	8.5	82.4	(33.0-169.7)
<u>Leukemia</u>					Female	41	25.6	160.3	(115.0-217.4)
Male	12	11.1	108.3	(55.9-189.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	8.3	132.5	(66.1-237.1)	Female	15	22.2	67.5	(37.8-111.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	14	8.4	166.1	(90.7-278.7)	Male	299	318.7	93.8	(83.5-105.1)
Female	9	2.9	315.0	(143.7-598.0)	Female	381	351.3	108.5	(97.8-119.9)
<u>Lung and Bronchus</u>									
Male	53	39.0	135.8	(101.7-177.7)					
Female	64	44.1	145.1	(111.7-185.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Cheshire

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	4.7	127.6	(46.6-277.7)	Male	5	2.8	176.8	(57.0-412.7)
Female	2	1.5	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	14	17.1	81.8	(44.7-137.2)	Female	2	2.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.9	nc	(nc-nc)
Male	8	4.8	165.6	(71.3-326.2)	<u>Ovary</u>				
Female	2	4.3	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.2	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	17	15.5	109.6	(63.8-175.5)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.1	nc	(nc-nc)
Male	3	2.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.9	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.2	nc	(nc-nc)	Female	7	4.0	174.8	(70.0-360.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.6	nc	(nc-nc)	Male	64	59.5	107.5	(82.8-137.3)
Female	0	0.5	nc	(nc-nc)	Female	42	56.9	73.8	(53.1-99.7)
<u>Lung and Bronchus</u>									
Male	14	8.4	166.8	(91.1-280.0)					
Female	3	8.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.2	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	4	5.9	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	5	1.6	317.3	(102.3-740.5)	<u>Ovary</u>				
Female	1	1.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	6	5.1	118.6	(43.3-258.1)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.3	nc	(nc-nc)
Male	2	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.2	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	0.6	nc	(nc-nc)	Male	23	19.1	120.5	(76.4-180.8)
Female	0	0.2	nc	(nc-nc)	Female	12	18.5	64.8	(33.4-113.2)
<u>Lung and Bronchus</u>									
Male	2	2.4	nc	(nc-nc)					
Female	2	2.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chesterfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.3	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	5.8	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.3	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	5.2	95.7	(30.8-223.3)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	0.3	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.1	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	17	19.1	89.1	(51.9-142.7)
Female	0	0.2	nc	(nc-nc)	Female	10	18.1	55.3	(26.5-101.8)
<u>Lung and Bronchus</u>									
Male	3	2.4	nc	(nc-nc)					
Female	1	2.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chicopee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	63	64.5	97.7	(75.1-125.0)	Male	25	40.1	62.3	(40.3-91.9)
Female	16	23.6	67.8	(38.7-110.1)	Female	20	31.2	64.1	(39.1-99.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	12.1	90.9	(45.3-162.7)	Male	12	12.9	92.9	(48.0-162.3)
Female	12	9.9	121.3	(62.6-211.9)	Female	8	10.6	75.6	(32.6-149.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	2.2	nc	(nc-nc)	Male	30	35.9	83.6	(56.4-119.3)
Female	253	248.9	101.7	(89.5-115.0)	Female	36	32.4	111.1	(77.8-153.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	11	8.0	137.1	(68.4-245.4)	Male	33	29.1	113.3	(78.0-159.2)
<u>Colon / Rectum</u>					Female	24	13.4	178.5	(114.4-265.7)
Male	97	67.7	143.3	(116.2-174.8)	<u>Ovary</u>				
Female	62	67.7	91.6	(70.2-117.4)	Female	30	21.7	138.5	(93.4-197.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	16	16.2	98.6	(56.3-160.1)	Male	21	22.6	92.7	(57.4-141.7)
Female	7	4.6	152.1	(60.9-313.4)	Female	26	23.9	108.8	(71.0-159.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	4.7	127.9	(46.7-278.4)	Male	115	194.7	59.1	(48.8-70.9)
Female	1	4.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	9	15.3	58.7	(26.8-111.4)
Male	44	34.4	128.0	(93.0-171.9)	Female	9	9.2	97.9	(44.7-185.8)
Female	27	20.2	133.7	(88.1-194.6)	<u>Testis</u>				
<u>Larynx</u>					Male	10	8.3	120.0	(57.4-220.7)
Male	12	9.4	127.6	(65.9-222.9)	<u>Thyroid</u>				
Female	0	2.8	nc	(nc-nc)	Male	11	15.3	71.9	(35.8-128.6)
<u>Leukemia</u>					Female	32	44.5	71.9	(49.1-101.4)
Male	20	25.8	77.6	(47.4-119.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	12	18.7	64.3	(33.2-112.4)	Female	51	55.6	91.7	(68.3-120.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	21.7	46.2	(22.1-84.9)	Male	740	813.5	91.0	(84.5-97.8)
Female	7	7.6	92.5	(37.1-190.6)	Female	846	852.3	99.3	(92.7-106.2)
<u>Lung and Bronchus</u>									
Male	139	114.1	121.9	(102.4-143.9)					
Female	130	123.9	105.0	(87.7-124.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chilmark

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.3	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	2	6.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.2	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	4	1.3	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.0	nc	(nc-nc)
Male	2	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.4	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	19	16.3	116.7	(70.2-182.2)
Female	0	0.2	nc	(nc-nc)	Female	8	19.3	41.4	(17.8-81.5)
<u>Lung and Bronchus</u>									
Male	2	2.3	nc	(nc-nc)					
Female	2	2.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Clarksburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.7	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	5	8.2	61.3	(19.7-143.0)	Female	1	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	2	2.7	nc	(nc-nc)	<u>Ovary</u>				
Female	3	2.1	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	0.7	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	8	7.7	104.0	(44.8-205.0)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.6	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.3	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.6	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.9	nc	(nc-nc)	Male	30	32.7	91.8	(61.9-131.0)
Female	0	0.3	nc	(nc-nc)	Female	25	27.5	90.8	(58.8-134.1)
<u>Lung and Bronchus</u>									
Male	5	4.8	103.4	(33.3-241.3)					
Female	5	4.1	122.1	(39.3-284.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Clinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	13.4	194.1	(126.7-284.4)	Male	6	8.9	67.7	(24.7-147.5)
Female	5	5.1	97.2	(31.3-226.8)	Female	12	7.4	161.2	(83.2-281.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.8	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	4	2.3	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	6	8.0	75.3	(27.5-163.8)
Female	51	59.0	86.4	(64.4-113.7)	Female	8	7.4	108.5	(46.7-213.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.1	nc	(nc-nc)	Male	5	6.9	73.0	(23.5-170.2)
<u>Colon / Rectum</u>					Female	1	3.1	nc	(nc-nc)
Male	17	14.9	113.9	(66.3-182.4)	<u>Ovary</u>				
Female	14	15.5	90.4	(49.4-151.7)	Female	5	5.1	98.0	(31.6-228.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.6	138.6	(44.7-323.5)	Male	3	4.9	nc	(nc-nc)
Female	4	1.0	nc	(nc-nc)	Female	3	5.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.2	nc	(nc-nc)	Male	56	45.2	123.8	(93.5-160.8)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	3.3	nc	(nc-nc)
Male	7	8.0	87.2	(34.9-179.6)	Female	1	2.1	nc	(nc-nc)
Female	5	4.6	108.6	(35.0-253.5)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.2	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.7	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
<u>Leukemia</u>					Female	11	11.4	96.7	(48.2-173.1)
Male	9	5.6	159.7	(72.9-303.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	4.3	139.8	(51.1-304.4)	Female	13	13.2	98.3	(52.3-168.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	4.9	164.3	(70.7-323.7)	Male	199	181.2	109.8	(95.1-126.2)
Female	1	1.7	nc	(nc-nc)	Female	205	197.2	104.0	(90.2-119.2)
<u>Lung and Bronchus</u>									
Male	28	24.2	115.9	(77.0-167.5)					
Female	37	26.5	139.9	(98.5-192.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Cohasset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	9.4	85.2	(36.7-167.9)	Male	5	6.1	82.3	(26.5-192.1)
Female	6	3.4	175.8	(64.2-382.6)	Female	15	4.4	339.0	(189.6-559.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.8	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	5.4	111.6	(40.8-243.0)
Female	41	37.0	110.9	(79.6-150.4)	Female	3	4.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.2	nc	(nc-nc)	Male	5	4.6	108.4	(34.9-253.0)
<u>Colon / Rectum</u>					Female	2	2.0	nc	(nc-nc)
Male	12	10.0	119.9	(61.9-209.4)	<u>Ovary</u>				
Female	6	9.7	61.8	(22.6-134.5)	Female	4	3.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.5	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	31	30.0	103.3	(70.2-146.6)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.3	nc	(nc-nc)
Male	5	5.3	94.0	(30.3-219.3)	Female	0	1.3	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.0	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	7	6.3	110.8	(44.4-228.3)
Male	3	3.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	2.7	185.5	(59.8-432.9)	Female	6	8.2	72.9	(26.6-158.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	3.5	nc	(nc-nc)	Male	110	122.9	89.5	(73.6-107.9)
Female	1	1.1	nc	(nc-nc)	Female	131	124.4	105.3	(88.0-124.9)
<u>Lung and Bronchus</u>									
Male	10	17.1	58.5	(28.0-107.6)					
Female	13	18.2	71.4	(38.0-122.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Colrain

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.5	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	10	7.8	128.7	(61.6-236.7)	Female	0	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.2	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	2	2.6	nc	(nc-nc)	<u>Ovary</u>				
Female	3	2.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.6	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	7.5	66.5	(21.4-155.2)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	0.6	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.4	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	5	1.8	276.0	(89.0-644.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.8	nc	(nc-nc)	Male	22	31.3	70.3	(44.1-106.5)
Female	0	0.2	nc	(nc-nc)	Female	31	25.6	120.9	(82.1-171.6)
<u>Lung and Bronchus</u>									
Male	3	4.5	nc	(nc-nc)					
Female	4	3.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Concord

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	30	26.5	113.3	(76.4-161.8)	Male	22	16.3	134.6	(84.3-203.8)
Female	10	9.3	107.4	(51.4-197.5)	Female	25	11.3	220.5	(142.6-325.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	4.7	106.6	(34.4-248.8)	Male	4	5.4	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)	Female	4	4.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.9	nc	(nc-nc)	Male	13	14.7	88.5	(47.1-151.4)
Female	122	94.1	129.6	(107.7-154.8)	Female	9	12.5	72.1	(32.9-136.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.7	nc	(nc-nc)	Male	10	12.1	82.8	(39.6-152.3)
<u>Colon / Rectum</u>					Female	7	5.2	134.2	(53.8-276.5)
Male	19	28.3	67.2	(40.5-105.0)	<u>Ovary</u>				
Female	35	27.1	129.4	(90.1-179.9)	Female	14	8.2	171.1	(93.4-287.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	6.7	nc	(nc-nc)	Male	8	9.3	86.1	(37.1-169.7)
Female	0	1.8	nc	(nc-nc)	Female	7	9.6	73.0	(29.3-150.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.6	nc	(nc-nc)	Male	87	80.1	108.6	(87.0-133.9)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	6.3	nc	(nc-nc)
Male	8	14.2	56.2	(24.2-110.8)	Female	0	3.7	nc	(nc-nc)
Female	11	7.6	144.6	(72.1-258.7)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.7	nc	(nc-nc)
Male	1	3.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.1	nc	(nc-nc)	Male	5	6.2	81.2	(26.2-189.4)
<u>Leukemia</u>					Female	15	14.5	103.6	(58.0-170.9)
Male	7	10.3	67.9	(27.2-139.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	7.1	nc	(nc-nc)	Female	23	21.2	108.6	(68.8-163.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	8.9	89.5	(38.6-176.4)	Male	286	332.5	86.0	(76.3-96.6)
Female	4	3.0	nc	(nc-nc)	Female	357	323.7	110.3	(99.1-122.4)
<u>Lung and Bronchus</u>									
Male	22	46.3	47.5	(29.8-71.9)					
Female	27	47.0	57.4	(37.8-83.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Conway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	2.2	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	7	9.7	72.4	(29.0-149.2)	Female	0	1.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.5	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	<u>Ovary</u>				
Female	2	2.1	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	8.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.2	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.6	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.6	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.9	nc	(nc-nc)	Male	28	30.1	93.1	(61.9-134.6)
Female	0	0.3	nc	(nc-nc)	Female	21	30.3	69.3	(42.9-105.9)
<u>Lung and Bronchus</u>									
Male	3	4.0	nc	(nc-nc)					
Female	1	4.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Cummington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.6	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	9	5.1	177.3	(80.9-336.7)	Female	1	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	3	1.6	nc	(nc-nc)	<u>Ovary</u>				
Female	4	1.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	3.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.8	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	14	17.7	79.0	(43.1-132.5)
Female	1	0.2	nc	(nc-nc)	Female	21	17.3	121.6	(75.2-185.8)
<u>Lung and Bronchus</u>									
Male	1	2.6	nc	(nc-nc)					
Female	1	2.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dalton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	9.9	70.9	(28.4-146.0)	Male	10	5.9	169.6	(81.2-311.9)
Female	4	3.6	nc	(nc-nc)	Female	4	4.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.7	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.3	nc	(nc-nc)
Female	26	35.6	73.0	(47.7-107.0)	Female	2	4.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.0	nc	(nc-nc)	Male	1	4.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	2.0	nc	(nc-nc)
Male	9	10.2	88.7	(40.5-168.3)	<u>Ovary</u>				
Female	9	10.1	89.1	(40.6-169.1)	Female	3	3.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.4	nc	(nc-nc)	Male	1	3.4	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	3.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	30	26.8	112.0	(75.5-159.8)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.3	nc	(nc-nc)
Male	2	4.9	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.9	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
<u>Leukemia</u>					Female	1	5.5	nc	(nc-nc)
Male	2	3.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.7	nc	(nc-nc)	Female	10	8.0	124.9	(59.8-229.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	3.1	nc	(nc-nc)	Male	100	118.1	84.7	(68.9-103.0)
Female	0	1.1	nc	(nc-nc)	Female	97	123.0	78.8	(63.9-96.2)
<u>Lung and Bronchus</u>									
Male	14	17.3	81.0	(44.2-135.9)					
Female	18	18.4	97.6	(57.8-154.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Danvers

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	36	35.4	101.6	(71.2-140.7)	Male	18	21.7	83.1	(49.2-131.3)
Female	11	12.8	85.7	(42.7-153.4)	Female	12	16.1	74.7	(38.6-130.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	6.2	176.3	(87.9-315.5)	Male	3	7.0	nc	(nc-nc)
Female	5	5.1	97.4	(31.4-227.4)	Female	3	5.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.2	nc	(nc-nc)	Male	15	19.4	77.4	(43.3-127.7)
Female	138	129.3	106.7	(89.6-126.1)	Female	25	17.3	144.9	(93.7-213.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.0	nc	(nc-nc)	Male	16	15.5	103.1	(58.9-167.4)
<u>Colon / Rectum</u>					Female	8	7.1	112.4	(48.4-221.5)
Male	34	36.9	92.1	(63.8-128.7)	<u>Ovary</u>				
Female	37	37.2	99.5	(70.1-137.2)	Female	13	11.3	115.5	(61.4-197.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	8.7	115.0	(55.0-211.4)	Male	12	12.4	97.1	(50.1-169.7)
Female	3	2.4	nc	(nc-nc)	Female	14	13.2	106.4	(58.1-178.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.3	nc	(nc-nc)	Male	104	101.2	102.7	(83.9-124.5)
Female	3	1.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	8.3	59.9	(19.3-139.8)
Male	21	18.3	114.8	(71.0-175.5)	Female	5	5.1	98.0	(31.6-228.7)
Female	12	10.5	114.5	(59.1-200.0)	<u>Testis</u>				
<u>Larynx</u>					Male	7	3.8	183.7	(73.6-378.6)
Male	4	5.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.4	nc	(nc-nc)	Male	11	7.9	138.4	(69.0-247.7)
<u>Leukemia</u>					Female	30	21.7	138.0	(93.1-197.0)
Male	12	13.8	86.8	(44.8-151.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	15	10.0	149.6	(83.7-246.8)	Female	42	28.5	147.6	(106.3-199.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	11.5	69.7	(30.0-137.3)	Male	434	434.8	99.8	(90.7-109.7)
Female	3	4.1	nc	(nc-nc)	Female	479	447.9	107.0	(97.6-117.0)
<u>Lung and Bronchus</u>									
Male	66	61.8	106.8	(82.6-135.9)					
Female	54	64.8	83.4	(62.6-108.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dartmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	57	41.2	138.3	(104.7-179.2)	Male	24	25.1	95.6	(61.2-142.3)
Female	18	15.0	120.0	(71.1-189.7)	Female	14	19.0	73.6	(40.2-123.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	7.4	67.3	(21.7-157.0)	Male	5	8.1	61.9	(19.9-144.4)
Female	6	6.1	98.4	(35.9-214.2)	Female	4	6.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.4	nc	(nc-nc)	Male	23	22.7	101.2	(64.1-151.8)
Female	129	151.4	85.2	(71.1-101.2)	Female	15	20.2	74.1	(41.4-122.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	4.7	106.2	(34.2-247.9)	Male	17	18.0	94.4	(55.0-151.2)
<u>Colon / Rectum</u>					Female	10	8.5	117.9	(56.5-216.9)
Male	39	43.2	90.2	(64.1-123.3)	<u>Ovary</u>				
Female	50	43.7	114.4	(84.9-150.8)	Female	8	13.3	60.0	(25.8-118.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	10.1	109.0	(54.4-195.1)	Male	13	14.2	91.2	(48.5-156.0)
Female	2	2.9	nc	(nc-nc)	Female	8	15.7	51.1	(22.0-100.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	3.2	nc	(nc-nc)	Male	142	118.4	119.9	(101.0-141.3)
Female	2	2.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	15	9.7	155.1	(86.8-255.9)
Male	21	21.2	99.1	(61.3-151.5)	Female	11	6.0	183.9	(91.7-329.0)
Female	18	12.2	147.1	(87.1-232.5)	<u>Testis</u>				
<u>Larynx</u>					Male	6	5.5	109.6	(40.0-238.5)
Male	7	5.7	122.0	(48.9-251.3)	<u>Thyroid</u>				
Female	1	1.8	nc	(nc-nc)	Male	7	9.4	74.2	(29.7-152.9)
<u>Leukemia</u>					Female	33	26.0	126.9	(87.3-178.2)
Male	14	16.2	86.2	(47.1-144.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	11.7	68.3	(29.4-134.6)	Female	32	33.9	94.3	(64.5-133.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	12	13.3	90.4	(46.7-158.0)	Male	517	507.9	101.8	(93.2-111.0)
Female	1	4.7	nc	(nc-nc)	Female	450	526.7	85.4	(77.7-93.7)
<u>Lung and Bronchus</u>									
Male	71	71.1	99.9	(78.0-126.0)					
Female	42	75.5	55.6	(40.1-75.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dedham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	29	30.5	95.0	(63.6-136.4)	Male	24	18.6	128.9	(82.6-191.8)
Female	12	12.7	94.2	(48.6-164.6)	Female	19	15.5	122.4	(73.6-191.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	5.5	145.7	(62.7-287.0)	Male	9	6.0	149.0	(68.0-283.0)
Female	5	4.9	102.4	(33.0-239.1)	Female	2	5.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	23	16.9	136.1	(86.3-204.3)
Female	155	123.4	125.7	(106.6-147.1)	Female	16	16.9	94.9	(54.2-154.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.8	nc	(nc-nc)	Male	16	13.1	122.5	(69.9-198.9)
<u>Colon / Rectum</u>					Female	12	6.9	173.8	(89.7-303.7)
Male	31	32.0	96.8	(65.8-137.4)	<u>Ovary</u>				
Female	28	36.9	75.9	(50.4-109.6)	Female	9	10.8	83.2	(38.0-158.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	7.4	nc	(nc-nc)	Male	14	10.5	132.7	(72.5-222.7)
Female	3	2.4	nc	(nc-nc)	Female	18	13.0	138.0	(81.7-218.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.1	nc	(nc-nc)	Male	89	85.6	104.0	(83.5-128.0)
Female	5	1.7	288.0	(92.8-672.0)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	7.2	83.4	(30.5-181.6)
Male	20	15.8	126.8	(77.4-195.9)	Female	8	5.1	157.9	(68.0-311.1)
Female	11	10.1	108.5	(54.1-194.2)	<u>Testis</u>				
<u>Larynx</u>					Male	4	3.8	nc	(nc-nc)
Male	4	4.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.4	nc	(nc-nc)	Male	6	7.1	84.8	(31.0-184.7)
<u>Leukemia</u>					Female	29	20.6	140.7	(94.2-202.1)
Male	12	12.1	99.4	(51.3-173.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	9.8	91.6	(41.8-174.0)	Female	27	26.8	100.8	(66.4-146.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	9.5	115.4	(57.5-206.5)	Male	405	373.1	108.6	(98.2-119.7)
Female	6	3.9	152.5	(55.7-331.9)	Female	486	434.2	111.9	(102.2-122.3)
<u>Lung and Bronchus</u>									
Male	52	52.4	99.2	(74.1-130.1)					
Female	79	63.8	123.9	(98.1-154.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Deerfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	4.3	nc	(nc-nc)	Male	5	3.2	157.6	(50.8-367.8)
Female	4	2.2	nc	(nc-nc)	Female	6	3.1	195.0	(71.2-424.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	21	25.5	82.2	(50.9-125.7)	Female	2	3.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.3	nc	(nc-nc)
Male	6	5.4	111.7	(40.8-243.1)	<u>Ovary</u>				
Female	6	6.3	94.6	(34.6-206.0)	Female	1	2.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.3	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	14	16.8	83.6	(45.6-140.2)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.1	nc	(nc-nc)
Male	5	3.0	164.4	(53.0-383.7)	Female	0	0.9	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.7	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	3	4.6	nc	(nc-nc)
Male	0	1.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.7	nc	(nc-nc)	Female	8	5.7	139.4	(60.0-274.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.9	nc	(nc-nc)	Male	55	64.5	85.3	(64.3-111.1)
Female	0	0.7	nc	(nc-nc)	Female	72	83.6	86.1	(67.4-108.4)
<u>Lung and Bronchus</u>									
Male	3	8.1	nc	(nc-nc)					
Female	7	11.7	60.0	(24.0-123.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dennis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	50	29.3	170.6	(126.6-224.9)	Male	36	16.2	222.3	(155.7-307.8)
Female	15	10.9	137.4	(76.8-226.6)	Female	22	11.7	187.4	(117.4-283.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	4.2	nc	(nc-nc)	Male	11	5.4	202.2	(100.8-361.8)
Female	2	3.7	nc	(nc-nc)	Female	1	4.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	14	14.4	97.0	(53.0-162.7)
Female	109	100.6	108.3	(89.0-130.7)	Female	11	13.8	79.5	(39.6-142.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.6	nc	(nc-nc)	Male	16	10.5	151.8	(86.7-246.5)
<u>Colon / Rectum</u>					Female	4	5.6	nc	(nc-nc)
Male	25	27.4	91.2	(59.0-134.7)	<u>Ovary</u>				
Female	26	28.6	91.0	(59.4-133.3)	Female	15	8.8	170.6	(95.4-281.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	14	6.8	206.5	(112.8-346.5)	Male	12	9.7	123.9	(64.0-216.5)
Female	4	2.1	nc	(nc-nc)	Female	13	10.8	120.0	(63.8-205.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.2	nc	(nc-nc)	Male	100	78.8	126.9	(103.2-154.3)
Female	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	6.6	nc	(nc-nc)
Male	8	13.1	61.3	(26.4-120.8)	Female	2	3.9	nc	(nc-nc)
Female	5	8.6	58.1	(18.7-135.6)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.6	nc	(nc-nc)
Male	3	3.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.3	nc	(nc-nc)	Male	2	4.6	nc	(nc-nc)
<u>Leukemia</u>					Female	15	13.4	111.8	(62.5-184.5)
Male	12	10.3	116.0	(59.9-202.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	7.6	79.3	(29.0-172.6)	Female	17	23.4	72.7	(42.3-116.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	8.3	96.6	(41.6-190.3)	Male	396	332.8	119.0	(107.6-131.3)
Female	2	3.4	nc	(nc-nc)	Female	363	355.1	102.2	(92.0-113.3)
<u>Lung and Bronchus</u>									
Male	45	51.7	87.1	(63.5-116.5)					
Female	58	58.6	98.9	(75.1-127.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dighton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	8.8	113.9	(54.5-209.4)	Male	7	5.5	128.1	(51.3-263.9)
Female	1	2.5	nc	(nc-nc)	Female	4	3.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	4.8	103.2	(33.2-240.7)
Female	19	28.2	67.3	(40.5-105.0)	Female	3	3.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.5	nc	(nc-nc)
Male	13	9.4	137.8	(73.3-235.7)	<u>Ovary</u>				
Female	5	7.5	66.7	(21.5-155.7)	Female	3	2.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.2	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	22	25.4	86.7	(54.3-131.2)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.1	nc	(nc-nc)
Male	3	4.6	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	5	2.3	220.7	(71.1-515.1)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.1	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	4	2.1	nc	(nc-nc)
<u>Leukemia</u>					Female	4	5.2	nc	(nc-nc)
Male	1	3.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	2.1	nc	(nc-nc)	Female	7	6.2	113.4	(45.4-233.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.0	nc	(nc-nc)	Male	102	109.6	93.1	(75.9-113.0)
Female	2	0.8	nc	(nc-nc)	Female	79	95.2	83.0	(65.7-103.5)
<u>Lung and Bronchus</u>									
Male	8	15.4	51.9	(22.4-102.3)					
Female	14	13.4	104.3	(57.0-175.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Douglas

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	7.7	90.3	(36.2-186.1)	Male	9	5.4	166.2	(75.8-315.5)
Female	5	2.0	248.5	(80.1-580.0)	Female	3	3.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.7	nc	(nc-nc)	Male	4	1.8	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	4	4.9	nc	(nc-nc)
Female	33	31.3	105.4	(72.6-148.1)	Female	1	3.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.2	nc	(nc-nc)	Male	5	4.3	116.3	(37.5-271.5)
<u>Colon / Rectum</u>					Female	1	1.5	nc	(nc-nc)
Male	6	9.0	66.8	(24.4-145.5)	<u>Ovary</u>				
Female	8	6.3	126.7	(54.6-249.7)	Female	2	2.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.2	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	2.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	24	27.4	87.4	(56.0-130.1)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.0	nc	(nc-nc)
Male	9	4.9	182.6	(83.3-346.7)	Female	0	0.8	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.2	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	5	2.4	208.5	(67.2-486.5)
<u>Leukemia</u>					Female	8	6.6	121.4	(52.3-239.2)
Male	1	3.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	1.9	nc	(nc-nc)	Female	9	7.1	126.4	(57.7-240.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.2	nc	(nc-nc)	Male	111	109.7	101.2	(83.2-121.8)
Female	0	0.8	nc	(nc-nc)	Female	105	95.0	110.6	(90.4-133.8)
<u>Lung and Bronchus</u>									
Male	14	14.4	96.9	(52.9-162.6)					
Female	14	11.7	119.3	(65.1-200.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	7.7	nc	(nc-nc)	Male	11	5.4	203.1	(101.3-363.5)
Female	0	2.0	nc	(nc-nc)	Female	1	2.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.7	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	7	4.9	144.0	(57.7-296.7)
Female	28	25.6	109.2	(72.5-157.8)	Female	3	3.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	2	4.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.3	nc	(nc-nc)
Male	7	9.0	78.0	(31.2-160.7)	<u>Ovary</u>				
Female	3	6.0	nc	(nc-nc)	Female	0	2.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.2	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	23	27.4	83.8	(53.1-125.8)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.0	nc	(nc-nc)
Male	4	4.9	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.2	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	5	2.4	208.5	(67.2-486.5)
<u>Leukemia</u>					Female	5	4.5	111.8	(36.0-261.0)
Male	1	3.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.6	nc	(nc-nc)	Female	3	5.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	3.2	nc	(nc-nc)	Male	91	109.7	82.9	(66.8-101.8)
Female	0	0.7	nc	(nc-nc)	Female	66	81.4	81.0	(62.7-103.1)
<u>Lung and Bronchus</u>									
Male	9	14.4	62.3	(28.4-118.3)					
Female	7	11.3	62.1	(24.9-127.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dracut

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	40	29.8	134.3	(95.9-182.8)	Male	13	19.9	65.4	(34.8-111.8)
Female	20	10.5	190.5	(116.3-294.2)	Female	15	15.7	95.8	(53.6-158.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	6.4	125.2	(53.9-246.8)	Male	7	6.3	111.0	(44.5-228.8)
Female	5	5.0	100.1	(32.3-233.7)	Female	3	4.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.1	nc	(nc-nc)	Male	14	17.7	79.2	(43.2-132.8)
Female	135	126.9	106.4	(89.2-125.9)	Female	14	15.2	91.9	(50.2-154.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	4.4	135.5	(49.5-295.0)	Male	10	15.6	64.2	(30.8-118.1)
<u>Colon / Rectum</u>					Female	10	6.5	154.1	(73.8-283.4)
Male	40	33.1	120.8	(86.3-164.4)	<u>Ovary</u>				
Female	44	30.9	142.2	(103.3-191.0)	Female	11	10.8	102.1	(50.9-182.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	8.1	159.6	(84.9-272.9)	Male	9	10.9	82.3	(37.5-156.2)
Female	5	2.1	239.3	(77.1-558.4)	Female	14	10.5	133.0	(72.6-223.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	2.5	nc	(nc-nc)	Male	96	103.1	93.1	(75.4-113.7)
Female	2	2.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	11	7.4	149.5	(74.5-267.6)
Male	21	18.0	116.5	(72.1-178.1)	Female	5	4.2	119.2	(38.4-278.2)
Female	14	9.9	141.3	(77.2-237.1)	<u>Testis</u>				
<u>Larynx</u>					Male	5	4.7	107.5	(34.6-250.9)
Male	8	4.8	167.7	(72.2-330.5)	<u>Thyroid</u>				
Female	1	1.4	nc	(nc-nc)	Male	5	8.4	59.8	(19.3-139.5)
<u>Leukemia</u>					Female	23	24.6	93.5	(59.2-140.3)
Male	18	12.7	142.0	(84.1-224.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	8.8	102.1	(46.6-193.9)	Female	21	28.4	73.9	(45.7-113.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	11.3	88.2	(42.2-162.2)	Male	441	407.9	108.1	(98.3-118.7)
Female	5	3.6	139.0	(44.8-324.5)	Female	480	415.0	115.7	(105.5-126.5)
<u>Lung and Bronchus</u>									
Male	64	54.8	116.7	(89.9-149.0)					
Female	73	56.8	128.6	(100.8-161.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dudley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	11.1	99.3	(49.5-177.7)	Male	6	7.2	83.0	(30.3-180.8)
Female	4	3.1	nc	(nc-nc)	Female	5	5.0	100.3	(32.3-234.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.3	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	4	6.6	nc	(nc-nc)
Female	45	40.7	110.6	(80.7-148.0)	Female	5	4.7	106.3	(34.3-248.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.5	nc	(nc-nc)	Male	3	5.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	2.0	nc	(nc-nc)
Male	13	12.0	108.6	(57.8-185.8)	<u>Ovary</u>				
Female	11	9.5	115.6	(57.6-206.9)	Female	4	3.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.8	nc	(nc-nc)	Male	5	4.0	126.3	(40.7-294.7)
Female	3	0.6	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.0	nc	(nc-nc)	Male	34	33.0	102.9	(71.2-143.8)
Female	2	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	2.7	185.1	(59.6-431.9)
Male	11	6.2	177.3	(88.4-317.2)	Female	0	1.3	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.9	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
<u>Leukemia</u>					Female	11	8.3	132.2	(65.9-236.6)
Male	10	4.7	212.9	(101.9-391.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	2.7	181.9	(58.6-424.4)	Female	17	9.0	188.6	(109.8-302.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.8	nc	(nc-nc)	Male	155	143.7	107.9	(91.6-126.3)
Female	1	1.1	nc	(nc-nc)	Female	167	130.5	128.0	(109.3-148.9)
<u>Lung and Bronchus</u>									
Male	25	19.7	126.7	(82.0-187.0)					
Female	24	17.0	141.2	(90.4-210.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dunstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	3.1	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.7	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
Female	15	15.1	99.4	(55.6-164.0)	Female	2	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	0.8	nc	(nc-nc)
Male	4	3.7	nc	(nc-nc)	<u>Ovary</u>				
Female	0	3.5	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	0.9	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	10	11.9	84.0	(40.2-154.5)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.8	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	0.4	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.9	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.0	nc	(nc-nc)	Female	5	3.4	147.8	(47.6-345.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.3	nc	(nc-nc)	Male	41	45.1	90.9	(65.2-123.3)
Female	0	0.4	nc	(nc-nc)	Female	45	47.3	95.1	(69.4-127.3)
<u>Lung and Bronchus</u>									
Male	2	5.9	nc	(nc-nc)					
Female	9	6.0	151.3	(69.0-287.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Duxbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	18.6	140.0	(91.4-205.1)	Male	30	11.5	260.2	(175.5-371.5)
Female	2	6.3	nc	(nc-nc)	Female	13	8.6	151.6	(80.6-259.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.5	144.6	(46.6-337.5)	Male	9	3.9	233.8	(106.7-443.8)
Female	1	2.8	nc	(nc-nc)	Female	1	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	18	10.5	172.1	(101.9-272.0)
Female	86	72.7	118.3	(94.6-146.1)	Female	6	8.9	67.6	(24.7-147.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.2	nc	(nc-nc)	Male	5	8.8	56.7	(18.3-132.3)
<u>Colon / Rectum</u>					Female	4	3.8	nc	(nc-nc)
Male	10	20.0	49.9	(23.9-91.7)	<u>Ovary</u>				
Female	11	18.9	58.3	(29.1-104.4)	Female	8	6.2	129.7	(55.8-255.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	4.8	nc	(nc-nc)	Male	5	6.6	75.4	(24.3-176.1)
Female	1	1.2	nc	(nc-nc)	Female	7	6.5	107.8	(43.2-222.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.1	nc	(nc-nc)	Male	81	59.6	135.9	(107.9-168.9)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	4.5	nc	(nc-nc)
Male	15	10.4	144.9	(81.1-239.0)	Female	0	2.6	nc	(nc-nc)
Female	2	5.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.7	nc	(nc-nc)
Male	1	2.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	2	4.3	nc	(nc-nc)
<u>Leukemia</u>					Female	8	12.4	64.6	(27.8-127.3)
Male	7	7.4	94.3	(37.8-194.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	5.0	119.0	(43.5-259.1)	Female	9	16.1	55.9	(25.5-106.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	6.5	nc	(nc-nc)	Male	266	239.1	111.3	(98.3-125.5)
Female	0	2.1	nc	(nc-nc)	Female	212	238.6	88.9	(77.3-101.7)
<u>Lung and Bronchus</u>									
Male	26	32.9	78.9	(51.5-115.7)					
Female	21	33.0	63.7	(39.4-97.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

East Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	13.5	103.4	(56.5-173.5)	Male	12	9.0	132.6	(68.4-231.6)
Female	3	5.9	nc	(nc-nc)	Female	9	8.1	111.5	(50.9-211.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.8	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	10	8.1	123.2	(59.0-226.5)
Female	45	67.6	66.6	(48.6-89.1)	Female	11	8.3	132.7	(66.2-237.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.2	nc	(nc-nc)	Male	9	7.0	128.9	(58.8-244.6)
<u>Colon / Rectum</u>					Female	1	3.5	nc	(nc-nc)
Male	21	15.2	138.3	(85.6-211.4)	<u>Ovary</u>				
Female	10	17.0	58.8	(28.1-108.1)	Female	7	5.8	121.7	(48.8-250.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.6	137.3	(44.2-320.3)	Male	3	5.0	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	7	6.0	116.8	(46.8-240.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.1	nc	(nc-nc)	Male	50	45.1	110.8	(82.3-146.1)
Female	2	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.4	nc	(nc-nc)
Male	13	8.2	158.6	(84.3-271.2)	Female	2	2.3	nc	(nc-nc)
Female	5	5.3	93.8	(30.2-218.9)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.0	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
<u>Leukemia</u>					Female	11	11.9	92.3	(46.0-165.1)
Male	3	5.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	4.7	nc	(nc-nc)	Female	11	15.3	71.8	(35.8-128.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	5.0	100.4	(32.4-234.4)	Male	198	183.4	108.0	(93.5-124.1)
Female	1	1.9	nc	(nc-nc)	Female	178	223.6	79.6	(68.4-92.2)
<u>Lung and Bronchus</u>									
Male	26	24.9	104.4	(68.2-153.0)					
Female	26	32.0	81.3	(53.1-119.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

East Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	2.9	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.5	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	5	10.6	47.2	(15.2-110.2)	Female	0	1.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	4	3.0	nc	(nc-nc)	<u>Ovary</u>				
Female	0	2.4	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	10	9.0	111.2	(53.2-204.5)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.7	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.0	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.7	nc	(nc-nc)	Female	3	2.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	0.9	nc	(nc-nc)	Male	34	36.2	94.0	(65.1-131.4)
Female	0	0.3	nc	(nc-nc)	Female	25	33.7	74.3	(48.0-109.6)
<u>Lung and Bronchus</u>									
Male	3	4.9	nc	(nc-nc)					
Female	6	4.6	131.5	(48.0-286.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

East Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	20.8	77.0	(44.0-125.0)	Male	18	12.6	143.3	(84.9-226.5)
Female	5	8.4	59.5	(19.2-138.9)	Female	9	10.2	88.5	(40.4-168.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.6	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
Female	3	3.2	nc	(nc-nc)	Female	4	3.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	10	11.3	88.2	(42.2-162.2)
Female	83	81.7	101.6	(80.9-125.9)	Female	7	11.2	62.5	(25.0-128.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.5	nc	(nc-nc)	Male	8	9.1	87.6	(37.7-172.6)
<u>Colon / Rectum</u>					Female	3	4.6	nc	(nc-nc)
Male	24	21.8	110.0	(70.4-163.6)	<u>Ovary</u>				
Female	32	24.3	131.5	(89.9-185.6)	Female	14	7.2	194.6	(106.3-326.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	5.2	nc	(nc-nc)	Male	6	7.2	83.0	(30.3-180.6)
Female	1	1.6	nc	(nc-nc)	Female	10	8.6	116.2	(55.6-213.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.3	nc	(nc-nc)	Male	51	61.6	82.8	(61.7-108.9)
Female	0	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	4.9	122.6	(44.8-266.9)
Male	15	10.8	139.1	(77.8-229.4)	Female	6	3.4	178.9	(65.3-389.5)
Female	5	6.7	74.5	(24.0-173.7)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.0	nc	(nc-nc)
Male	2	3.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.0	nc	(nc-nc)	Male	3	4.6	nc	(nc-nc)
<u>Leukemia</u>					Female	12	13.3	90.6	(46.7-158.2)
Male	5	8.0	62.4	(20.1-145.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	6.5	nc	(nc-nc)	Female	17	18.1	94.1	(54.8-150.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	6.7	nc	(nc-nc)	Male	234	256.5	91.2	(79.9-103.7)
Female	1	2.6	nc	(nc-nc)	Female	290	287.1	101.0	(89.7-113.3)
<u>Lung and Bronchus</u>									
Male	37	36.1	102.5	(72.2-141.3)					
Female	52	42.3	123.0	(91.9-161.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Eastham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	11.2	98.0	(48.9-175.4)	Male	7	6.3	111.9	(44.8-230.5)
Female	2	3.5	nc	(nc-nc)	Female	12	4.0	300.8	(155.2-525.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.6	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	5.5	90.3	(29.1-210.6)
Female	52	34.2	152.2	(113.6-199.6)	Female	4	4.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.9	nc	(nc-nc)	Male	6	4.4	135.5	(49.5-294.8)
<u>Colon / Rectum</u>					Female	2	1.9	nc	(nc-nc)
Male	10	10.8	92.8	(44.4-170.7)	<u>Ovary</u>				
Female	11	9.4	117.1	(58.4-209.6)	Female	3	3.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.7	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	5	3.5	142.3	(45.8-332.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	40	33.1	120.8	(86.3-164.5)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.5	nc	(nc-nc)
Male	6	5.3	114.2	(41.7-248.7)	Female	2	1.3	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<u>Leukemia</u>					Female	3	4.7	nc	(nc-nc)
Male	8	4.0	201.3	(86.7-396.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.5	nc	(nc-nc)	Female	4	8.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	3.4	nc	(nc-nc)	Male	149	131.6	113.3	(95.8-133.0)
Female	1	1.1	nc	(nc-nc)	Female	133	118.3	112.4	(94.1-133.2)
<u>Lung and Bronchus</u>									
Male	23	19.6	117.1	(74.2-175.7)					
Female	12	18.8	63.8	(32.9-111.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Easthampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	17.9	72.7	(38.7-124.3)	Male	8	11.9	67.4	(29.0-132.7)
Female	3	7.2	nc	(nc-nc)	Female	7	9.8	71.6	(28.7-147.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.6	140.4	(45.2-327.6)	Male	3	3.8	nc	(nc-nc)
Female	1	3.0	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	13	10.5	123.2	(65.6-210.8)
Female	76	77.8	97.7	(77.0-122.3)	Female	9	10.0	90.1	(41.1-171.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.6	nc	(nc-nc)	Male	11	9.2	119.5	(59.6-213.9)
<u>Colon / Rectum</u>					Female	5	4.2	119.4	(38.5-278.7)
Male	29	19.9	145.4	(97.4-208.8)	<u>Ovary</u>				
Female	22	21.1	104.4	(65.4-158.1)	Female	1	6.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	4.8	nc	(nc-nc)	Male	4	6.6	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	11	7.2	151.9	(75.7-271.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.4	nc	(nc-nc)	Male	49	60.2	81.4	(60.2-107.7)
Female	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	4.4	112.6	(36.3-262.8)
Male	10	10.6	94.4	(45.2-173.6)	Female	2	2.8	nc	(nc-nc)
Female	8	6.2	128.7	(55.4-253.6)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.5	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.9	nc	(nc-nc)	Male	0	4.9	nc	(nc-nc)
<u>Leukemia</u>					Female	7	14.3	48.9	(19.6-100.9)
Male	4	7.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	5.6	nc	(nc-nc)	Female	19	17.4	109.2	(65.7-170.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	6.7	nc	(nc-nc)	Male	203	241.0	84.2	(73.0-96.6)
Female	4	2.4	nc	(nc-nc)	Female	238	263.9	90.2	(79.1-102.4)
<u>Lung and Bronchus</u>									
Male	29	32.6	89.1	(59.6-127.9)					
Female	35	37.4	93.6	(65.2-130.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Easton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	21.0	128.3	(84.5-186.7)	Male	20	14.3	140.0	(85.5-216.3)
Female	11	7.0	156.8	(78.2-280.6)	Female	14	10.9	128.3	(70.1-215.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	4.7	128.3	(46.9-279.3)	Male	4	4.6	nc	(nc-nc)
Female	4	3.6	nc	(nc-nc)	Female	5	3.3	150.8	(48.6-351.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	12	12.9	93.2	(48.1-162.8)
Female	110	88.9	123.8	(101.7-149.2)	Female	9	10.5	85.9	(39.2-163.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.1	nc	(nc-nc)	Male	9	11.4	79.0	(36.0-150.0)
<u>Colon / Rectum</u>					Female	4	4.5	nc	(nc-nc)
Male	12	23.9	50.1	(25.9-87.6)	<u>Ovary</u>				
Female	30	20.9	143.6	(96.9-205.1)	Female	9	7.5	119.8	(54.7-227.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	5.9	nc	(nc-nc)	Male	12	7.8	153.4	(79.2-267.9)
Female	3	1.4	nc	(nc-nc)	Female	8	7.1	113.5	(48.9-223.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.9	nc	(nc-nc)	Male	87	74.9	116.1	(93.0-143.3)
Female	0	1.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	5.3	nc	(nc-nc)
Male	13	13.2	98.4	(52.4-168.4)	Female	3	2.9	nc	(nc-nc)
Female	4	6.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.5	nc	(nc-nc)
Male	2	3.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	10	6.2	160.7	(76.9-295.5)
<u>Leukemia</u>					Female	19	17.8	107.0	(64.4-167.1)
Male	15	9.1	164.2	(91.9-270.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	6.1	nc	(nc-nc)	Female	17	19.9	85.4	(49.7-136.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	13	8.2	158.6	(84.3-271.2)	Male	317	294.6	107.6	(96.1-120.1)
Female	4	2.5	nc	(nc-nc)	Female	339	287.0	118.1	(105.9-131.4)
<u>Lung and Bronchus</u>									
Male	40	39.1	102.4	(73.1-139.4)					
Female	49	38.1	128.7	(95.2-170.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Edgartown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	7.0	100.6	(40.3-207.4)	Male	17	4.5	378.0	(220.1-605.3)
Female	1	1.6	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.3	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
Female	24	17.7	135.9	(87.0-202.2)	Female	3	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	0.9	nc	(nc-nc)
Male	10	7.6	132.2	(63.3-243.1)	<u>Ovary</u>				
Female	4	4.6	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.0	nc	(nc-nc)	Male	0	2.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	24	25.5	94.1	(60.3-140.1)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.7	nc	(nc-nc)
Male	0	4.2	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.8	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.2	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<u>Leukemia</u>					Female	6	3.0	197.8	(72.2-430.5)
Male	2	2.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.2	nc	(nc-nc)	Female	0	4.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.7	nc	(nc-nc)	Male	91	95.0	95.8	(77.1-117.6)
Female	0	0.5	nc	(nc-nc)	Female	64	58.6	109.1	(84.0-139.4)
<u>Lung and Bronchus</u>									
Male	10	12.6	79.5	(38.0-146.2)					
Female	10	8.2	121.2	(58.0-222.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Egremont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.5	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	6	7.2	83.4	(30.5-181.6)	Female	1	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.2	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	5	2.5	202.0	(65.1-471.4)	<u>Ovary</u>				
Female	0	2.1	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	6	7.8	77.0	(28.1-167.6)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.0	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.6	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.8	nc	(nc-nc)	Male	23	30.4	75.7	(48.0-113.6)
Female	0	0.2	nc	(nc-nc)	Female	22	25.3	86.9	(54.4-131.5)
<u>Lung and Bronchus</u>									
Male	0	4.4	nc	(nc-nc)					
Female	3	3.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Erving

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.8	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	6	7.7	77.6	(28.4-169.0)	Female	2	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	3	2.0	nc	(nc-nc)	<u>Ovary</u>				
Female	1	2.0	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	6.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.5	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.5	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.6	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.7	nc	(nc-nc)	Male	15	24.7	60.8	(34.0-100.3)
Female	0	0.2	nc	(nc-nc)	Female	21	25.6	81.9	(50.7-125.3)
<u>Lung and Bronchus</u>									
Male	4	3.3	nc	(nc-nc)					
Female	3	3.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Essex

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	4.5	155.3	(62.2-320.0)	Male	8	2.9	276.8	(119.2-545.4)
Female	1	1.3	nc	(nc-nc)	Female	0	2.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.8	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	3	0.6	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	13	16.5	78.7	(41.8-134.5)	Female	2	1.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	5	2.2	222.3	(71.6-518.8)
<u>Colon / Rectum</u>					Female	0	0.8	nc	(nc-nc)
Male	1	4.9	nc	(nc-nc)	<u>Ovary</u>				
Female	3	3.8	nc	(nc-nc)	Female	4	1.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.2	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	8	15.3	52.4	(22.5-103.2)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.1	nc	(nc-nc)
Male	2	2.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.5	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	2	3.1	nc	(nc-nc)
Male	3	1.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.0	nc	(nc-nc)	Female	1	3.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.6	nc	(nc-nc)	Male	62	59.9	103.6	(79.4-132.8)
Female	0	0.5	nc	(nc-nc)	Female	49	52.6	93.2	(69.0-123.3)
<u>Lung and Bronchus</u>									
Male	11	8.2	134.8	(67.2-241.2)					
Female	8	7.1	112.7	(48.5-222.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Everett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	33	36.5	90.3	(62.2-126.8)	Male	18	24.4	73.6	(43.6-116.4)
Female	12	13.2	90.8	(46.9-158.6)	Female	7	20.5	34.1	(13.7-70.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	8.1	nc	(nc-nc)	Male	9	7.6	118.3	(54.0-224.6)
Female	2	6.5	nc	(nc-nc)	Female	2	6.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.3	nc	(nc-nc)	Male	17	21.9	77.8	(45.3-124.5)
Female	139	157.3	88.4	(74.3-104.3)	Female	19	19.3	98.2	(59.1-153.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	16	6.1	264.3	(151.0-429.3)	Male	20	17.9	111.4	(68.0-172.1)
<u>Colon / Rectum</u>					Female	10	8.1	123.4	(59.1-226.9)
Male	39	40.6	96.0	(68.2-131.2)	<u>Ovary</u>				
Female	30	40.9	73.3	(49.4-104.6)	Female	11	13.4	82.1	(40.9-147.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	14	9.4	148.6	(81.1-249.3)	Male	9	13.0	69.0	(31.5-131.1)
Female	1	2.5	nc	(nc-nc)	Female	15	13.5	110.9	(62.0-182.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	3.7	nc	(nc-nc)	Male	97	110.9	87.4	(70.9-106.7)
Female	3	2.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	17	9.0	189.6	(110.4-303.5)
Male	28	21.3	131.4	(87.3-189.9)	Female	6	5.6	108.1	(39.5-235.3)
Female	17	12.2	139.6	(81.3-223.5)	<u>Testis</u>				
<u>Larynx</u>					Male	5	7.3	68.9	(22.2-160.7)
Male	6	5.5	109.0	(39.8-237.3)	<u>Thyroid</u>				
Female	2	1.6	nc	(nc-nc)	Male	12	10.7	112.5	(58.1-196.6)
<u>Leukemia</u>					Female	27	33.8	79.8	(52.6-116.1)
Male	15	15.9	94.5	(52.8-155.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	11.6	94.9	(47.3-169.8)	Female	27	33.2	81.4	(53.7-118.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	20	12.9	155.0	(94.6-239.4)	Male	467	483.4	96.6	(88.0-105.8)
Female	6	4.4	137.9	(50.4-300.2)	Female	485	523.1	92.7	(84.6-101.3)
<u>Lung and Bronchus</u>									
Male	71	65.8	107.8	(84.2-136.0)					
Female	84	68.4	122.8	(98.0-152.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Fairhaven

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	21.1	108.9	(69.0-163.4)	Male	5	13.0	38.5	(12.4-89.9)
Female	18	8.6	209.4	(124.1-331.0)	Female	7	10.6	65.9	(26.4-135.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.7	nc	(nc-nc)	Male	5	4.2	118.3	(38.1-276.2)
Female	4	3.3	nc	(nc-nc)	Female	2	3.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	9	11.6	77.3	(35.3-146.7)
Female	79	84.6	93.4	(73.9-116.4)	Female	15	11.5	131.0	(73.2-216.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.6	nc	(nc-nc)	Male	7	9.7	72.4	(29.0-149.1)
<u>Colon / Rectum</u>					Female	2	4.8	nc	(nc-nc)
Male	10	22.3	44.9	(21.5-82.5)	<u>Ovary</u>				
Female	19	24.9	76.4	(46.0-119.4)	Female	14	7.5	187.3	(102.3-314.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	5.4	nc	(nc-nc)	Male	6	7.5	80.4	(29.3-174.9)
Female	2	1.6	nc	(nc-nc)	Female	9	8.9	101.5	(46.3-192.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.3	nc	(nc-nc)	Male	60	66.7	90.0	(68.6-115.8)
Female	0	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	5.0	99.9	(32.2-233.1)
Male	17	11.3	149.9	(87.3-240.1)	Female	3	3.4	nc	(nc-nc)
Female	8	7.0	115.0	(49.5-226.7)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.1	nc	(nc-nc)
Male	4	3.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.0	nc	(nc-nc)	Male	2	4.8	nc	(nc-nc)
<u>Leukemia</u>					Female	12	14.0	85.6	(44.2-149.5)
Male	7	8.1	85.9	(34.4-177.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	6.6	165.7	(82.6-296.5)	Female	19	19.0	99.8	(60.0-155.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	7.1	nc	(nc-nc)	Male	236	267.2	88.3	(77.4-100.3)
Female	1	2.7	nc	(nc-nc)	Female	289	296.5	97.5	(86.6-109.4)
<u>Lung and Bronchus</u>									
Male	42	37.1	113.1	(81.5-152.9)					
Female	39	43.3	90.0	(64.0-123.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Fall River

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	101	85.8	117.7	(95.9-143.0)	Male	31	55.2	56.2	(38.2-79.8)
Female	39	37.8	103.2	(73.4-141.0)	Female	25	50.3	49.7	(32.1-73.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	18	17.3	103.8	(61.5-164.1)	Male	12	17.5	68.5	(35.3-119.6)
Female	10	16.1	62.2	(29.8-114.4)	Female	16	16.9	94.4	(53.9-153.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	3.0	nc	(nc-nc)	Male	42	49.7	84.5	(60.9-114.2)
Female	328	395.2	83.0	(74.3-92.5)	Female	49	52.0	94.2	(69.7-124.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	17	13.2	128.4	(74.7-205.5)	Male	41	40.9	100.3	(71.9-136.0)
<u>Colon / Rectum</u>					Female	18	21.6	83.5	(49.4-131.9)
Male	109	93.2	117.0	(96.0-141.1)	<u>Ovary</u>				
Female	112	110.6	101.3	(83.4-121.9)	Female	16	34.5	46.4	(26.5-75.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	21	22.1	95.2	(58.9-145.5)	Male	30	30.7	97.8	(66.0-139.7)
Female	4	7.3	nc	(nc-nc)	Female	49	38.7	126.7	(93.7-167.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	10	7.3	137.0	(65.6-252.0)	Male	291	269.6	107.9	(95.9-121.1)
Female	7	6.4	108.9	(43.6-224.3)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	30	20.7	144.6	(97.5-206.5)
Male	50	48.3	103.5	(76.8-136.4)	Female	26	15.1	172.4	(112.6-252.7)
Female	32	31.9	100.2	(68.5-141.5)	<u>Testis</u>				
<u>Larynx</u>					Male	10	13.6	73.4	(35.1-134.9)
Male	20	12.8	156.3	(95.4-241.4)	<u>Thyroid</u>				
Female	8	4.5	176.8	(76.1-348.4)	Male	15	22.6	66.5	(37.2-109.7)
<u>Leukemia</u>					Female	81	73.2	110.7	(87.9-137.6)
Male	40	35.6	112.4	(80.3-153.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	35	30.5	114.8	(79.9-159.6)	Female	95	86.8	109.4	(88.5-133.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	31	29.6	104.7	(71.1-148.6)	Male	1233	1117.9	110.3	(104.2-116.6)
Female	14	12.0	116.8	(63.8-195.9)	Female	1313	1363.3	96.3	(91.2-101.7)
<u>Lung and Bronchus</u>									
Male	236	152.5	154.8	(135.7-175.9)					
Female	211	194.5	108.5	(94.3-124.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Falmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	53	56.6	93.7	(70.2-122.5)	Male	33	32.2	102.5	(70.5-143.9)
Female	13	20.5	63.4	(33.7-108.4)	Female	36	23.4	154.0	(107.9-213.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	14	8.6	163.0	(89.0-273.5)	Male	6	10.7	56.2	(20.5-122.4)
Female	9	7.4	122.3	(55.8-232.2)	Female	8	9.0	88.9	(38.3-175.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.8	nc	(nc-nc)	Male	35	28.8	121.6	(84.7-169.1)
Female	208	196.3	106.0	(92.0-121.4)	Female	18	26.7	67.5	(40.0-106.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	5.4	nc	(nc-nc)	Male	29	22.1	131.3	(87.9-188.6)
<u>Colon / Rectum</u>					Female	9	11.0	82.0	(37.4-155.6)
Male	43	55.2	77.9	(56.4-105.0)	<u>Ovary</u>				
Female	53	56.2	94.3	(70.6-123.4)	Female	20	17.2	116.4	(71.1-179.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	13.4	89.3	(46.1-156.0)	Male	12	19.1	62.9	(32.5-109.8)
Female	6	4.0	150.0	(54.8-326.4)	Female	13	20.8	62.6	(33.3-107.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.7	nc	(nc-nc)	Male	169	159.0	106.3	(90.9-123.6)
Female	1	2.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	12	12.9	93.2	(48.1-162.9)
Male	32	26.6	120.1	(82.1-169.6)	Female	5	7.6	65.6	(21.2-153.2)
Female	16	16.4	97.4	(55.6-158.2)	<u>Testis</u>				
<u>Larynx</u>					Male	4	3.7	nc	(nc-nc)
Male	12	7.7	155.7	(80.3-272.0)	<u>Thyroid</u>				
Female	2	2.4	nc	(nc-nc)	Male	7	9.9	70.5	(28.3-145.3)
<u>Leukemia</u>					Female	14	28.3	49.5	(27.0-83.0)
Male	22	20.5	107.2	(67.2-162.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	14.8	54.0	(23.2-106.3)	Female	33	45.1	73.1	(50.3-102.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	16	17.0	94.4	(53.9-153.2)	Male	648	662.8	97.8	(90.4-105.6)
Female	4	6.4	nc	(nc-nc)	Female	643	686.9	93.6	(86.5-101.1)
<u>Lung and Bronchus</u>									
Male	76	99.7	76.2	(60.0-95.4)					
Female	113	107.9	104.7	(86.3-125.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Fitchburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	56	36.6	152.9	(115.5-198.6)	Male	13	24.2	53.8	(28.6-92.0)
Female	16	13.8	115.8	(66.1-188.1)	Female	10	19.1	52.4	(25.1-96.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	8.0	nc	(nc-nc)	Male	6	7.6	78.6	(28.7-171.1)
Female	12	6.3	191.0	(98.6-333.7)	Female	7	6.2	112.7	(45.2-232.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.3	nc	(nc-nc)	Male	13	21.8	59.7	(31.8-102.1)
Female	143	149.0	96.0	(80.9-113.1)	Female	19	19.2	98.9	(59.5-154.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	11	5.1	216.0	(107.7-386.5)	Male	23	18.2	126.6	(80.3-190.0)
<u>Colon / Rectum</u>					Female	9	8.0	112.3	(51.3-213.2)
Male	37	40.3	91.7	(64.6-126.4)	<u>Ovary</u>				
Female	43	40.1	107.1	(77.5-144.3)	Female	13	13.0	99.9	(53.2-170.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	9.6	72.7	(29.1-149.8)	Male	13	13.2	98.5	(52.4-168.5)
Female	1	2.7	nc	(nc-nc)	Female	6	14.0	43.0	(15.7-93.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	3.6	nc	(nc-nc)	Male	99	118.1	83.8	(68.1-102.0)
Female	0	2.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	15	8.9	167.6	(93.7-276.5)
Male	24	21.3	112.7	(72.2-167.7)	Female	7	5.5	128.4	(51.4-264.5)
Female	12	12.1	99.5	(51.3-173.8)	<u>Testis</u>				
<u>Larynx</u>					Male	6	6.7	88.9	(32.5-193.6)
Male	2	5.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.7	nc	(nc-nc)	Male	6	10.3	58.3	(21.3-127.0)
<u>Leukemia</u>					Female	27	28.9	93.4	(61.5-135.9)
Male	14	15.8	88.7	(48.5-148.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	13	11.4	113.7	(60.5-194.5)	Female	26	32.8	79.4	(51.8-116.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	18	13.2	136.2	(80.7-215.3)	Male	486	489.4	99.3	(90.7-108.5)
Female	6	4.5	134.7	(49.2-293.2)	Female	519	510.6	101.7	(93.1-110.8)
<u>Lung and Bronchus</u>									
Male	86	65.8	130.7	(104.5-161.4)					
Female	85	72.7	116.9	(93.4-144.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Florida

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.9	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	3	4.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.0	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	3.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	1	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.7	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.3	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	8	12.1	66.2	(28.5-130.5)
Female	0	0.1	nc	(nc-nc)	Female	8	13.5	59.4	(25.6-117.0)
<u>Lung and Bronchus</u>									
Male	0	1.6	nc	(nc-nc)					
Female	1	1.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Foxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	17.5	68.7	(35.4-120.0)	Male	21	11.3	185.0	(114.5-282.9)
Female	3	6.3	nc	(nc-nc)	Female	10	9.2	108.7	(52.0-199.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	3.5	201.2	(80.6-414.7)	Male	2	3.7	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	Female	2	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	12	10.2	117.6	(60.7-205.4)
Female	87	76.5	113.7	(91.1-140.2)	Female	7	9.1	76.6	(30.7-157.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.6	nc	(nc-nc)	Male	7	8.6	81.1	(32.5-167.2)
<u>Colon / Rectum</u>					Female	0	3.9	nc	(nc-nc)
Male	21	19.5	107.5	(66.5-164.3)	<u>Ovary</u>				
Female	19	18.3	104.1	(62.6-162.6)	Female	8	6.5	123.8	(53.3-243.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	4.6	131.6	(48.1-286.5)	Male	3	6.3	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	5	6.2	80.4	(25.9-187.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	1.4	366.9	(118.2-856.2)	Male	66	54.2	121.7	(94.1-154.9)
Female	0	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	4.3	187.2	(80.6-368.8)
Male	12	10.0	119.7	(61.8-209.1)	Female	2	2.5	nc	(nc-nc)
Female	8	6.0	134.3	(57.8-264.6)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.4	nc	(nc-nc)
Male	0	2.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	8	4.7	170.4	(73.3-335.7)
<u>Leukemia</u>					Female	17	14.3	119.1	(69.3-190.6)
Male	10	7.2	139.1	(66.6-255.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	5.2	115.5	(42.2-251.3)	Female	20	17.3	115.7	(70.7-178.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	6.2	nc	(nc-nc)	Male	252	228.2	110.4	(97.2-124.9)
Female	1	2.2	nc	(nc-nc)	Female	267	248.4	107.5	(95.0-121.2)
<u>Lung and Bronchus</u>									
Male	30	30.7	97.6	(65.8-139.3)					
Female	43	34.6	124.4	(90.0-167.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Framingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	59	66.6	88.5	(67.4-114.2)	Male	42	43.1	97.4	(70.2-131.6)
Female	21	25.8	81.4	(50.4-124.5)	Female	27	37.0	73.1	(48.1-106.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	13.5	66.5	(30.4-126.3)	Male	14	13.6	102.6	(56.1-172.2)
Female	5	11.9	41.9	(13.5-97.7)	Female	11	11.7	93.7	(46.7-167.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	2.3	nc	(nc-nc)	Male	41	38.7	105.9	(76.0-143.6)
Female	288	287.3	100.3	(89.0-112.5)	Female	27	36.4	74.2	(48.9-107.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	18	10.3	175.6	(104.0-277.5)	Male	28	31.5	88.8	(59.0-128.4)
<u>Colon / Rectum</u>					Female	10	15.3	65.2	(31.2-120.0)
Male	64	72.2	88.7	(68.3-113.2)	<u>Ovary</u>				
Female	77	77.0	99.9	(78.9-124.9)	Female	27	24.8	108.7	(71.6-158.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	17.0	58.8	(28.1-108.1)	Male	34	23.8	142.7	(98.8-199.4)
Female	5	5.0	100.2	(32.3-233.9)	Female	29	26.5	109.4	(73.2-157.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	5.6	nc	(nc-nc)	Male	201	204.1	98.5	(85.3-113.1)
Female	9	5.0	179.4	(81.9-340.6)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	22	16.2	136.0	(85.2-205.9)
Male	50	37.3	133.9	(99.4-176.5)	Female	8	10.5	76.3	(32.8-150.3)
Female	22	22.8	96.6	(60.5-146.3)	<u>Testis</u>				
<u>Larynx</u>					Male	9	10.8	83.4	(38.1-158.3)
Male	6	9.9	60.5	(22.1-131.8)	<u>Thyroid</u>				
Female	3	3.1	nc	(nc-nc)	Male	24	17.8	135.2	(86.6-201.1)
<u>Leukemia</u>					Female	62	57.1	108.5	(83.2-139.2)
Male	24	27.8	86.3	(55.3-128.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	21	21.9	96.1	(59.4-146.8)	Female	55	62.8	87.6	(66.0-114.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	27	23.1	117.0	(77.1-170.3)	Male	831	863.9	96.2	(89.8-103.0)
Female	7	8.4	83.2	(33.3-171.4)	Female	949	973.5	97.5	(91.4-103.9)
<u>Lung and Bronchus</u>									
Male	113	117.9	95.9	(79.0-115.2)					
Female	128	132.6	96.5	(80.5-114.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Franklin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	27.8	97.2	(64.0-141.4)	Male	21	18.7	112.1	(69.4-171.4)
Female	10	10.0	99.8	(47.8-183.6)	Female	17	15.3	111.0	(64.7-177.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	6.2	80.9	(26.1-188.8)	Male	11	5.9	185.8	(92.6-332.5)
Female	6	5.1	118.0	(43.1-256.8)	Female	5	4.7	107.4	(34.6-250.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	15	16.9	88.9	(49.7-146.6)
Female	136	124.1	109.6	(91.9-129.6)	Female	13	14.7	88.5	(47.1-151.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	4.5	156.8	(62.8-323.1)	Male	17	14.5	117.0	(68.1-187.3)
<u>Colon / Rectum</u>					Female	2	6.3	nc	(nc-nc)
Male	29	31.6	91.8	(61.5-131.9)	<u>Ovary</u>				
Female	27	30.6	88.2	(58.1-128.3)	Female	12	10.4	115.0	(59.3-200.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	7.5	134.2	(64.2-246.8)	Male	14	10.2	136.8	(74.7-229.5)
Female	1	2.0	nc	(nc-nc)	Female	7	10.2	68.9	(27.6-142.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.5	nc	(nc-nc)	Male	96	91.0	105.5	(85.5-128.8)
Female	5	2.1	242.5	(78.2-566.0)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	12	6.9	173.7	(89.7-303.5)
Male	14	16.9	82.8	(45.2-139.0)	Female	5	4.2	119.9	(38.6-279.7)
Female	17	9.5	178.5	(103.9-285.8)	<u>Testis</u>				
<u>Larynx</u>					Male	8	4.5	177.7	(76.5-350.2)
Male	9	4.3	207.0	(94.5-393.0)	<u>Thyroid</u>				
Female	0	1.3	nc	(nc-nc)	Male	16	8.2	195.3	(111.6-317.2)
<u>Leukemia</u>					Female	33	25.0	132.1	(90.9-185.5)
Male	12	12.2	98.4	(50.8-171.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	8.8	68.5	(25.0-149.2)	Female	38	26.7	142.4	(100.8-195.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	10.3	77.7	(33.5-153.1)	Male	398	377.5	105.4	(95.3-116.3)
Female	0	3.4	nc	(nc-nc)	Female	414	403.5	102.6	(93.0-113.0)
<u>Lung and Bronchus</u>									
Male	43	50.2	85.7	(62.0-115.4)					
Female	42	53.2	79.0	(56.9-106.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Freetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	9.7	103.2	(49.4-189.9)	Male	3	6.4	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	Female	4	4.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.0	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	3	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.8	nc	(nc-nc)
Female	43	37.6	114.3	(82.7-154.0)	Female	5	4.3	117.1	(37.7-273.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.3	nc	(nc-nc)	Male	7	5.1	137.2	(55.0-282.6)
<u>Colon / Rectum</u>					Female	4	1.9	nc	(nc-nc)
Male	12	10.8	110.8	(57.2-193.6)	<u>Ovary</u>				
Female	3	8.4	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.7	nc	(nc-nc)	Male	0	3.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	5	2.9	174.6	(56.3-407.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	42	33.9	124.1	(89.4-167.7)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.4	nc	(nc-nc)
Male	5	5.9	85.0	(27.4-198.5)	Female	1	1.1	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.3	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<u>Leukemia</u>					Female	6	7.3	81.8	(29.9-178.1)
Male	2	4.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.4	nc	(nc-nc)	Female	10	8.5	117.3	(56.1-215.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.7	nc	(nc-nc)	Male	127	132.3	96.0	(80.0-114.2)
Female	1	1.0	nc	(nc-nc)	Female	138	119.1	115.9	(97.4-136.9)
<u>Lung and Bronchus</u>									
Male	16	17.6	90.7	(51.8-147.3)					
Female	27	15.8	171.0	(112.6-248.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gardner

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	22.1	63.2	(34.5-106.1)	Male	5	14.1	35.6	(11.5-83.0)
Female	11	8.2	133.6	(66.6-239.1)	Female	8	10.9	73.4	(31.6-144.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	4.3	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
Female	6	3.5	171.9	(62.8-374.2)	Female	3	3.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	10	12.7	78.9	(37.8-145.1)
Female	65	85.7	75.8	(58.5-96.7)	Female	11	11.3	97.2	(48.4-173.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.9	nc	(nc-nc)	Male	13	10.2	127.4	(67.8-217.9)
<u>Colon / Rectum</u>					Female	4	4.7	nc	(nc-nc)
Male	27	24.0	112.7	(74.2-164.0)	<u>Ovary</u>				
Female	23	23.8	96.5	(61.2-144.8)	Female	9	7.5	120.6	(55.0-228.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	5.6	233.9	(124.4-399.9)	Male	8	7.8	102.8	(44.3-202.6)
Female	2	1.6	nc	(nc-nc)	Female	7	8.4	83.6	(33.5-172.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.8	nc	(nc-nc)	Male	43	64.7	66.5	(48.1-89.6)
Female	2	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	5.3	nc	(nc-nc)
Male	15	12.0	124.6	(69.7-205.6)	Female	4	3.3	nc	(nc-nc)
Female	7	7.0	100.5	(40.3-207.2)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.3	nc	(nc-nc)
Male	2	3.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.9	nc	(nc-nc)	Male	2	5.7	nc	(nc-nc)
<u>Leukemia</u>					Female	9	15.5	58.2	(26.6-110.6)
Male	11	9.0	122.1	(60.9-218.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	6.7	150.3	(72.0-276.5)	Female	21	19.2	109.2	(67.6-167.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	13	7.5	173.0	(92.0-295.9)	Male	265	280.4	94.5	(83.5-106.6)
Female	4	2.7	nc	(nc-nc)	Female	286	295.5	96.8	(85.9-108.7)
<u>Lung and Bronchus</u>									
Male	53	38.4	138.0	(103.3-180.5)					
Female	53	42.0	126.1	(94.4-164.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Georgetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	8.6	nc	(nc-nc)	Male	7	5.7	123.5	(49.5-254.5)
Female	1	2.6	nc	(nc-nc)	Female	2	4.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.8	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	8	5.1	156.6	(67.4-308.6)
Female	32	35.1	91.2	(62.4-128.8)	Female	1	4.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.2	nc	(nc-nc)	Male	1	4.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.7	nc	(nc-nc)
Male	7	9.7	72.3	(29.0-149.0)	<u>Ovary</u>				
Female	7	8.0	87.5	(35.1-180.4)	Female	0	2.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.3	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	35	29.3	119.5	(83.2-166.2)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.1	nc	(nc-nc)
Male	5	5.2	95.6	(30.8-223.1)	Female	0	1.0	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.1	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
<u>Leukemia</u>					Female	4	6.7	nc	(nc-nc)
Male	1	3.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.2	nc	(nc-nc)	Female	11	7.9	139.3	(69.4-249.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	3.1	nc	(nc-nc)	Male	105	116.4	90.2	(73.8-109.2)
Female	1	0.9	nc	(nc-nc)	Female	96	110.7	86.8	(70.3-105.9)
<u>Lung and Bronchus</u>									
Male	8	15.8	50.7	(21.8-100.0)					
Female	12	14.7	81.6	(42.1-142.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gill

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	1.9	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	6	7.7	77.6	(28.3-168.8)	Female	0	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	0.4	nc	(nc-nc)
Male	1	2.1	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.8	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.1	nc	(nc-nc)	Male	3	6.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.4	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.8	nc	(nc-nc)	Male	22	26.0	84.8	(53.1-128.3)
Female	0	0.2	nc	(nc-nc)	Female	22	24.7	88.9	(55.7-134.7)
<u>Lung and Bronchus</u>									
Male	9	3.4	261.2	(119.2-495.9)					
Female	4	3.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gloucester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	41	38.3	107.1	(76.9-145.3)	Male	27	23.7	113.8	(75.0-165.6)
Female	23	14.8	155.6	(98.6-233.4)	Female	19	19.1	99.6	(60.0-155.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	6.8	nc	(nc-nc)	Male	7	7.8	89.3	(35.8-183.9)
Female	5	6.0	83.5	(26.9-194.8)	Female	3	6.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.3	nc	(nc-nc)	Male	25	21.3	117.2	(75.8-173.0)
Female	171	158.7	107.7	(92.2-125.1)	Female	24	20.3	118.4	(75.8-176.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	4.8	nc	(nc-nc)	Male	22	18.2	120.9	(75.8-183.1)
<u>Colon / Rectum</u>					Female	10	8.5	117.4	(56.2-215.9)
Male	41	40.3	101.7	(73.0-138.0)	<u>Ovary</u>				
Female	49	42.1	116.3	(86.0-153.7)	Female	20	13.7	146.1	(89.2-225.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	14	10.1	138.6	(75.7-232.5)	Male	24	13.8	174.4	(111.7-259.5)
Female	1	2.9	nc	(nc-nc)	Female	11	15.0	73.5	(36.7-131.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.4	nc	(nc-nc)	Male	134	128.3	104.5	(87.5-123.7)
Female	4	2.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	9	9.2	98.3	(44.9-186.7)
Male	22	21.1	104.2	(65.3-157.8)	Female	2	5.7	nc	(nc-nc)
Female	13	12.7	102.3	(54.4-174.9)	<u>Testis</u>				
<u>Larynx</u>					Male	4	3.9	nc	(nc-nc)
Male	8	5.9	136.1	(58.6-268.2)	<u>Thyroid</u>				
Female	3	1.8	nc	(nc-nc)	Male	12	8.8	136.8	(70.6-239.0)
<u>Leukemia</u>					Female	26	26.1	99.5	(65.0-145.8)
Male	24	14.9	160.6	(102.9-239.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	12	11.3	105.8	(54.6-184.8)	Female	27	36.3	74.4	(49.0-108.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	13.6	44.2	(16.1-96.2)	Male	561	497.0	112.9	(103.7-122.6)
Female	6	4.8	123.8	(45.2-269.4)	Female	575	534.9	107.5	(98.9-116.6)
<u>Lung and Bronchus</u>									
Male	88	68.7	128.1	(102.7-157.8)					
Female	101	78.0	129.5	(105.5-157.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Goshen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	3	0.7	nc	(nc-nc)
Female	4	5.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.1	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.5	nc	(nc-nc)	Male	13	16.9	77.0	(41.0-131.7)
Female	0	0.2	nc	(nc-nc)	Female	11	18.5	59.5	(29.7-106.5)
<u>Lung and Bronchus</u>									
Male	1	2.3	nc	(nc-nc)					
Female	0	2.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gosnold

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.0	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	2.8	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	0	0.3	nc	(nc-nc)					
Female	0	0.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Grafton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	16.5	115.4	(69.5-180.3)	Male	9	11.1	81.3	(37.1-154.4)
Female	5	5.7	88.3	(28.5-206.2)	Female	9	8.7	103.6	(47.3-196.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	3.6	251.1	(114.6-476.7)	Male	4	3.4	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	6	9.9	60.4	(22.1-131.5)
Female	78	70.4	110.8	(87.5-138.2)	Female	7	8.3	84.6	(33.9-174.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.6	nc	(nc-nc)	Male	14	8.4	165.8	(90.6-278.3)
<u>Colon / Rectum</u>					Female	3	3.5	nc	(nc-nc)
Male	14	18.8	74.3	(40.6-124.7)	<u>Ovary</u>				
Female	19	17.0	111.9	(67.3-174.7)	Female	4	5.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	4.3	nc	(nc-nc)	Male	3	6.0	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	4	5.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.4	nc	(nc-nc)	Male	59	52.0	113.5	(86.4-146.5)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	4.1	nc	(nc-nc)
Male	14	9.8	142.5	(77.8-239.1)	Female	2	2.3	nc	(nc-nc)
Female	5	5.4	91.9	(29.6-214.5)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.7	nc	(nc-nc)
Male	7	2.5	279.8	(112.1-576.5)	<u>Thyroid</u>				
Female	2	0.8	nc	(nc-nc)	Male	7	4.8	145.5	(58.3-299.8)
<u>Leukemia</u>					Female	15	14.3	104.6	(58.5-172.5)
Male	11	7.2	153.8	(76.7-275.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	4.9	185.0	(84.4-351.2)	Female	15	15.3	98.2	(54.9-162.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	6.0	nc	(nc-nc)	Male	232	220.3	105.3	(92.2-119.8)
Female	0	1.9	nc	(nc-nc)	Female	243	228.7	106.3	(93.3-120.5)
<u>Lung and Bronchus</u>									
Male	32	29.1	109.9	(75.1-155.1)					
Female	36	30.8	117.0	(81.9-162.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Granby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	6.1	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.3	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	3.7	189.9	(76.1-391.4)
Female	18	30.3	59.4	(35.2-93.9)	Female	2	3.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.0	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.6	nc	(nc-nc)
Male	8	6.9	115.2	(49.6-227.0)	<u>Ovary</u>				
Female	7	7.6	92.1	(36.9-189.9)	Female	4	2.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	1.7	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.5	nc	(nc-nc)	Male	18	22.2	80.9	(47.9-127.9)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.5	nc	(nc-nc)
Male	4	3.8	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Female	8	2.3	347.8	(149.8-685.4)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.8	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
<u>Leukemia</u>					Female	1	5.7	nc	(nc-nc)
Male	2	2.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.1	nc	(nc-nc)	Female	6	6.9	87.4	(31.9-190.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.5	nc	(nc-nc)	Male	83	85.7	96.8	(77.1-120.0)
Female	2	0.9	nc	(nc-nc)	Female	77	99.1	77.7	(61.3-97.1)
<u>Lung and Bronchus</u>									
Male	15	11.2	134.2	(75.1-221.4)					
Female	11	13.1	84.2	(42.0-150.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Granville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	2.2	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	1.2	nc	(nc-nc)
Female	7	7.5	93.0	(37.2-191.6)	Female	0	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	<u>Ovary</u>				
Female	2	1.8	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	10	7.6	131.9	(63.1-242.5)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	3	1.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	3	1.3	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	5	1.8	285.2	(91.9-665.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.8	nc	(nc-nc)	Male	28	28.8	97.4	(64.7-140.7)
Female	0	0.2	nc	(nc-nc)	Female	25	24.2	103.3	(66.8-152.5)
<u>Lung and Bronchus</u>									
Male	2	4.0	nc	(nc-nc)					
Female	4	3.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Great Barrington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	7.8	167.4	(89.1-286.3)	Male	8	4.9	162.1	(69.8-319.4)
Female	6	3.8	159.8	(58.3-347.8)	Female	3	4.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.5	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
Female	38	35.4	107.5	(76.1-147.5)	Female	4	4.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.0	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	2.0	nc	(nc-nc)
Male	6	8.4	71.3	(26.0-155.3)	<u>Ovary</u>				
Female	11	10.5	104.3	(52.0-186.7)	Female	2	3.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	2.0	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	3.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	31	23.1	134.4	(91.3-190.7)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	1.9	nc	(nc-nc)
Male	4	4.2	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
Female	1	2.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.1	nc	(nc-nc)
Male	3	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
<u>Leukemia</u>					Female	8	5.4	147.2	(63.4-290.1)
Male	3	3.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.8	nc	(nc-nc)	Female	5	8.1	61.9	(20.0-144.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.7	nc	(nc-nc)	Male	116	98.7	117.5	(97.1-140.9)
Female	1	1.2	nc	(nc-nc)	Female	126	125.5	100.4	(83.7-119.6)
<u>Lung and Bronchus</u>									
Male	17	13.4	126.8	(73.8-203.0)					
Female	23	19.0	121.1	(76.8-181.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Greenfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	21.5	83.6	(49.5-132.2)	Male	9	13.5	66.4	(30.3-126.1)
Female	6	7.7	77.9	(28.4-169.5)	Female	7	10.2	68.7	(27.5-141.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	4.0	150.0	(54.8-326.5)	Male	4	4.4	nc	(nc-nc)
Female	6	3.2	187.5	(68.5-408.1)	Female	3	3.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	4	12.1	nc	(nc-nc)
Female	71	80.7	88.0	(68.7-111.0)	Female	12	10.6	113.1	(58.4-197.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.7	nc	(nc-nc)	Male	9	10.0	89.6	(40.9-170.1)
<u>Colon / Rectum</u>					Female	3	4.4	nc	(nc-nc)
Male	26	22.8	114.1	(74.5-167.2)	<u>Ovary</u>				
Female	27	22.6	119.3	(78.6-173.6)	Female	6	7.0	85.4	(31.2-185.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	5.5	nc	(nc-nc)	Male	9	7.7	116.5	(53.2-221.1)
Female	3	1.5	nc	(nc-nc)	Female	8	8.0	100.4	(43.2-197.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	1.5	326.3	(105.2-761.5)	Male	36	68.4	52.7	(36.9-72.9)
Female	2	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	5.2	nc	(nc-nc)
Male	7	11.7	59.6	(23.9-122.8)	Female	4	3.1	nc	(nc-nc)
Female	5	6.5	77.2	(24.9-180.1)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.7	nc	(nc-nc)
Male	1	3.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	3	5.2	nc	(nc-nc)
<u>Leukemia</u>					Female	4	14.3	nc	(nc-nc)
Male	6	8.6	70.1	(25.6-152.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	6.2	97.3	(35.5-211.7)	Female	20	18.2	109.9	(67.1-169.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	7.6	nc	(nc-nc)	Male	205	276.9	74.0	(64.2-84.9)
Female	5	2.5	200.2	(64.5-467.1)	Female	275	277.2	99.2	(87.8-111.7)
<u>Lung and Bronchus</u>									
Male	27	38.3	70.6	(46.5-102.7)					
Female	48	38.8	123.7	(91.2-164.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Groton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	11.1	62.8	(25.2-129.4)	Male	3	7.5	nc	(nc-nc)
Female	0	3.6	nc	(nc-nc)	Female	4	5.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.3	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	3	6.8	nc	(nc-nc)
Female	38	48.0	79.1	(56.0-108.6)	Female	5	5.4	92.3	(29.7-215.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.6	nc	(nc-nc)	Male	6	6.0	99.6	(36.4-216.8)
<u>Colon / Rectum</u>					Female	1	2.4	nc	(nc-nc)
Male	16	12.8	124.7	(71.2-202.5)	<u>Ovary</u>				
Female	10	11.1	90.4	(43.3-166.2)	Female	2	4.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	3.1	nc	(nc-nc)	Male	4	4.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	3	3.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.9	nc	(nc-nc)	Male	31	38.6	80.2	(54.5-113.9)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.8	nc	(nc-nc)
Male	4	6.9	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
Female	2	3.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	5	1.4	358.0	(115.4-835.4)
Male	1	1.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	6	3.2	190.2	(69.5-414.0)
<u>Leukemia</u>					Female	8	9.1	88.0	(37.9-173.5)
Male	3	4.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	3.0	nc	(nc-nc)	Female	12	10.8	110.8	(57.2-193.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	4.4	nc	(nc-nc)	Male	122	153.5	79.5	(66.0-94.9)
Female	2	1.3	nc	(nc-nc)	Female	110	151.1	72.8	(59.8-87.7)
<u>Lung and Bronchus</u>									
Male	11	20.3	54.1	(27.0-96.9)					
Female	10	19.8	50.5	(24.2-92.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Groveland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	8.5	70.8	(25.8-154.0)	Male	5	5.4	93.4	(30.1-218.0)
Female	3	2.8	nc	(nc-nc)	Female	11	3.9	285.4	(142.3-510.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.6	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	4.8	145.6	(58.3-300.0)
Female	39	33.0	118.2	(84.0-161.5)	Female	6	3.9	152.1	(55.5-331.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.0	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.7	nc	(nc-nc)
Male	3	9.1	nc	(nc-nc)	<u>Ovary</u>				
Female	6	8.0	74.9	(27.4-163.1)	Female	4	2.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.2	nc	(nc-nc)	Male	5	3.0	165.0	(53.2-385.1)
Female	1	0.6	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	29	26.6	108.8	(72.9-156.3)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.0	nc	(nc-nc)
Male	2	4.7	nc	(nc-nc)	Female	3	1.1	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.0	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<u>Leukemia</u>					Female	8	5.5	145.2	(62.5-286.1)
Male	2	3.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.2	nc	(nc-nc)	Female	5	7.7	65.3	(21.0-152.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.9	nc	(nc-nc)	Male	86	109.3	78.7	(62.9-97.2)
Female	1	1.0	nc	(nc-nc)	Female	121	107.2	112.8	(93.6-134.8)
<u>Lung and Bronchus</u>									
Male	10	15.3	65.3	(31.2-120.0)					
Female	14	15.1	92.8	(50.7-155.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	7.0	86.2	(31.5-187.6)	Male	2	4.2	nc	(nc-nc)
Female	2	3.2	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.2	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
Female	27	30.1	89.7	(59.1-130.5)	Female	5	4.2	120.3	(38.8-280.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.9	nc	(nc-nc)	Male	6	3.1	196.7	(71.8-428.1)
<u>Colon / Rectum</u>					Female	0	1.7	nc	(nc-nc)
Male	5	7.1	70.4	(22.7-164.4)	<u>Ovary</u>				
Female	12	8.8	137.1	(70.7-239.4)	Female	2	2.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.8	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	3.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	19	21.6	88.1	(53.0-137.6)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.6	nc	(nc-nc)
Male	2	3.6	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.8	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	4	4.6	nc	(nc-nc)
Male	1	2.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	2.4	nc	(nc-nc)	Female	13	6.9	188.8	(100.4-322.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.3	nc	(nc-nc)	Male	66	86.7	76.1	(58.8-96.8)
Female	1	1.0	nc	(nc-nc)	Female	88	106.3	82.8	(66.4-102.0)
<u>Lung and Bronchus</u>									
Male	5	12.3	40.6	(13.1-94.7)					
Female	7	16.1	43.4	(17.4-89.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Halifax

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	7.7	90.8	(36.4-187.1)	Male	4	5.2	nc	(nc-nc)
Female	1	3.0	nc	(nc-nc)	Female	3	4.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	4.7	nc	(nc-nc)
Female	32	34.9	91.8	(62.8-129.5)	Female	6	4.3	139.9	(51.1-304.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.2	nc	(nc-nc)	Male	5	4.0	126.2	(40.7-294.5)
<u>Colon / Rectum</u>					Female	1	1.8	nc	(nc-nc)
Male	13	8.9	146.6	(78.0-250.7)	<u>Ovary</u>				
Female	13	9.0	143.8	(76.5-245.9)	Female	3	2.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.0	nc	(nc-nc)	Male	8	2.8	283.7	(122.1-559.0)
Female	1	0.6	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	36	23.9	150.5	(105.4-208.3)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.9	nc	(nc-nc)
Male	8	4.6	172.8	(74.4-340.6)	Female	1	1.2	nc	(nc-nc)
Female	5	2.7	183.3	(59.1-427.7)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.2	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
<u>Leukemia</u>					Female	12	6.3	190.8	(98.5-333.3)
Male	4	3.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.4	nc	(nc-nc)	Female	13	7.4	175.5	(93.4-300.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.8	nc	(nc-nc)	Male	131	102.7	127.5	(106.6-151.3)
Female	2	1.0	nc	(nc-nc)	Female	128	114.9	111.4	(92.9-132.5)
<u>Lung and Bronchus</u>									
Male	17	13.9	122.2	(71.2-195.7)					
Female	16	16.2	98.5	(56.3-159.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hamilton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	8.0	75.1	(27.4-163.4)	Male	4	5.2	nc	(nc-nc)
Female	4	2.9	nc	(nc-nc)	Female	6	4.2	143.8	(52.5-313.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.7	nc	(nc-nc)	Male	4	1.7	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	4.7	nc	(nc-nc)
Female	41	34.5	118.8	(85.2-161.1)	Female	11	4.2	263.3	(131.3-471.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.8	nc	(nc-nc)
Male	3	8.8	nc	(nc-nc)	<u>Ovary</u>				
Female	11	8.6	127.4	(63.5-228.0)	Female	1	3.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.1	nc	(nc-nc)	Male	0	2.9	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	2.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	26	26.4	98.4	(64.3-144.2)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.9	nc	(nc-nc)
Male	8	4.7	171.5	(73.8-337.9)	Female	0	1.2	nc	(nc-nc)
Female	3	2.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.2	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	5	2.1	232.7	(75.0-543.0)
<u>Leukemia</u>					Female	7	6.3	111.1	(44.5-228.9)
Male	5	3.4	148.5	(47.9-346.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.4	nc	(nc-nc)	Female	5	7.7	64.6	(20.8-150.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.9	nc	(nc-nc)	Male	100	106.6	93.8	(76.3-114.1)
Female	0	1.0	nc	(nc-nc)	Female	122	113.1	107.9	(89.6-128.8)
<u>Lung and Bronchus</u>									
Male	14	14.5	96.8	(52.9-162.4)					
Female	12	15.7	76.3	(39.4-133.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hampden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	8.4	95.6	(41.2-188.4)	Male	2	5.1	nc	(nc-nc)
Female	0	2.5	nc	(nc-nc)	Female	2	3.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.4	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	8	4.5	177.1	(76.2-348.9)
Female	23	26.6	86.4	(54.7-129.6)	Female	2	3.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.8	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.4	nc	(nc-nc)
Male	4	8.5	nc	(nc-nc)	<u>Ovary</u>				
Female	3	7.2	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.1	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	20	25.7	77.7	(47.4-120.0)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.0	nc	(nc-nc)
Male	5	4.4	114.1	(36.8-266.2)	Female	1	1.0	nc	(nc-nc)
Female	0	2.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	5	0.6	801.5	(258.3-1870.3)
Male	0	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<u>Leukemia</u>					Female	4	4.3	nc	(nc-nc)
Male	3	3.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.9	nc	(nc-nc)	Female	5	6.0	82.7	(26.7-193.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.8	nc	(nc-nc)	Male	81	104.3	77.7	(61.7-96.6)
Female	0	0.8	nc	(nc-nc)	Female	63	89.8	70.2	(53.9-89.8)
<u>Lung and Bronchus</u>									
Male	9	15.2	59.2	(27.0-112.3)					
Female	8	13.0	61.6	(26.5-121.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hancock

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	2	3.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.6	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.3	nc	(nc-nc)	Male	11	10.7	102.7	(51.2-183.8)
Female	0	0.1	nc	(nc-nc)	Female	9	11.0	81.9	(37.4-155.5)
<u>Lung and Bronchus</u>									
Male	0	1.4	nc	(nc-nc)					
Female	2	1.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hanover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	12.5	112.2	(61.3-188.2)	Male	20	8.6	233.9	(142.8-361.2)
Female	7	5.2	134.4	(53.8-276.8)	Female	4	7.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	2.8	178.9	(57.7-417.6)	Male	2	2.8	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	8	7.7	104.5	(45.0-205.9)
Female	80	61.0	131.2	(104.0-163.3)	Female	10	7.4	134.3	(64.3-247.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.0	nc	(nc-nc)	Male	7	6.8	102.4	(41.0-210.9)
<u>Colon / Rectum</u>					Female	2	3.2	nc	(nc-nc)
Male	18	14.2	126.5	(74.9-200.0)	<u>Ovary</u>				
Female	18	15.1	119.1	(70.5-188.2)	Female	5	5.2	96.4	(31.1-225.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.5	142.6	(45.9-332.7)	Male	1	4.7	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	3	5.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.1	nc	(nc-nc)	Male	64	43.8	146.2	(112.6-186.7)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.1	nc	(nc-nc)
Male	4	7.9	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
Female	5	4.8	105.1	(33.9-245.4)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.9	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.7	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
<u>Leukemia</u>					Female	12	11.2	106.7	(55.1-186.4)
Male	6	5.5	109.1	(39.8-237.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	4.3	nc	(nc-nc)	Female	18	13.9	129.6	(76.8-204.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	4.9	nc	(nc-nc)	Male	188	174.4	107.8	(92.9-124.3)
Female	0	1.8	nc	(nc-nc)	Female	215	200.9	107.0	(93.2-122.3)
<u>Lung and Bronchus</u>									
Male	17	23.0	73.9	(43.0-118.4)					
Female	30	27.7	108.4	(73.1-154.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hanson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	9.5	115.9	(57.8-207.5)	Male	7	6.6	105.5	(42.3-217.5)
Female	3	3.1	nc	(nc-nc)	Female	3	5.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.1	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	2	6.0	nc	(nc-nc)
Female	31	43.0	72.0	(48.9-102.2)	Female	4	4.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.5	nc	(nc-nc)	Male	9	5.5	162.9	(74.3-309.2)
<u>Colon / Rectum</u>					Female	2	2.1	nc	(nc-nc)
Male	13	11.1	116.6	(62.0-199.4)	<u>Ovary</u>				
Female	11	9.2	119.6	(59.6-213.9)	Female	3	3.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	2.8	nc	(nc-nc)	Male	5	3.6	137.4	(44.3-320.7)
Female	1	0.6	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	31	36.3	85.5	(58.1-121.4)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.4	nc	(nc-nc)
Male	5	6.3	79.1	(25.5-184.5)	Female	0	1.2	nc	(nc-nc)
Female	6	3.2	187.4	(68.4-407.8)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.5	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
<u>Leukemia</u>					Female	7	8.4	83.0	(33.3-171.0)
Male	2	4.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	2.7	nc	(nc-nc)	Female	10	9.6	103.9	(49.7-191.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	3.9	nc	(nc-nc)	Male	133	137.8	96.5	(80.8-114.4)
Female	3	1.1	nc	(nc-nc)	Female	121	133.6	90.6	(75.1-108.2)
<u>Lung and Bronchus</u>									
Male	24	17.8	135.0	(86.5-200.9)					
Female	22	17.7	124.4	(77.9-188.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hardwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	4.9	nc	(nc-nc)	Male	5	3.0	169.4	(54.6-395.3)
Female	1	1.1	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	11	13.4	81.8	(40.8-146.4)	Female	1	1.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.7	nc	(nc-nc)
Male	6	5.0	119.4	(43.6-259.8)	<u>Ovary</u>				
Female	4	3.1	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.3	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	15.5	45.2	(18.1-93.1)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.2	nc	(nc-nc)
Male	3	2.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.4	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.4	nc	(nc-nc)
Male	0	1.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.9	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	1.7	nc	(nc-nc)	Male	45	61.6	73.1	(53.3-97.8)
Female	0	0.4	nc	(nc-nc)	Female	35	43.1	81.2	(56.5-112.9)
<u>Lung and Bronchus</u>									
Male	7	8.9	79.0	(31.7-162.8)					
Female	8	5.9	136.5	(58.8-268.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Harvard

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	8.2	60.6	(19.5-141.5)	Male	1	5.7	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.7	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	6	5.1	117.5	(42.9-255.8)
Female	21	23.6	88.9	(55.0-135.9)	Female	3	2.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	5	4.7	105.4	(34.0-245.9)
<u>Colon / Rectum</u>					Female	0	1.2	nc	(nc-nc)
Male	5	9.8	51.2	(16.5-119.6)	<u>Ovary</u>				
Female	9	5.3	168.8	(77.0-320.5)	Female	3	2.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.4	nc	(nc-nc)	Male	0	3.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	22	30.9	71.2	(44.6-107.7)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.1	nc	(nc-nc)
Male	2	5.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.2	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
<u>Leukemia</u>					Female	5	4.4	113.7	(36.7-265.4)
Male	4	3.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.5	nc	(nc-nc)	Female	6	5.3	114.1	(41.7-248.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	3.4	nc	(nc-nc)	Male	77	118.1	65.2	(51.4-81.5)
Female	0	0.6	nc	(nc-nc)	Female	67	73.8	90.8	(70.4-115.3)
<u>Lung and Bronchus</u>									
Male	5	15.5	32.3	(10.4-75.4)					
Female	6	9.9	60.6	(22.1-132.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Harwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	20.7	116.0	(74.3-172.6)	Male	21	11.9	176.3	(109.1-269.4)
Female	9	8.2	110.3	(50.3-209.3)	Female	17	9.4	181.4	(105.6-290.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.2	nc	(nc-nc)	Male	8	4.0	201.7	(86.8-397.4)
Female	4	3.0	nc	(nc-nc)	Female	7	3.6	195.1	(78.2-402.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	17	10.7	159.2	(92.7-254.9)
Female	109	79.3	137.5	(112.9-165.9)	Female	7	10.7	65.6	(26.3-135.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.2	nc	(nc-nc)	Male	9	8.2	109.6	(50.0-208.1)
<u>Colon / Rectum</u>					Female	5	4.4	113.5	(36.6-264.9)
Male	24	20.2	119.1	(76.3-177.2)	<u>Ovary</u>				
Female	35	22.2	157.4	(109.6-218.9)	Female	6	6.9	87.1	(31.8-189.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	5.0	nc	(nc-nc)	Male	7	7.0	99.9	(40.0-205.9)
Female	0	1.6	nc	(nc-nc)	Female	11	8.2	133.4	(66.5-238.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	1.0	479.9	(154.6-1119.8)	Male	98	59.7	164.1	(133.2-199.9)
Female	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	4.7	148.4	(59.5-305.9)
Male	10	10.0	100.0	(47.9-183.9)	Female	1	3.0	nc	(nc-nc)
Female	8	6.6	121.4	(52.3-239.3)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.5	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.9	nc	(nc-nc)	Male	5	3.8	131.4	(42.3-306.6)
<u>Leukemia</u>					Female	4	11.4	nc	(nc-nc)
Male	9	7.6	119.0	(54.3-225.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	5.9	101.3	(37.0-220.5)	Female	20	18.4	108.5	(66.3-167.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	6.2	nc	(nc-nc)	Male	326	245.7	132.7	(118.7-147.9)
Female	3	2.6	nc	(nc-nc)	Female	326	275.2	118.4	(105.9-132.0)
<u>Lung and Bronchus</u>									
Male	48	36.8	130.5	(96.2-173.0)					
Female	42	42.7	98.3	(70.8-132.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hatfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.1	98.0	(31.6-228.6)	Male	4	3.1	nc	(nc-nc)
Female	3	1.8	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.9	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
Female	16	19.8	80.9	(46.2-131.3)	Female	2	2.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.0	nc	(nc-nc)
Male	5	5.3	93.7	(30.2-218.6)	<u>Ovary</u>				
Female	10	5.2	191.7	(91.8-352.7)	Female	4	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.3	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	16	15.5	103.1	(58.9-167.4)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.2	nc	(nc-nc)
Male	6	2.7	221.9	(81.0-482.9)	Female	1	0.7	nc	(nc-nc)
Female	5	1.6	315.5	(101.7-736.2)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	1	3.1	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.4	nc	(nc-nc)	Female	6	4.4	136.7	(49.9-297.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.7	nc	(nc-nc)	Male	61	63.8	95.7	(73.2-122.9)
Female	0	0.6	nc	(nc-nc)	Female	64	66.1	96.9	(74.6-123.7)
<u>Lung and Bronchus</u>									
Male	8	9.4	85.2	(36.7-167.9)					
Female	5	9.9	50.5	(16.3-117.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Haverhill

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	53	60.1	88.3	(66.1-115.4)	Male	28	38.7	72.3	(48.1-104.6)
Female	31	21.8	142.2	(96.6-201.9)	Female	19	31.9	59.6	(35.9-93.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	14	12.2	115.2	(62.9-193.3)	Male	11	12.3	89.6	(44.7-160.4)
Female	12	10.3	116.3	(60.0-203.2)	Female	7	10.1	69.6	(27.9-143.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	2.1	nc	(nc-nc)	Male	33	35.0	94.4	(65.0-132.6)
Female	246	250.4	98.2	(86.4-111.3)	Female	41	31.2	131.4	(94.3-178.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	8.9	90.2	(38.9-177.8)	Male	32	28.9	110.9	(75.8-156.5)
<u>Colon / Rectum</u>					Female	14	13.3	105.2	(57.5-176.6)
Male	68	66.2	102.7	(79.8-130.2)	<u>Ovary</u>				
Female	72	65.8	109.4	(85.6-137.7)	Female	20	21.7	92.3	(56.4-142.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	15.3	71.7	(35.8-128.4)	Male	27	21.5	125.6	(82.7-182.7)
Female	5	4.3	117.2	(37.8-273.5)	Female	24	22.5	106.5	(68.2-158.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	5.0	118.9	(43.4-258.8)	Male	148	184.5	80.2	(67.8-94.2)
Female	3	4.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	17	14.6	116.6	(67.9-186.7)
Male	33	33.8	97.8	(67.3-137.3)	Female	8	8.9	89.8	(38.7-177.0)
Female	24	19.7	121.7	(77.9-181.1)	<u>Testis</u>				
<u>Larynx</u>					Male	7	9.5	73.4	(29.4-151.2)
Male	10	8.9	113.0	(54.1-207.8)	<u>Thyroid</u>				
Female	6	2.7	219.7	(80.2-478.2)	Male	17	16.0	106.3	(61.9-170.2)
<u>Leukemia</u>					Female	57	49.2	115.9	(87.8-150.2)
Male	21	25.1	83.6	(51.7-127.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	18	18.7	96.2	(57.0-152.0)	Female	62	55.8	111.2	(85.3-142.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	17	21.1	80.7	(47.0-129.2)	Male	711	779.2	91.2	(84.7-98.2)
Female	6	7.3	82.7	(30.2-180.0)	Female	888	839.3	105.8	(99.0-113.0)
<u>Lung and Bronchus</u>									
Male	105	104.3	100.6	(82.3-121.8)					
Female	138	112.5	122.7	(103.0-144.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hawley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.5	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.4	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	9.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	3	6.8	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	1	1.4	nc	(nc-nc)					
Female	0	0.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Heath

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	0.9	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	2	3.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.7	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	3.6	139.8	(45.0-326.2)
Female	1	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.5	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	3	0.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	14	12.7	110.2	(60.2-185.0)
Female	0	0.1	nc	(nc-nc)	Female	11	10.7	103.0	(51.3-184.2)
<u>Lung and Bronchus</u>									
Male	4	1.7	nc	(nc-nc)					
Female	1	1.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	29	30.7	94.5	(63.2-135.7)	Male	34	18.2	187.3	(129.7-261.7)
Female	9	11.5	78.3	(35.7-148.6)	Female	29	13.9	208.8	(139.8-299.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	5.2	134.1	(53.7-276.3)	Male	7	5.8	120.4	(48.2-248.1)
Female	6	4.5	133.2	(48.6-289.9)	Female	5	5.1	98.3	(31.7-229.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.0	nc	(nc-nc)	Male	13	16.3	79.7	(42.4-136.3)
Female	113	113.5	99.5	(82.0-119.7)	Female	25	15.3	163.5	(105.8-241.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.4	nc	(nc-nc)	Male	17	12.7	133.6	(77.8-214.0)
<u>Colon / Rectum</u>					Female	5	6.3	79.0	(25.5-184.3)
Male	31	31.5	98.3	(66.8-139.6)	<u>Ovary</u>				
Female	35	33.2	105.5	(73.5-146.8)	Female	9	9.9	90.8	(41.5-172.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	7.3	nc	(nc-nc)	Male	8	10.5	75.9	(32.7-149.6)
Female	7	2.2	318.8	(127.7-656.9)	Female	11	11.8	93.2	(46.4-166.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.7	nc	(nc-nc)	Male	96	84.8	113.2	(91.7-138.2)
Female	1	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	13	7.1	182.5	(97.1-312.2)
Male	14	15.2	92.3	(50.4-154.9)	Female	1	4.5	nc	(nc-nc)
Female	8	9.3	85.7	(36.9-168.9)	<u>Testis</u>				
<u>Larynx</u>					Male	5	2.8	181.2	(58.4-422.9)
Male	2	4.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.3	nc	(nc-nc)	Male	4	6.3	nc	(nc-nc)
<u>Leukemia</u>					Female	30	18.0	166.6	(112.4-237.8)
Male	15	11.9	126.4	(70.7-208.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	14	8.9	157.7	(86.2-264.7)	Female	20	25.3	79.1	(48.3-122.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	9.5	nc	(nc-nc)	Male	365	366.6	99.6	(89.6-110.3)
Female	1	3.6	nc	(nc-nc)	Female	402	395.6	101.6	(91.9-112.1)
<u>Lung and Bronchus</u>									
Male	29	52.7	55.0	(36.8-79.0)					
Female	40	58.5	68.4	(48.8-93.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hinsdale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.9	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.5	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	17	9.6	177.0	(103.0-283.4)	Female	3	1.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.5	nc	(nc-nc)
Male	3	3.2	nc	(nc-nc)	<u>Ovary</u>				
Female	4	2.5	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.7	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	8	9.1	88.0	(37.9-173.4)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.7	nc	(nc-nc)
Male	2	1.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	4	1.7	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.7	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.1	nc	(nc-nc)	Male	35	37.1	94.3	(65.7-131.2)
Female	0	0.3	nc	(nc-nc)	Female	43	31.3	137.6	(99.6-185.3)
<u>Lung and Bronchus</u>									
Male	7	5.0	141.4	(56.6-291.3)					
Female	6	4.2	144.4	(52.7-314.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holbrook

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	12.8	132.4	(77.1-212.0)	Male	5	8.3	60.2	(19.4-140.6)
Female	8	4.4	180.0	(77.5-354.6)	Female	3	6.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.5	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	5	1.9	257.7	(83.1-601.4)	Female	6	2.0	292.7	(106.9-637.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	10	7.4	135.9	(65.0-249.9)
Female	58	52.0	111.5	(84.6-144.1)	Female	8	6.3	127.5	(54.9-251.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.7	nc	(nc-nc)	Male	6	6.1	97.9	(35.7-213.0)
<u>Colon / Rectum</u>					Female	1	2.7	nc	(nc-nc)
Male	22	14.0	157.1	(98.4-237.8)	<u>Ovary</u>				
Female	20	13.1	152.7	(93.2-235.8)	Female	9	4.4	203.4	(92.8-386.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	3.3	181.7	(66.3-395.4)	Male	6	4.6	130.9	(47.8-284.9)
Female	0	0.9	nc	(nc-nc)	Female	5	4.5	111.5	(35.9-260.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.0	nc	(nc-nc)	Male	51	38.8	131.5	(97.9-172.9)
Female	2	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.1	nc	(nc-nc)
Male	15	7.1	210.2	(117.6-346.8)	Female	1	1.8	nc	(nc-nc)
Female	4	4.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.8	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.6	nc	(nc-nc)	Male	0	3.3	nc	(nc-nc)
<u>Leukemia</u>					Female	8	9.4	84.8	(36.5-167.1)
Male	7	5.1	136.1	(54.5-280.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	3.6	197.1	(78.9-406.0)	Female	9	11.6	77.9	(35.5-147.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	4.5	110.5	(35.6-258.0)	Male	194	165.3	117.4	(101.4-135.1)
Female	1	1.5	nc	(nc-nc)	Female	203	170.9	118.8	(103.0-136.3)
<u>Lung and Bronchus</u>									
Male	20	22.9	87.2	(53.2-134.7)					
Female	34	24.1	141.1	(97.7-197.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	19.1	78.6	(43.9-129.6)	Male	22	12.3	178.2	(111.6-269.8)
Female	11	6.9	159.6	(79.6-285.6)	Female	11	9.6	114.2	(56.9-204.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.8	nc	(nc-nc)	Male	7	4.0	175.6	(70.3-361.7)
Female	6	3.1	194.4	(71.0-423.2)	Female	2	3.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	13	11.1	116.9	(62.2-199.9)
Female	94	77.8	120.8	(97.6-147.8)	Female	8	9.8	81.8	(35.2-161.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.7	nc	(nc-nc)	Male	13	9.5	137.5	(73.2-235.2)
<u>Colon / Rectum</u>					Female	5	4.1	121.1	(39.0-282.6)
Male	15	21.2	70.8	(39.6-116.8)	<u>Ovary</u>				
Female	19	20.6	92.3	(55.5-144.1)	Female	7	6.7	104.6	(41.9-215.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	5.0	120.0	(43.8-261.1)	Male	11	6.9	158.4	(79.0-283.4)
Female	0	1.3	nc	(nc-nc)	Female	6	7.0	85.6	(31.3-186.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.4	nc	(nc-nc)	Male	62	60.9	101.7	(78.0-130.4)
Female	1	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	4.7	nc	(nc-nc)
Male	7	10.9	64.2	(25.7-132.3)	Female	5	2.8	178.8	(57.6-417.3)
Female	6	6.1	98.1	(35.8-213.5)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.5	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	4	5.0	nc	(nc-nc)
<u>Leukemia</u>					Female	11	14.5	76.0	(37.9-136.0)
Male	7	7.8	89.2	(35.7-183.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	5.6	89.0	(28.7-207.6)	Female	30	17.2	174.0	(117.3-248.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	6.9	72.1	(23.2-168.3)	Male	242	250.6	96.6	(84.8-109.5)
Female	4	2.3	nc	(nc-nc)	Female	289	260.3	111.0	(98.6-124.6)
<u>Lung and Bronchus</u>									
Male	24	33.8	71.1	(45.5-105.8)					
Female	29	35.9	80.9	(54.2-116.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	3.1	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	3	0.7	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	8	10.5	76.0	(32.7-149.8)	Female	2	1.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	1	3.4	nc	(nc-nc)	<u>Ovary</u>				
Female	1	2.3	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.9	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	5	10.3	48.4	(15.6-112.9)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.8	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.4	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<u>Leukemia</u>					Female	4	2.1	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	0.6	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.2	nc	(nc-nc)	Male	28	42.0	66.6	(44.3-96.3)
Female	0	0.3	nc	(nc-nc)	Female	34	32.4	104.8	(72.6-146.5)
<u>Lung and Bronchus</u>									
Male	5	5.9	85.4	(27.5-199.2)					
Female	6	4.1	145.1	(53.0-315.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holliston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	13.8	145.2	(88.6-224.2)	Male	11	9.2	119.9	(59.8-214.6)
Female	3	5.0	nc	(nc-nc)	Female	9	7.3	122.7	(56.0-232.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	2.9	239.7	(96.0-493.8)	Male	5	3.0	169.0	(54.5-394.3)
Female	2	2.4	nc	(nc-nc)	Female	0	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	10	8.3	120.9	(57.9-222.4)
Female	77	62.2	123.8	(97.7-154.7)	Female	5	7.3	68.9	(22.2-160.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.1	nc	(nc-nc)	Male	8	7.3	110.2	(47.4-217.1)
<u>Colon / Rectum</u>					Female	5	3.2	158.1	(50.9-368.9)
Male	15	15.7	95.6	(53.4-157.6)	<u>Ovary</u>				
Female	14	15.1	93.0	(50.8-156.0)	Female	3	5.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.7	nc	(nc-nc)	Male	3	5.1	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	3	5.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.1	nc	(nc-nc)	Male	53	47.2	112.4	(84.2-147.0)
Female	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.4	nc	(nc-nc)
Male	10	8.4	119.5	(57.2-219.7)	Female	1	2.0	nc	(nc-nc)
Female	4	4.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	5	1.9	265.4	(85.5-619.4)
Male	3	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	5	3.9	128.5	(41.4-300.0)
<u>Leukemia</u>					Female	14	11.4	123.0	(67.2-206.4)
Male	6	5.9	102.5	(37.4-223.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	4.1	nc	(nc-nc)	Female	19	13.9	136.3	(82.0-212.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	5.2	nc	(nc-nc)	Male	205	188.1	109.0	(94.6-125.0)
Female	4	1.7	nc	(nc-nc)	Female	206	199.9	103.0	(89.5-118.1)
<u>Lung and Bronchus</u>									
Male	15	24.8	60.4	(33.8-99.7)					
Female	23	27.0	85.2	(54.0-127.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holyoke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	29	37.8	76.7	(51.4-110.2)	Male	15	23.5	63.7	(35.6-105.1)
Female	13	15.6	83.2	(44.2-142.2)	Female	11	21.1	52.2	(26.0-93.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	7.5	145.9	(72.7-261.0)	Male	4	7.4	nc	(nc-nc)
Female	5	6.9	72.9	(23.5-170.1)	Female	1	7.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.3	nc	(nc-nc)	Male	17	21.4	79.4	(46.2-127.2)
Female	128	162.9	78.6	(65.5-93.4)	Female	18	21.4	84.1	(49.8-132.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	5.6	124.6	(49.9-256.7)	Male	27	16.7	161.5	(106.4-235.0)
<u>Colon / Rectum</u>					Female	7	8.9	78.9	(31.6-162.6)
Male	41	40.6	101.0	(72.5-137.0)	<u>Ovary</u>				
Female	45	45.9	97.9	(71.4-131.1)	Female	13	14.2	91.4	(48.6-156.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	9.1	66.0	(24.1-143.7)	Male	14	13.2	106.0	(57.9-177.9)
Female	0	3.0	nc	(nc-nc)	Female	22	16.0	137.1	(85.9-207.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	3.2	nc	(nc-nc)	Male	95	105.2	90.3	(73.1-110.4)
Female	7	2.8	253.1	(101.4-521.5)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	9.0	77.9	(31.2-160.5)
Male	21	19.8	106.2	(65.7-162.3)	Female	9	6.2	144.2	(65.8-273.7)
Female	10	13.3	75.4	(36.1-138.7)	<u>Testis</u>				
<u>Larynx</u>					Male	1	6.0	nc	(nc-nc)
Male	8	5.2	154.2	(66.4-303.8)	<u>Thyroid</u>				
Female	3	1.8	nc	(nc-nc)	Male	1	9.3	nc	(nc-nc)
<u>Leukemia</u>					Female	24	31.1	77.2	(49.4-114.8)
Male	10	15.8	63.2	(30.3-116.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	13.0	61.7	(26.5-121.5)	Female	43	35.3	121.7	(88.1-163.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	25	12.3	202.9	(131.3-299.6)	Male	464	469.3	98.9	(90.1-108.3)
Female	6	4.9	121.5	(44.4-264.6)	Female	511	564.6	90.5	(82.8-98.7)
<u>Lung and Bronchus</u>									
Male	75	64.2	116.8	(91.8-146.4)					
Female	76	79.7	95.3	(75.1-119.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hopedale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	6.1	98.2	(35.9-213.7)	Male	3	3.8	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.2	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	26	24.9	104.5	(68.3-153.2)	Female	1	3.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.9	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.3	nc	(nc-nc)
Male	6	6.9	87.0	(31.8-189.4)	<u>Ovary</u>				
Female	8	6.9	115.2	(49.6-227.1)	Female	1	2.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.5	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	2.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	22	17.1	128.8	(80.7-195.0)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	1.5	nc	(nc-nc)
Male	2	3.3	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.8	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	8	4.8	167.7	(72.2-330.4)
Male	3	2.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.9	nc	(nc-nc)	Female	6	5.2	114.6	(41.9-249.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.1	nc	(nc-nc)	Male	86	76.2	112.8	(90.2-139.3)
Female	0	0.7	nc	(nc-nc)	Female	82	83.8	97.8	(77.8-121.4)
<u>Lung and Bronchus</u>									
Male	13	10.0	130.3	(69.3-222.8)					
Female	11	11.1	98.9	(49.3-177.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hopkinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	11.8	93.1	(46.4-166.6)	Male	9	8.5	105.5	(48.1-200.2)
Female	9	4.3	211.4	(96.4-401.2)	Female	11	7.1	155.5	(77.5-278.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	2.9	172.7	(55.6-403.0)	Male	2	2.7	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	7	7.7	91.1	(36.5-187.7)
Female	58	59.6	97.4	(73.9-125.9)	Female	6	6.6	91.3	(33.3-198.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.2	nc	(nc-nc)	Male	8	7.1	112.8	(48.6-222.2)
<u>Colon / Rectum</u>					Female	1	2.9	nc	(nc-nc)
Male	10	14.6	68.6	(32.8-126.1)	<u>Ovary</u>				
Female	12	13.5	88.6	(45.7-154.8)	Female	3	4.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.4	nc	(nc-nc)	Male	5	4.5	110.2	(35.5-257.1)
Female	1	0.8	nc	(nc-nc)	Female	7	4.3	162.6	(65.1-335.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.1	nc	(nc-nc)	Male	53	42.9	123.7	(92.6-161.7)
Female	3	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	3.1	nc	(nc-nc)
Male	4	8.1	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
Female	0	4.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.1	nc	(nc-nc)
Male	3	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	9	4.1	220.3	(100.5-418.3)
<u>Leukemia</u>					Female	16	12.1	132.1	(75.5-214.6)
Male	2	5.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	3.9	nc	(nc-nc)	Female	12	12.7	94.4	(48.7-165.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.9	nc	(nc-nc)	Male	166	172.5	96.2	(82.2-112.0)
Female	0	1.5	nc	(nc-nc)	Female	179	185.6	96.5	(82.8-111.7)
<u>Lung and Bronchus</u>									
Male	15	21.7	69.1	(38.7-114.0)					
Female	22	23.3	94.3	(59.1-142.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hubbardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	4.3	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.9	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	2.7	188.4	(60.7-439.6)
Female	16	17.8	89.8	(51.3-145.8)	Female	2	1.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	6	0.8	708.2	(258.6-1541.5)
Male	0	5.1	nc	(nc-nc)	<u>Ovary</u>				
Female	5	3.9	129.4	(41.7-302.0)	Female	2	1.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.2	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	12	14.7	81.6	(42.1-142.5)
Female	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	1.1	nc	(nc-nc)
Male	3	2.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.6	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	5	3.6	138.7	(44.7-323.6)
Male	2	1.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.1	nc	(nc-nc)	Female	2	3.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.6	nc	(nc-nc)	Male	45	59.5	75.7	(55.2-101.3)
Female	0	0.4	nc	(nc-nc)	Female	60	54.2	110.7	(84.4-142.5)
<u>Lung and Bronchus</u>									
Male	4	7.7	nc	(nc-nc)					
Female	8	6.5	122.2	(52.6-240.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hudson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	22.0	104.7	(66.3-157.1)	Male	13	14.2	91.7	(48.8-156.8)
Female	8	8.2	97.3	(41.9-191.8)	Female	10	11.2	89.5	(42.9-164.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	4.3	162.3	(65.0-334.4)	Male	4	4.6	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.8	nc	(nc-nc)	Male	7	12.7	55.2	(22.1-113.8)
Female	89	92.8	95.9	(77.0-118.0)	Female	11	11.4	96.8	(48.3-173.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.0	nc	(nc-nc)	Male	13	10.8	120.3	(64.0-205.8)
<u>Colon / Rectum</u>					Female	6	4.8	124.7	(45.5-271.5)
Male	26	23.9	108.8	(71.1-159.4)	<u>Ovary</u>				
Female	34	23.2	146.6	(101.5-204.8)	Female	8	7.9	101.4	(43.7-199.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	5.8	nc	(nc-nc)	Male	1	7.9	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	7	8.3	84.8	(34.0-174.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.6	nc	(nc-nc)	Male	69	73.5	93.8	(73.0-118.8)
Female	2	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	5.3	nc	(nc-nc)
Male	8	12.8	62.6	(27.0-123.3)	Female	5	3.1	159.1	(51.3-371.4)
Female	10	7.4	134.5	(64.4-247.4)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.9	nc	(nc-nc)
Male	1	3.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.0	nc	(nc-nc)	Male	6	5.8	103.8	(37.9-226.0)
<u>Leukemia</u>					Female	28	16.5	170.1	(113.0-245.9)
Male	6	8.9	67.4	(24.6-146.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	6.5	nc	(nc-nc)	Female	22	20.8	105.6	(66.1-159.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	7.7	65.0	(20.9-151.6)	Male	251	291.6	86.1	(75.8-97.4)
Female	2	2.7	nc	(nc-nc)	Female	309	308.1	100.3	(89.4-112.1)
<u>Lung and Bronchus</u>									
Male	28	40.4	69.3	(46.1-100.2)					
Female	34	44.8	75.8	(52.5-106.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hull

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	13.8	115.8	(66.1-188.0)	Male	17	8.8	193.1	(112.4-309.2)
Female	7	5.4	130.7	(52.3-269.2)	Female	14	7.1	195.8	(107.0-328.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.5	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	3	7.8	nc	(nc-nc)
Female	60	60.9	98.5	(75.1-126.8)	Female	12	7.4	161.1	(83.2-281.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	1.8	nc	(nc-nc)	Male	6	6.8	88.8	(32.4-193.3)
<u>Colon / Rectum</u>					Female	7	3.2	220.5	(88.3-454.3)
Male	15	14.7	102.3	(57.2-168.8)	<u>Ovary</u>				
Female	15	15.1	99.5	(55.7-164.2)	Female	6	5.2	115.1	(42.0-250.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.7	nc	(nc-nc)	Male	5	5.0	99.5	(32.1-232.1)
Female	1	1.1	nc	(nc-nc)	Female	6	5.3	112.8	(41.2-245.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	0.8	nc	(nc-nc)	Male	43	46.9	91.8	(66.4-123.6)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	3.4	nc	(nc-nc)
Male	11	7.8	140.6	(70.1-251.6)	Female	1	2.0	nc	(nc-nc)
Female	6	4.9	123.3	(45.0-268.5)	<u>Testis</u>				
<u>Larynx</u>					Male	5	1.3	385.4	(124.2-899.4)
Male	4	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.7	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
<u>Leukemia</u>					Female	7	10.1	69.4	(27.8-143.0)
Male	4	5.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	4.1	nc	(nc-nc)	Female	17	14.2	119.8	(69.8-191.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	13	5.1	253.2	(134.7-433.1)	Male	193	182.3	105.9	(91.5-121.9)
Female	0	1.8	nc	(nc-nc)	Female	218	200.6	108.7	(94.7-124.1)
<u>Lung and Bronchus</u>									
Male	22	25.6	86.0	(53.9-130.2)					
Female	33	29.6	111.6	(76.8-156.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Huntington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.1	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	10	9.2	108.7	(52.0-199.9)	Female	3	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	<u>Ovary</u>				
Female	3	2.0	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	0.6	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	7.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	3	1.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	3	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	4	1.7	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.6	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.8	nc	(nc-nc)	Male	33	29.7	111.0	(76.4-155.9)
Female	0	0.2	nc	(nc-nc)	Female	33	29.1	113.5	(78.1-159.5)
<u>Lung and Bronchus</u>									
Male	6	3.9	154.5	(56.4-336.3)					
Female	5	4.1	120.8	(38.9-281.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ipswich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	17.8	95.4	(55.6-152.8)	Male	17	11.3	150.4	(87.6-240.8)
Female	9	6.7	133.6	(61.0-253.6)	Female	8	8.6	93.4	(40.2-183.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.3	nc	(nc-nc)	Male	1	3.7	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)	Female	1	3.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	13	10.1	128.4	(68.3-219.6)
Female	88	72.2	121.9	(97.7-150.1)	Female	8	9.3	86.4	(37.2-170.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.2	nc	(nc-nc)	Male	9	8.6	104.6	(47.7-198.5)
<u>Colon / Rectum</u>					Female	7	3.9	180.7	(72.4-372.4)
Male	17	19.3	87.9	(51.2-140.7)	<u>Ovary</u>				
Female	16	19.3	82.7	(47.2-134.3)	Female	5	6.2	80.6	(26.0-188.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	4.7	214.5	(102.7-394.5)	Male	7	6.4	108.6	(43.5-223.8)
Female	3	1.3	nc	(nc-nc)	Female	6	6.9	87.5	(31.9-190.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.1	nc	(nc-nc)	Male	66	58.0	113.8	(88.0-144.8)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.3	nc	(nc-nc)
Male	6	10.0	59.9	(21.9-130.4)	Female	6	2.6	228.7	(83.5-497.8)
Female	6	5.7	104.5	(38.1-227.4)	<u>Testis</u>				
<u>Larynx</u>					Male	4	1.8	nc	(nc-nc)
Male	2	2.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
<u>Leukemia</u>					Female	14	11.5	121.8	(66.5-204.4)
Male	4	7.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	5.1	97.7	(31.5-228.0)	Female	14	16.5	84.8	(46.3-142.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	6.3	78.9	(25.4-184.1)	Male	239	232.0	103.0	(90.4-117.0)
Female	4	2.2	nc	(nc-nc)	Female	251	242.6	103.5	(91.1-117.1)
<u>Lung and Bronchus</u>									
Male	22	32.3	68.1	(42.7-103.1)					
Female	26	35.2	73.9	(48.3-108.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Kingston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	14.3	83.9	(43.3-146.5)	Male	16	9.1	175.4	(100.2-284.9)
Female	6	5.6	106.6	(38.9-232.0)	Female	10	7.5	133.5	(63.9-245.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.7	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	4	2.4	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	7	8.1	86.1	(34.5-177.4)
Female	51	61.8	82.5	(61.5-108.5)	Female	8	7.8	102.8	(44.3-202.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.0	nc	(nc-nc)	Male	5	6.7	74.1	(23.9-173.0)
<u>Colon / Rectum</u>					Female	4	3.2	nc	(nc-nc)
Male	14	15.4	90.7	(49.5-152.1)	<u>Ovary</u>				
Female	9	16.6	54.1	(24.7-102.7)	Female	2	5.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.6	nc	(nc-nc)	Male	12	5.1	234.3	(120.9-409.3)
Female	4	1.1	nc	(nc-nc)	Female	9	5.7	157.0	(71.6-298.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.0	nc	(nc-nc)	Male	41	43.0	95.3	(68.3-129.2)
Female	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	3.5	144.0	(46.4-336.1)
Male	7	7.8	89.3	(35.8-184.1)	Female	1	2.3	nc	(nc-nc)
Female	2	4.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.8	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	5	3.5	142.6	(45.9-332.7)
<u>Leukemia</u>					Female	15	10.9	137.0	(76.6-226.0)
Male	9	5.8	156.3	(71.3-296.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	4.5	nc	(nc-nc)	Female	15	13.3	113.2	(63.3-186.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	5.1	nc	(nc-nc)	Male	183	182.9	100.1	(86.1-115.7)
Female	1	1.8	nc	(nc-nc)	Female	203	207.0	98.1	(85.0-112.5)
<u>Lung and Bronchus</u>									
Male	26	25.6	101.6	(66.3-148.8)					
Female	27	29.3	92.2	(60.7-134.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lakeville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	11.5	87.0	(41.7-160.1)	Male	8	7.7	103.8	(44.7-204.5)
Female	5	3.9	127.0	(40.9-296.4)	Female	4	6.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.4	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	6.9	72.7	(23.4-169.8)
Female	49	50.6	96.9	(71.7-128.1)	Female	5	5.8	85.6	(27.6-199.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.7	nc	(nc-nc)	Male	7	6.3	111.5	(44.7-229.6)
<u>Colon / Rectum</u>					Female	4	2.6	nc	(nc-nc)
Male	10	13.0	76.9	(36.8-141.5)	<u>Ovary</u>				
Female	9	11.8	76.5	(34.9-145.2)	Female	5	4.2	117.7	(37.9-274.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.2	nc	(nc-nc)	Male	2	4.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	4	4.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	35	42.2	82.9	(57.7-115.3)
Female	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	2.9	nc	(nc-nc)
Male	5	7.2	69.5	(22.4-162.1)	Female	0	1.6	nc	(nc-nc)
Female	2	3.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.4	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	5	3.2	156.4	(50.4-364.9)
<u>Leukemia</u>					Female	15	9.3	160.9	(90.0-265.4)
Male	3	4.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.3	nc	(nc-nc)	Female	13	11.7	111.6	(59.4-190.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.5	nc	(nc-nc)	Male	139	160.5	86.6	(72.8-102.2)
Female	3	1.4	nc	(nc-nc)	Female	161	161.2	99.9	(85.1-116.6)
<u>Lung and Bronchus</u>									
Male	14	21.6	64.8	(35.4-108.8)					
Female	19	21.4	88.8	(53.4-138.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lancaster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	8.2	84.9	(34.0-175.0)	Male	6	5.5	108.7	(39.7-236.6)
Female	4	2.2	nc	(nc-nc)	Female	4	3.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.8	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	7	5.0	141.0	(56.5-290.6)
Female	28	28.2	99.5	(66.1-143.7)	Female	3	3.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.4	nc	(nc-nc)
Male	9	9.0	99.6	(45.5-189.1)	<u>Ovary</u>				
Female	4	6.7	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.2	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.9	nc	(nc-nc)	Male	34	28.5	119.2	(82.6-166.6)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.0	nc	(nc-nc)
Male	3	4.9	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.7	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	4	2.4	nc	(nc-nc)
<u>Leukemia</u>					Female	5	5.6	90.1	(29.0-210.2)
Male	4	3.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.0	nc	(nc-nc)	Female	3	6.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	3.0	nc	(nc-nc)	Male	100	112.9	88.6	(72.1-107.7)
Female	1	0.8	nc	(nc-nc)	Female	81	91.3	88.7	(70.4-110.3)
<u>Lung and Bronchus</u>									
Male	7	15.0	46.6	(18.7-96.0)					
Female	11	12.3	89.5	(44.6-160.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lanesborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.8	nc	(nc-nc)	Male	5	2.0	246.4	(79.4-575.0)
Female	1	1.0	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	11	12.5	87.9	(43.8-157.3)	Female	1	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.4	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.6	nc	(nc-nc)
Male	1	3.3	nc	(nc-nc)	<u>Ovary</u>				
Female	3	3.1	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	0.9	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	10	11.3	88.6	(42.4-162.9)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.7	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	3	1.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.4	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	0.8	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.2	nc	(nc-nc)	Male	45	42.2	106.7	(77.8-142.8)
Female	1	0.3	nc	(nc-nc)	Female	36	40.3	89.2	(62.5-123.5)
<u>Lung and Bronchus</u>									
Male	9	5.5	164.1	(74.9-311.6)					
Female	3	5.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lawrence

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	54	49.4	109.4	(82.2-142.7)	Male	9	34.6	26.0	(11.9-49.4)
Female	16	19.7	81.1	(46.3-131.7)	Female	9	32.8	27.4	(12.5-52.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	12.8	70.4	(32.1-133.7)	Male	11	10.7	103.2	(51.5-184.7)
Female	8	11.3	71.1	(30.6-140.1)	Female	18	9.3	193.4	(114.5-305.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.8	nc	(nc-nc)	Male	21	31.3	67.1	(41.5-102.6)
Female	175	250.4	69.9	(59.9-81.1)	Female	35	29.9	117.2	(81.6-163.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	18	9.9	182.0	(107.8-287.7)	Male	31	26.6	116.4	(79.1-165.2)
<u>Colon / Rectum</u>					Female	12	12.8	93.5	(48.2-163.3)
Male	57	57.1	99.8	(75.6-129.3)	<u>Ovary</u>				
Female	44	61.3	71.8	(52.2-96.4)	Female	10	21.4	46.7	(22.3-85.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	13.4	59.6	(25.7-117.5)	Male	19	18.3	104.0	(62.6-162.3)
Female	9	3.9	230.4	(105.1-437.4)	Female	14	20.3	68.8	(37.6-115.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	6.1	nc	(nc-nc)	Male	217	165.2	131.4	(114.5-150.1)
Female	7	5.3	132.4	(53.1-272.9)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	21	12.4	168.7	(104.4-257.9)
Male	24	31.2	77.0	(49.3-114.6)	Female	16	8.3	192.6	(110.0-312.8)
Female	24	19.3	124.6	(79.8-185.5)	<u>Testis</u>				
<u>Larynx</u>					Male	9	12.0	74.8	(34.1-142.0)
Male	10	7.9	127.0	(60.8-233.5)	<u>Thyroid</u>				
Female	3	2.6	nc	(nc-nc)	Male	14	16.4	85.6	(46.8-143.7)
<u>Leukemia</u>					Female	62	56.7	109.4	(83.9-140.2)
Male	16	23.4	68.3	(39.0-110.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	19	18.8	101.3	(60.9-158.1)	Female	49	54.5	89.9	(66.5-118.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	37	19.0	195.0	(137.3-268.8)	Male	723	694.7	104.1	(96.6-111.9)
Female	14	6.8	205.1	(112.0-344.2)	Female	716	823.3	87.0	(80.7-93.6)
<u>Lung and Bronchus</u>									
Male	92	89.4	102.9	(83.0-126.2)					
Female	97	103.4	93.8	(76.1-114.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	9.1	165.3	(92.4-272.6)	Male	6	5.3	113.1	(41.3-246.1)
Female	1	2.6	nc	(nc-nc)	Female	6	3.5	172.3	(62.9-374.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.5	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	5	1.1	438.5	(141.3-1023.3)	Female	0	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	4.7	nc	(nc-nc)
Female	26	28.9	89.9	(58.7-131.7)	Female	3	3.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.9	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.5	nc	(nc-nc)
Male	6	9.0	67.0	(24.5-145.9)	<u>Ovary</u>				
Female	6	7.2	83.7	(30.6-182.1)	Female	2	2.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	2.3	222.1	(71.6-518.4)	Male	3	3.1	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	20	27.1	73.8	(45.1-114.1)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.1	nc	(nc-nc)
Male	5	4.5	111.5	(35.9-260.2)	Female	4	1.0	nc	(nc-nc)
Female	4	2.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.9	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.3	nc	(nc-nc)	Male	4	1.8	nc	(nc-nc)
<u>Leukemia</u>					Female	3	4.9	nc	(nc-nc)
Male	2	3.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.0	nc	(nc-nc)	Female	5	6.8	73.9	(23.8-172.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.9	nc	(nc-nc)	Male	107	110.0	97.2	(79.7-117.5)
Female	1	0.9	nc	(nc-nc)	Female	97	96.8	100.2	(81.3-122.2)
<u>Lung and Bronchus</u>									
Male	19	16.1	118.2	(71.2-184.7)					
Female	18	14.3	125.9	(74.6-199.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Leicester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	12.0	100.4	(51.8-175.4)	Male	14	7.8	178.4	(97.4-299.3)
Female	5	4.8	104.9	(33.8-244.8)	Female	7	6.4	109.0	(43.7-224.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.4	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	2	7.0	nc	(nc-nc)
Female	43	52.5	81.9	(59.3-110.3)	Female	4	6.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	1.7	nc	(nc-nc)	Male	8	6.0	132.3	(57.0-260.8)
<u>Colon / Rectum</u>					Female	3	2.8	nc	(nc-nc)
Male	11	13.2	83.6	(41.7-149.6)	<u>Ovary</u>				
Female	7	13.6	51.6	(20.7-106.2)	Female	6	4.6	131.9	(48.2-287.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.2	154.8	(49.9-361.4)	Male	1	4.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	4	4.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.0	nc	(nc-nc)	Male	29	40.0	72.4	(48.5-104.0)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.9	nc	(nc-nc)
Male	5	7.0	71.4	(23.0-166.6)	Female	0	1.8	nc	(nc-nc)
Female	6	4.2	141.6	(51.7-308.1)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.7	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
<u>Leukemia</u>					Female	5	9.3	53.5	(17.3-124.9)
Male	12	4.9	244.5	(126.2-427.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	3.7	135.5	(43.7-316.1)	Female	13	12.0	108.7	(57.8-185.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	4.5	nc	(nc-nc)	Male	144	160.5	89.7	(75.6-105.6)
Female	0	1.6	nc	(nc-nc)	Female	148	176.4	83.9	(70.9-98.5)
<u>Lung and Bronchus</u>									
Male	17	21.8	77.8	(45.3-124.7)					
Female	19	25.7	73.9	(44.4-115.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lenox

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	11.3	150.1	(87.4-240.3)	Male	8	6.0	133.4	(57.5-262.9)
Female	2	3.9	nc	(nc-nc)	Female	6	4.1	146.4	(53.4-318.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.5	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	5.4	110.9	(40.5-241.3)
Female	38	33.5	113.4	(80.3-155.7)	Female	4	4.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	2.0	nc	(nc-nc)
Male	15	10.6	141.6	(79.2-233.6)	<u>Ovary</u>				
Female	16	10.9	146.3	(83.6-237.7)	Female	6	3.0	198.1	(72.3-431.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.5	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	5	4.1	122.0	(39.3-284.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	24	27.6	86.9	(55.7-129.4)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.5	nc	(nc-nc)
Male	5	4.6	108.3	(34.9-252.7)	Female	0	1.5	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<u>Leukemia</u>					Female	2	4.3	nc	(nc-nc)
Male	2	3.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.8	nc	(nc-nc)	Female	7	7.7	90.6	(36.3-186.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.0	nc	(nc-nc)	Male	110	122.1	90.1	(74.1-108.6)
Female	0	1.2	nc	(nc-nc)	Female	127	122.7	103.5	(86.3-123.2)
<u>Lung and Bronchus</u>									
Male	12	18.5	65.0	(33.5-113.5)					
Female	18	19.3	93.5	(55.4-147.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Leominster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	60	46.9	127.9	(97.6-164.7)	Male	22	29.5	74.6	(46.7-112.9)
Female	28	15.2	183.7	(122.0-265.5)	Female	17	21.8	78.0	(45.4-124.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	8.7	57.3	(18.5-133.6)	Male	11	9.5	116.2	(57.9-208.0)
Female	8	6.9	115.2	(49.6-227.1)	Female	4	7.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.6	nc	(nc-nc)	Male	24	26.5	90.5	(57.9-134.6)
Female	176	173.7	101.3	(86.9-117.5)	Female	24	21.6	110.9	(71.0-165.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	6.0	149.2	(68.1-283.3)	Male	22	21.5	102.2	(64.0-154.8)
<u>Colon / Rectum</u>					Female	10	9.2	109.1	(52.2-200.7)
Male	43	50.8	84.7	(61.3-114.1)	<u>Ovary</u>				
Female	33	46.0	71.8	(49.4-100.8)	Female	30	14.9	200.8	(135.5-286.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	11.7	111.0	(59.0-189.8)	Male	13	16.5	78.7	(41.9-134.6)
Female	3	2.9	nc	(nc-nc)	Female	17	15.6	109.1	(63.5-174.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	3.5	nc	(nc-nc)	Male	136	137.6	98.8	(82.9-116.9)
Female	3	2.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	13	11.2	115.6	(61.5-197.7)
Male	30	25.3	118.6	(80.0-169.3)	Female	2	6.2	nc	(nc-nc)
Female	14	13.7	102.5	(56.0-172.0)	<u>Testis</u>				
<u>Larynx</u>					Male	3	6.3	nc	(nc-nc)
Male	9	6.8	133.3	(60.8-253.0)	<u>Thyroid</u>				
Female	0	1.9	nc	(nc-nc)	Male	12	11.6	103.4	(53.3-180.5)
<u>Leukemia</u>					Female	23	33.5	68.7	(43.6-103.2)
Male	17	18.8	90.6	(52.7-145.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	12	12.7	94.6	(48.8-165.3)	Female	43	38.1	113.0	(81.8-152.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	15.8	44.4	(17.8-91.5)	Male	559	590.8	94.6	(86.9-102.8)
Female	3	5.0	nc	(nc-nc)	Female	597	581.1	102.7	(94.7-111.3)
<u>Lung and Bronchus</u>									
Male	79	81.4	97.0	(76.8-120.9)					
Female	90	79.4	113.3	(91.1-139.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Leverett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	3.0	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	11	10.6	103.5	(51.6-185.2)	Female	1	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	3	3.0	nc	(nc-nc)	<u>Ovary</u>				
Female	1	2.4	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	10.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.7	nc	(nc-nc)
Male	3	1.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	3	1.7	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	0.7	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.0	nc	(nc-nc)	Male	24	38.8	61.9	(39.6-92.1)
Female	0	0.3	nc	(nc-nc)	Female	34	34.5	98.5	(68.2-137.7)
<u>Lung and Bronchus</u>									
Male	5	5.5	90.7	(29.2-211.8)					
Female	3	5.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lexington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	25	40.7	61.4	(39.8-90.7)	Male	28	25.1	111.5	(74.1-161.2)
Female	5	15.6	32.1	(10.3-74.9)	Female	22	19.5	112.9	(70.7-170.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	7.3	82.0	(30.0-178.6)	Male	11	8.2	133.6	(66.6-239.1)
Female	4	6.3	nc	(nc-nc)	Female	8	7.0	114.8	(49.4-226.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.4	nc	(nc-nc)	Male	18	22.5	79.9	(47.3-126.3)
Female	175	162.0	108.0	(92.6-125.3)	Female	24	21.1	113.7	(72.9-169.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	4.9	nc	(nc-nc)	Male	17	18.6	91.2	(53.1-146.0)
<u>Colon / Rectum</u>					Female	7	8.8	79.5	(31.8-163.8)
Male	38	43.1	88.2	(62.4-121.1)	<u>Ovary</u>				
Female	32	45.3	70.6	(48.3-99.7)	Female	15	14.0	107.3	(60.0-176.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	10.3	nc	(nc-nc)	Male	10	14.4	69.6	(33.3-128.1)
Female	0	3.0	nc	(nc-nc)	Female	17	15.9	106.8	(62.2-171.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.4	nc	(nc-nc)	Male	131	124.0	105.6	(88.3-125.3)
Female	1	2.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	9.7	nc	(nc-nc)
Male	17	21.9	77.8	(45.3-124.6)	Female	6	6.2	97.3	(35.5-211.9)
Female	4	13.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	3.8	nc	(nc-nc)
Male	3	6.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.8	nc	(nc-nc)	Male	8	9.3	86.0	(37.0-169.4)
<u>Leukemia</u>					Female	36	26.3	136.9	(95.9-189.5)
Male	14	16.0	87.2	(47.7-146.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	12	12.1	99.2	(51.2-173.3)	Female	29	36.0	80.7	(54.0-115.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	13.8	nc	(nc-nc)	Male	405	512.1	79.1	(71.6-87.2)
Female	5	5.0	100.9	(32.5-235.5)	Female	490	552.5	88.7	(81.0-96.9)
<u>Lung and Bronchus</u>									
Male	28	71.8	39.0	(25.9-56.4)					
Female	45	80.2	56.1	(40.9-75.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Leyden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	0.8	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	3.9	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.2	nc	(nc-nc)
Male	2	1.0	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.1	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.7	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.2	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	10	11.8	84.7	(40.5-155.7)
Female	0	0.1	nc	(nc-nc)	Female	13	11.9	109.0	(58.0-186.5)
<u>Lung and Bronchus</u>									
Male	0	1.5	nc	(nc-nc)					
Female	2	1.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lincoln

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	9.4	nc	(nc-nc)	Male	7	5.5	127.7	(51.2-263.1)
Female	8	2.6	306.1	(131.8-603.2)	Female	8	3.6	222.5	(95.8-438.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	1.6	318.9	(102.8-744.3)	Male	3	1.8	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	4	4.9	nc	(nc-nc)
Female	47	29.1	161.8	(118.9-215.1)	Female	4	3.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	5	3.7	136.7	(44.0-319.0)
<u>Colon / Rectum</u>					Female	1	1.6	nc	(nc-nc)
Male	7	9.5	73.5	(29.5-151.5)	<u>Ovary</u>				
Female	5	7.8	64.3	(20.7-150.2)	Female	4	2.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.1	nc	(nc-nc)	Male	5	3.2	157.8	(50.8-368.2)
Female	0	0.5	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	43	23.5	183.2	(132.6-246.8)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.2	nc	(nc-nc)
Male	2	4.4	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.9	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
<u>Leukemia</u>					Female	4	5.3	nc	(nc-nc)
Male	6	3.6	165.7	(60.5-360.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	2.3	309.0	(123.8-636.7)	Female	11	6.5	168.3	(83.9-301.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.8	nc	(nc-nc)	Male	121	108.4	111.6	(92.6-133.3)
Female	1	0.9	nc	(nc-nc)	Female	126	98.0	128.5	(107.1-153.0)
<u>Lung and Bronchus</u>									
Male	7	15.6	44.7	(17.9-92.2)					
Female	9	13.5	66.6	(30.4-126.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Littleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	8.0	174.0	(95.0-291.9)	Male	6	5.7	104.7	(38.2-227.8)
Female	1	3.6	nc	(nc-nc)	Female	4	5.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.8	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	10	5.1	195.4	(93.5-359.3)
Female	42	42.4	99.0	(71.3-133.8)	Female	4	5.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.4	nc	(nc-nc)	Male	6	4.6	130.2	(47.5-283.4)
<u>Colon / Rectum</u>					Female	0	2.2	nc	(nc-nc)
Male	5	9.6	52.3	(16.9-122.2)	<u>Ovary</u>				
Female	7	10.8	64.8	(26.0-133.5)	Female	6	3.6	165.0	(60.3-359.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.3	nc	(nc-nc)	Male	6	3.1	192.1	(70.1-418.1)
Female	0	0.7	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.7	nc	(nc-nc)	Male	33	28.7	114.9	(79.1-161.4)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.1	nc	(nc-nc)
Male	4	5.3	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
Female	3	3.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.3	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
<u>Leukemia</u>					Female	9	7.7	117.5	(53.6-223.1)
Male	3	3.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.0	nc	(nc-nc)	Female	14	9.5	148.0	(80.8-248.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	3.3	nc	(nc-nc)	Male	130	115.3	112.8	(94.2-133.9)
Female	2	1.2	nc	(nc-nc)	Female	122	139.8	87.3	(72.5-104.2)
<u>Lung and Bronchus</u>									
Male	20	15.1	132.8	(81.1-205.0)					
Female	14	19.4	72.2	(39.5-121.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	22.3	67.1	(37.5-110.7)	Male	18	13.2	136.9	(81.1-216.3)
Female	7	8.2	85.6	(34.3-176.3)	Female	14	10.0	140.6	(76.8-236.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.6	nc	(nc-nc)	Male	2	4.3	nc	(nc-nc)
Female	4	3.2	nc	(nc-nc)	Female	1	3.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	10	11.9	84.3	(40.3-155.0)
Female	86	80.2	107.2	(85.8-132.4)	Female	12	10.9	110.6	(57.1-193.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.4	nc	(nc-nc)	Male	5	9.4	53.3	(17.2-124.4)
<u>Colon / Rectum</u>					Female	0	4.5	nc	(nc-nc)
Male	11	23.2	47.5	(23.7-85.0)	<u>Ovary</u>				
Female	15	24.3	61.7	(34.5-101.7)	Female	5	7.1	70.6	(22.7-164.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	5.3	nc	(nc-nc)	Male	3	7.7	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	4	8.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	54	63.1	85.6	(64.3-111.7)
Female	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	5.2	96.1	(31.0-224.3)
Male	11	11.0	99.9	(49.8-178.9)	Female	2	3.3	nc	(nc-nc)
Female	3	6.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.8	nc	(nc-nc)
Male	1	3.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	5	4.5	111.5	(35.9-260.2)
<u>Leukemia</u>					Female	9	12.9	69.9	(31.9-132.8)
Male	15	8.4	178.3	(99.7-294.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	6.4	nc	(nc-nc)	Female	12	17.7	67.8	(35.0-118.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	7.0	nc	(nc-nc)	Male	213	267.6	79.6	(69.3-91.0)
Female	6	2.5	238.0	(86.9-518.0)	Female	234	281.3	83.2	(72.9-94.6)
<u>Lung and Bronchus</u>									
Male	24	38.2	62.9	(40.3-93.6)					
Female	24	40.5	59.3	(38.0-88.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lowell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	75	81.8	91.7	(72.1-114.9)	Male	32	56.9	56.2	(38.5-79.4)
Female	37	31.9	115.9	(81.6-159.7)	Female	26	49.1	53.0	(34.6-77.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	15	19.8	75.9	(42.5-125.2)	Male	17	17.5	97.1	(56.5-155.4)
Female	14	16.1	87.0	(47.5-146.0)	Female	23	14.7	156.5	(99.2-234.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	3.0	nc	(nc-nc)	Male	44	51.3	85.8	(62.3-115.2)
Female	307	371.9	82.5	(73.6-92.3)	Female	36	46.5	77.4	(54.2-107.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	17	14.0	121.2	(70.6-194.1)	Male	58	44.1	131.5	(99.9-170.0)
<u>Colon / Rectum</u>					Female	13	19.6	66.4	(35.3-113.5)
Male	87	94.7	91.9	(73.6-113.4)	<u>Ovary</u>				
Female	101	96.5	104.7	(85.3-127.2)	Female	25	32.3	77.4	(50.1-114.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	22	22.2	99.0	(62.0-150.0)	Male	29	30.5	95.2	(63.8-136.8)
Female	4	6.2	nc	(nc-nc)	Female	28	32.5	86.2	(57.2-124.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	14	9.3	149.8	(81.8-251.4)	Male	214	277.2	77.2	(67.2-88.3)
Female	4	7.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	25	20.6	121.2	(78.4-178.9)
Male	59	51.1	115.6	(88.0-149.1)	Female	32	13.1	244.5	(167.2-345.2)
Female	34	29.4	115.7	(80.1-161.7)	<u>Testis</u>				
<u>Larynx</u>					Male	14	18.6	75.4	(41.2-126.6)
Male	16	13.1	122.2	(69.8-198.5)	<u>Thyroid</u>				
Female	6	4.0	151.1	(55.2-329.0)	Male	17	26.2	64.9	(37.8-104.0)
<u>Leukemia</u>					Female	79	80.0	98.7	(78.1-123.0)
Male	35	37.3	94.0	(65.4-130.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	35	28.4	123.4	(85.9-171.6)	Female	81	81.2	99.7	(79.2-124.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	65	31.6	205.9	(158.9-262.4)	Male	1135	1145.1	99.1	(93.4-105.1)
Female	7	10.7	65.5	(26.2-135.0)	Female	1200	1252.9	95.8	(90.4-101.4)
<u>Lung and Bronchus</u>									
Male	178	147.7	120.5	(103.4-139.6)					
Female	191	166.5	114.7	(99.0-132.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ludlow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	28	25.4	110.2	(73.2-159.3)	Male	12	16.3	73.7	(38.0-128.7)
Female	4	10.2	nc	(nc-nc)	Female	15	13.1	114.1	(63.8-188.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	4.8	nc	(nc-nc)	Male	3	5.2	nc	(nc-nc)
Female	2	4.2	nc	(nc-nc)	Female	5	4.6	108.4	(34.9-253.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.9	nc	(nc-nc)	Male	14	14.5	96.7	(52.8-162.2)
Female	88	108.1	81.4	(65.3-100.3)	Female	13	14.0	92.8	(49.4-158.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	3.3	209.7	(84.0-432.1)	Male	7	12.5	56.0	(22.4-115.5)
<u>Colon / Rectum</u>					Female	4	5.9	nc	(nc-nc)
Male	29	27.6	104.9	(70.3-150.7)	<u>Ovary</u>				
Female	27	29.5	91.5	(60.3-133.1)	Female	9	9.3	96.5	(44.0-183.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	6.7	nc	(nc-nc)	Male	8	9.2	87.3	(37.6-172.0)
Female	2	2.0	nc	(nc-nc)	Female	12	10.4	114.9	(59.3-200.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.8	nc	(nc-nc)	Male	67	83.1	80.6	(62.5-102.4)
Female	1	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	6.2	129.8	(55.9-255.8)
Male	23	14.4	159.5	(101.1-239.4)	Female	4	4.0	nc	(nc-nc)
Female	5	8.7	57.6	(18.6-134.4)	<u>Testis</u>				
<u>Larynx</u>					Male	1	3.1	nc	(nc-nc)
Male	4	3.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.2	nc	(nc-nc)	Male	4	6.4	nc	(nc-nc)
<u>Leukemia</u>					Female	6	18.0	33.3	(12.2-72.4)
Male	7	10.1	69.1	(27.7-142.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	8.0	75.3	(27.5-163.8)	Female	22	24.4	90.3	(56.6-136.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	9.3	75.6	(30.3-155.8)	Male	292	333.2	87.6	(77.9-98.3)
Female	2	3.3	nc	(nc-nc)	Female	299	367.4	81.4	(72.4-91.1)
<u>Lung and Bronchus</u>									
Male	32	45.6	70.2	(48.0-99.1)					
Female	34	53.2	63.9	(44.2-89.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lunenburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	12.7	70.8	(32.3-134.3)	Male	8	8.0	99.6	(42.9-196.3)
Female	6	4.2	142.3	(52.0-309.8)	Female	3	6.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.4	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	7.3	69.0	(22.2-160.9)
Female	55	50.8	108.2	(81.5-140.8)	Female	6	6.2	97.5	(35.6-212.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.6	nc	(nc-nc)	Male	9	6.1	147.0	(67.1-279.2)
<u>Colon / Rectum</u>					Female	0	2.7	nc	(nc-nc)
Male	14	14.0	99.7	(54.5-167.3)	<u>Ovary</u>				
Female	14	12.5	112.1	(61.2-188.1)	Female	3	4.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	3.3	nc	(nc-nc)	Male	4	4.5	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	2	4.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	0.9	nc	(nc-nc)	Male	42	40.1	104.8	(75.5-141.7)
Female	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.1	nc	(nc-nc)
Male	7	7.2	97.7	(39.1-201.3)	Female	1	1.7	nc	(nc-nc)
Female	3	3.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.5	nc	(nc-nc)
Male	3	1.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
<u>Leukemia</u>					Female	10	9.0	110.6	(52.9-203.4)
Male	8	5.1	157.9	(68.0-311.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	3.4	nc	(nc-nc)	Female	15	11.9	126.2	(70.6-208.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	4.4	nc	(nc-nc)	Male	168	164.2	102.3	(87.4-119.0)
Female	3	1.5	nc	(nc-nc)	Female	156	165.8	94.1	(79.9-110.1)
<u>Lung and Bronchus</u>									
Male	24	22.4	107.0	(68.6-159.3)					
Female	16	22.7	70.5	(40.3-114.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lynn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	72	71.3	101.0	(79.1-127.3)	Male	43	48.4	88.8	(64.3-119.6)
Female	25	28.7	87.1	(56.4-128.7)	Female	31	42.7	72.6	(49.3-103.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	19	16.5	115.4	(69.4-180.2)	Male	32	15.2	211.1	(144.4-298.0)
Female	17	14.2	119.4	(69.5-191.2)	Female	16	13.1	121.7	(69.5-197.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	5	2.6	194.2	(62.6-453.2)	Male	51	43.8	116.4	(86.7-153.1)
Female	325	328.7	98.9	(88.4-110.2)	Female	51	41.2	123.8	(92.2-162.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	16	12.0	133.8	(76.4-217.2)	Male	50	36.8	135.9	(100.8-179.1)
<u>Colon / Rectum</u>					Female	19	17.4	109.2	(65.7-170.6)
Male	120	81.8	146.8	(121.7-175.5)	<u>Ovary</u>				
Female	111	85.6	129.6	(106.6-156.1)	Female	24	28.6	84.0	(53.8-125.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	21	18.9	111.0	(68.7-169.7)	Male	27	26.1	103.6	(68.3-150.8)
Female	5	5.6	89.4	(28.8-208.6)	Female	24	29.2	82.2	(52.7-122.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	7.4	67.4	(21.7-157.2)	Male	290	232.0	125.0	(111.0-140.2)
Female	2	6.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	21	17.8	118.1	(73.1-180.5)
Male	35	43.1	81.2	(56.5-112.9)	Female	22	11.6	189.9	(118.9-287.5)
Female	28	26.2	106.9	(71.0-154.6)	<u>Testis</u>				
<u>Larynx</u>					Male	14	14.6	96.1	(52.5-161.3)
Male	15	11.1	134.8	(75.4-222.4)	<u>Thyroid</u>				
Female	4	3.6	nc	(nc-nc)	Male	20	21.7	92.2	(56.3-142.4)
<u>Leukemia</u>					Female	53	68.3	77.6	(58.2-101.6)
Male	46	31.6	145.6	(106.6-194.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	32	25.3	126.6	(86.6-178.7)	Female	73	72.3	101.0	(79.2-127.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	57	26.3	216.5	(164.0-280.6)	Male	1230	972.1	126.5	(119.6-133.8)
Female	18	9.5	188.7	(111.8-298.2)	Female	1176	1110.3	105.9	(99.9-112.1)
<u>Lung and Bronchus</u>									
Male	195	127.2	153.3	(132.5-176.4)					
Female	171	150.5	113.7	(97.3-132.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lynnfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	15.7	76.2	(39.3-133.1)	Male	24	9.9	242.3	(155.2-360.5)
Female	10	5.4	184.8	(88.5-339.8)	Female	13	7.1	184.4	(98.1-315.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.8	nc	(nc-nc)	Male	5	3.2	154.8	(49.9-361.4)
Female	4	2.3	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	14	8.8	158.9	(86.8-266.6)
Female	60	58.7	102.2	(78.0-131.6)	Female	13	7.4	175.1	(93.2-299.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.8	nc	(nc-nc)	Male	5	7.5	67.0	(21.6-156.3)
<u>Colon / Rectum</u>					Female	2	3.1	nc	(nc-nc)
Male	13	17.0	76.6	(40.7-130.9)	<u>Ovary</u>				
Female	21	15.7	133.8	(82.8-204.6)	Female	8	5.0	158.6	(68.3-312.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	4.1	nc	(nc-nc)	Male	5	5.6	89.4	(28.8-208.5)
Female	0	1.1	nc	(nc-nc)	Female	7	5.5	127.3	(51.0-262.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.0	nc	(nc-nc)	Male	44	49.7	88.6	(64.4-118.9)
Female	2	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.8	nc	(nc-nc)
Male	7	8.7	80.6	(32.3-166.0)	Female	3	2.1	nc	(nc-nc)
Female	4	4.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	6	1.6	373.7	(136.4-813.3)
Male	1	2.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	6	3.8	159.3	(58.2-346.7)
<u>Leukemia</u>					Female	18	9.9	181.4	(107.5-286.8)
Male	11	6.1	179.5	(89.5-321.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	4.2	nc	(nc-nc)	Female	17	13.1	129.8	(75.6-207.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	5.5	nc	(nc-nc)	Male	190	202.0	94.1	(81.2-108.4)
Female	1	1.8	nc	(nc-nc)	Female	233	197.4	118.0	(103.4-134.2)
<u>Lung and Bronchus</u>									
Male	19	28.2	67.3	(40.5-105.1)					
Female	29	28.4	102.0	(68.3-146.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Malden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	46.7	57.8	(38.1-84.1)	Male	10	32.5	30.7	(14.7-56.5)
Female	21	18.9	111.4	(68.9-170.3)	Female	16	29.4	54.3	(31.0-88.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	10.9	46.1	(14.8-107.5)	Male	7	10.1	69.1	(27.7-142.4)
Female	7	9.3	75.0	(30.0-154.5)	Female	5	8.7	57.3	(18.4-133.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.7	nc	(nc-nc)	Male	43	29.2	147.2	(106.5-198.3)
Female	185	223.3	82.9	(71.3-95.7)	Female	26	27.6	94.3	(61.6-138.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	15	8.7	172.8	(96.7-285.1)	Male	23	24.7	93.2	(59.1-139.9)
<u>Colon / Rectum</u>					Female	11	11.6	94.7	(47.2-169.4)
Male	71	53.4	132.9	(103.8-167.6)	<u>Ovary</u>				
Female	72	57.6	125.0	(97.8-157.5)	Female	16	19.2	83.4	(47.6-135.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	17	12.6	134.9	(78.6-216.1)	Male	20	17.2	116.2	(70.9-179.4)
Female	8	3.6	219.8	(94.6-433.1)	Female	18	19.3	93.3	(55.3-147.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	5.3	nc	(nc-nc)	Male	128	152.3	84.0	(70.1-99.9)
Female	4	4.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	16	11.7	136.3	(77.9-221.4)
Male	36	28.9	124.8	(87.4-172.7)	Female	7	7.8	89.7	(35.9-184.9)
Female	21	17.4	120.9	(74.8-184.8)	<u>Testis</u>				
<u>Larynx</u>					Male	7	10.8	65.0	(26.0-133.9)
Male	9	7.4	121.4	(55.4-230.5)	<u>Thyroid</u>				
Female	2	2.3	nc	(nc-nc)	Male	15	15.1	99.4	(55.6-163.9)
<u>Leukemia</u>					Female	59	49.1	120.3	(91.5-155.1)
Male	22	20.7	106.1	(66.5-160.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	16	16.6	96.5	(55.1-156.6)	Female	50	48.0	104.2	(77.3-137.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	25	17.7	141.5	(91.6-208.9)	Male	639	644.5	99.1	(91.6-107.1)
Female	16	6.3	255.2	(145.8-414.5)	Female	740	746.7	99.1	(92.1-106.5)
<u>Lung and Bronchus</u>									
Male	116	83.9	138.3	(114.3-165.9)					
Female	108	97.9	110.3	(90.5-133.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Manchester by the Sea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	8.1	nc	(nc-nc)	Male	9	4.7	191.1	(87.2-362.7)
Female	1	2.7	nc	(nc-nc)	Female	5	3.4	146.6	(47.2-342.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.3	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.3	nc	(nc-nc)	Male	8	4.2	188.5	(81.2-371.4)
Female	29	29.3	99.0	(66.3-142.2)	Female	2	3.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.6	nc	(nc-nc)
Male	2	8.3	nc	(nc-nc)	<u>Ovary</u>				
Female	6	7.6	79.4	(29.0-172.7)	Female	1	2.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.0	nc	(nc-nc)	Male	0	2.8	nc	(nc-nc)
Female	3	0.5	nc	(nc-nc)	Female	4	2.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	24	23.3	102.9	(65.9-153.1)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.9	nc	(nc-nc)
Male	3	4.0	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	0	2.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	0.6	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.3	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<u>Leukemia</u>					Female	8	4.6	174.3	(75.1-343.5)
Male	1	3.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.1	nc	(nc-nc)	Female	6	6.7	89.1	(32.5-193.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.6	nc	(nc-nc)	Male	84	97.0	86.6	(69.1-107.2)
Female	0	0.9	nc	(nc-nc)	Female	86	97.8	87.9	(70.3-108.6)
<u>Lung and Bronchus</u>									
Male	8	13.7	58.3	(25.1-114.9)					
Female	8	14.6	55.0	(23.7-108.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mansfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	16.7	143.3	(91.8-213.2)	Male	25	12.2	205.5	(132.9-303.3)
Female	0	5.8	nc	(nc-nc)	Female	21	10.3	203.9	(126.2-311.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	4.2	189.3	(81.5-373.0)	Male	5	3.8	131.9	(42.5-307.8)
Female	6	3.4	178.9	(65.3-389.3)	Female	1	2.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.6	nc	(nc-nc)	Male	13	11.0	118.4	(63.0-202.5)
Female	93	83.6	111.3	(89.8-136.3)	Female	3	9.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.2	nc	(nc-nc)	Male	10	9.9	101.0	(48.4-185.8)
<u>Colon / Rectum</u>					Female	1	4.0	nc	(nc-nc)
Male	25	20.6	121.3	(78.4-179.0)	<u>Ovary</u>				
Female	27	19.0	142.4	(93.8-207.1)	Female	8	7.0	114.7	(49.4-226.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	4.8	nc	(nc-nc)	Male	5	6.4	77.8	(25.1-181.5)
Female	1	1.2	nc	(nc-nc)	Female	6	5.9	101.3	(37.0-220.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.8	nc	(nc-nc)	Male	60	59.3	101.1	(77.2-130.2)
Female	1	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	4.4	114.7	(37.0-267.8)
Male	13	11.4	114.5	(60.9-195.8)	Female	4	2.5	nc	(nc-nc)
Female	5	6.2	81.2	(26.2-189.4)	<u>Testis</u>				
<u>Larynx</u>					Male	8	3.5	231.6	(99.7-456.4)
Male	0	2.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	15	5.9	254.9	(142.6-420.5)
<u>Leukemia</u>					Female	17	18.1	93.7	(54.6-150.0)
Male	6	7.8	76.6	(28.0-166.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	5.4	202.7	(101.0-362.6)	Female	11	18.0	61.2	(30.5-109.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	9	6.9	131.0	(59.8-248.7)	Male	284	243.5	116.6	(103.4-131.0)
Female	3	2.1	nc	(nc-nc)	Female	282	260.5	108.2	(96.0-121.6)
<u>Lung and Bronchus</u>									
Male	35	30.6	114.5	(79.7-159.2)					
Female	34	31.7	107.4	(74.4-150.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marblehead

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	27.4	83.8	(53.1-125.8)	Male	41	16.5	248.1	(178.0-336.6)
Female	10	9.7	103.2	(49.4-189.7)	Female	26	12.6	205.7	(134.3-301.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	4.7	nc	(nc-nc)	Male	8	5.5	146.7	(63.2-289.2)
Female	3	4.1	nc	(nc-nc)	Female	7	4.4	158.3	(63.4-326.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.9	nc	(nc-nc)	Male	14	14.9	94.1	(51.4-157.9)
Female	126	107.1	117.6	(98.0-140.0)	Female	13	13.4	97.3	(51.7-166.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	3.3	151.9	(49.0-354.6)	Male	11	11.9	92.1	(45.9-164.9)
<u>Colon / Rectum</u>					Female	7	5.7	123.3	(49.4-254.0)
Male	25	28.5	87.8	(56.8-129.6)	<u>Ovary</u>				
Female	23	28.1	81.9	(51.9-122.9)	Female	6	9.1	65.6	(23.9-142.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	6.8	132.6	(60.5-251.7)	Male	10	9.6	104.5	(50.0-192.2)
Female	2	1.9	nc	(nc-nc)	Female	13	9.9	131.9	(70.2-225.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.5	nc	(nc-nc)	Male	95	80.5	118.0	(95.5-144.3)
Female	1	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	6.5	92.9	(33.9-202.3)
Male	12	14.2	84.6	(43.7-147.8)	Female	1	3.8	nc	(nc-nc)
Female	6	8.5	70.4	(25.7-153.3)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.2	nc	(nc-nc)
Male	2	3.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.2	nc	(nc-nc)	Male	7	5.8	120.6	(48.3-248.4)
<u>Leukemia</u>					Female	14	17.7	79.2	(43.3-132.9)
Male	11	10.6	104.0	(51.9-186.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	7.6	105.9	(45.6-208.6)	Female	20	24.2	82.5	(50.4-127.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	8.9	nc	(nc-nc)	Male	339	336.8	100.7	(90.2-112.0)
Female	1	3.2	nc	(nc-nc)	Female	364	356.9	102.0	(91.8-113.0)
<u>Lung and Bronchus</u>									
Male	28	48.2	58.1	(38.6-83.9)					
Female	39	51.5	75.8	(53.9-103.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marion

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	7.5	66.6	(21.5-155.4)	Male	10	4.5	222.1	(106.3-408.5)
Female	4	2.8	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.3	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	11	4.1	269.8	(134.5-482.7)
Female	34	27.1	125.5	(86.9-175.4)	Female	3	3.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.8	nc	(nc-nc)	Male	1	3.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.5	nc	(nc-nc)
Male	9	7.7	117.4	(53.6-222.8)	<u>Ovary</u>				
Female	11	8.0	137.9	(68.7-246.7)	Female	0	2.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.9	nc	(nc-nc)	Male	0	2.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	2.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	14	24.9	56.3	(30.7-94.4)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.8	nc	(nc-nc)
Male	2	4.0	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.6	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
<u>Leukemia</u>					Female	5	4.1	122.3	(39.4-285.5)
Male	8	2.8	281.2	(121.1-554.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	2.1	nc	(nc-nc)	Female	7	6.2	112.9	(45.2-232.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.5	nc	(nc-nc)	Male	84	95.2	88.3	(70.4-109.3)
Female	1	0.9	nc	(nc-nc)	Female	107	94.7	113.0	(92.6-136.6)
<u>Lung and Bronchus</u>									
Male	7	13.4	52.1	(20.9-107.3)					
Female	18	13.8	130.3	(77.2-205.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	34	39.5	86.0	(59.6-120.2)	Male	25	26.3	95.2	(61.6-140.5)
Female	11	13.4	81.8	(40.8-146.4)	Female	14	19.9	70.4	(38.5-118.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	8.2	73.2	(26.7-159.3)	Male	7	8.3	84.5	(33.8-174.1)
Female	10	6.3	157.6	(75.5-289.9)	Female	6	6.2	96.8	(35.4-210.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.4	nc	(nc-nc)	Male	18	23.4	76.9	(45.6-121.5)
Female	144	158.9	90.6	(76.4-106.7)	Female	23	19.4	118.6	(75.1-177.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	5.7	105.1	(38.4-228.9)	Male	20	19.6	101.9	(62.2-157.4)
<u>Colon / Rectum</u>					Female	19	8.2	232.2	(139.7-362.6)
Male	43	44.2	97.2	(70.3-130.9)	<u>Ovary</u>				
Female	50	39.8	125.7	(93.3-165.7)	Female	15	13.5	111.1	(62.2-183.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	10.3	116.6	(60.2-203.7)	Male	13	14.3	91.1	(48.5-155.9)
Female	6	2.6	227.7	(83.2-495.6)	Female	15	13.5	110.9	(62.0-182.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	7	3.4	207.3	(83.1-427.2)	Male	107	122.6	87.3	(71.5-105.4)
Female	3	2.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	9.7	51.3	(16.5-119.7)
Male	22	23.0	95.6	(59.9-144.7)	Female	5	5.4	93.1	(30.0-217.2)
Female	10	12.5	80.1	(38.4-147.3)	<u>Testis</u>				
<u>Larynx</u>					Male	3	6.5	nc	(nc-nc)
Male	7	6.0	115.8	(46.4-238.6)	<u>Thyroid</u>				
Female	1	1.7	nc	(nc-nc)	Male	11	11.1	99.1	(49.4-177.4)
<u>Leukemia</u>					Female	44	31.7	139.0	(101.0-186.5)
Male	14	16.6	84.2	(46.0-141.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	14	11.3	123.6	(67.5-207.4)	Female	33	35.1	94.1	(64.8-132.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	13	14.2	91.2	(48.5-156.0)	Male	451	521.9	86.4	(78.6-94.8)
Female	8	4.5	177.0	(76.2-348.8)	Female	551	525.2	104.9	(96.3-114.0)
<u>Lung and Bronchus</u>									
Male	52	70.8	73.5	(54.9-96.4)					
Female	71	71.8	98.8	(77.2-124.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marshfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	27.4	69.3	(41.7-108.2)	Male	31	17.9	172.8	(117.4-245.2)
Female	10	9.0	110.8	(53.0-203.8)	Female	28	13.5	206.8	(137.4-298.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	5.5	180.2	(86.3-331.4)	Male	13	5.8	225.1	(119.7-384.9)
Female	5	4.4	113.7	(36.6-265.3)	Female	1	4.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	13	16.1	80.8	(43.0-138.1)
Female	142	114.7	123.8	(104.3-145.9)	Female	12	13.4	89.4	(46.2-156.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	3.8	159.4	(58.2-347.0)	Male	12	14.4	83.3	(43.0-145.4)
<u>Colon / Rectum</u>					Female	4	5.8	nc	(nc-nc)
Male	21	30.7	68.4	(42.3-104.6)	<u>Ovary</u>				
Female	26	26.4	98.5	(64.4-144.4)	Female	10	9.7	103.3	(49.4-189.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	7.5	106.4	(45.8-209.7)	Male	12	10.2	118.1	(61.0-206.4)
Female	0	1.9	nc	(nc-nc)	Female	12	9.1	132.0	(68.1-230.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.0	nc	(nc-nc)	Male	112	97.0	115.4	(95.0-138.9)
Female	3	1.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	6.8	nc	(nc-nc)
Male	20	16.5	121.2	(74.0-187.2)	Female	3	3.6	nc	(nc-nc)
Female	6	8.8	68.6	(25.0-149.2)	<u>Testis</u>				
<u>Larynx</u>					Male	4	3.4	nc	(nc-nc)
Male	1	4.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.3	nc	(nc-nc)	Male	9	7.3	123.0	(56.1-233.5)
<u>Leukemia</u>					Female	19	21.0	90.6	(54.5-141.5)
Male	15	11.4	131.8	(73.7-217.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	7.4	80.6	(29.4-175.4)	Female	21	26.7	78.7	(48.7-120.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	13	10.4	125.2	(66.6-214.2)	Male	390	374.1	104.2	(94.2-115.1)
Female	1	3.2	nc	(nc-nc)	Female	407	366.7	111.0	(100.5-122.3)
<u>Lung and Bronchus</u>									
Male	46	50.0	92.0	(67.3-122.7)					
Female	65	50.0	130.0	(100.3-165.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mashpee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	30	23.0	130.3	(87.9-186.1)	Male	14	13.3	104.9	(57.3-176.1)
Female	7	9.0	77.7	(31.1-160.1)	Female	18	10.2	176.7	(104.7-279.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.6	nc	(nc-nc)	Male	5	4.4	112.6	(36.3-262.8)
Female	1	3.3	nc	(nc-nc)	Female	2	3.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	15	11.9	125.9	(70.4-207.6)
Female	88	86.6	101.6	(81.5-125.2)	Female	15	11.6	128.9	(72.1-212.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.3	nc	(nc-nc)	Male	15	9.2	162.3	(90.8-267.7)
<u>Colon / Rectum</u>					Female	5	4.8	104.3	(33.6-243.3)
Male	19	22.7	83.8	(50.4-130.8)	<u>Ovary</u>				
Female	21	24.3	86.3	(53.4-131.9)	Female	5	7.6	66.1	(21.3-154.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	5.6	89.7	(28.9-209.3)	Male	10	7.8	128.5	(61.5-236.3)
Female	0	1.7	nc	(nc-nc)	Female	9	9.0	100.5	(45.8-190.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.2	nc	(nc-nc)	Male	65	66.1	98.3	(75.9-125.4)
Female	2	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	5.3	nc	(nc-nc)
Male	11	11.2	98.5	(49.1-176.2)	Female	2	3.2	nc	(nc-nc)
Female	8	7.3	109.0	(46.9-214.8)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.7	nc	(nc-nc)
Male	4	3.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	3	1.1	nc	(nc-nc)	Male	3	4.4	nc	(nc-nc)
<u>Leukemia</u>					Female	10	12.3	81.0	(38.8-149.0)
Male	9	8.5	106.2	(48.5-201.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	6.5	154.1	(73.8-283.3)	Female	12	20.0	60.1	(31.0-104.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	7.0	85.3	(31.2-185.8)	Male	278	273.9	101.5	(89.9-114.2)
Female	0	2.8	nc	(nc-nc)	Female	287	302.3	94.9	(84.3-106.6)
<u>Lung and Bronchus</u>									
Male	39	40.6	96.0	(68.3-131.3)					
Female	48	48.5	99.0	(73.0-131.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mattapoisett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	8.0	149.3	(77.0-260.8)	Male	7	5.1	138.5	(55.5-285.4)
Female	4	2.7	nc	(nc-nc)	Female	4	3.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.5	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	1	4.5	nc	(nc-nc)
Female	38	31.4	120.9	(85.6-166.0)	Female	5	3.8	131.1	(42.2-305.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.9	nc	(nc-nc)	Male	13	3.9	337.5	(179.5-577.1)
<u>Colon / Rectum</u>					Female	1	1.6	nc	(nc-nc)
Male	12	8.3	144.6	(74.6-252.6)	<u>Ovary</u>				
Female	4	7.5	nc	(nc-nc)	Female	5	2.7	187.2	(60.3-436.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.2	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	42	27.5	152.9	(110.2-206.7)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	1.9	nc	(nc-nc)
Male	3	4.6	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	0	2.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<u>Leukemia</u>					Female	4	5.2	nc	(nc-nc)
Male	2	3.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	2.1	nc	(nc-nc)	Female	12	7.4	162.3	(83.7-283.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.8	nc	(nc-nc)	Male	139	105.6	131.7	(110.7-155.5)
Female	3	0.9	nc	(nc-nc)	Female	106	102.6	103.3	(84.6-125.0)
<u>Lung and Bronchus</u>									
Male	18	15.1	119.1	(70.5-188.2)					
Female	10	14.8	67.3	(32.2-123.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Maynard

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	12.3	97.6	(50.4-170.5)	Male	6	7.9	75.9	(27.7-165.2)
Female	2	3.6	nc	(nc-nc)	Female	6	5.5	109.1	(39.8-237.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.4	nc	(nc-nc)	Male	0	2.6	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	4	7.1	nc	(nc-nc)
Female	45	44.0	102.3	(74.6-136.9)	Female	3	5.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.6	nc	(nc-nc)	Male	5	6.0	83.8	(27.0-195.6)
<u>Colon / Rectum</u>					Female	4	2.3	nc	(nc-nc)
Male	19	13.4	142.1	(85.5-221.9)	<u>Ovary</u>				
Female	16	10.7	149.1	(85.2-242.1)	Female	1	3.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.2	nc	(nc-nc)	Male	4	4.4	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	4	3.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	31	38.7	80.2	(54.5-113.8)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.0	nc	(nc-nc)
Male	3	7.0	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
Female	3	3.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.5	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.5	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
<u>Leukemia</u>					Female	11	8.7	127.1	(63.4-227.4)
Male	3	5.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	3.0	nc	(nc-nc)	Female	4	10.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	4.4	nc	(nc-nc)	Male	119	160.0	74.4	(61.6-89.0)
Female	2	1.3	nc	(nc-nc)	Female	139	143.6	96.8	(81.4-114.3)
<u>Lung and Bronchus</u>									
Male	10	22.0	45.5	(21.8-83.6)					
Female	17	18.9	89.8	(52.3-143.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Medfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	13.4	67.3	(30.7-127.8)	Male	12	8.7	137.3	(70.8-239.8)
Female	4	3.5	nc	(nc-nc)	Female	8	5.8	138.7	(59.7-273.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.7	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	4	7.9	nc	(nc-nc)
Female	40	48.7	82.1	(58.7-111.9)	Female	5	5.4	93.1	(30.0-217.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.7	nc	(nc-nc)	Male	9	6.7	133.4	(60.9-253.3)
<u>Colon / Rectum</u>					Female	1	2.4	nc	(nc-nc)
Male	14	14.9	93.9	(51.3-157.6)	<u>Ovary</u>				
Female	9	11.1	80.9	(36.9-153.6)	Female	3	4.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.5	nc	(nc-nc)	Male	4	4.9	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	3.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.9	nc	(nc-nc)	Male	53	43.1	122.8	(92.0-160.7)
Female	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.3	nc	(nc-nc)
Male	6	7.8	77.2	(28.2-168.0)	Female	2	1.5	nc	(nc-nc)
Female	2	3.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.5	nc	(nc-nc)
Male	0	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
<u>Leukemia</u>					Female	6	9.5	63.1	(23.1-137.4)
Male	4	5.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	3.1	194.1	(70.9-422.5)	Female	8	10.8	74.1	(31.9-146.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	4.9	nc	(nc-nc)	Male	149	176.9	84.2	(71.2-98.9)
Female	0	1.3	nc	(nc-nc)	Female	119	151.5	78.5	(65.1-94.0)
<u>Lung and Bronchus</u>									
Male	11	23.9	46.1	(23.0-82.5)					
Female	11	18.9	58.0	(28.9-103.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Medford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	56	55.3	101.3	(76.5-131.6)	Male	20	35.2	56.8	(34.7-87.8)
Female	19	22.2	85.7	(51.6-133.9)	Female	18	31.3	57.6	(34.1-91.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	14	10.9	128.5	(70.2-215.6)	Male	11	11.0	99.6	(49.6-178.1)
Female	11	9.8	112.6	(56.1-201.4)	Female	11	10.0	110.0	(54.9-196.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.9	nc	(nc-nc)	Male	29	31.6	91.7	(61.4-131.6)
Female	228	236.6	96.3	(84.2-109.7)	Female	27	31.1	86.9	(57.3-126.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	8.5	94.6	(40.7-186.5)	Male	28	24.8	112.7	(74.9-162.9)
<u>Colon / Rectum</u>					Female	14	12.9	108.8	(59.4-182.5)
Male	70	59.4	117.8	(91.8-148.8)	<u>Ovary</u>				
Female	75	64.5	116.3	(91.5-145.8)	Female	23	20.8	110.5	(70.1-165.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	14	13.6	102.9	(56.2-172.7)	Male	16	19.3	82.8	(47.3-134.5)
Female	7	4.3	164.3	(65.8-338.4)	Female	16	22.5	71.2	(40.7-115.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	5.0	119.2	(43.5-259.5)	Male	153	158.6	96.5	(81.8-113.0)
Female	5	4.5	111.3	(35.9-259.8)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	15	13.3	113.2	(63.3-186.7)
Male	27	29.6	91.2	(60.1-132.7)	Female	8	8.8	91.1	(39.2-179.4)
Female	25	19.1	130.9	(84.7-193.2)	<u>Testis</u>				
<u>Larynx</u>					Male	12	9.9	120.8	(62.4-211.0)
Male	9	7.9	114.2	(52.1-216.8)	<u>Thyroid</u>				
Female	3	2.6	nc	(nc-nc)	Male	11	14.3	76.8	(38.3-137.5)
<u>Leukemia</u>					Female	41	47.5	86.2	(61.9-117.0)
Male	28	22.6	124.2	(82.5-179.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	17	18.2	93.4	(54.4-149.6)	Female	54	52.8	102.2	(76.8-133.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	25	18.1	137.7	(89.1-203.4)	Male	715	697.2	102.6	(95.2-110.4)
Female	7	7.3	96.5	(38.7-198.8)	Female	828	816.6	101.4	(94.6-108.5)
<u>Lung and Bronchus</u>									
Male	114	96.3	118.4	(97.7-142.2)					
Female	134	114.2	117.4	(98.3-139.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Medway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	11.5	112.9	(60.1-193.1)	Male	9	7.9	113.5	(51.8-215.5)
Female	2	4.4	nc	(nc-nc)	Female	3	6.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.5	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	11	7.2	152.9	(76.2-273.7)
Female	58	54.5	106.5	(80.9-137.7)	Female	9	6.6	137.0	(62.5-260.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.9	nc	(nc-nc)	Male	3	6.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	2.8	nc	(nc-nc)
Male	17	13.7	124.2	(72.3-198.9)	<u>Ovary</u>				
Female	9	14.3	63.1	(28.8-119.9)	Female	5	4.6	107.5	(34.7-251.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.3	152.8	(49.2-356.5)	Male	3	4.4	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	3	4.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.0	nc	(nc-nc)	Male	54	41.7	129.6	(97.3-169.1)
Female	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.9	nc	(nc-nc)
Male	6	7.4	81.0	(29.6-176.4)	Female	0	1.9	nc	(nc-nc)
Female	1	4.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.8	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
<u>Leukemia</u>					Female	11	10.5	104.5	(52.1-186.9)
Male	4	5.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	3.9	128.7	(41.5-300.3)	Female	12	11.8	101.5	(52.4-177.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	4.7	106.7	(34.4-249.1)	Male	175	163.4	107.1	(91.8-124.2)
Female	2	1.5	nc	(nc-nc)	Female	161	177.7	90.6	(77.2-105.7)
<u>Lung and Bronchus</u>									
Male	19	21.0	90.5	(54.5-141.4)					
Female	21	22.6	93.0	(57.5-142.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Melrose

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	30.0	50.0	(28.0-82.5)	Male	16	19.1	83.6	(47.8-135.8)
Female	9	11.2	80.2	(36.6-152.3)	Female	22	15.6	141.5	(88.6-214.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	5.8	86.2	(27.8-201.1)	Male	4	6.1	nc	(nc-nc)
Female	9	4.9	182.3	(83.2-346.2)	Female	3	5.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	23	17.2	133.6	(84.7-200.5)
Female	130	124.2	104.7	(87.4-124.3)	Female	19	15.8	120.4	(72.4-188.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	4.3	nc	(nc-nc)	Male	11	14.1	78.0	(38.9-139.6)
<u>Colon / Rectum</u>					Female	5	6.7	75.0	(24.2-175.1)
Male	45	32.5	138.5	(101.0-185.3)	<u>Ovary</u>				
Female	34	33.1	102.7	(71.1-143.6)	Female	7	10.7	65.3	(26.1-134.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	7.7	117.4	(53.6-222.9)	Male	16	10.6	150.5	(86.0-244.4)
Female	0	2.2	nc	(nc-nc)	Female	13	11.5	113.1	(60.2-193.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	2.2	nc	(nc-nc)	Male	83	92.8	89.4	(71.2-110.9)
Female	2	1.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	7.2	69.2	(22.3-161.5)
Male	13	16.8	77.2	(41.1-132.1)	Female	3	4.5	nc	(nc-nc)
Female	8	9.9	81.1	(34.9-159.7)	<u>Testis</u>				
<u>Larynx</u>					Male	3	4.3	nc	(nc-nc)
Male	7	4.4	158.9	(63.7-327.4)	<u>Thyroid</u>				
Female	2	1.4	nc	(nc-nc)	Male	9	7.8	115.2	(52.6-218.8)
<u>Leukemia</u>					Female	26	23.2	111.9	(73.1-164.0)
Male	19	12.2	155.5	(93.6-242.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	9.2	109.1	(52.2-200.7)	Female	32	27.9	114.6	(78.3-161.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	10.2	48.9	(15.8-114.2)	Male	371	386.5	96.0	(86.5-106.3)
Female	5	3.7	135.6	(43.7-316.5)	Female	437	419.3	104.2	(94.7-114.5)
<u>Lung and Bronchus</u>									
Male	47	52.9	88.8	(65.3-118.1)					
Female	60	58.3	102.9	(78.5-132.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	6.1	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.2	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
Female	17	24.2	70.2	(40.9-112.4)	Female	5	2.7	187.5	(60.4-437.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	5	3.3	150.5	(48.5-351.2)
<u>Colon / Rectum</u>					Female	0	1.2	nc	(nc-nc)
Male	3	7.0	nc	(nc-nc)	<u>Ovary</u>				
Female	5	5.1	97.2	(31.3-226.9)	Female	2	2.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.7	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	4	1.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	21	22.0	95.6	(59.2-146.2)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.5	nc	(nc-nc)
Male	4	3.8	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.8	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
<u>Leukemia</u>					Female	6	4.7	126.8	(46.3-275.9)
Male	5	2.6	195.3	(63.0-455.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.5	nc	(nc-nc)	Female	8	5.6	143.6	(61.9-283.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.3	nc	(nc-nc)	Male	62	84.7	73.2	(56.1-93.9)
Female	1	0.6	nc	(nc-nc)	Female	75	74.8	100.3	(78.9-125.7)
<u>Lung and Bronchus</u>									
Male	5	10.9	45.7	(14.7-106.6)					
Female	7	9.5	73.6	(29.5-151.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Merrimac

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	7.0	85.3	(31.1-185.6)	Male	4	4.6	nc	(nc-nc)
Female	4	2.4	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.4	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
Female	22	30.9	71.1	(44.6-107.7)	Female	3	3.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.0	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.6	nc	(nc-nc)
Male	9	7.8	116.1	(53.0-220.4)	<u>Ovary</u>				
Female	5	7.5	67.1	(21.6-156.6)	Female	5	2.6	190.5	(61.4-444.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.9	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	23	23.7	97.0	(61.4-145.5)
Female	2	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	1.7	nc	(nc-nc)
Male	1	4.1	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	0.9	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<u>Leukemia</u>					Female	2	5.7	nc	(nc-nc)
Male	4	2.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.0	nc	(nc-nc)	Female	1	7.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.6	nc	(nc-nc)	Male	90	94.1	95.6	(76.9-117.5)
Female	3	0.8	nc	(nc-nc)	Female	92	99.0	92.9	(74.9-113.9)
<u>Lung and Bronchus</u>									
Male	13	12.9	100.6	(53.5-172.1)					
Female	22	13.3	164.8	(103.3-249.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Methuen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	43	45.8	93.8	(67.9-126.3)	Male	21	30.5	68.9	(42.6-105.3)
Female	22	18.3	120.1	(75.3-181.9)	Female	24	25.6	93.9	(60.2-139.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	9.8	123.0	(63.5-214.8)	Male	10	9.7	102.7	(49.2-188.9)
Female	11	8.2	134.1	(66.8-239.9)	Female	8	8.4	95.7	(41.2-188.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	1.6	nc	(nc-nc)	Male	34	27.4	124.2	(86.0-173.6)
Female	184	206.6	89.1	(76.7-102.9)	Female	25	25.8	96.7	(62.6-142.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	7.0	128.1	(58.5-243.2)	Male	22	23.6	93.3	(58.4-141.2)
<u>Colon / Rectum</u>					Female	8	10.9	73.7	(31.7-145.2)
Male	46	51.1	90.1	(66.0-120.2)	<u>Ovary</u>				
Female	54	53.5	100.9	(75.8-131.6)	Female	15	17.7	84.8	(47.4-139.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	12.4	72.8	(33.2-138.2)	Male	14	16.9	82.8	(45.2-138.9)
Female	3	3.6	nc	(nc-nc)	Female	22	18.5	118.6	(74.3-179.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	7	3.9	178.7	(71.6-368.2)	Male	149	154.7	96.3	(81.5-113.1)
Female	1	3.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	17	11.4	149.6	(87.1-239.5)
Male	30	27.4	109.7	(74.0-156.6)	Female	3	7.2	nc	(nc-nc)
Female	23	16.4	140.4	(88.9-210.6)	<u>Testis</u>				
<u>Larynx</u>					Male	13	7.1	183.9	(97.8-314.5)
Male	10	7.3	136.7	(65.4-251.3)	<u>Thyroid</u>				
Female	5	2.3	219.1	(70.6-511.2)	Male	16	12.8	125.1	(71.4-203.1)
<u>Leukemia</u>					Female	42	38.7	108.5	(78.2-146.7)
Male	27	19.5	138.4	(91.2-201.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	18	14.9	120.5	(71.4-190.4)	Female	46	45.9	100.3	(73.4-133.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	15	17.2	87.0	(48.7-143.6)	Male	639	622.3	102.7	(94.9-111.0)
Female	6	6.0	99.8	(36.4-217.2)	Female	721	691.2	104.3	(96.8-112.2)
<u>Lung and Bronchus</u>									
Male	101	83.5	120.9	(98.5-146.9)					
Female	128	97.1	131.8	(109.9-156.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Middleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	24.9	128.4	(87.8-181.2)	Male	19	16.2	117.0	(70.4-182.7)
Female	12	8.8	136.7	(70.5-238.7)	Female	9	12.7	70.7	(32.2-134.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.1	117.6	(42.9-256.0)	Male	5	5.3	95.2	(30.7-222.1)
Female	5	4.0	125.0	(40.3-291.7)	Female	6	4.1	147.2	(53.8-320.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	12	14.7	81.7	(42.2-142.8)
Female	115	104.3	110.3	(91.1-132.4)	Female	8	12.5	63.8	(27.5-125.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	3.5	172.1	(62.8-374.6)	Male	12	12.7	94.4	(48.7-165.0)
<u>Colon / Rectum</u>					Female	8	5.3	149.7	(64.5-295.0)
Male	33	27.8	118.8	(81.8-166.9)	<u>Ovary</u>				
Female	25	25.8	97.1	(62.8-143.3)	Female	11	8.9	124.3	(62.0-222.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	6.7	118.7	(51.1-233.9)	Male	13	9.1	142.8	(76.0-244.3)
Female	3	1.7	nc	(nc-nc)	Female	11	8.9	123.8	(61.7-221.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.9	nc	(nc-nc)	Male	90	86.5	104.0	(83.6-127.8)
Female	2	1.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	6.1	98.2	(35.8-213.7)
Male	21	14.9	140.7	(87.1-215.1)	Female	0	3.4	nc	(nc-nc)
Female	5	8.2	61.3	(19.8-143.1)	<u>Testis</u>				
<u>Larynx</u>					Male	5	3.4	148.3	(47.8-346.2)
Male	4	3.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	6	1.1	526.8	(192.3-1146.6)	Male	7	6.7	104.3	(41.8-214.9)
<u>Leukemia</u>					Female	24	19.5	122.9	(78.7-182.9)
Male	12	10.4	115.4	(59.6-201.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	13	7.2	181.6	(96.6-310.6)	Female	31	23.3	133.1	(90.4-189.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	13	9.1	143.0	(76.1-244.6)	Male	384	337.6	113.7	(102.6-125.7)
Female	7	2.9	238.9	(95.7-492.3)	Female	407	341.8	119.1	(107.8-131.2)
<u>Lung and Bronchus</u>									
Male	62	45.4	136.4	(104.6-174.9)					
Female	69	47.7	144.6	(112.5-183.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Middlefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	3.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	2	1.0	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.7	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.3	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.5	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	9	13.2	68.3	(31.2-129.7)
Female	0	0.1	nc	(nc-nc)	Female	8	9.9	80.8	(34.8-159.3)
<u>Lung and Bronchus</u>									
Male	1	1.9	nc	(nc-nc)					
Female	2	1.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Middleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	10.7	139.6	(78.1-230.3)	Male	9	7.2	124.7	(56.9-236.8)
Female	2	2.8	nc	(nc-nc)	Female	3	4.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.3	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	14	6.5	214.1	(117.0-359.3)
Female	43	33.2	129.6	(93.8-174.6)	Female	7	4.0	175.6	(70.3-361.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	5	5.7	87.8	(28.3-204.9)
<u>Colon / Rectum</u>					Female	2	1.7	nc	(nc-nc)
Male	11	12.3	89.2	(44.5-159.7)	<u>Ovary</u>				
Female	11	8.1	136.3	(68.0-244.0)	Female	0	2.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.9	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.0	nc	(nc-nc)	Male	35	37.5	93.3	(65.0-129.8)
Female	2	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	2.7	nc	(nc-nc)
Male	2	6.6	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Female	5	2.6	191.2	(61.6-446.2)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.9	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
<u>Leukemia</u>					Female	8	6.0	132.9	(57.2-261.8)
Male	5	4.5	110.0	(35.5-256.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.3	nc	(nc-nc)	Female	12	7.5	159.9	(82.5-279.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.0	nc	(nc-nc)	Male	156	148.1	105.4	(89.5-123.3)
Female	0	0.9	nc	(nc-nc)	Female	128	108.7	117.8	(98.3-140.1)
<u>Lung and Bronchus</u>									
Male	21	19.1	110.0	(68.0-168.1)					
Female	16	15.4	103.6	(59.2-168.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Milford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	45	26.3	170.9	(124.6-228.7)	Male	14	17.4	80.3	(43.9-134.7)
Female	14	9.7	144.0	(78.6-241.6)	Female	14	14.3	97.6	(53.3-163.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	5.5	nc	(nc-nc)	Male	4	5.5	nc	(nc-nc)
Female	5	4.6	108.2	(34.9-252.6)	Female	8	4.5	177.6	(76.5-349.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	23	15.7	146.4	(92.8-219.6)
Female	110	113.7	96.8	(79.5-116.6)	Female	21	14.1	149.4	(92.5-228.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.0	nc	(nc-nc)	Male	14	13.1	106.7	(58.3-179.0)
<u>Colon / Rectum</u>					Female	5	5.9	84.1	(27.1-196.3)
Male	31	29.7	104.3	(70.8-148.0)	<u>Ovary</u>				
Female	30	29.2	102.7	(69.3-146.6)	Female	9	9.8	92.3	(42.1-175.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	6.8	146.0	(69.9-268.6)	Male	8	9.5	83.8	(36.1-165.2)
Female	2	1.9	nc	(nc-nc)	Female	7	9.9	70.4	(28.2-145.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	2.3	218.4	(70.4-509.7)	Male	105	82.4	127.4	(104.2-154.3)
Female	1	1.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	14	6.5	215.3	(117.6-361.3)
Male	17	15.4	110.5	(64.3-176.9)	Female	1	4.0	nc	(nc-nc)
Female	13	8.9	146.7	(78.1-250.9)	<u>Testis</u>				
<u>Larynx</u>					Male	4	4.4	nc	(nc-nc)
Male	2	4.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.2	nc	(nc-nc)	Male	3	7.5	nc	(nc-nc)
<u>Leukemia</u>					Female	23	22.4	102.8	(65.1-154.2)
Male	11	11.2	98.5	(49.1-176.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	8.3	133.0	(66.3-238.0)	Female	30	25.1	119.6	(80.7-170.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	9.4	63.7	(23.2-138.6)	Male	396	348.7	113.6	(102.7-125.3)
Female	3	3.2	nc	(nc-nc)	Female	404	377.7	107.0	(96.8-117.9)
<u>Lung and Bronchus</u>									
Male	47	46.5	101.1	(74.3-134.4)					
Female	60	50.9	117.9	(90.0-151.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Millbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	14.3	132.8	(79.9-207.5)	Male	6	9.5	63.3	(23.1-137.8)
Female	2	4.9	nc	(nc-nc)	Female	9	7.2	125.3	(57.2-238.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.9	nc	(nc-nc)	Male	6	3.0	196.8	(71.9-428.3)
Female	1	2.3	nc	(nc-nc)	Female	7	2.3	305.8	(122.5-630.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	17	8.6	198.8	(115.7-318.3)
Female	63	58.7	107.3	(82.5-137.3)	Female	3	7.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.0	nc	(nc-nc)	Male	10	7.4	135.2	(64.7-248.6)
<u>Colon / Rectum</u>					Female	3	3.0	nc	(nc-nc)
Male	10	15.9	62.9	(30.1-115.6)	<u>Ovary</u>				
Female	15	14.7	101.8	(56.9-167.9)	Female	5	5.0	100.6	(32.4-234.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	3.9	154.0	(56.2-335.3)	Male	6	5.3	113.4	(41.4-246.7)
Female	4	1.0	nc	(nc-nc)	Female	10	5.0	199.8	(95.7-367.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.1	nc	(nc-nc)	Male	54	49.5	109.1	(81.9-142.3)
Female	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.5	nc	(nc-nc)
Male	14	8.7	160.7	(87.8-269.7)	Female	3	2.0	nc	(nc-nc)
Female	6	4.6	130.5	(47.7-284.1)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.9	nc	(nc-nc)
Male	4	2.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.6	nc	(nc-nc)	Male	10	4.0	248.6	(119.0-457.2)
<u>Leukemia</u>					Female	13	11.2	116.3	(61.9-198.9)
Male	8	5.9	134.8	(58.0-265.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	4.1	145.9	(53.3-317.6)	Female	9	13.2	68.4	(31.2-129.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	5.1	117.0	(42.7-254.7)	Male	247	194.4	127.1	(111.7-144.0)
Female	1	1.7	nc	(nc-nc)	Female	208	192.7	108.0	(93.8-123.7)
<u>Lung and Bronchus</u>									
Male	46	26.2	175.5	(128.5-234.1)					
Female	31	26.2	118.1	(80.3-167.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Millis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	6.3	174.4	(86.9-312.1)	Male	3	4.7	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)	Female	4	4.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	4.2	nc	(nc-nc)
Female	32	35.0	91.4	(62.5-129.0)	Female	5	4.1	121.9	(39.3-284.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.2	nc	(nc-nc)	Male	6	4.1	147.7	(53.9-321.6)
<u>Colon / Rectum</u>					Female	1	1.8	nc	(nc-nc)
Male	10	8.2	122.3	(58.5-224.9)	<u>Ovary</u>				
Female	10	8.5	117.8	(56.4-216.6)	Female	1	3.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.9	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	31	24.5	126.6	(86.0-179.7)
Female	3	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.7	nc	(nc-nc)
Male	6	4.5	132.1	(48.3-287.6)	Female	0	1.1	nc	(nc-nc)
Female	4	2.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.1	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
<u>Leukemia</u>					Female	11	6.7	164.1	(81.8-293.7)
Male	4	2.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	2.4	211.4	(68.1-493.4)	Female	7	7.8	89.8	(36.0-185.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.9	nc	(nc-nc)	Male	106	96.1	110.2	(90.3-133.3)
Female	1	1.0	nc	(nc-nc)	Female	117	113.4	103.2	(85.4-123.7)
<u>Lung and Bronchus</u>									
Male	9	12.1	74.6	(34.1-141.7)					
Female	15	15.4	97.1	(54.3-160.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Millville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	2.1	242.6	(78.2-566.2)	Male	1	1.6	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	13	12.8	101.9	(54.2-174.3)	Female	2	1.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	4	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.6	nc	(nc-nc)
Male	3	2.8	nc	(nc-nc)	<u>Ovary</u>				
Female	1	3.1	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.6	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	12	7.9	151.0	(77.9-263.7)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	0.6	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.5	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<u>Leukemia</u>					Female	0	2.6	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.9	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	0.9	nc	(nc-nc)	Male	44	32.2	136.6	(99.2-183.3)
Female	1	0.3	nc	(nc-nc)	Female	37	41.0	90.3	(63.5-124.4)
<u>Lung and Bronchus</u>									
Male	7	3.9	179.3	(71.8-369.5)					
Female	11	5.3	207.2	(103.3-370.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Milton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	27.2	62.5	(36.4-100.1)	Male	34	17.1	199.2	(137.9-278.4)
Female	9	10.7	84.1	(38.4-159.7)	Female	24	14.2	168.8	(108.1-251.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	5.4	nc	(nc-nc)	Male	5	5.5	90.9	(29.3-212.0)
Female	5	4.7	105.5	(34.0-246.2)	Female	11	4.8	228.6	(114.0-409.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.9	nc	(nc-nc)	Male	17	15.5	109.6	(63.8-175.6)
Female	141	114.4	123.3	(103.7-145.4)	Female	11	14.8	74.3	(37.0-132.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	3.8	nc	(nc-nc)	Male	8	12.7	63.0	(27.1-124.1)
<u>Colon / Rectum</u>					Female	4	6.2	nc	(nc-nc)
Male	24	29.3	81.9	(52.5-121.9)	<u>Ovary</u>				
Female	28	31.5	89.0	(59.1-128.7)	Female	18	9.9	181.5	(107.5-286.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	6.9	130.3	(59.4-247.3)	Male	9	9.7	93.2	(42.5-176.9)
Female	4	2.1	nc	(nc-nc)	Female	11	11.0	100.4	(50.1-179.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.1	nc	(nc-nc)	Male	100	83.8	119.3	(97.0-145.1)
Female	5	1.9	269.0	(86.7-627.7)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	6.5	76.7	(24.7-179.1)
Male	12	14.9	80.3	(41.4-140.3)	Female	5	4.3	116.8	(37.6-272.6)
Female	12	9.2	130.7	(67.5-228.4)	<u>Testis</u>				
<u>Larynx</u>					Male	2	3.7	nc	(nc-nc)
Male	1	4.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.3	nc	(nc-nc)	Male	5	6.8	73.8	(23.8-172.2)
<u>Leukemia</u>					Female	34	20.9	162.5	(112.5-227.0)
Male	13	11.2	115.8	(61.6-198.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	8.7	91.9	(39.6-181.1)	Female	33	25.2	131.1	(90.2-184.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	9.3	53.8	(17.3-125.6)	Male	338	348.9	96.9	(86.8-107.8)
Female	1	3.4	nc	(nc-nc)	Female	445	390.6	113.9	(103.6-125.0)
<u>Lung and Bronchus</u>									
Male	34	47.8	71.2	(49.3-99.5)					
Female	48	55.2	87.0	(64.2-115.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Monroe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	2.6	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	0	0.2	nc	(nc-nc)					
Female	0	0.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Monson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	11.3	88.4	(42.3-162.6)	Male	5	7.1	69.9	(22.5-163.2)
Female	1	3.2	nc	(nc-nc)	Female	1	4.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.0	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	3	6.4	nc	(nc-nc)
Female	45	41.5	108.4	(79.0-145.0)	Female	7	4.8	144.7	(58.0-298.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.3	nc	(nc-nc)	Male	2	5.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	2.1	nc	(nc-nc)
Male	9	12.4	72.6	(33.1-137.8)	<u>Ovary</u>				
Female	5	9.5	52.7	(17.0-122.9)	Female	0	3.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.0	nc	(nc-nc)	Male	4	4.1	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	28	37.6	74.5	(49.5-107.6)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.7	nc	(nc-nc)
Male	5	6.4	77.8	(25.1-181.6)	Female	2	1.3	nc	(nc-nc)
Female	0	3.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.2	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
<u>Leukemia</u>					Female	3	7.4	nc	(nc-nc)
Male	4	4.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.6	nc	(nc-nc)	Female	7	9.8	71.2	(28.5-146.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	4.1	nc	(nc-nc)	Male	106	148.1	71.6	(58.6-86.6)
Female	0	1.2	nc	(nc-nc)	Female	106	132.1	80.3	(65.7-97.1)
<u>Lung and Bronchus</u>									
Male	15	20.2	74.4	(41.6-122.7)					
Female	14	17.9	78.2	(42.7-131.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Montague

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	10.1	79.6	(34.3-156.8)	Male	8	6.2	129.5	(55.8-255.2)
Female	6	3.9	152.5	(55.7-332.0)	Female	1	5.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	1.8	276.7	(89.2-645.8)	Male	3	2.0	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.5	90.3	(29.1-210.6)
Female	35	42.2	83.0	(57.8-115.4)	Female	3	5.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.4	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	2.3	nc	(nc-nc)
Male	9	10.5	85.4	(39.0-162.1)	<u>Ovary</u>				
Female	12	11.6	103.7	(53.5-181.1)	Female	8	3.7	217.6	(93.7-428.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.5	nc	(nc-nc)	Male	0	3.5	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	2	4.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	21	30.7	68.4	(42.3-104.6)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	2.4	nc	(nc-nc)
Male	4	5.3	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
Female	4	3.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.2	nc	(nc-nc)
Male	3	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	3	7.3	nc	(nc-nc)
Male	7	4.0	176.6	(70.8-363.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	3.1	160.2	(51.6-373.8)	Female	12	9.8	122.9	(63.4-214.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	3.3	nc	(nc-nc)	Male	119	126.1	94.4	(78.2-112.9)
Female	0	1.3	nc	(nc-nc)	Female	125	143.5	87.1	(72.5-103.8)
<u>Lung and Bronchus</u>									
Male	18	17.5	102.8	(60.9-162.5)					
Female	17	20.1	84.5	(49.2-135.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Monterey

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.7	nc	(nc-nc)	Male	3	1.0	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	5	4.5	111.2	(35.9-259.6)	Female	0	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	0	1.7	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	5.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.6	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	11	20.7	53.2	(26.5-95.2)
Female	1	0.1	nc	(nc-nc)	Female	11	15.4	71.6	(35.7-128.1)
<u>Lung and Bronchus</u>									
Male	1	3.0	nc	(nc-nc)					
Female	1	2.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Montgomery

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.2	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	3	4.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.3	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	8	4.1	194.7	(83.8-383.7)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.8	nc	(nc-nc)
Male	2	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	17	15.8	107.6	(62.6-172.2)
Female	0	0.1	nc	(nc-nc)	Female	7	14.8	47.4	(19.0-97.7)
<u>Lung and Bronchus</u>									
Male	0	2.1	nc	(nc-nc)					
Female	0	2.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mount Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<u>Ovary</u>				
Female	2	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.2	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.1	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	3	4.8	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	0	0.5	nc	(nc-nc)					
Female	0	0.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Nahant

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	4.6	109.2	(35.2-254.7)	Male	8	2.8	290.0	(124.9-571.4)
Female	1	2.2	nc	(nc-nc)	Female	7	2.6	270.7	(108.4-557.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	17	20.8	81.7	(47.6-130.9)	Female	2	2.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.6	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.2	nc	(nc-nc)
Male	5	4.8	105.0	(33.8-245.0)	<u>Ovary</u>				
Female	6	6.3	95.6	(34.9-208.2)	Female	1	1.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.2	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	21	14.7	142.4	(88.1-217.7)
Female	2	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.1	nc	(nc-nc)
Male	1	2.4	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.4	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	2	3.2	nc	(nc-nc)
Male	3	1.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.6	nc	(nc-nc)	Female	5	4.8	105.2	(33.9-245.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.5	nc	(nc-nc)	Male	73	57.8	126.3	(99.0-158.8)
Female	1	0.7	nc	(nc-nc)	Female	64	73.3	87.3	(67.2-111.5)
<u>Lung and Bronchus</u>									
Male	10	8.0	125.0	(59.8-229.8)					
Female	6	10.8	55.6	(20.3-121.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Nantucket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	10.9	82.7	(37.7-157.0)	Male	18	7.3	246.9	(146.3-390.3)
Female	3	3.3	nc	(nc-nc)	Female	19	5.0	380.9	(229.2-594.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.3	nc	(nc-nc)	Male	8	2.3	341.4	(147.0-672.8)
Female	2	1.6	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	3	6.5	nc	(nc-nc)
Female	52	40.3	128.9	(96.3-169.1)	Female	4	4.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.5	nc	(nc-nc)	Male	10	5.5	182.3	(87.3-335.3)
<u>Colon / Rectum</u>					Female	5	2.1	243.5	(78.5-568.3)
Male	7	12.0	58.3	(23.3-120.1)	<u>Ovary</u>				
Female	13	9.6	134.7	(71.7-230.4)	Female	3	3.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.9	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
Female	4	0.7	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	1.0	nc	(nc-nc)	Male	33	35.6	92.6	(63.7-130.0)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.7	nc	(nc-nc)
Male	3	6.5	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Female	0	3.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.8	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
<u>Leukemia</u>					Female	13	8.1	161.4	(85.8-276.0)
Male	7	4.6	153.3	(61.4-315.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	2.8	nc	(nc-nc)	Female	11	9.1	121.5	(60.6-217.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	4.0	nc	(nc-nc)	Male	141	146.4	96.3	(81.1-113.6)
Female	0	1.1	nc	(nc-nc)	Female	168	131.9	127.4	(108.9-148.2)
<u>Lung and Bronchus</u>									
Male	15	19.8	75.8	(42.4-125.0)					
Female	20	18.1	110.7	(67.6-171.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Natick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	29	34.4	84.2	(56.4-120.9)	Male	17	22.6	75.3	(43.9-120.6)
Female	11	13.4	82.2	(41.0-147.0)	Female	18	18.9	95.1	(56.3-150.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	7.1	99.1	(39.7-204.3)	Male	3	7.2	nc	(nc-nc)
Female	8	6.1	131.6	(56.7-259.3)	Female	5	6.2	80.9	(26.1-188.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.2	nc	(nc-nc)	Male	16	20.3	78.9	(45.1-128.2)
Female	135	157.0	86.0	(72.1-101.8)	Female	13	19.0	68.4	(36.4-117.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	5.3	nc	(nc-nc)	Male	18	17.2	104.9	(62.1-165.8)
<u>Colon / Rectum</u>					Female	12	8.1	148.3	(76.5-259.1)
Male	38	38.1	99.8	(70.6-136.9)	<u>Ovary</u>				
Female	44	39.5	111.4	(80.9-149.5)	Female	19	13.3	143.0	(86.1-223.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	9.1	110.2	(52.7-202.6)	Male	10	12.5	80.0	(38.3-147.0)
Female	4	2.6	nc	(nc-nc)	Female	10	13.5	74.1	(35.5-136.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.8	nc	(nc-nc)	Male	110	110.9	99.2	(81.5-119.5)
Female	1	2.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	9	8.4	106.6	(48.7-202.4)
Male	20	20.1	99.7	(60.9-154.0)	Female	1	5.3	nc	(nc-nc)
Female	12	12.3	97.3	(50.2-169.9)	<u>Testis</u>				
<u>Larynx</u>					Male	7	5.1	136.5	(54.7-281.2)
Male	6	5.3	113.5	(41.4-247.0)	<u>Thyroid</u>				
Female	4	1.7	nc	(nc-nc)	Male	13	9.4	138.4	(73.6-236.6)
<u>Leukemia</u>					Female	28	28.8	97.1	(64.5-140.4)
Male	13	14.4	90.1	(47.9-154.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	11.0	45.6	(14.7-106.5)	Female	40	34.8	114.9	(82.1-156.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	12.4	56.5	(22.7-116.5)	Male	415	456.6	90.9	(82.4-100.1)
Female	3	4.5	nc	(nc-nc)	Female	462	516.0	89.5	(81.5-98.1)
<u>Lung and Bronchus</u>									
Male	47	61.6	76.3	(56.0-101.4)					
Female	55	72.1	76.3	(57.4-99.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Needham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	35	36.8	95.0	(66.2-132.2)	Male	30	22.1	135.6	(91.5-193.6)
Female	16	13.1	122.5	(70.0-199.0)	Female	18	17.0	106.0	(62.8-167.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	6.5	138.9	(63.4-263.8)	Male	8	7.1	113.0	(48.7-222.7)
Female	11	5.5	199.5	(99.4-357.0)	Female	4	5.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.2	nc	(nc-nc)	Male	27	20.0	135.1	(89.0-196.5)
Female	170	137.6	123.5	(105.7-143.6)	Female	24	17.9	134.2	(85.9-199.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	4.4	nc	(nc-nc)	Male	11	16.0	68.7	(34.2-122.9)
<u>Colon / Rectum</u>					Female	5	7.6	66.1	(21.3-154.3)
Male	29	38.7	74.9	(50.1-107.5)	<u>Ovary</u>				
Female	41	39.0	105.1	(75.4-142.6)	Female	11	11.9	92.1	(45.9-164.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	8.9	78.5	(31.5-161.8)	Male	9	12.8	70.2	(32.0-133.2)
Female	2	2.5	nc	(nc-nc)	Female	16	13.7	116.8	(66.7-189.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.2	nc	(nc-nc)	Male	115	106.0	108.5	(89.6-130.2)
Female	2	1.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	8.6	57.9	(18.7-135.1)
Male	17	18.8	90.5	(52.7-144.9)	Female	3	5.3	nc	(nc-nc)
Female	11	10.9	100.6	(50.1-180.0)	<u>Testis</u>				
<u>Larynx</u>					Male	4	3.5	nc	(nc-nc)
Male	2	5.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.6	nc	(nc-nc)	Male	8	8.0	100.1	(43.1-197.2)
<u>Leukemia</u>					Female	31	23.6	131.2	(89.1-186.3)
Male	10	14.5	68.8	(32.9-126.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	14	10.5	132.7	(72.5-222.7)	Female	31	30.5	101.7	(69.1-144.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	11.9	42.0	(13.5-97.9)	Male	404	449.5	89.9	(81.3-99.1)
Female	1	4.2	nc	(nc-nc)	Female	486	470.1	103.4	(94.4-113.0)
<u>Lung and Bronchus</u>									
Male	41	62.5	65.6	(47.1-89.1)					
Female	39	65.3	59.7	(42.5-81.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Ashford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.2	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	4	3.9	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	0	0.5	nc	(nc-nc)					
Female	0	0.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	102	94.8	107.5	(87.7-130.6)	Male	27	60.1	44.9	(29.6-65.4)
Female	31	38.4	80.7	(54.8-114.5)	Female	23	51.3	44.8	(28.4-67.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	16	18.8	85.3	(48.7-138.6)	Male	19	19.1	99.6	(59.9-155.5)
Female	13	16.7	77.9	(41.4-133.1)	Female	15	17.2	87.4	(48.9-144.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	3.3	nc	(nc-nc)	Male	44	54.1	81.3	(59.0-109.1)
Female	345	396.4	87.0	(78.1-96.7)	Female	49	52.7	93.0	(68.8-123.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	16	13.5	118.6	(67.8-192.7)	Male	55	43.9	125.3	(94.4-163.1)
<u>Colon / Rectum</u>					Female	27	21.9	123.4	(81.3-179.5)
Male	121	101.9	118.7	(98.5-141.9)	<u>Ovary</u>				
Female	105	112.8	93.1	(76.1-112.7)	Female	28	34.9	80.3	(53.4-116.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	28	23.9	116.9	(77.7-169.0)	Male	36	33.6	107.3	(75.1-148.5)
Female	9	7.3	122.8	(56.0-233.1)	Female	53	39.5	134.2	(100.5-175.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	8	7.7	104.4	(44.9-205.7)	Male	307	288.8	106.3	(94.7-118.9)
Female	5	6.8	73.8	(23.8-172.3)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	39	22.8	171.4	(121.9-234.3)
Male	56	52.0	107.8	(81.4-139.9)	Female	21	15.4	136.5	(84.4-208.6)
Female	35	32.2	108.8	(75.7-151.3)	<u>Testis</u>				
<u>Larynx</u>					Male	10	14.2	70.3	(33.7-129.3)
Male	27	13.8	195.1	(128.5-283.8)	<u>Thyroid</u>				
Female	8	4.5	179.1	(77.1-353.0)	Male	21	23.9	88.0	(54.4-134.5)
<u>Leukemia</u>					Female	77	74.8	102.9	(81.2-128.7)
Male	33	39.0	84.6	(58.2-118.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	20	31.6	63.4	(38.7-97.9)	Female	83	87.2	95.2	(75.8-118.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	65	32.2	202.0	(155.9-257.5)	Male	1370	1214.1	112.8	(106.9-119.0)
Female	13	12.2	106.3	(56.6-181.8)	Female	1297	1379.1	94.0	(89.0-99.3)
<u>Lung and Bronchus</u>									
Male	254	166.9	152.2	(134.0-172.1)					
Female	198	194.5	101.8	(88.1-117.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.1	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	2	4.6	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Ovary</u>				
Female	4	1.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	6	4.2	143.9	(52.6-313.3)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.8	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.3	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	19	15.7	120.9	(72.8-188.8)
Female	0	0.1	nc	(nc-nc)	Female	13	15.2	85.4	(45.4-146.1)
<u>Lung and Bronchus</u>									
Male	1	2.0	nc	(nc-nc)					
Female	2	2.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.8	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	10	9.0	111.4	(53.3-204.9)	Female	1	1.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	0.5	nc	(nc-nc)
Male	2	2.8	nc	(nc-nc)	<u>Ovary</u>				
Female	3	2.3	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.7	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	9.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.7	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.4	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.6	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.0	nc	(nc-nc)	Male	19	35.3	53.8	(32.4-84.0)
Female	0	0.3	nc	(nc-nc)	Female	24	29.6	81.2	(52.0-120.8)
<u>Lung and Bronchus</u>									
Male	1	5.0	nc	(nc-nc)					
Female	3	4.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	3	5.2	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.2	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.3	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<u>Ovary</u>				
Female	4	1.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	5.1	98.4	(31.7-229.6)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.9	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.3	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	15	18.6	80.7	(45.2-133.2)
Female	0	0.1	nc	(nc-nc)	Female	16	16.8	95.0	(54.3-154.3)
<u>Lung and Bronchus</u>									
Male	1	2.5	nc	(nc-nc)					
Female	1	2.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	8.2	97.1	(41.8-191.4)	Male	14	5.4	257.1	(140.5-431.5)
Female	3	2.7	nc	(nc-nc)	Female	4	3.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	1.6	313.2	(100.9-730.9)	Male	2	1.8	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	4.8	nc	(nc-nc)
Female	35	34.0	102.9	(71.7-143.2)	Female	4	3.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	2	4.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.7	nc	(nc-nc)
Male	9	9.3	96.9	(44.2-183.9)	<u>Ovary</u>				
Female	4	7.8	nc	(nc-nc)	Female	4	2.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.3	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	31	28.5	108.8	(73.9-154.4)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.1	nc	(nc-nc)
Male	3	4.9	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	6	2.6	230.9	(84.3-502.5)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.8	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
<u>Leukemia</u>					Female	8	6.2	130.1	(56.0-256.3)
Male	1	3.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	2.1	nc	(nc-nc)	Female	8	7.7	104.2	(44.9-205.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.2	nc	(nc-nc)	Male	106	111.8	94.8	(77.6-114.6)
Female	1	0.9	nc	(nc-nc)	Female	95	108.0	88.0	(71.2-107.6)
<u>Lung and Bronchus</u>									
Male	14	15.3	91.6	(50.0-153.7)					
Female	9	15.2	59.2	(27.0-112.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Newburyport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	20.0	85.1	(49.5-136.3)	Male	23	13.0	176.9	(112.1-265.4)
Female	8	8.5	94.6	(40.8-186.5)	Female	18	11.2	160.2	(94.9-253.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.9	nc	(nc-nc)	Male	1	4.2	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)	Female	5	3.9	128.8	(41.5-300.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	0.7	nc	(nc-nc)	Male	15	11.6	129.1	(72.2-212.9)
Female	98	93.6	104.7	(85.0-127.6)	Female	10	11.8	85.0	(40.7-156.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.9	nc	(nc-nc)	Male	13	10.2	127.3	(67.7-217.7)
<u>Colon / Rectum</u>					Female	5	5.0	100.0	(32.2-233.3)
Male	25	22.2	112.8	(73.0-166.5)	<u>Ovary</u>				
Female	22	24.3	90.6	(56.8-137.2)	Female	6	8.1	74.4	(27.2-161.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	5.4	nc	(nc-nc)	Male	5	7.3	68.1	(22.0-159.0)
Female	0	1.7	nc	(nc-nc)	Female	5	8.6	58.2	(18.8-135.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.4	nc	(nc-nc)	Male	91	68.7	132.5	(106.7-162.7)
Female	3	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	4.9	nc	(nc-nc)
Male	9	11.8	76.3	(34.8-144.8)	Female	3	3.3	nc	(nc-nc)
Female	3	7.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.4	nc	(nc-nc)
Male	0	3.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.1	nc	(nc-nc)	Male	11	5.2	211.8	(105.6-379.0)
<u>Leukemia</u>					Female	23	15.7	146.1	(92.6-219.3)
Male	7	8.1	86.2	(34.5-177.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	6.6	nc	(nc-nc)	Female	25	21.7	115.3	(74.6-170.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	7.5	nc	(nc-nc)	Male	283	268.7	105.3	(93.4-118.4)
Female	3	2.8	nc	(nc-nc)	Female	309	312.7	98.8	(88.1-110.5)
<u>Lung and Bronchus</u>									
Male	27	36.4	74.2	(48.9-108.0)					
Female	39	44.9	86.9	(61.8-118.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Newton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	95	96.7	98.3	(79.5-120.2)	Male	72	59.7	120.7	(94.4-152.0)
Female	43	34.2	125.6	(90.9-169.1)	Female	67	46.8	143.2	(110.9-181.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	22	17.9	122.6	(76.8-185.6)	Male	31	19.4	159.8	(108.6-226.9)
Female	17	15.4	110.2	(64.2-176.5)	Female	16	15.6	102.7	(58.7-166.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	3.3	nc	(nc-nc)	Male	66	53.9	122.4	(94.6-155.7)
Female	434	377.4	115.0	(104.4-126.4)	Female	61	47.9	127.3	(97.4-163.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	12.5	64.0	(27.5-126.0)	Male	26	43.5	59.7	(39.0-87.5)
<u>Colon / Rectum</u>					Female	32	20.3	157.9	(108.0-223.0)
Male	88	101.9	86.4	(69.3-106.4)	<u>Ovary</u>				
Female	76	100.7	75.4	(59.4-94.4)	Female	46	32.6	141.1	(103.3-188.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	24.3	49.3	(25.5-86.2)	Male	34	33.9	100.2	(69.4-140.1)
Female	7	6.7	105.0	(42.1-216.4)	Female	49	35.1	139.6	(103.3-184.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	7	6.9	101.9	(40.8-210.0)	Male	326	294.3	110.8	(99.1-123.5)
Female	3	6.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	21	22.9	91.6	(56.7-140.0)
Male	51	51.6	98.9	(73.6-130.0)	Female	14	13.7	102.1	(55.8-171.3)
Female	19	30.0	63.3	(38.1-98.9)	<u>Testis</u>				
<u>Larynx</u>					Male	12	11.6	103.2	(53.3-180.3)
Male	10	14.1	71.1	(34.0-130.7)	<u>Thyroid</u>				
Female	1	4.2	nc	(nc-nc)	Male	34	22.6	150.4	(104.1-210.1)
<u>Leukemia</u>					Female	87	69.0	126.0	(100.9-155.5)
Male	37	38.5	96.1	(67.7-132.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	25	28.1	88.9	(57.5-131.2)	Female	91	84.5	107.7	(86.7-132.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	25	32.3	77.5	(50.1-114.4)	Male	1166	1218.8	95.7	(90.3-101.3)
Female	9	11.2	80.0	(36.5-151.9)	Female	1376	1274.1	108.0	(102.4-113.9)
<u>Lung and Bronchus</u>									
Male	124	170.1	72.9	(60.6-86.9)					
Female	157	177.5	88.5	(75.2-103.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norfolk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	11.4	70.4	(30.3-138.8)	Male	20	8.6	233.1	(142.3-360.0)
Female	1	2.5	nc	(nc-nc)	Female	4	4.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.8	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	7.6	65.8	(21.2-153.5)
Female	42	37.2	112.9	(81.4-152.7)	Female	1	4.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	5	7.3	68.2	(22.0-159.1)
<u>Colon / Rectum</u>					Female	2	1.8	nc	(nc-nc)
Male	12	14.0	85.6	(44.2-149.5)	<u>Ovary</u>				
Female	7	7.8	90.3	(36.2-186.0)	Female	1	3.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	3.5	170.5	(62.3-371.1)	Male	2	4.5	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	40	45.7	87.4	(62.5-119.1)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	3.0	nc	(nc-nc)
Male	11	8.3	133.3	(66.5-238.5)	Female	1	1.0	nc	(nc-nc)
Female	4	2.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.4	nc	(nc-nc)
Male	4	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
<u>Leukemia</u>					Female	8	7.2	110.5	(47.6-217.8)
Male	4	5.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.3	nc	(nc-nc)	Female	5	8.6	58.2	(18.7-135.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	5.2	nc	(nc-nc)	Male	154	174.6	88.2	(74.8-103.3)
Female	1	1.0	nc	(nc-nc)	Female	103	113.7	90.6	(74.0-109.9)
<u>Lung and Bronchus</u>									
Male	18	21.7	83.0	(49.2-131.2)					
Female	12	14.2	84.6	(43.7-147.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	17.2	98.6	(57.4-157.9)	Male	5	10.4	47.9	(15.4-111.7)
Female	11	6.1	179.7	(89.6-321.6)	Female	7	7.8	89.9	(36.0-185.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.0	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
Female	0	2.5	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	8	9.3	85.7	(36.9-168.9)
Female	52	63.1	82.5	(61.6-108.1)	Female	7	8.3	84.6	(33.9-174.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.0	nc	(nc-nc)	Male	9	7.2	124.6	(56.8-236.5)
<u>Colon / Rectum</u>					Female	3	3.4	nc	(nc-nc)
Male	26	17.6	147.8	(96.5-216.6)	<u>Ovary</u>				
Female	16	17.5	91.5	(52.3-148.6)	Female	5	5.5	91.2	(29.4-212.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	4.2	192.8	(83.0-379.9)	Male	0	5.9	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	10	6.3	159.8	(76.5-293.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	43	47.7	90.2	(65.2-121.4)
Female	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	4.0	nc	(nc-nc)
Male	13	8.7	149.9	(79.7-256.3)	Female	2	2.4	nc	(nc-nc)
Female	2	5.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.1	nc	(nc-nc)
Male	3	2.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	4	0.7	nc	(nc-nc)	Male	5	3.8	131.6	(42.4-307.2)
<u>Leukemia</u>					Female	7	10.8	64.6	(25.9-133.0)
Male	5	6.7	74.7	(24.1-174.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	4.8	nc	(nc-nc)	Female	12	14.0	85.9	(44.3-150.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	9	5.4	166.9	(76.2-316.8)	Male	206	208.5	98.8	(85.7-113.2)
Female	3	1.9	nc	(nc-nc)	Female	209	217.0	96.3	(83.7-110.3)
<u>Lung and Bronchus</u>									
Male	27	30.2	89.4	(58.9-130.0)					
Female	46	31.8	144.6	(105.9-192.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	42	29.3	143.5	(103.4-194.0)	Male	15	19.0	79.0	(44.2-130.3)
Female	9	11.5	78.3	(35.7-148.7)	Female	16	15.6	102.7	(58.7-166.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.9	101.2	(37.0-220.3)	Male	6	6.0	99.5	(36.3-216.6)
Female	6	5.0	119.9	(43.8-261.0)	Female	6	5.2	115.4	(42.1-251.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.0	nc	(nc-nc)	Male	19	17.1	111.0	(66.8-173.4)
Female	115	126.4	91.0	(75.1-109.2)	Female	15	15.9	94.1	(52.7-155.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	4.2	nc	(nc-nc)	Male	9	14.4	62.4	(28.5-118.5)
<u>Colon / Rectum</u>					Female	3	6.7	nc	(nc-nc)
Male	28	32.6	85.8	(57.0-124.1)	<u>Ovary</u>				
Female	43	34.3	125.3	(90.7-168.8)	Female	8	10.8	74.0	(31.8-145.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	7.6	79.2	(28.9-172.4)	Male	10	10.5	94.9	(45.4-174.6)
Female	1	2.2	nc	(nc-nc)	Female	9	11.8	76.2	(34.8-144.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.4	nc	(nc-nc)	Male	93	91.4	101.7	(82.1-124.6)
Female	4	1.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	7.1	98.1	(39.3-202.1)
Male	15	16.7	89.8	(50.2-148.1)	Female	7	4.7	150.1	(60.1-309.3)
Female	5	10.0	50.0	(16.1-116.8)	<u>Testis</u>				
<u>Larynx</u>					Male	4	4.2	nc	(nc-nc)
Male	0	4.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.4	nc	(nc-nc)	Male	13	7.8	165.8	(88.2-283.6)
<u>Leukemia</u>					Female	21	23.0	91.3	(56.5-139.6)
Male	12	12.2	98.0	(50.6-171.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	9.3	117.9	(58.8-211.0)	Female	22	27.5	80.1	(50.2-121.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	10.5	57.3	(20.9-124.8)	Male	372	382.9	97.2	(87.5-107.6)
Female	5	3.7	135.2	(43.6-315.5)	Female	388	425.4	91.2	(82.4-100.8)
<u>Lung and Bronchus</u>									
Male	37	51.2	72.2	(50.8-99.5)					
Female	47	59.1	79.5	(58.4-105.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Attleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	22.5	93.5	(57.8-142.9)	Male	14	16.0	87.4	(47.7-146.6)
Female	7	8.5	82.1	(32.9-169.3)	Female	22	13.4	164.1	(102.8-248.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	5.4	92.1	(29.7-214.9)	Male	6	5.0	119.1	(43.5-259.2)
Female	7	4.4	158.9	(63.7-327.5)	Female	3	4.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.9	nc	(nc-nc)	Male	17	14.4	117.6	(68.5-188.4)
Female	107	108.0	99.1	(81.2-119.7)	Female	14	12.7	110.2	(60.2-184.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	4.0	nc	(nc-nc)	Male	11	13.0	84.5	(42.1-151.3)
<u>Colon / Rectum</u>					Female	6	5.5	109.6	(40.0-238.6)
Male	34	26.9	126.3	(87.5-176.5)	<u>Ovary</u>				
Female	23	26.5	86.9	(55.1-130.4)	Female	4	9.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	6.4	125.0	(53.8-246.3)	Male	10	8.6	116.1	(55.6-213.5)
Female	1	1.7	nc	(nc-nc)	Female	9	8.8	102.7	(46.9-195.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.3	nc	(nc-nc)	Male	84	81.8	102.7	(81.9-127.2)
Female	1	1.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	5.8	nc	(nc-nc)
Male	15	14.9	100.3	(56.1-165.5)	Female	4	3.6	nc	(nc-nc)
Female	10	8.2	121.6	(58.2-223.6)	<u>Testis</u>				
<u>Larynx</u>					Male	4	4.3	nc	(nc-nc)
Male	6	3.8	157.4	(57.5-342.5)	<u>Thyroid</u>				
Female	1	1.1	nc	(nc-nc)	Male	7	7.5	93.3	(37.4-192.2)
<u>Leukemia</u>					Female	22	22.1	99.5	(62.3-150.6)
Male	6	10.2	58.6	(21.4-127.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	7.6	79.0	(28.9-172.0)	Female	19	23.5	80.7	(48.6-126.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	9.2	87.1	(37.5-171.7)	Male	333	325.4	102.3	(91.6-113.9)
Female	1	2.9	nc	(nc-nc)	Female	337	349.5	96.4	(86.4-107.3)
<u>Lung and Bronchus</u>									
Male	40	41.6	96.3	(68.8-131.1)					
Female	41	45.0	91.2	(65.4-123.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	4.5	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	0	2.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.0	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
Female	13	19.5	66.7	(35.5-114.0)	Female	3	2.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.6	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.0	nc	(nc-nc)
Male	4	5.2	nc	(nc-nc)	<u>Ovary</u>				
Female	7	5.1	136.4	(54.6-281.0)	Female	4	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.2	nc	(nc-nc)	Male	4	1.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	18	15.1	119.1	(70.6-188.3)
Female	2	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.2	nc	(nc-nc)
Male	3	2.8	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	1	3.6	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.4	nc	(nc-nc)	Female	8	4.2	190.0	(81.8-374.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.8	nc	(nc-nc)	Male	68	62.5	108.7	(84.4-137.8)
Female	2	0.6	nc	(nc-nc)	Female	63	65.0	96.9	(74.4-123.9)
<u>Lung and Bronchus</u>									
Male	9	8.6	105.0	(47.9-199.4)					
Female	7	9.1	77.3	(31.0-159.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	14.2	91.3	(48.6-156.1)	Male	15	9.9	152.2	(85.1-251.1)
Female	9	5.4	166.0	(75.7-315.1)	Female	12	8.3	145.4	(75.0-254.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.2	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	Female	0	2.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	9	8.8	101.8	(46.5-193.3)
Female	83	69.2	119.9	(95.5-148.6)	Female	5	8.0	62.5	(20.1-145.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.3	nc	(nc-nc)	Male	5	8.0	62.7	(20.2-146.3)
<u>Colon / Rectum</u>					Female	1	3.5	nc	(nc-nc)
Male	17	16.6	102.4	(59.6-164.0)	<u>Ovary</u>				
Female	13	16.5	78.9	(42.0-135.0)	Female	4	5.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	4.1	172.8	(69.2-356.1)	Male	4	5.4	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	6	5.5	108.7	(39.7-236.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.2	nc	(nc-nc)	Male	51	51.9	98.2	(73.1-129.1)
Female	2	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	3.6	nc	(nc-nc)
Male	10	9.2	108.9	(52.2-200.4)	Female	0	2.2	nc	(nc-nc)
Female	2	5.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.3	nc	(nc-nc)
Male	3	2.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.7	nc	(nc-nc)	Male	4	4.4	nc	(nc-nc)
<u>Leukemia</u>					Female	17	13.1	130.0	(75.7-208.2)
Male	9	6.1	146.6	(66.9-278.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	4.5	155.9	(62.4-321.1)	Female	17	15.3	111.0	(64.6-177.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	5.7	87.5	(28.2-204.3)	Male	201	202.4	99.3	(86.1-114.1)
Female	3	1.8	nc	(nc-nc)	Female	221	221.1	100.0	(87.2-114.1)
<u>Lung and Bronchus</u>									
Male	19	26.4	71.9	(43.3-112.3)					
Female	25	29.8	83.8	(54.2-123.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	31	29.0	106.9	(72.6-151.7)	Male	12	18.5	64.9	(33.5-113.3)
Female	11	11.2	98.5	(49.1-176.3)	Female	10	15.9	62.7	(30.0-115.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	5.6	126.0	(50.5-259.7)	Male	1	6.0	nc	(nc-nc)
Female	5	5.2	97.0	(31.3-226.5)	Female	10	5.1	194.6	(93.1-357.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.0	nc	(nc-nc)	Male	16	16.7	96.0	(54.8-155.9)
Female	166	124.5	133.3	(113.8-155.2)	Female	13	15.9	81.9	(43.6-140.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	4.2	nc	(nc-nc)	Male	13	13.8	94.1	(50.1-161.0)
<u>Colon / Rectum</u>					Female	6	6.8	88.8	(32.4-193.2)
Male	30	31.2	96.2	(64.9-137.4)	<u>Ovary</u>				
Female	33	32.7	101.0	(69.5-141.8)	Female	15	11.0	136.6	(76.4-225.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	7.6	92.1	(36.9-189.7)	Male	8	10.3	77.4	(33.3-152.5)
Female	4	2.2	nc	(nc-nc)	Female	14	11.4	122.8	(67.1-206.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.3	nc	(nc-nc)	Male	62	93.6	66.2	(50.8-84.9)
Female	2	2.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	7.0	85.8	(31.3-186.8)
Male	8	16.3	49.0	(21.1-96.6)	Female	4	4.4	nc	(nc-nc)
Female	7	9.9	70.8	(28.4-145.9)	<u>Testis</u>				
<u>Larynx</u>					Male	6	4.1	147.4	(53.8-320.9)
Male	3	4.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	3	1.4	nc	(nc-nc)	Male	4	7.4	nc	(nc-nc)
<u>Leukemia</u>					Female	9	24.1	37.3	(17.0-70.8)
Male	11	11.6	94.6	(47.1-169.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	9.2	75.9	(30.4-156.4)	Female	36	28.7	125.6	(87.9-173.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	10.1	49.7	(16.0-116.0)	Male	294	378.0	77.8	(69.1-87.2)
Female	3	3.8	nc	(nc-nc)	Female	440	422.2	104.2	(94.7-114.4)
<u>Lung and Bronchus</u>									
Male	39	51.7	75.4	(53.6-103.1)					
Female	46	58.3	79.0	(57.8-105.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	16.0	131.5	(81.4-201.0)	Male	9	10.3	87.4	(39.9-166.0)
Female	8	5.5	146.1	(62.9-288.0)	Female	6	7.7	78.0	(28.5-169.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.1	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	Female	5	2.5	199.0	(64.1-464.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	9	9.3	97.0	(44.2-184.1)
Female	80	62.4	128.1	(101.6-159.5)	Female	6	7.8	77.2	(28.2-168.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.1	nc	(nc-nc)	Male	5	7.8	63.9	(20.6-149.1)
<u>Colon / Rectum</u>					Female	3	3.3	nc	(nc-nc)
Male	10	17.9	56.0	(26.8-103.0)	<u>Ovary</u>				
Female	15	16.6	90.6	(50.7-149.4)	Female	2	5.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	4.1	219.1	(100.0-415.9)	Male	6	5.8	103.9	(37.9-226.2)
Female	0	1.1	nc	(nc-nc)	Female	6	5.6	107.5	(39.2-233.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.2	nc	(nc-nc)	Male	48	49.7	96.5	(71.2-128.0)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.9	nc	(nc-nc)
Male	7	9.0	77.6	(31.1-159.8)	Female	2	2.2	nc	(nc-nc)
Female	4	4.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.1	nc	(nc-nc)
Male	1	2.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
<u>Leukemia</u>					Female	9	11.5	78.5	(35.8-148.9)
Male	9	6.5	138.5	(63.2-262.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	4.5	109.9	(35.4-256.6)	Female	15	13.7	109.1	(61.0-180.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	5.7	nc	(nc-nc)	Male	179	207.7	86.2	(74.0-99.8)
Female	1	1.8	nc	(nc-nc)	Female	206	208.0	99.0	(86.0-113.5)
<u>Lung and Bronchus</u>									
Male	13	28.1	46.3	(24.6-79.1)					
Female	24	28.5	84.1	(53.9-125.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	15.6	108.7	(63.3-174.0)	Male	11	10.3	107.0	(53.4-191.5)
Female	6	5.6	106.4	(38.9-231.7)	Female	10	8.2	121.6	(58.2-223.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	3.2	nc	(nc-nc)	Male	10	3.3	301.4	(144.3-554.3)
Female	1	2.7	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	6	9.2	65.1	(23.8-141.7)
Female	53	65.3	81.2	(60.8-106.2)	Female	9	8.1	111.1	(50.7-210.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.3	nc	(nc-nc)	Male	10	7.8	128.6	(61.6-236.5)
<u>Colon / Rectum</u>					Female	3	3.4	nc	(nc-nc)
Male	10	17.4	57.4	(27.5-105.6)	<u>Ovary</u>				
Female	24	16.9	141.9	(90.9-211.1)	Female	5	5.6	89.4	(28.8-208.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	4.1	nc	(nc-nc)	Male	5	5.7	87.9	(28.3-205.1)
Female	1	1.1	nc	(nc-nc)	Female	7	5.8	121.3	(48.6-249.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.2	nc	(nc-nc)	Male	54	50.1	107.8	(80.9-140.6)
Female	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	3.9	nc	(nc-nc)
Male	14	9.1	154.2	(84.2-258.7)	Female	2	2.3	nc	(nc-nc)
Female	4	5.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.2	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.7	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
<u>Leukemia</u>					Female	11	12.8	85.7	(42.7-153.4)
Male	3	6.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	4.9	nc	(nc-nc)	Female	21	14.4	146.0	(90.3-223.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	5.7	nc	(nc-nc)	Male	197	207.3	95.1	(82.2-109.3)
Female	1	1.9	nc	(nc-nc)	Female	213	217.8	97.8	(85.1-111.9)
<u>Lung and Bronchus</u>									
Male	28	28.2	99.4	(66.0-143.7)					
Female	25	29.3	85.4	(55.2-126.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	3.7	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
Female	11	13.9	79.4	(39.6-142.0)	Female	1	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.7	nc	(nc-nc)
Male	5	4.1	121.7	(39.2-283.9)	<u>Ovary</u>				
Female	2	3.3	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.0	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	13.1	53.3	(21.3-109.8)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.9	nc	(nc-nc)
Male	4	2.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.4	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.5	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	0.9	nc	(nc-nc)	Female	5	3.2	156.2	(50.3-364.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.4	nc	(nc-nc)	Male	35	50.0	70.0	(48.7-97.3)
Female	0	0.4	nc	(nc-nc)	Female	39	45.0	86.6	(61.6-118.4)
<u>Lung and Bronchus</u>									
Male	3	6.6	nc	(nc-nc)					
Female	5	6.2	81.0	(26.1-189.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	17.5	74.3	(39.5-127.0)	Male	14	11.8	119.0	(65.0-199.7)
Female	7	6.2	113.7	(45.6-234.3)	Female	11	9.3	117.8	(58.7-210.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.8	132.8	(42.8-310.0)	Male	2	3.7	nc	(nc-nc)
Female	3	3.1	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	7	10.6	66.0	(26.5-136.0)
Female	75	75.2	99.8	(78.5-125.1)	Female	10	9.0	110.5	(52.9-203.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.6	nc	(nc-nc)	Male	8	9.4	85.3	(36.7-168.2)
<u>Colon / Rectum</u>					Female	3	3.9	nc	(nc-nc)
Male	26	20.0	129.7	(84.7-190.0)	<u>Ovary</u>				
Female	20	19.0	105.2	(64.3-162.5)	Female	7	6.5	108.0	(43.3-222.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	4.8	125.2	(45.7-272.6)	Male	9	6.5	139.4	(63.6-264.7)
Female	1	1.2	nc	(nc-nc)	Female	11	6.4	172.9	(86.2-309.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.6	nc	(nc-nc)	Male	51	59.9	85.1	(63.4-111.9)
Female	0	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.3	nc	(nc-nc)
Male	14	10.7	130.5	(71.3-218.9)	Female	2	2.6	nc	(nc-nc)
Female	8	5.8	138.9	(59.8-273.6)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.9	nc	(nc-nc)
Male	2	2.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	8	5.1	155.8	(67.1-307.0)
<u>Leukemia</u>					Female	15	14.8	101.6	(56.8-167.6)
Male	8	7.5	106.7	(45.9-210.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	5.3	151.9	(65.4-299.4)	Female	22	16.8	131.1	(82.1-198.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	6.7	104.3	(41.8-214.9)	Male	237	240.8	98.4	(86.3-111.8)
Female	1	2.1	nc	(nc-nc)	Female	256	246.3	103.9	(91.6-117.5)
<u>Lung and Bronchus</u>									
Male	27	31.6	85.3	(56.2-124.2)					
Female	26	32.3	80.6	(52.6-118.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norwell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	12.5	96.1	(49.6-167.9)	Male	8	7.8	102.5	(44.2-202.1)
Female	4	4.6	nc	(nc-nc)	Female	13	6.0	218.2	(116.1-373.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	2.4	254.4	(92.9-553.7)	Male	1	2.5	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	Female	5	2.1	239.2	(77.1-558.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	7	7.0	99.7	(39.9-205.4)
Female	48	50.1	95.8	(70.7-127.1)	Female	11	6.4	173.1	(86.3-309.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.5	nc	(nc-nc)	Male	5	5.9	85.2	(27.5-198.9)
<u>Colon / Rectum</u>					Female	5	2.7	187.6	(60.4-437.7)
Male	10	13.5	73.8	(35.3-135.7)	<u>Ovary</u>				
Female	8	13.5	59.1	(25.4-116.4)	Female	6	4.3	139.9	(51.1-304.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.2	nc	(nc-nc)	Male	4	4.4	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	4	4.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.8	nc	(nc-nc)	Male	39	38.3	101.8	(72.4-139.2)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	3.0	nc	(nc-nc)
Male	6	6.8	88.0	(32.1-191.6)	Female	1	1.8	nc	(nc-nc)
Female	2	4.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.4	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
<u>Leukemia</u>					Female	4	8.2	nc	(nc-nc)
Male	4	5.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.6	nc	(nc-nc)	Female	16	11.1	144.5	(82.6-234.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	4.3	163.0	(65.3-335.9)	Male	147	159.0	92.5	(78.1-108.7)
Female	0	1.5	nc	(nc-nc)	Female	161	168.0	95.8	(81.6-111.8)
<u>Lung and Bronchus</u>									
Male	13	21.9	59.4	(31.6-101.5)					
Female	13	24.2	53.8	(28.6-92.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	32.1	49.9	(28.5-81.0)	Male	34	20.0	169.7	(117.5-237.1)
Female	10	12.7	78.8	(37.7-144.9)	Female	25	16.5	151.5	(98.0-223.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	6.0	166.1	(79.5-305.5)	Male	7	6.4	109.0	(43.7-224.6)
Female	6	5.3	114.3	(41.7-248.7)	Female	7	5.7	123.4	(49.4-254.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.1	nc	(nc-nc)	Male	18	17.9	100.7	(59.7-159.2)
Female	137	131.0	104.6	(87.8-123.6)	Female	20	17.3	115.5	(70.5-178.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.3	nc	(nc-nc)	Male	17	14.2	120.0	(69.9-192.2)
<u>Colon / Rectum</u>					Female	6	7.1	84.1	(30.7-183.1)
Male	52	33.9	153.4	(114.6-201.2)	<u>Ovary</u>				
Female	56	37.2	150.7	(113.8-195.7)	Female	12	11.4	105.3	(54.3-183.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	7.9	126.6	(60.6-232.8)	Male	17	11.1	153.2	(89.2-245.3)
Female	3	2.4	nc	(nc-nc)	Female	19	12.9	146.8	(88.3-229.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.4	nc	(nc-nc)	Male	79	90.5	87.3	(69.1-108.8)
Female	3	1.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	7.6	131.2	(62.8-241.4)
Male	14	16.9	82.9	(45.3-139.1)	Female	5	5.1	98.8	(31.8-230.5)
Female	16	10.6	150.9	(86.2-245.1)	<u>Testis</u>				
<u>Larynx</u>					Male	7	4.4	158.0	(63.3-325.5)
Male	7	4.6	153.7	(61.6-316.7)	<u>Thyroid</u>				
Female	3	1.5	nc	(nc-nc)	Male	13	7.8	167.6	(89.1-286.6)
<u>Leukemia</u>					Female	27	23.4	115.5	(76.1-168.0)
Male	11	12.9	85.5	(42.6-153.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	12	10.1	118.7	(61.3-207.3)	Female	30	28.4	105.6	(71.2-150.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	13	10.5	124.2	(66.1-212.4)	Male	449	397.7	112.9	(102.7-123.9)
Female	2	4.0	nc	(nc-nc)	Female	522	452.3	115.4	(105.7-125.8)
<u>Lung and Bronchus</u>									
Male	58	56.1	103.4	(78.5-133.7)					
Female	87	65.3	133.3	(106.8-164.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oak Bluffs

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	7.6	118.2	(53.9-224.4)	Male	8	4.5	176.6	(76.0-348.0)
Female	0	2.4	nc	(nc-nc)	Female	4	2.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.2	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
Female	24	24.0	100.1	(64.1-148.9)	Female	1	3.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.7	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	1.3	nc	(nc-nc)
Male	9	7.5	120.0	(54.8-227.8)	<u>Ovary</u>				
Female	4	6.8	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.8	nc	(nc-nc)	Male	5	2.6	189.0	(60.9-441.0)
Female	0	0.5	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	16	21.1	75.7	(43.2-122.9)
Female	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.8	nc	(nc-nc)
Male	3	3.7	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.5	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Leukemia</u>					Female	4	3.7	nc	(nc-nc)
Male	1	2.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.8	nc	(nc-nc)	Female	7	5.5	128.0	(51.3-263.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.4	nc	(nc-nc)	Male	84	90.7	92.6	(73.9-114.6)
Female	0	0.8	nc	(nc-nc)	Female	81	83.2	97.3	(77.3-121.0)
<u>Lung and Bronchus</u>									
Male	11	13.8	80.0	(39.9-143.1)					
Female	15	12.5	119.9	(67.1-197.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oakham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.2	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	2	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	7	7.5	93.8	(37.6-193.2)	Female	2	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	0	2.4	nc	(nc-nc)	<u>Ovary</u>				
Female	2	1.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	8	7.4	107.5	(46.3-211.9)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	0.5	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	3	1.5	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	0.5	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	0.9	nc	(nc-nc)	Male	23	29.1	78.9	(50.0-118.5)
Female	0	0.2	nc	(nc-nc)	Female	22	23.4	94.0	(58.9-142.3)
<u>Lung and Bronchus</u>									
Male	4	3.9	nc	(nc-nc)					
Female	1	3.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Orange

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	9.4	85.4	(36.8-168.2)	Male	1	6.0	nc	(nc-nc)
Female	4	3.0	nc	(nc-nc)	Female	2	4.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.8	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
Female	4	1.3	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	5.4	111.2	(40.6-242.1)
Female	33	35.2	93.7	(64.5-131.6)	Female	4	4.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.8	nc	(nc-nc)
Male	5	10.0	49.8	(16.1-116.3)	<u>Ovary</u>				
Female	6	8.7	69.1	(25.2-150.4)	Female	2	3.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.5	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	3	3.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.7	nc	(nc-nc)	Male	28	30.6	91.5	(60.8-132.2)
Female	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.3	nc	(nc-nc)
Male	7	5.3	131.9	(52.8-271.8)	Female	0	1.2	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.2	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.4	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	5	6.2	80.7	(26.0-188.3)
Male	4	3.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.4	nc	(nc-nc)	Female	12	8.1	147.7	(76.2-258.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.4	nc	(nc-nc)	Male	111	123.1	90.2	(74.2-108.6)
Female	1	1.0	nc	(nc-nc)	Female	118	115.3	102.3	(84.7-122.5)
<u>Lung and Bronchus</u>									
Male	20	17.2	116.4	(71.1-179.7)					
Female	19	16.3	116.7	(70.3-182.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Orleans

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	15.4	84.2	(44.8-144.1)	Male	21	8.4	249.4	(154.3-381.3)
Female	5	5.1	98.9	(31.9-230.7)	Female	12	5.3	224.3	(115.8-391.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.1	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	13	7.5	172.8	(91.9-295.5)
Female	61	46.2	132.1	(101.0-169.7)	Female	6	6.4	93.4	(34.1-203.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	4	5.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	2.6	nc	(nc-nc)
Male	14	14.2	98.8	(54.0-165.7)	<u>Ovary</u>				
Female	13	13.4	97.0	(51.6-165.8)	Female	3	4.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	3.7	nc	(nc-nc)	Male	5	5.1	98.3	(31.7-229.3)
Female	0	1.0	nc	(nc-nc)	Female	8	5.1	157.7	(67.9-310.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	32	43.8	73.1	(50.0-103.2)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.4	nc	(nc-nc)
Male	2	6.9	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
Female	2	3.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.6	nc	(nc-nc)
Male	1	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	4	5.8	nc	(nc-nc)
Male	10	5.2	190.6	(91.2-350.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.5	nc	(nc-nc)	Female	8	10.9	73.6	(31.7-145.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.3	nc	(nc-nc)	Male	153	176.3	86.8	(73.6-101.7)
Female	0	1.6	nc	(nc-nc)	Female	175	163.2	107.2	(91.9-124.3)
<u>Lung and Bronchus</u>									
Male	8	27.6	29.0	(12.5-57.2)					
Female	18	26.7	67.3	(39.9-106.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Otis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	2.7	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	14	7.6	185.0	(101.1-310.4)	Female	3	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	1	2.8	nc	(nc-nc)	<u>Ovary</u>				
Female	2	1.9	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	7	8.5	82.7	(33.1-170.3)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	2	1.2	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.9	nc	(nc-nc)	Male	24	33.8	71.1	(45.5-105.8)
Female	0	0.2	nc	(nc-nc)	Female	32	25.1	127.7	(87.3-180.3)
<u>Lung and Bronchus</u>									
Male	7	4.9	141.4	(56.7-291.4)					
Female	6	3.8	156.5	(57.2-340.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	10.9	137.6	(77.0-227.0)	Male	12	7.9	151.2	(78.0-264.1)
Female	6	4.9	123.1	(44.9-267.9)	Female	12	7.2	167.4	(86.4-292.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.7	nc	(nc-nc)	Male	6	2.5	241.0	(88.0-524.7)
Female	0	2.3	nc	(nc-nc)	Female	4	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	11	7.1	155.0	(77.3-277.4)
Female	58	58.3	99.6	(75.6-128.7)	Female	11	7.1	155.2	(77.4-277.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.0	nc	(nc-nc)	Male	8	6.5	122.5	(52.8-241.4)
<u>Colon / Rectum</u>					Female	4	3.0	nc	(nc-nc)
Male	11	13.3	82.8	(41.3-148.2)	<u>Ovary</u>				
Female	15	14.5	103.2	(57.7-170.2)	Female	8	5.0	160.7	(69.2-316.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.2	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	6	4.9	123.1	(44.9-267.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.1	nc	(nc-nc)	Male	40	41.2	97.1	(69.3-132.2)
Female	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.8	nc	(nc-nc)
Male	6	7.5	79.6	(29.1-173.2)	Female	3	1.9	nc	(nc-nc)
Female	6	4.6	131.8	(48.1-286.9)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.1	nc	(nc-nc)
Male	4	1.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.6	nc	(nc-nc)	Male	7	3.8	185.5	(74.3-382.2)
<u>Leukemia</u>					Female	15	11.1	135.2	(75.6-223.0)
Male	10	5.0	198.4	(95.0-364.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	4.1	172.7	(69.2-355.9)	Female	20	13.1	152.6	(93.2-235.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	9	4.6	197.3	(90.0-374.5)	Male	202	161.3	125.2	(108.5-143.7)
Female	1	1.7	nc	(nc-nc)	Female	223	191.3	116.6	(101.8-132.9)
<u>Lung and Bronchus</u>									
Male	41	20.5	200.2	(143.6-271.5)					
Female	26	26.1	99.5	(65.0-145.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Palmer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	11.1	179.7	(109.7-277.5)	Male	13	7.8	165.6	(88.1-283.3)
Female	8	4.9	163.7	(70.5-322.5)	Female	7	6.7	104.6	(41.9-215.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	2.5	279.4	(111.9-575.8)	Male	1	2.5	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	3	6.9	nc	(nc-nc)
Female	61	54.1	112.7	(86.2-144.8)	Female	8	6.8	117.6	(50.6-231.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.8	nc	(nc-nc)	Male	6	6.3	94.8	(34.6-206.3)
<u>Colon / Rectum</u>					Female	2	2.9	nc	(nc-nc)
Male	13	13.1	99.5	(52.9-170.1)	<u>Ovary</u>				
Female	13	14.2	91.6	(48.7-156.7)	Female	8	4.7	171.0	(73.6-337.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.2	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	6	5.0	119.2	(43.5-259.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.0	nc	(nc-nc)	Male	35	39.8	88.0	(61.3-122.4)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	2.9	174.8	(56.3-407.8)
Male	15	7.2	209.5	(117.2-345.6)	Female	4	1.9	nc	(nc-nc)
Female	5	4.3	116.9	(37.7-272.9)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.9	nc	(nc-nc)
Male	5	1.9	261.7	(84.3-610.7)	<u>Thyroid</u>				
Female	1	0.6	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
<u>Leukemia</u>					Female	8	9.8	81.3	(35.0-160.1)
Male	6	4.8	124.5	(45.5-271.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	3.9	127.1	(41.0-296.6)	Female	13	12.2	106.2	(56.5-181.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	4.6	nc	(nc-nc)	Male	184	158.6	116.0	(99.9-134.0)
Female	2	1.6	nc	(nc-nc)	Female	182	182.0	100.0	(86.0-115.6)
<u>Lung and Bronchus</u>									
Male	31	20.9	148.2	(100.7-210.4)					
Female	15	25.5	58.8	(32.9-96.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Paxton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.1	97.7	(31.5-227.9)	Male	7	3.3	211.8	(84.8-436.3)
Female	2	1.8	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.0	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
Female	19	20.2	94.0	(56.6-146.8)	Female	1	2.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.1	nc	(nc-nc)
Male	0	5.5	nc	(nc-nc)	<u>Ovary</u>				
Female	6	5.1	118.0	(43.1-256.8)	Female	1	1.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.4	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	22	17.6	124.8	(78.2-189.0)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.2	nc	(nc-nc)
Male	4	3.0	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.7	nc	(nc-nc)
Male	3	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	1	3.6	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.4	nc	(nc-nc)	Female	5	4.8	105.2	(33.9-245.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.9	nc	(nc-nc)	Male	74	68.9	107.3	(84.3-134.7)
Female	1	0.6	nc	(nc-nc)	Female	56	67.2	83.3	(62.9-108.2)
<u>Lung and Bronchus</u>									
Male	5	9.4	52.9	(17.1-123.6)					
Female	5	9.4	52.9	(17.1-123.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Peabody

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	95	74.7	127.2	(102.9-155.5)	Male	40	43.8	91.2	(65.2-124.3)
Female	39	27.7	140.7	(100.0-192.3)	Female	37	33.5	110.5	(77.8-152.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	12.2	65.6	(28.2-129.2)	Male	18	14.3	125.5	(74.3-198.3)
Female	12	10.5	114.8	(59.3-200.6)	Female	17	12.1	140.1	(81.6-224.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	2.4	nc	(nc-nc)	Male	39	39.3	99.1	(70.5-135.5)
Female	288	265.3	108.6	(96.4-121.8)	Female	63	36.7	171.8	(132.0-219.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	12	8.2	146.3	(75.5-255.7)	Male	33	30.3	108.8	(74.9-152.8)
<u>Colon / Rectum</u>					Female	14	15.0	93.2	(50.9-156.3)
Male	62	75.6	82.1	(62.9-105.2)	<u>Ovary</u>				
Female	85	80.6	105.5	(84.3-130.5)	Female	19	23.4	81.3	(48.9-126.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	16	17.8	90.0	(51.4-146.1)	Male	23	25.3	91.0	(57.7-136.6)
Female	3	5.3	nc	(nc-nc)	Female	23	28.6	80.3	(50.9-120.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	4.3	nc	(nc-nc)	Male	215	204.5	105.1	(91.5-120.1)
Female	7	3.7	191.6	(76.7-394.7)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	14	17.2	81.4	(44.4-136.5)
Male	29	36.2	80.0	(53.6-114.9)	Female	6	11.1	54.1	(19.7-117.7)
Female	12	21.8	55.0	(28.4-96.0)	<u>Testis</u>				
<u>Larynx</u>					Male	9	7.1	125.9	(57.5-239.1)
Male	17	10.1	168.6	(98.1-269.9)	<u>Thyroid</u>				
Female	2	3.1	nc	(nc-nc)	Male	16	15.1	106.1	(60.6-172.2)
<u>Leukemia</u>					Female	44	43.6	100.9	(73.3-135.4)
Male	27	28.2	95.8	(63.1-139.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	27	21.2	127.5	(84.0-185.5)	Female	53	58.1	91.2	(68.3-119.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	18	22.9	78.4	(46.5-124.0)	Male	908	884.8	102.6	(96.1-109.5)
Female	13	8.5	152.9	(81.3-261.5)	Female	1032	938.5	110.0	(103.3-116.9)
<u>Lung and Bronchus</u>									
Male	128	127.8	100.2	(83.6-119.1)					
Female	159	137.8	115.4	(98.1-134.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pelham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.9	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	6	7.7	78.3	(28.6-170.4)	Female	0	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	3	2.0	nc	(nc-nc)	<u>Ovary</u>				
Female	1	2.0	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	6.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.2	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.7	nc	(nc-nc)	Male	17	25.4	67.0	(39.0-107.3)
Female	1	0.2	nc	(nc-nc)	Female	15	25.6	58.7	(32.8-96.8)
<u>Lung and Bronchus</u>									
Male	2	3.5	nc	(nc-nc)					
Female	1	3.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pembroke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	16.3	116.6	(70.1-182.0)	Male	7	11.1	63.2	(25.3-130.2)
Female	7	5.8	121.3	(48.6-250.0)	Female	15	9.1	164.5	(92.0-271.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.5	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	2	3.0	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	13	9.9	131.2	(69.8-224.4)
Female	78	75.7	103.0	(81.4-128.6)	Female	8	8.8	91.4	(39.4-180.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.7	nc	(nc-nc)	Male	12	8.8	135.8	(70.1-237.3)
<u>Colon / Rectum</u>					Female	4	3.8	nc	(nc-nc)
Male	28	18.6	150.2	(99.8-217.1)	<u>Ovary</u>				
Female	19	17.6	107.9	(64.9-168.5)	Female	6	6.4	94.3	(34.4-205.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	4.5	110.0	(35.5-256.8)	Male	7	6.1	115.6	(46.3-238.1)
Female	1	1.2	nc	(nc-nc)	Female	5	5.9	85.4	(27.5-199.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.4	nc	(nc-nc)	Male	69	58.1	118.8	(92.4-150.4)
Female	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	4.1	146.8	(53.6-319.6)
Male	11	10.2	107.8	(53.8-192.9)	Female	1	2.4	nc	(nc-nc)
Female	7	5.7	122.8	(49.2-253.1)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.5	nc	(nc-nc)
Male	3	2.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	7	4.8	144.4	(57.9-297.6)
<u>Leukemia</u>					Female	24	14.8	161.7	(103.6-240.7)
Male	10	7.0	143.2	(68.6-263.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	5.0	99.8	(32.1-232.8)	Female	17	17.1	99.4	(57.9-159.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	6.4	nc	(nc-nc)	Male	262	227.5	115.2	(101.7-130.0)
Female	1	2.1	nc	(nc-nc)	Female	269	241.0	111.6	(98.7-125.8)
<u>Lung and Bronchus</u>									
Male	34	29.9	113.6	(78.6-158.7)					
Female	46	31.3	146.8	(107.5-195.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pepperell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	11.0	45.4	(14.6-106.0)	Male	6	7.6	79.3	(29.0-172.6)
Female	3	3.4	nc	(nc-nc)	Female	2	5.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.4	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	4	1.8	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	6.8	73.7	(23.7-172.0)
Female	52	47.2	110.1	(82.2-144.4)	Female	4	5.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.7	nc	(nc-nc)	Male	6	6.3	95.9	(35.0-208.8)
<u>Colon / Rectum</u>					Female	2	2.3	nc	(nc-nc)
Male	14	13.0	107.6	(58.8-180.6)	<u>Ovary</u>				
Female	15	10.5	142.8	(79.9-235.5)	Female	4	3.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.1	nc	(nc-nc)	Male	6	4.2	144.3	(52.7-314.0)
Female	0	0.7	nc	(nc-nc)	Female	4	3.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.9	nc	(nc-nc)	Male	30	39.7	75.6	(51.0-107.9)
Female	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.8	nc	(nc-nc)
Male	6	7.0	85.1	(31.1-185.3)	Female	0	1.4	nc	(nc-nc)
Female	5	3.5	141.3	(45.6-329.9)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.6	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	5	3.3	150.6	(48.5-351.5)
<u>Leukemia</u>					Female	8	9.4	85.3	(36.7-168.2)
Male	5	4.7	105.3	(33.9-245.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	3.0	nc	(nc-nc)	Female	18	10.6	169.9	(100.6-268.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	4.5	nc	(nc-nc)	Male	143	155.7	91.8	(77.4-108.2)
Female	0	1.2	nc	(nc-nc)	Female	154	147.7	104.3	(88.4-122.1)
<u>Lung and Bronchus</u>									
Male	26	20.2	128.7	(84.1-188.6)					
Female	17	19.2	88.6	(51.6-141.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Peru

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.9	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	2	3.7	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.9	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.8	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.4	nc	(nc-nc)	Male	10	13.1	76.2	(36.5-140.1)
Female	0	0.1	nc	(nc-nc)	Female	4	11.6	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	0	1.7	nc	(nc-nc)					
Female	0	1.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Petersham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	1.9	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	4	6.8	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	3	2.0	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.7	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	6	5.3	112.3	(41.0-244.5)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.2	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.6	nc	(nc-nc)	Male	21	22.5	93.5	(57.9-142.9)
Female	1	0.2	nc	(nc-nc)	Female	11	22.4	49.0	(24.4-87.7)
<u>Lung and Bronchus</u>									
Male	3	3.1	nc	(nc-nc)					
Female	0	3.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Phillipston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.4	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	6	6.8	88.1	(32.2-191.8)	Female	0	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.3	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	9	5.7	158.5	(72.3-300.8)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.4	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	3	1.4	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.4	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	23	21.3	107.7	(68.3-161.7)
Female	0	0.2	nc	(nc-nc)	Female	21	20.7	101.5	(62.8-155.2)
<u>Lung and Bronchus</u>									
Male	4	2.6	nc	(nc-nc)					
Female	5	2.5	197.6	(63.7-461.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pittsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	70	52.9	132.4	(103.2-167.3)	Male	29	32.7	88.6	(59.3-127.2)
Female	21	20.8	100.9	(62.5-154.3)	Female	22	27.0	81.6	(51.1-123.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	14	9.7	144.7	(79.0-242.8)	Male	10	10.6	93.9	(45.0-172.8)
Female	5	8.5	59.0	(19.0-137.6)	Female	3	9.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.8	nc	(nc-nc)	Male	29	29.4	98.5	(66.0-141.5)
Female	189	215.3	87.8	(75.7-101.2)	Female	26	28.4	91.6	(59.8-134.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	6.9	nc	(nc-nc)	Male	31	24.2	128.0	(86.9-181.7)
<u>Colon / Rectum</u>					Female	10	11.8	84.7	(40.5-155.8)
Male	62	56.1	110.6	(84.8-141.7)	<u>Ovary</u>				
Female	79	60.3	131.0	(103.7-163.3)	Female	13	18.8	69.2	(36.8-118.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	27	13.5	200.7	(132.2-292.0)	Male	18	18.6	96.5	(57.2-152.6)
Female	5	4.0	123.9	(39.9-289.2)	Female	19	21.3	89.1	(53.6-139.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	3.6	nc	(nc-nc)	Male	155	164.7	94.1	(79.9-110.2)
Female	1	3.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	11	12.6	87.3	(43.5-156.3)
Male	30	28.4	105.5	(71.1-150.6)	Female	8	8.2	97.2	(41.9-191.6)
Female	21	17.4	120.6	(74.6-184.3)	<u>Testis</u>				
<u>Larynx</u>					Male	10	6.4	156.6	(75.0-288.0)
Male	11	7.8	141.3	(70.4-252.9)	<u>Thyroid</u>				
Female	2	2.5	nc	(nc-nc)	Male	14	12.4	112.8	(61.6-189.3)
<u>Leukemia</u>					Female	33	37.4	88.1	(60.6-123.8)
Male	22	20.9	105.4	(66.0-159.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	16.4	55.0	(25.1-104.3)	Female	52	48.2	107.8	(80.5-141.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	17	18.0	94.4	(54.9-151.1)	Male	726	671.7	108.1	(100.4-116.2)
Female	6	6.6	90.4	(33.0-196.7)	Female	737	741.4	99.4	(92.4-106.9)
<u>Lung and Bronchus</u>									
Male	102	93.2	109.5	(89.3-132.9)					
Female	149	106.8	139.5	(118.0-163.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plainfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	4	3.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.9	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.3	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.5	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	9	13.3	67.9	(31.0-128.9)
Female	0	0.1	nc	(nc-nc)	Female	9	11.6	77.7	(35.5-147.5)
<u>Lung and Bronchus</u>									
Male	1	1.9	nc	(nc-nc)					
Female	3	1.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plainville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	6.9	158.7	(79.1-283.9)	Male	6	5.0	120.5	(44.0-262.3)
Female	2	2.9	nc	(nc-nc)	Female	3	4.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	4	1.6	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.3	nc	(nc-nc)	Male	10	4.5	221.3	(106.0-407.1)
Female	40	36.5	109.7	(78.4-149.4)	Female	3	4.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.3	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.8	nc	(nc-nc)
Male	8	8.5	94.0	(40.5-185.2)	<u>Ovary</u>				
Female	9	8.9	100.8	(46.0-191.3)	Female	6	3.1	194.1	(70.9-422.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	2.0	nc	(nc-nc)	Male	7	2.7	256.3	(102.7-528.1)
Female	0	0.6	nc	(nc-nc)	Female	4	2.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	32	26.7	119.8	(81.9-169.1)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.8	nc	(nc-nc)
Male	10	4.7	212.1	(101.5-390.0)	Female	1	1.2	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.3	nc	(nc-nc)
Male	3	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	6	7.4	80.8	(29.5-175.9)
Male	4	3.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	2.5	282.1	(113.0-581.2)	Female	7	8.0	87.4	(35.0-180.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.9	nc	(nc-nc)	Male	136	102.5	132.7	(111.3-156.9)
Female	0	1.0	nc	(nc-nc)	Female	128	117.8	108.6	(90.6-129.2)
<u>Lung and Bronchus</u>									
Male	18	12.9	139.8	(82.8-221.0)					
Female	20	15.4	129.7	(79.2-200.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	71	64.4	110.3	(86.2-139.2)	Male	64	41.9	152.7	(117.6-195.0)
Female	22	23.7	92.8	(58.1-140.4)	Female	53	32.7	162.0	(121.3-211.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	14	12.7	110.5	(60.3-185.4)	Male	11	13.6	81.0	(40.4-144.9)
Female	11	10.5	104.3	(52.0-186.7)	Female	10	11.0	90.8	(43.5-167.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	2.3	nc	(nc-nc)	Male	48	37.5	127.9	(94.3-169.5)
Female	303	274.6	110.3	(98.3-123.5)	Female	28	33.5	83.5	(55.5-120.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	8.8	68.2	(24.9-148.4)	Male	37	32.5	113.9	(80.2-156.9)
<u>Colon / Rectum</u>					Female	15	14.3	104.6	(58.5-172.5)
Male	72	70.3	102.5	(80.2-129.1)	<u>Ovary</u>				
Female	62	69.1	89.7	(68.8-115.0)	Female	34	23.3	145.7	(100.9-203.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	20	17.4	114.7	(70.0-177.1)	Male	27	23.5	114.8	(75.7-167.1)
Female	1	4.7	nc	(nc-nc)	Female	23	24.2	94.9	(60.2-142.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	4.9	nc	(nc-nc)	Male	237	222.6	106.5	(93.3-120.9)
Female	1	3.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	12	15.7	76.3	(39.4-133.2)
Male	37	38.0	97.5	(68.6-134.3)	Female	10	9.3	107.8	(51.6-198.2)
Female	21	21.5	97.6	(60.4-149.1)	<u>Testis</u>				
<u>Larynx</u>					Male	6	8.7	69.3	(25.3-151.0)
Male	12	10.2	117.4	(60.6-205.1)	<u>Thyroid</u>				
Female	1	3.1	nc	(nc-nc)	Male	23	17.1	134.5	(85.2-201.8)
<u>Leukemia</u>					Female	72	48.0	149.9	(117.3-188.8)
Male	28	26.2	107.0	(71.1-154.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	15	19.0	78.8	(44.1-130.0)	Female	70	62.5	112.0	(87.3-141.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	30	23.6	127.3	(85.9-181.8)	Male	987	866.8	113.9	(106.9-121.2)
Female	6	7.9	76.0	(27.8-165.5)	Female	987	904.0	109.2	(102.5-116.2)
<u>Lung and Bronchus</u>									
Male	144	117.9	122.1	(103.0-143.8)					
Female	144	127.3	113.1	(95.4-133.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plympton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	3.5	172.5	(63.0-375.4)	Male	2	2.3	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.7	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	15	12.5	119.8	(67.0-197.7)	Female	0	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.4	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	0.6	nc	(nc-nc)
Male	2	3.8	nc	(nc-nc)	<u>Ovary</u>				
Female	4	2.7	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.0	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	13	12.8	101.6	(54.1-173.8)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.9	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.4	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.8	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.3	nc	(nc-nc)	Male	40	48.0	83.3	(59.5-113.4)
Female	0	0.3	nc	(nc-nc)	Female	50	39.8	125.7	(93.3-165.7)
<u>Lung and Bronchus</u>									
Male	1	6.5	nc	(nc-nc)					
Female	7	5.5	128.3	(51.4-264.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Princeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	3.2	154.1	(49.6-359.5)	Male	6	2.3	260.2	(95.0-566.3)
Female	0	1.2	nc	(nc-nc)	Female	4	1.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	0.7	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	16	16.3	98.2	(56.1-159.5)	Female	1	1.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	10	2.0	501.4	(240.1-922.2)
<u>Colon / Rectum</u>					Female	0	0.8	nc	(nc-nc)
Male	5	3.9	127.8	(41.2-298.3)	<u>Ovary</u>				
Female	1	3.6	nc	(nc-nc)	Female	5	1.4	361.3	(116.4-843.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.0	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	16	13.0	122.9	(70.2-199.6)
Female	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.8	nc	(nc-nc)
Male	5	2.2	227.1	(73.2-530.0)	Female	0	0.5	nc	(nc-nc)
Female	4	1.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	2	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	4	2.9	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.0	nc	(nc-nc)	Female	4	4.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.5	nc	(nc-nc)	Male	70	48.3	145.0	(113.0-183.2)
Female	0	0.5	nc	(nc-nc)	Female	49	51.3	95.5	(70.7-126.3)
<u>Lung and Bronchus</u>									
Male	2	6.1	nc	(nc-nc)					
Female	3	6.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Provincetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	5.6	nc	(nc-nc)	Male	6	3.6	167.6	(61.2-364.9)
Female	5	1.7	297.5	(95.9-694.2)	Female	3	2.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.0	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
Female	15	17.4	86.0	(48.1-141.9)	Female	1	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	5	3.0	168.8	(54.4-393.9)
<u>Colon / Rectum</u>					Female	3	1.0	nc	(nc-nc)
Male	7	6.4	109.7	(44.0-226.1)	<u>Ovary</u>				
Female	9	4.6	195.2	(89.1-370.6)	Female	4	1.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.6	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	12	20.3	59.2	(30.5-103.4)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.4	nc	(nc-nc)
Male	4	3.3	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Leukemia</u>					Female	3	2.5	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.2	nc	(nc-nc)	Female	4	4.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.1	nc	(nc-nc)	Male	74	75.8	97.6	(76.6-122.5)
Female	1	0.5	nc	(nc-nc)	Female	71	59.0	120.4	(94.0-151.8)
<u>Lung and Bronchus</u>									
Male	10	10.1	98.8	(47.3-181.8)					
Female	10	9.1	109.8	(52.5-201.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Quincy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	103	94.8	108.7	(88.7-131.8)	Male	53	61.4	86.3	(64.7-112.9)
Female	32	35.0	91.4	(62.5-129.0)	Female	61	50.2	121.4	(92.9-156.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	20	19.1	104.9	(64.0-161.9)	Male	14	19.4	72.1	(39.4-121.0)
Female	16	15.6	102.9	(58.8-167.0)	Female	14	16.0	87.5	(47.8-146.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	5	3.3	152.0	(49.0-354.6)	Male	46	55.2	83.4	(61.0-111.2)
Female	382	389.5	98.1	(88.5-108.4)	Female	63	49.5	127.4	(97.9-163.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	22	13.7	160.3	(100.4-242.7)	Male	64	44.7	143.1	(110.2-182.7)
<u>Colon / Rectum</u>					Female	25	20.8	120.3	(77.8-177.6)
Male	133	103.1	129.0	(108.0-152.9)	<u>Ovary</u>				
Female	96	103.5	92.8	(75.1-113.3)	Female	31	33.9	91.5	(62.1-129.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	28	24.1	116.2	(77.2-168.0)	Male	27	33.9	79.6	(52.5-115.9)
Female	11	6.8	161.0	(80.3-288.1)	Female	36	35.7	100.9	(70.7-139.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	9	8.3	107.8	(49.2-204.7)	Male	254	288.8	87.9	(77.5-99.5)
Female	8	6.7	119.6	(51.5-235.7)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	30	23.1	130.2	(87.8-185.8)
Male	48	52.9	90.8	(66.9-120.4)	Female	15	14.0	107.3	(60.0-177.0)
Female	29	31.0	93.5	(62.6-134.3)	<u>Testis</u>				
<u>Larynx</u>					Male	18	16.5	109.1	(64.6-172.4)
Male	17	14.1	120.6	(70.2-193.1)	<u>Thyroid</u>				
Female	5	4.4	114.4	(36.9-266.9)	Male	26	25.3	102.6	(67.0-150.3)
<u>Leukemia</u>					Female	59	77.0	76.6	(58.3-98.9)
Male	26	39.1	66.4	(43.4-97.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	25	28.8	86.9	(56.2-128.3)	Female	81	86.4	93.8	(74.5-116.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	62	32.6	190.0	(145.7-243.6)	Male	1323	1227.5	107.8	(102.0-113.7)
Female	16	11.4	140.0	(80.0-227.4)	Female	1362	1319.7	103.2	(97.8-108.8)
<u>Lung and Bronchus</u>									
Male	242	167.3	144.7	(127.0-164.1)					
Female	237	183.5	129.2	(113.3-146.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Randolph

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	34	35.8	95.0	(65.8-132.7)	Male	12	22.6	53.2	(27.4-92.9)
Female	7	13.2	52.9	(21.2-108.9)	Female	15	18.6	80.5	(45.0-132.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	6.8	88.1	(32.2-191.8)	Male	7	7.3	95.9	(38.4-197.6)
Female	5	5.9	84.0	(27.1-196.1)	Female	10	6.1	164.4	(78.7-302.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.2	nc	(nc-nc)	Male	13	20.3	63.9	(34.0-109.3)
Female	127	149.9	84.7	(70.6-100.8)	Female	18	18.8	95.6	(56.6-151.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	5.1	97.5	(31.4-227.5)	Male	7	16.6	42.3	(16.9-87.1)
<u>Colon / Rectum</u>					Female	9	7.9	113.3	(51.7-215.1)
Male	38	38.4	99.0	(70.0-135.8)	<u>Ovary</u>				
Female	44	39.0	112.7	(81.9-151.3)	Female	10	12.9	77.8	(37.2-143.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	9.1	66.0	(24.1-143.7)	Male	10	12.7	78.9	(37.8-145.2)
Female	3	2.6	nc	(nc-nc)	Female	7	13.5	52.0	(20.8-107.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.7	nc	(nc-nc)	Male	114	108.8	104.8	(86.4-125.9)
Female	0	2.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	8.6	93.0	(40.1-183.3)
Male	22	19.5	112.8	(70.7-170.8)	Female	6	5.3	112.3	(41.0-244.4)
Female	10	11.8	84.9	(40.7-156.2)	<u>Testis</u>				
<u>Larynx</u>					Male	0	4.9	nc	(nc-nc)
Male	6	5.3	113.3	(41.4-246.5)	<u>Thyroid</u>				
Female	1	1.7	nc	(nc-nc)	Male	13	8.8	147.9	(78.7-252.9)
<u>Leukemia</u>					Female	33	28.1	117.6	(81.0-165.2)
Male	9	14.4	62.4	(28.5-118.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	10.8	nc	(nc-nc)	Female	35	33.6	104.2	(72.6-145.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	12	12.3	97.9	(50.5-171.0)	Male	384	456.6	84.1	(75.9-93.0)
Female	2	4.4	nc	(nc-nc)	Female	434	501.1	86.6	(78.7-95.2)
<u>Lung and Bronchus</u>									
Male	38	63.2	60.1	(42.6-82.6)					
Female	56	69.2	80.9	(61.1-105.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Raynham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	13.8	122.8	(71.5-196.5)	Male	8	9.2	87.2	(37.6-171.9)
Female	7	5.4	129.8	(52.0-267.4)	Female	10	7.3	136.6	(65.4-251.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.9	nc	(nc-nc)	Male	5	2.9	173.0	(55.8-403.8)
Female	1	2.4	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	12	8.2	147.0	(75.9-256.8)
Female	64	59.1	108.3	(83.4-138.2)	Female	6	7.5	79.9	(29.2-173.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.0	nc	(nc-nc)	Male	5	7.2	69.6	(22.4-162.4)
<u>Colon / Rectum</u>					Female	2	3.2	nc	(nc-nc)
Male	28	15.6	179.6	(119.3-259.6)	<u>Ovary</u>				
Female	18	15.5	116.1	(68.7-183.4)	Female	5	5.1	98.0	(31.6-228.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.7	134.7	(43.4-314.2)	Male	7	5.1	137.1	(54.9-282.5)
Female	3	1.1	nc	(nc-nc)	Female	5	5.4	92.0	(29.6-214.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.0	nc	(nc-nc)	Male	47	46.7	100.7	(73.9-133.8)
Female	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.4	nc	(nc-nc)
Male	13	8.3	157.3	(83.7-269.1)	Female	4	2.1	nc	(nc-nc)
Female	10	4.7	211.3	(101.2-388.7)	<u>Testis</u>				
<u>Larynx</u>					Male	4	1.9	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.7	nc	(nc-nc)	Male	6	3.8	159.1	(58.1-346.3)
<u>Leukemia</u>					Female	27	10.8	249.2	(164.2-362.6)
Male	1	5.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	4.3	nc	(nc-nc)	Female	16	13.2	120.9	(69.1-196.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	5.3	nc	(nc-nc)	Male	219	187.3	117.0	(102.0-133.5)
Female	3	1.8	nc	(nc-nc)	Female	245	199.7	122.7	(107.8-139.0)
<u>Lung and Bronchus</u>									
Male	29	25.2	115.2	(77.1-165.5)					
Female	32	28.6	111.7	(76.4-157.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	29	24.7	117.3	(78.6-168.5)	Male	12	16.3	73.6	(38.0-128.5)
Female	11	10.2	108.2	(53.9-193.6)	Female	16	13.8	115.9	(66.2-188.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.1	116.7	(42.6-254.0)	Male	5	5.2	95.6	(30.8-223.2)
Female	7	4.5	156.3	(62.6-322.0)	Female	3	4.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.9	nc	(nc-nc)	Male	16	14.6	109.2	(62.4-177.4)
Female	131	111.9	117.1	(97.9-138.9)	Female	6	14.2	42.2	(15.4-92.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.7	nc	(nc-nc)	Male	11	12.7	86.4	(43.1-154.6)
<u>Colon / Rectum</u>					Female	7	6.0	117.2	(46.9-241.4)
Male	33	27.6	119.8	(82.4-168.2)	<u>Ovary</u>				
Female	23	29.8	77.1	(48.9-115.7)	Female	13	9.6	135.0	(71.8-230.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	6.7	104.8	(42.0-215.9)	Male	7	9.1	77.2	(30.9-159.1)
Female	1	2.0	nc	(nc-nc)	Female	9	10.4	86.6	(39.5-164.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.0	nc	(nc-nc)	Male	62	83.9	73.9	(56.7-94.8)
Female	4	1.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	6.1	nc	(nc-nc)
Male	14	14.8	94.6	(51.7-158.7)	Female	1	4.1	nc	(nc-nc)
Female	9	8.9	101.7	(46.4-193.0)	<u>Testis</u>				
<u>Larynx</u>					Male	5	3.5	141.4	(45.6-330.1)
Male	1	3.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.2	nc	(nc-nc)	Male	7	6.9	102.0	(40.9-210.2)
<u>Leukemia</u>					Female	25	20.3	122.9	(79.5-181.4)
Male	13	10.4	125.0	(66.5-213.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	8.2	121.3	(58.1-223.1)	Female	27	24.9	108.6	(71.6-158.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	9.1	120.5	(60.1-215.7)	Male	305	334.2	91.3	(81.3-102.1)
Female	5	3.3	150.1	(48.4-350.4)	Female	391	376.8	103.8	(93.7-114.6)
<u>Lung and Bronchus</u>									
Male	36	44.7	80.5	(56.3-111.4)					
Female	43	52.5	81.9	(59.2-110.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rehoboth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	13.8	58.1	(25.0-114.6)	Male	8	8.9	89.9	(38.7-177.1)
Female	3	3.5	nc	(nc-nc)	Female	4	5.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.7	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	6	8.0	74.7	(27.3-162.6)
Female	44	47.5	92.6	(67.3-124.3)	Female	7	5.3	131.5	(52.7-270.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.7	nc	(nc-nc)	Male	0	7.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	2.4	nc	(nc-nc)
Male	11	15.3	71.9	(35.9-128.7)	<u>Ovary</u>				
Female	11	10.5	105.2	(52.4-188.2)	Female	3	4.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	3.7	nc	(nc-nc)	Male	1	5.0	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	3.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.0	nc	(nc-nc)	Male	38	46.7	81.4	(57.6-111.7)
Female	2	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.4	nc	(nc-nc)
Male	6	8.1	74.2	(27.1-161.5)	Female	0	1.4	nc	(nc-nc)
Female	6	3.5	170.3	(62.2-370.7)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.8	nc	(nc-nc)
Male	0	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	3	0.5	nc	(nc-nc)	Male	0	3.7	nc	(nc-nc)
<u>Leukemia</u>					Female	7	9.3	75.5	(30.2-155.5)
Male	5	5.6	88.6	(28.5-206.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.0	nc	(nc-nc)	Female	14	11.0	127.5	(69.7-214.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	5.1	nc	(nc-nc)	Male	126	184.2	68.4	(57.0-81.4)
Female	1	1.3	nc	(nc-nc)	Female	139	148.8	93.4	(78.6-110.3)
<u>Lung and Bronchus</u>									
Male	23	24.4	94.3	(59.7-141.5)					
Female	17	19.1	89.1	(51.9-142.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Revere

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	49	49.7	98.6	(73.0-130.4)	Male	23	33.5	68.6	(43.5-102.9)
Female	15	19.6	76.4	(42.7-125.9)	Female	27	27.6	97.8	(64.4-142.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	10.8	102.0	(50.8-182.5)	Male	7	10.3	67.9	(27.2-139.9)
Female	11	8.6	127.3	(63.5-227.8)	Female	9	8.9	100.8	(46.0-191.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.8	nc	(nc-nc)	Male	30	30.0	99.9	(67.4-142.6)
Female	195	217.3	89.7	(77.6-103.2)	Female	25	27.7	90.4	(58.5-133.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	7.5	66.8	(21.5-155.9)	Male	20	24.8	80.8	(49.3-124.8)
<u>Colon / Rectum</u>					Female	16	11.5	138.7	(79.2-225.2)
Male	60	55.9	107.3	(81.9-138.1)	<u>Ovary</u>				
Female	42	57.2	73.4	(52.9-99.2)	Female	14	18.8	74.5	(40.7-125.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	12.9	62.1	(26.7-122.4)	Male	24	18.0	133.5	(85.5-198.6)
Female	3	3.9	nc	(nc-nc)	Female	14	19.9	70.3	(38.4-117.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	8	4.9	161.7	(69.6-318.5)	Male	123	155.9	78.9	(65.6-94.1)
Female	8	3.5	231.5	(99.7-456.2)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	21	12.3	170.9	(105.8-261.3)
Male	33	29.3	112.6	(77.5-158.2)	Female	12	7.8	153.2	(79.1-267.6)
Female	27	17.3	156.0	(102.8-227.0)	<u>Testis</u>				
<u>Larynx</u>					Male	8	10.1	79.5	(34.2-156.6)
Male	9	7.5	119.9	(54.7-227.6)	<u>Thyroid</u>				
Female	7	2.4	287.9	(115.4-593.3)	Male	11	14.9	73.9	(36.9-132.3)
<u>Leukemia</u>					Female	51	41.4	123.2	(91.7-162.0)
Male	27	21.3	126.7	(83.5-184.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	15	16.1	93.5	(52.3-154.1)	Female	36	48.3	74.5	(52.2-103.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	25	17.7	141.6	(91.6-209.0)	Male	663	663.5	99.9	(92.5-107.8)
Female	7	6.4	108.9	(43.6-224.4)	Female	729	734.4	99.3	(92.2-106.7)
<u>Lung and Bronchus</u>									
Male	117	88.3	132.5	(109.6-158.8)					
Female	136	103.1	131.9	(110.7-156.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Richmond

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	3.4	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	6	9.7	61.8	(22.6-134.5)	Female	1	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.5	nc	(nc-nc)
Male	1	3.3	nc	(nc-nc)	<u>Ovary</u>				
Female	1	2.6	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	9	10.2	87.9	(40.1-166.8)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.8	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.4	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.7	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.1	nc	(nc-nc)	Male	20	40.5	49.4	(30.2-76.3)
Female	0	0.3	nc	(nc-nc)	Female	19	32.9	57.8	(34.8-90.2)
<u>Lung and Bronchus</u>									
Male	2	6.0	nc	(nc-nc)					
Female	1	5.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rochester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	5.3	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
Female	5	1.9	269.8	(87.0-629.7)	Female	2	2.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
Female	26	22.4	116.2	(75.9-170.3)	Female	2	2.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.2	nc	(nc-nc)
Male	5	6.0	83.2	(26.8-194.3)	<u>Ovary</u>				
Female	8	5.7	140.3	(60.4-276.5)	Female	2	1.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.5	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	25	19.6	127.6	(82.6-188.4)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.3	nc	(nc-nc)
Male	4	3.4	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<u>Leukemia</u>					Female	2	4.3	nc	(nc-nc)
Male	2	2.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.6	nc	(nc-nc)	Female	3	5.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.2	nc	(nc-nc)	Male	74	75.3	98.3	(77.2-123.4)
Female	0	0.6	nc	(nc-nc)	Female	67	73.5	91.1	(70.6-115.7)
<u>Lung and Bronchus</u>									
Male	11	10.0	110.0	(54.8-196.8)					
Female	6	9.5	63.5	(23.2-138.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rockland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	17.8	112.6	(68.7-173.9)	Male	14	11.9	117.7	(64.3-197.5)
Female	10	7.2	139.4	(66.8-256.5)	Female	12	9.5	126.1	(65.1-220.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.8	132.4	(42.7-309.0)	Male	4	3.8	nc	(nc-nc)
Female	3	3.1	nc	(nc-nc)	Female	1	3.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	11	10.7	102.8	(51.2-183.9)
Female	82	79.6	103.1	(82.0-127.9)	Female	17	10.0	170.4	(99.2-272.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.6	nc	(nc-nc)	Male	10	9.2	108.9	(52.1-200.2)
<u>Colon / Rectum</u>					Female	4	4.2	nc	(nc-nc)
Male	22	19.9	110.8	(69.4-167.7)	<u>Ovary</u>				
Female	23	20.3	113.2	(71.7-169.9)	Female	6	6.7	88.9	(32.5-193.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	4.8	165.3	(71.2-325.8)	Male	7	6.5	107.0	(42.9-220.4)
Female	1	1.4	nc	(nc-nc)	Female	7	7.2	97.1	(38.9-200.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.6	nc	(nc-nc)	Male	67	61.6	108.7	(84.3-138.1)
Female	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	4.4	113.2	(36.5-264.2)
Male	14	10.8	129.9	(71.0-218.0)	Female	8	2.7	291.6	(125.5-574.6)
Female	16	6.4	251.1	(143.4-407.8)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.0	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	3	5.1	nc	(nc-nc)
<u>Leukemia</u>					Female	19	13.9	136.6	(82.2-213.3)
Male	10	7.5	133.7	(64.0-246.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	5.7	194.3	(96.9-347.6)	Female	22	18.0	122.1	(76.5-184.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	6.7	nc	(nc-nc)	Male	267	243.7	109.6	(96.8-123.5)
Female	4	2.4	nc	(nc-nc)	Female	324	265.7	121.9	(109.0-136.0)
<u>Lung and Bronchus</u>									
Male	34	32.5	104.6	(72.4-146.1)					
Female	51	38.5	132.4	(98.6-174.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rockport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	11.7	77.1	(35.2-146.3)	Male	8	6.9	116.5	(50.2-229.5)
Female	2	4.7	nc	(nc-nc)	Female	7	5.5	126.5	(50.7-260.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.8	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	3	1.7	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.4	nc	(nc-nc)	Male	3	6.1	nc	(nc-nc)
Female	47	46.1	102.0	(74.9-135.6)	Female	5	6.2	80.8	(26.0-188.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	5	5.0	99.4	(32.0-232.0)
<u>Colon / Rectum</u>					Female	6	2.6	232.4	(84.9-505.8)
Male	10	11.6	86.1	(41.2-158.4)	<u>Ovary</u>				
Female	5	13.3	37.7	(12.1-87.9)	Female	5	4.1	123.4	(39.8-287.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.0	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	3	4.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	40	37.2	107.6	(76.8-146.5)
Female	2	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.7	nc	(nc-nc)
Male	8	5.9	135.0	(58.1-266.1)	Female	1	1.8	nc	(nc-nc)
Female	6	3.8	158.9	(58.0-345.9)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.7	nc	(nc-nc)
Male	0	1.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	5	6.8	73.7	(23.8-172.0)
Male	4	4.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	3.4	nc	(nc-nc)	Female	9	10.6	85.2	(38.9-161.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.8	nc	(nc-nc)	Male	130	144.3	90.1	(75.3-107.0)
Female	1	1.5	nc	(nc-nc)	Female	141	160.0	88.1	(74.2-103.9)
<u>Lung and Bronchus</u>									
Male	16	21.0	76.2	(43.5-123.8)					
Female	14	24.2	57.7	(31.5-96.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rowe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	2	0.7	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.5	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.4	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	8.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	7.2	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	0	1.2	nc	(nc-nc)					
Female	0	1.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rowley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	5.9	102.0	(37.2-222.0)	Male	4	4.1	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	Female	5	3.4	147.6	(47.6-344.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.3	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
Female	26	27.8	93.5	(61.1-137.0)	Female	4	3.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.9	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.4	nc	(nc-nc)
Male	9	6.7	133.5	(60.9-253.5)	<u>Ovary</u>				
Female	7	7.0	100.2	(40.1-206.4)	Female	3	2.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.8	nc	(nc-nc)	Male	5	2.3	216.3	(69.7-504.8)
Female	0	0.4	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	21	23.9	87.8	(54.3-134.2)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.5	nc	(nc-nc)
Male	1	3.9	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<u>Leukemia</u>					Female	8	5.2	153.3	(66.0-302.1)
Male	3	2.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.9	nc	(nc-nc)	Female	4	6.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.5	nc	(nc-nc)	Male	78	86.4	90.3	(71.4-112.7)
Female	1	0.8	nc	(nc-nc)	Female	83	90.2	92.0	(73.3-114.1)
<u>Lung and Bronchus</u>									
Male	11	11.2	98.3	(49.0-176.0)					
Female	5	11.8	42.2	(13.6-98.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Royalston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.5	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	9	5.4	165.8	(75.7-314.8)	Female	1	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.2	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	10	5.2	192.2	(92.0-353.5)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.0	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	3	1.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	21	20.5	102.4	(63.4-156.6)
Female	0	0.1	nc	(nc-nc)	Female	19	17.1	111.1	(66.9-173.6)
<u>Lung and Bronchus</u>									
Male	1	2.8	nc	(nc-nc)					
Female	1	2.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Russell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.5	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	11	6.9	158.3	(78.9-283.2)	Female	0	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.4	nc	(nc-nc)
Male	4	1.7	nc	(nc-nc)	<u>Ovary</u>				
Female	6	1.7	362.9	(132.5-789.9)	Female	2	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	5.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	2	1.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.3	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	18	20.8	86.4	(51.2-136.6)
Female	0	0.2	nc	(nc-nc)	Female	29	22.7	127.5	(85.4-183.1)
<u>Lung and Bronchus</u>									
Male	4	2.8	nc	(nc-nc)					
Female	3	3.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rutland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	6.7	74.9	(24.1-174.8)	Male	6	4.7	126.4	(46.1-275.1)
Female	2	2.1	nc	(nc-nc)	Female	0	3.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.6	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	4.3	115.2	(37.1-268.9)
Female	40	29.9	133.8	(95.6-182.2)	Female	3	3.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	4	3.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.5	nc	(nc-nc)
Male	10	8.2	122.7	(58.7-225.6)	<u>Ovary</u>				
Female	7	6.7	104.4	(41.8-215.2)	Female	2	2.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.9	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	26	25.4	102.3	(66.8-149.9)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.7	nc	(nc-nc)
Male	2	4.6	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	0	2.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.3	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	3	6.4	nc	(nc-nc)
Male	6	3.0	197.3	(72.0-429.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.9	nc	(nc-nc)	Female	6	6.6	91.1	(33.3-198.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.7	nc	(nc-nc)	Male	99	97.9	101.1	(82.2-123.1)
Female	1	0.8	nc	(nc-nc)	Female	88	93.0	94.6	(75.9-116.5)
<u>Lung and Bronchus</u>									
Male	17	12.2	139.6	(81.3-223.6)					
Female	9	11.3	79.8	(36.4-151.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	35	34.8	100.5	(70.0-139.7)	Male	32	23.5	136.3	(93.2-192.5)
Female	11	16.5	66.6	(33.2-119.2)	Female	22	23.3	94.3	(59.1-142.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	7.6	144.1	(71.8-257.8)	Male	4	7.3	nc	(nc-nc)
Female	2	7.4	nc	(nc-nc)	Female	13	7.5	173.2	(92.1-296.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.2	nc	(nc-nc)	Male	30	21.2	141.4	(95.4-201.9)
Female	169	180.0	93.9	(80.3-109.1)	Female	21	23.3	90.3	(55.9-138.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	6.3	79.9	(25.8-186.6)	Male	22	17.9	123.1	(77.1-186.4)
<u>Colon / Rectum</u>					Female	14	9.8	143.1	(78.2-240.1)
Male	42	39.8	105.5	(76.0-142.5)	<u>Ovary</u>				
Female	36	48.9	73.7	(51.6-102.0)	Female	9	15.8	56.9	(26.0-108.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	9.2	131.0	(67.6-228.9)	Male	10	12.8	78.2	(37.4-143.9)
Female	6	3.2	188.7	(68.9-410.8)	Female	14	16.9	83.1	(45.4-139.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	3.5	nc	(nc-nc)	Male	145	112.2	129.2	(109.1-152.1)
Female	9	3.3	276.6	(126.2-525.2)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	16	8.7	184.3	(105.3-299.3)
Male	26	20.8	125.1	(81.7-183.3)	Female	2	6.7	nc	(nc-nc)
Female	17	14.4	118.2	(68.8-189.2)	<u>Testis</u>				
<u>Larynx</u>					Male	6	6.9	87.1	(31.8-189.7)
Male	4	5.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	3	2.0	nc	(nc-nc)	Male	11	10.4	106.2	(52.9-190.0)
<u>Leukemia</u>					Female	45	35.3	127.6	(93.0-170.7)
Male	16	15.0	106.5	(60.8-173.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	16	13.7	117.0	(66.9-190.1)	Female	44	40.4	109.0	(79.2-146.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	14	12.8	109.5	(59.8-183.8)	Male	566	470.9	120.2	(110.5-130.5)
Female	2	5.5	nc	(nc-nc)	Female	613	615.3	99.6	(91.9-107.8)
<u>Lung and Bronchus</u>									
Male	74	62.1	119.1	(93.5-149.5)					
Female	98	84.7	115.7	(93.9-141.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Salisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	9.9	121.2	(62.5-211.7)	Male	10	6.5	154.3	(73.9-283.8)
Female	4	3.2	nc	(nc-nc)	Female	3	4.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.0	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	6	5.8	102.7	(37.5-223.6)
Female	47	40.7	115.4	(84.8-153.4)	Female	8	4.6	172.8	(74.4-340.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.3	nc	(nc-nc)	Male	14	5.2	270.7	(147.9-454.2)
<u>Colon / Rectum</u>					Female	3	2.0	nc	(nc-nc)
Male	15	10.8	138.3	(77.3-228.1)	<u>Ovary</u>				
Female	15	9.1	164.9	(92.2-271.9)	Female	7	3.4	205.7	(82.4-423.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.7	nc	(nc-nc)	Male	5	3.7	135.4	(43.6-315.9)
Female	1	0.7	nc	(nc-nc)	Female	6	3.2	187.1	(68.3-407.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	28	36.2	77.3	(51.3-111.7)
Female	2	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.4	nc	(nc-nc)
Male	8	6.0	133.7	(57.6-263.5)	Female	1	1.2	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.3	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
<u>Leukemia</u>					Female	8	7.3	109.2	(47.0-215.1)
Male	3	4.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.6	nc	(nc-nc)	Female	11	9.5	116.4	(58.0-208.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.7	nc	(nc-nc)	Male	139	136.2	102.0	(85.8-120.5)
Female	1	1.1	nc	(nc-nc)	Female	167	128.8	129.6	(110.7-150.9)
<u>Lung and Bronchus</u>									
Male	21	18.4	114.0	(70.5-174.3)					
Female	28	17.6	159.3	(105.8-230.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sandisfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.0	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	1	4.2	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.9	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	4.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.7	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	0.3	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	12	22.2	54.1	(27.9-94.5)
Female	0	0.1	nc	(nc-nc)	Female	9	13.2	68.1	(31.1-129.3)
<u>Lung and Bronchus</u>									
Male	2	3.4	nc	(nc-nc)					
Female	3	1.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sandwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	24.3	131.8	(90.1-186.0)	Male	19	15.5	122.9	(74.0-192.0)
Female	8	8.3	96.3	(41.5-189.7)	Female	15	11.7	128.4	(71.8-211.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	4.6	218.0	(104.4-401.0)	Male	4	5.1	nc	(nc-nc)
Female	6	3.8	159.4	(58.2-346.9)	Female	1	3.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	17	13.8	123.1	(71.7-197.1)
Female	116	97.4	119.0	(98.4-142.8)	Female	13	11.9	109.2	(58.1-186.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.1	nc	(nc-nc)	Male	10	11.9	83.7	(40.1-154.0)
<u>Colon / Rectum</u>					Female	8	5.1	157.1	(67.7-309.6)
Male	19	26.3	72.3	(43.5-113.0)	<u>Ovary</u>				
Female	20	24.1	83.0	(50.7-128.1)	Female	9	8.4	107.5	(49.1-204.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	6.5	77.4	(24.9-180.6)	Male	14	8.8	159.3	(87.0-267.3)
Female	3	1.7	nc	(nc-nc)	Female	10	8.4	119.4	(57.1-219.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.6	nc	(nc-nc)	Male	94	80.3	117.1	(94.7-143.3)
Female	1	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	5.9	101.9	(37.2-221.7)
Male	10	13.8	72.5	(34.7-133.3)	Female	4	3.3	nc	(nc-nc)
Female	7	7.6	91.8	(36.8-189.1)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.7	nc	(nc-nc)
Male	4	3.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.1	nc	(nc-nc)	Male	2	6.0	nc	(nc-nc)
<u>Leukemia</u>					Female	11	17.2	64.0	(31.9-114.5)
Male	10	9.7	102.8	(49.2-189.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	6.7	nc	(nc-nc)	Female	24	22.5	106.6	(68.3-158.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	8.8	67.9	(24.8-147.9)	Male	331	319.0	103.8	(92.9-115.6)
Female	1	2.8	nc	(nc-nc)	Female	333	320.1	104.0	(93.2-115.8)
<u>Lung and Bronchus</u>									
Male	30	44.0	68.1	(46.0-97.3)					
Female	44	44.9	98.0	(71.2-131.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Saugus

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	48	31.0	154.6	(114.0-205.0)	Male	18	20.0	90.1	(53.4-142.4)
Female	20	13.2	151.8	(92.7-234.4)	Female	20	17.4	115.1	(70.3-177.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	5.8	85.7	(27.6-200.1)	Male	6	6.5	91.8	(33.5-199.9)
Female	8	5.5	146.0	(62.9-287.8)	Female	5	6.0	83.2	(26.8-194.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.1	nc	(nc-nc)	Male	29	17.9	161.7	(108.3-232.3)
Female	147	143.8	102.2	(86.4-120.1)	Female	25	18.3	136.9	(88.6-202.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.5	nc	(nc-nc)	Male	19	14.8	128.6	(77.4-200.9)
<u>Colon / Rectum</u>					Female	6	7.7	78.2	(28.6-170.3)
Male	48	33.5	143.5	(105.8-190.2)	<u>Ovary</u>				
Female	32	37.8	84.6	(57.9-119.5)	Female	5	12.4	40.5	(13.0-94.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	8.1	161.3	(85.8-275.8)	Male	15	11.2	134.0	(74.9-221.0)
Female	4	2.6	nc	(nc-nc)	Female	15	13.4	112.1	(62.7-185.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.2	nc	(nc-nc)	Male	79	96.8	81.6	(64.6-101.7)
Female	3	1.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	7.6	79.3	(28.9-172.5)
Male	26	17.4	149.1	(97.4-218.5)	Female	2	5.1	nc	(nc-nc)
Female	8	11.5	69.6	(30.0-137.2)	<u>Testis</u>				
<u>Larynx</u>					Male	9	3.9	230.4	(105.1-437.4)
Male	7	4.8	145.9	(58.4-300.5)	<u>Thyroid</u>				
Female	0	1.6	nc	(nc-nc)	Male	11	7.8	140.4	(70.0-251.2)
<u>Leukemia</u>					Female	20	24.4	82.1	(50.1-126.8)
Male	17	12.4	137.3	(79.9-219.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	10.3	nc	(nc-nc)	Female	28	32.8	85.3	(56.7-123.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	17	11.0	155.1	(90.3-248.3)	Male	485	402.1	120.6	(110.1-131.8)
Female	5	4.3	115.8	(37.3-270.2)	Female	490	483.0	101.4	(92.7-110.8)
<u>Lung and Bronchus</u>									
Male	66	56.0	117.8	(91.1-149.9)					
Female	88	69.8	126.1	(101.1-155.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Savoy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	2	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	3	3.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.7	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.2	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	1	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	2	0.6	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	12.1	58.0	(23.2-119.4)
Female	0	0.1	nc	(nc-nc)	Female	10	9.6	103.7	(49.6-190.6)
<u>Lung and Bronchus</u>									
Male	2	1.6	nc	(nc-nc)					
Female	1	1.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Scituate

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	22.9	91.6	(56.7-140.1)	Male	40	14.2	281.8	(201.3-383.7)
Female	12	8.0	149.5	(77.2-261.2)	Female	29	10.7	271.7	(181.9-390.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	4.1	146.3	(53.4-318.4)	Male	7	4.6	151.2	(60.6-311.5)
Female	3	3.5	nc	(nc-nc)	Female	2	3.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	6	12.7	47.3	(17.3-103.0)
Female	89	89.5	99.4	(79.8-122.4)	Female	9	11.2	80.6	(36.8-153.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.8	nc	(nc-nc)	Male	9	10.6	84.8	(38.7-161.0)
<u>Colon / Rectum</u>					Female	7	4.7	147.6	(59.1-304.2)
Male	21	24.4	86.0	(53.2-131.5)	<u>Ovary</u>				
Female	20	23.6	84.7	(51.7-130.8)	Female	8	7.6	104.7	(45.1-206.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	5.8	120.0	(48.1-247.3)	Male	7	8.1	86.5	(34.7-178.2)
Female	1	1.5	nc	(nc-nc)	Female	4	8.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.4	nc	(nc-nc)	Male	66	69.5	94.9	(73.4-120.8)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	5.5	110.0	(40.1-239.3)
Male	7	12.3	56.7	(22.7-116.9)	Female	4	3.2	nc	(nc-nc)
Female	6	7.0	85.2	(31.1-185.4)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.2	nc	(nc-nc)
Male	2	3.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.0	nc	(nc-nc)	Male	1	5.2	nc	(nc-nc)
<u>Leukemia</u>					Female	18	15.2	118.6	(70.2-187.4)
Male	10	9.0	110.7	(53.0-203.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	6.4	109.4	(43.8-225.5)	Female	21	20.0	104.9	(64.9-160.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	7.9	101.7	(43.8-200.3)	Male	291	288.6	100.8	(89.6-113.1)
Female	3	2.7	nc	(nc-nc)	Female	316	297.8	106.1	(94.7-118.5)
<u>Lung and Bronchus</u>									
Male	33	40.4	81.6	(56.2-114.7)					
Female	45	41.9	107.4	(78.3-143.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Seekonk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	17.9	61.3	(30.6-109.7)	Male	6	11.5	52.3	(19.1-113.8)
Female	2	5.4	nc	(nc-nc)	Female	8	7.9	101.6	(43.7-200.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.3	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	15	10.2	147.5	(82.5-243.2)
Female	37	65.6	56.4	(39.7-77.7)	Female	5	7.8	63.7	(20.5-148.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.2	nc	(nc-nc)	Male	3	8.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	5	3.4	148.3	(47.8-346.0)
Male	12	19.1	62.9	(32.5-110.0)	<u>Ovary</u>				
Female	9	15.7	57.2	(26.1-108.6)	Female	6	5.6	107.6	(39.3-234.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	4.8	nc	(nc-nc)	Male	3	6.4	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	7	5.4	129.7	(52.0-267.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	35	58.5	59.8	(41.7-83.2)
Female	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	4.3	nc	(nc-nc)
Male	5	10.2	49.1	(15.8-114.5)	Female	1	2.2	nc	(nc-nc)
Female	0	5.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	2.0	nc	(nc-nc)
Male	1	2.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	0	4.4	nc	(nc-nc)
<u>Leukemia</u>					Female	8	12.1	66.3	(28.5-130.6)
Male	6	7.1	84.8	(31.0-184.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	4.4	nc	(nc-nc)	Female	8	15.0	53.4	(23.0-105.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	6.4	nc	(nc-nc)	Male	141	234.4	60.2	(50.6-70.9)
Female	0	1.9	nc	(nc-nc)	Female	139	213.4	65.1	(54.8-76.9)
<u>Lung and Bronchus</u>									
Male	20	33.2	60.2	(36.7-92.9)					
Female	26	29.7	87.5	(57.2-128.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sharon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	18.8	58.4	(29.1-104.5)	Male	13	12.4	105.2	(56.0-179.9)
Female	7	6.1	115.5	(46.3-237.9)	Female	17	9.3	181.9	(105.9-291.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.8	nc	(nc-nc)	Male	6	4.0	149.4	(54.6-325.2)
Female	1	3.1	nc	(nc-nc)	Female	1	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.7	nc	(nc-nc)	Male	14	11.1	126.2	(68.9-211.7)
Female	88	78.4	112.3	(90.1-138.3)	Female	6	9.1	66.1	(24.1-143.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.7	nc	(nc-nc)	Male	6	9.9	60.4	(22.1-131.5)
<u>Colon / Rectum</u>					Female	1	4.0	nc	(nc-nc)
Male	11	21.4	51.4	(25.6-92.0)	<u>Ovary</u>				
Female	10	18.6	53.8	(25.8-99.0)	Female	5	6.6	76.0	(24.5-177.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	5.2	nc	(nc-nc)	Male	9	7.0	128.6	(58.7-244.2)
Female	2	1.2	nc	(nc-nc)	Female	8	6.2	129.3	(55.7-254.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.3	nc	(nc-nc)	Male	64	65.9	97.1	(74.7-124.0)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	4.7	nc	(nc-nc)
Male	7	11.4	61.6	(24.7-126.9)	Female	3	2.5	nc	(nc-nc)
Female	8	6.0	134.4	(57.9-264.8)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.1	nc	(nc-nc)
Male	2	3.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	9	5.1	177.7	(81.1-337.4)
<u>Leukemia</u>					Female	26	14.8	175.5	(114.6-257.1)
Male	6	7.7	77.5	(28.3-168.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	5.2	nc	(nc-nc)	Female	18	17.7	101.8	(60.3-161.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	7.2	nc	(nc-nc)	Male	217	256.2	84.7	(73.8-96.7)
Female	3	2.1	nc	(nc-nc)	Female	265	250.1	106.0	(93.6-119.5)
<u>Lung and Bronchus</u>									
Male	17	34.1	49.9	(29.0-79.8)					
Female	38	32.9	115.5	(81.7-158.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sheffield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.1	97.2	(31.3-226.8)	Male	4	3.1	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.9	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
Female	14	17.7	79.2	(43.3-132.9)	Female	1	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	5	2.3	220.8	(71.2-515.3)
<u>Colon / Rectum</u>					Female	3	0.9	nc	(nc-nc)
Male	4	5.3	nc	(nc-nc)	<u>Ovary</u>				
Female	4	4.2	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.3	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	21	16.1	130.4	(80.7-199.3)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.2	nc	(nc-nc)
Male	2	2.7	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.2	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.9	nc	(nc-nc)
Male	0	1.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.2	nc	(nc-nc)	Female	6	4.2	142.1	(51.9-309.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.7	nc	(nc-nc)	Male	60	64.1	93.6	(71.4-120.5)
Female	0	0.5	nc	(nc-nc)	Female	55	57.9	95.1	(71.6-123.8)
<u>Lung and Bronchus</u>									
Male	5	9.3	54.0	(17.4-126.1)					
Female	11	8.5	129.6	(64.6-232.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shelburne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.8	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	3	1.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	11	11.7	94.0	(46.9-168.3)	Female	2	1.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.6	nc	(nc-nc)
Male	4	3.0	nc	(nc-nc)	<u>Ovary</u>				
Female	3	3.1	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.8	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	10	9.7	102.6	(49.1-188.7)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.7	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	3	1.8	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.8	nc	(nc-nc)	Female	7	2.7	255.4	(102.3-526.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.1	nc	(nc-nc)	Male	35	37.2	94.0	(65.4-130.7)
Female	0	0.4	nc	(nc-nc)	Female	45	39.6	113.5	(82.8-151.9)
<u>Lung and Bronchus</u>									
Male	3	5.2	nc	(nc-nc)					
Female	7	5.9	118.9	(47.6-245.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sherborn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	5.4	183.8	(88.0-338.0)	Male	5	3.4	148.3	(47.8-346.1)
Female	2	1.6	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
Female	18	19.5	92.3	(54.7-145.8)	Female	5	2.3	216.5	(69.8-505.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.0	nc	(nc-nc)
Male	8	5.8	137.2	(59.1-270.4)	<u>Ovary</u>				
Female	3	4.8	nc	(nc-nc)	Female	5	1.7	300.1	(96.7-700.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.4	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	14	17.3	80.7	(44.1-135.4)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.3	nc	(nc-nc)
Male	1	3.0	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.5	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	4	3.4	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.3	nc	(nc-nc)	Female	4	4.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.9	nc	(nc-nc)	Male	61	69.6	87.6	(67.0-112.6)
Female	0	0.6	nc	(nc-nc)	Female	54	63.4	85.2	(64.0-111.1)
<u>Lung and Bronchus</u>									
Male	5	9.7	51.8	(16.7-120.9)					
Female	5	8.9	56.4	(18.2-131.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shirley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	6.0	231.8	(126.6-389.0)	Male	2	4.8	nc	(nc-nc)
Female	6	2.0	292.8	(106.9-637.3)	Female	1	3.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.6	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	8	4.3	188.1	(81.0-370.7)
Female	28	25.6	109.2	(72.6-157.9)	Female	2	3.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.9	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.3	nc	(nc-nc)
Male	12	7.9	152.3	(78.6-266.0)	<u>Ovary</u>				
Female	7	5.9	117.8	(47.2-242.8)	Female	2	2.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	1.8	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	29	22.6	128.3	(85.9-184.2)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.7	nc	(nc-nc)
Male	7	4.5	156.1	(62.5-321.6)	Female	1	0.8	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.8	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
<u>Leukemia</u>					Female	4	4.8	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.7	nc	(nc-nc)	Female	12	5.8	208.2	(107.5-363.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	2.7	259.6	(104.0-534.8)	Male	122	93.4	130.6	(108.4-155.9)
Female	0	0.7	nc	(nc-nc)	Female	91	82.4	110.5	(89.0-135.7)
<u>Lung and Bronchus</u>									
Male	17	11.3	150.0	(87.4-240.3)					
Female	10	11.4	87.7	(42.0-161.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shrewsbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	42	36.7	114.5	(82.5-154.8)	Male	18	23.7	76.0	(45.0-120.2)
Female	12	12.3	97.8	(50.5-170.9)	Female	22	17.8	123.7	(77.5-187.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	7.4	67.9	(21.9-158.4)	Male	10	7.6	131.0	(62.7-240.9)
Female	0	5.8	nc	(nc-nc)	Female	4	5.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.3	nc	(nc-nc)	Male	25	21.4	116.6	(75.5-172.2)
Female	165	144.7	114.0	(97.3-132.8)	Female	15	17.7	85.0	(47.5-140.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	5.1	98.7	(31.8-230.2)	Male	12	17.9	67.2	(34.7-117.4)
<u>Colon / Rectum</u>					Female	4	7.4	nc	(nc-nc)
Male	44	40.5	108.6	(78.9-145.8)	<u>Ovary</u>				
Female	32	36.9	86.8	(59.3-122.5)	Female	14	12.2	114.4	(62.5-192.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	9.5	83.9	(36.1-165.3)	Male	9	13.2	68.3	(31.2-129.7)
Female	6	2.4	247.7	(90.5-539.2)	Female	10	12.5	80.3	(38.4-147.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.9	nc	(nc-nc)	Male	128	115.8	110.6	(92.2-131.5)
Female	4	2.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	8.9	nc	(nc-nc)
Male	24	21.0	114.3	(73.2-170.1)	Female	6	5.0	119.3	(43.6-259.8)
Female	7	11.3	62.2	(24.9-128.1)	<u>Testis</u>				
<u>Larynx</u>					Male	4	5.2	nc	(nc-nc)
Male	2	5.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.6	nc	(nc-nc)	Male	16	9.7	164.5	(94.0-267.1)
<u>Leukemia</u>					Female	19	28.0	67.8	(40.8-105.8)
Male	12	15.2	78.9	(40.7-137.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	10.3	106.6	(53.1-190.8)	Female	31	31.1	99.6	(67.7-141.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	13	12.9	100.9	(53.6-172.5)	Male	492	480.1	102.5	(93.6-112.0)
Female	3	4.0	nc	(nc-nc)	Female	475	477.1	99.6	(90.8-108.9)
<u>Lung and Bronchus</u>									
Male	63	65.0	96.9	(74.5-124.0)					
Female	66	65.1	101.4	(78.4-129.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shutesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.6	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	8	9.0	88.5	(38.1-174.4)	Female	1	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	0	1.9	nc	(nc-nc)	<u>Ovary</u>				
Female	2	2.0	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	3	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	6.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.4	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	2	1.7	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.6	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.8	nc	(nc-nc)	Male	11	24.4	45.1	(22.5-80.8)
Female	0	0.3	nc	(nc-nc)	Female	22	28.6	76.8	(48.1-116.3)
<u>Lung and Bronchus</u>									
Male	0	3.0	nc	(nc-nc)					
Female	2	3.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Somerset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	26.2	122.1	(83.5-172.4)	Male	7	15.7	44.5	(17.8-91.8)
Female	13	10.0	130.3	(69.3-222.9)	Female	10	11.9	83.9	(40.2-154.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	4.4	113.6	(36.6-265.2)	Male	0	5.1	nc	(nc-nc)
Female	3	3.8	nc	(nc-nc)	Female	6	4.4	137.1	(50.1-298.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.9	nc	(nc-nc)	Male	13	14.1	92.5	(49.2-158.2)
Female	79	98.0	80.6	(63.8-100.4)	Female	16	13.2	121.6	(69.5-197.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.9	nc	(nc-nc)	Male	8	11.2	71.5	(30.8-140.9)
<u>Colon / Rectum</u>					Female	7	5.4	129.5	(51.9-266.9)
Male	28	26.9	104.1	(69.1-150.4)	<u>Ovary</u>				
Female	34	28.1	121.0	(83.8-169.0)	Female	7	8.5	82.4	(33.0-169.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	6.4	109.4	(43.8-225.3)	Male	10	9.0	110.7	(53.0-203.6)
Female	0	1.9	nc	(nc-nc)	Female	15	10.2	147.2	(82.3-242.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.6	nc	(nc-nc)	Male	73	76.2	95.9	(75.1-120.5)
Female	0	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	6.1	163.7	(78.4-301.0)
Male	13	13.3	97.6	(51.9-166.9)	Female	5	3.8	130.1	(41.9-303.5)
Female	6	8.1	74.3	(27.1-161.7)	<u>Testis</u>				
<u>Larynx</u>					Male	6	2.6	232.8	(85.0-506.6)
Male	4	3.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.2	nc	(nc-nc)	Male	4	5.5	nc	(nc-nc)
<u>Leukemia</u>					Female	20	15.5	128.9	(78.7-199.1)
Male	13	10.0	130.3	(69.3-222.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	7.5	133.7	(64.0-246.0)	Female	14	21.7	64.5	(35.2-108.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	8.3	nc	(nc-nc)	Male	320	319.3	100.2	(89.5-111.8)
Female	0	3.1	nc	(nc-nc)	Female	314	341.1	92.0	(82.1-102.8)
<u>Lung and Bronchus</u>									
Male	48	46.0	104.3	(76.9-138.3)					
Female	38	51.7	73.4	(52.0-100.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Somerville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	34	50.5	67.4	(46.7-94.2)	Male	27	36.0	74.9	(49.4-109.0)
Female	17	19.0	89.3	(52.0-143.1)	Female	20	33.0	60.6	(37.0-93.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	13.0	69.1	(31.5-131.2)	Male	10	10.7	93.8	(44.9-172.5)
Female	11	10.2	108.0	(53.8-193.2)	Female	12	8.8	136.1	(70.3-237.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.8	nc	(nc-nc)	Male	35	32.4	107.9	(75.2-150.1)
Female	185	226.2	81.8	(70.4-94.5)	Female	21	28.8	73.0	(45.2-111.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	11	10.0	109.9	(54.8-196.6)	Male	21	25.4	82.7	(51.2-126.4)
<u>Colon / Rectum</u>					Female	12	11.9	101.2	(52.3-176.9)
Male	51	57.6	88.6	(65.9-116.4)	<u>Ovary</u>				
Female	45	57.7	78.0	(56.9-104.4)	Female	24	19.9	120.4	(77.1-179.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	13.0	100.2	(53.3-171.4)	Male	18	18.2	98.9	(58.6-156.3)
Female	3	3.7	nc	(nc-nc)	Female	19	19.3	98.6	(59.3-154.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	9	7.9	114.0	(52.0-216.5)	Male	137	152.6	89.8	(75.4-106.1)
Female	4	6.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	16	12.7	126.3	(72.1-205.1)
Male	35	30.5	114.7	(79.9-159.6)	Female	14	7.8	179.0	(97.8-300.4)
Female	22	17.9	123.1	(77.1-186.3)	<u>Testis</u>				
<u>Larynx</u>					Male	11	17.7	62.3	(31.1-111.5)
Male	9	7.6	117.9	(53.8-223.8)	<u>Thyroid</u>				
Female	3	2.3	nc	(nc-nc)	Male	21	18.0	116.5	(72.1-178.1)
<u>Leukemia</u>					Female	45	58.9	76.4	(55.7-102.2)
Male	17	23.3	72.9	(42.4-116.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	17	17.6	96.3	(56.1-154.3)	Female	49	48.6	100.9	(74.6-133.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	26	17.9	145.4	(94.9-213.0)	Male	664	693.2	95.8	(88.6-103.4)
Female	14	6.4	220.0	(120.2-369.1)	Female	705	774.7	91.0	(84.4-98.0)
<u>Lung and Bronchus</u>									
Male	115	88.8	129.5	(106.9-155.4)					
Female	98	99.7	98.3	(79.8-119.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

South Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	20.1	64.7	(34.4-110.6)	Male	15	12.5	120.3	(67.3-198.4)
Female	12	8.0	149.7	(77.3-261.6)	Female	12	10.5	114.1	(58.9-199.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.5	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)	Female	2	3.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	9	11.1	81.2	(37.0-154.1)
Female	96	84.1	114.2	(92.5-139.4)	Female	12	10.9	109.6	(56.6-191.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	2.6	189.0	(60.9-441.1)	Male	7	9.1	77.3	(31.0-159.2)
<u>Colon / Rectum</u>					Female	5	4.6	109.2	(35.2-254.7)
Male	22	21.0	104.8	(65.7-158.7)	<u>Ovary</u>				
Female	32	22.8	140.3	(95.9-198.0)	Female	6	7.4	81.4	(29.7-177.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	5.1	nc	(nc-nc)	Male	2	7.1	nc	(nc-nc)
Female	3	1.5	nc	(nc-nc)	Female	9	8.1	111.3	(50.8-211.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.3	nc	(nc-nc)	Male	54	60.9	88.6	(66.6-115.7)
Female	0	1.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	4.8	104.6	(33.7-244.0)
Male	8	10.7	75.0	(32.3-147.8)	Female	1	3.1	nc	(nc-nc)
Female	8	6.9	116.1	(50.0-228.8)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.1	nc	(nc-nc)
Male	4	3.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.9	nc	(nc-nc)	Male	4	4.6	nc	(nc-nc)
<u>Leukemia</u>					Female	14	15.4	91.2	(49.8-153.0)
Male	5	7.8	64.5	(20.8-150.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	6.5	123.5	(53.2-243.4)	Female	29	18.9	153.2	(102.6-220.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	6.8	nc	(nc-nc)	Male	220	252.1	87.3	(76.1-99.6)
Female	0	2.6	nc	(nc-nc)	Female	314	289.7	108.4	(96.7-121.1)
<u>Lung and Bronchus</u>									
Male	35	35.8	97.9	(68.2-136.1)					
Female	36	42.2	85.4	(59.8-118.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	8.1	74.2	(27.1-161.5)	Male	0	4.8	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.4	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	4.4	nc	(nc-nc)
Female	24	27.3	88.0	(56.4-130.9)	Female	3	3.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.4	nc	(nc-nc)
Male	8	8.4	95.4	(41.1-188.0)	<u>Ovary</u>				
Female	6	6.4	93.8	(34.3-204.2)	Female	1	2.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.0	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.5	nc	(nc-nc)	Male	20	24.0	83.2	(50.8-128.5)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	1.9	nc	(nc-nc)
Male	3	4.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	4	2.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.8	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<u>Leukemia</u>					Female	2	5.1	nc	(nc-nc)
Male	2	3.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.8	nc	(nc-nc)	Female	7	6.2	112.2	(45.0-231.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.6	nc	(nc-nc)	Male	73	99.4	73.5	(57.6-92.4)
Female	0	0.8	nc	(nc-nc)	Female	78	88.0	88.7	(70.1-110.6)
<u>Lung and Bronchus</u>									
Male	7	13.6	51.4	(20.6-105.8)					
Female	16	12.2	131.2	(75.0-213.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	9.4	95.8	(43.7-182.0)	Male	9	6.3	142.4	(65.0-270.3)
Female	5	3.2	155.9	(50.2-363.7)	Female	3	4.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.0	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	5.6	nc	(nc-nc)
Female	46	40.3	114.2	(83.6-152.3)	Female	4	4.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.4	nc	(nc-nc)	Male	5	5.1	98.8	(31.8-230.5)
<u>Colon / Rectum</u>					Female	2	2.0	nc	(nc-nc)
Male	6	10.9	54.8	(20.0-119.4)	<u>Ovary</u>				
Female	9	9.9	91.3	(41.7-173.3)	Female	1	3.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.5	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.7	nc	(nc-nc)	Male	28	31.6	88.5	(58.8-128.0)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.4	nc	(nc-nc)
Male	10	5.7	175.0	(83.8-321.8)	Female	1	1.3	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.3	nc	(nc-nc)
Male	4	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
<u>Leukemia</u>					Female	6	7.8	76.9	(28.1-167.4)
Male	4	4.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.8	nc	(nc-nc)	Female	6	8.7	68.9	(25.1-149.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.6	nc	(nc-nc)	Male	125	128.0	97.7	(81.3-116.4)
Female	0	1.1	nc	(nc-nc)	Female	115	130.0	88.5	(73.0-106.2)
<u>Lung and Bronchus</u>									
Male	14	16.6	84.3	(46.0-141.4)					
Female	12	17.3	69.2	(35.7-120.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	16.1	105.7	(61.5-169.2)	Male	6	10.4	57.5	(21.0-125.2)
Female	7	6.9	101.4	(40.6-209.0)	Female	4	9.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.3	nc	(nc-nc)	Male	6	3.3	184.3	(67.3-401.2)
Female	2	3.0	nc	(nc-nc)	Female	4	3.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	11	9.4	117.2	(58.4-209.7)
Female	58	72.6	79.9	(60.7-103.3)	Female	14	9.5	146.6	(80.1-246.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.4	nc	(nc-nc)	Male	8	7.7	103.7	(44.7-204.4)
<u>Colon / Rectum</u>					Female	0	4.0	nc	(nc-nc)
Male	20	17.8	112.4	(68.6-173.6)	<u>Ovary</u>				
Female	20	20.3	98.8	(60.3-152.5)	Female	10	6.4	157.4	(75.4-289.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	4.1	nc	(nc-nc)	Male	8	5.8	139.0	(59.9-273.9)
Female	0	1.3	nc	(nc-nc)	Female	2	7.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.4	nc	(nc-nc)	Male	52	48.3	107.7	(80.5-141.3)
Female	4	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	3.9	153.3	(56.0-333.7)
Male	8	9.0	88.6	(38.2-174.7)	Female	4	2.8	nc	(nc-nc)
Female	10	5.8	171.8	(82.3-316.0)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.6	nc	(nc-nc)
Male	7	2.4	297.9	(119.3-613.7)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	2	4.3	nc	(nc-nc)
<u>Leukemia</u>					Female	10	13.1	76.2	(36.5-140.2)
Male	7	6.8	102.8	(41.2-211.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	5.6	177.7	(85.1-326.8)	Female	19	16.4	116.0	(69.8-181.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	5.6	142.3	(61.3-280.3)	Male	245	208.0	117.8	(103.5-133.5)
Female	0	2.3	nc	(nc-nc)	Female	231	249.5	92.6	(81.0-105.3)
<u>Lung and Bronchus</u>									
Male	49	28.1	174.5	(129.1-230.7)					
Female	26	34.7	75.0	(49.0-109.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	10.3	116.4	(60.1-203.3)	Male	6	6.7	89.5	(32.7-194.7)
Female	2	4.2	nc	(nc-nc)	Female	3	5.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.0	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	2	6.1	nc	(nc-nc)
Female	45	44.9	100.3	(73.2-134.3)	Female	6	5.8	102.7	(37.5-223.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.4	nc	(nc-nc)	Male	5	5.1	98.2	(31.6-229.2)
<u>Colon / Rectum</u>					Female	1	2.4	nc	(nc-nc)
Male	7	11.5	61.0	(24.4-125.7)	<u>Ovary</u>				
Female	15	12.5	120.0	(67.1-197.9)	Female	3	3.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.7	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	2	4.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	30	32.9	91.3	(61.6-130.3)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.5	nc	(nc-nc)
Male	10	5.9	168.3	(80.6-309.6)	Female	2	1.7	nc	(nc-nc)
Female	4	3.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.5	nc	(nc-nc)
Male	2	1.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
<u>Leukemia</u>					Female	6	7.9	76.4	(27.9-166.3)
Male	2	4.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	3.3	149.5	(48.2-348.8)	Female	9	9.9	91.2	(41.6-173.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.7	nc	(nc-nc)	Male	122	135.7	89.9	(74.6-107.3)
Female	3	1.4	nc	(nc-nc)	Female	128	152.7	83.8	(69.9-99.7)
<u>Lung and Bronchus</u>									
Male	19	18.3	104.0	(62.6-162.4)					
Female	14	21.5	65.2	(35.6-109.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Spencer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	11.9	184.7	(115.7-279.7)	Male	12	8.1	148.1	(76.5-258.8)
Female	11	4.2	262.6	(130.9-469.8)	Female	5	6.0	83.3	(26.9-194.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.6	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	Female	6	1.9	308.7	(112.7-671.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	6	7.2	83.2	(30.4-181.1)
Female	45	49.2	91.4	(66.7-122.3)	Female	9	6.0	150.1	(68.5-284.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.6	nc	(nc-nc)	Male	11	6.5	168.3	(83.9-301.2)
<u>Colon / Rectum</u>					Female	3	2.6	nc	(nc-nc)
Male	9	13.3	67.5	(30.8-128.1)	<u>Ovary</u>				
Female	12	12.1	99.5	(51.4-173.9)	Female	1	4.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.4	147.0	(47.4-343.1)	Male	5	4.5	112.1	(36.1-261.6)
Female	1	0.8	nc	(nc-nc)	Female	5	4.2	117.7	(37.9-274.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.0	nc	(nc-nc)	Male	35	43.6	80.2	(55.9-111.5)
Female	3	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.0	nc	(nc-nc)
Male	10	7.5	133.0	(63.7-244.7)	Female	2	1.7	nc	(nc-nc)
Female	6	3.8	157.0	(57.3-341.7)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.9	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
<u>Leukemia</u>					Female	9	9.2	98.3	(44.9-186.7)
Male	11	5.1	216.4	(107.9-387.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	3.5	nc	(nc-nc)	Female	17	11.2	152.2	(88.6-243.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	4.7	127.6	(46.6-277.7)	Male	188	167.6	112.2	(96.7-129.4)
Female	2	1.4	nc	(nc-nc)	Female	182	162.0	112.3	(96.6-129.9)
<u>Lung and Bronchus</u>									
Male	34	22.2	153.5	(106.3-214.5)					
Female	25	22.4	111.7	(72.3-164.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	87	118.9	73.1	(58.6-90.2)	Male	28	78.8	35.5	(23.6-51.3)
Female	40	47.2	84.7	(60.5-115.3)	Female	26	71.0	36.6	(23.9-53.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	31	27.0	114.6	(77.9-162.7)	Male	22	24.9	88.2	(55.3-133.6)
Female	21	24.1	87.1	(53.9-133.1)	Female	29	21.8	133.0	(89.0-191.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	7	4.2	166.7	(66.8-343.4)	Male	76	71.5	106.3	(83.7-133.0)
Female	512	552.9	92.6	(84.8-101.0)	Female	67	68.6	97.6	(75.7-124.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	42	20.0	210.2	(151.5-284.2)	Male	71	59.5	119.3	(93.2-150.5)
<u>Colon / Rectum</u>					Female	20	29.1	68.8	(42.0-106.3)
Male	142	132.2	107.4	(90.5-126.6)	<u>Ovary</u>				
Female	155	140.0	110.7	(94.0-129.6)	Female	40	47.8	83.6	(59.7-113.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	33	31.4	105.2	(72.4-147.8)	Male	48	43.0	111.7	(82.4-148.1)
Female	8	9.3	85.9	(37.0-169.2)	Female	51	47.8	106.6	(79.4-140.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	14	12.1	115.5	(63.1-193.8)	Male	328	384.0	85.4	(76.4-95.2)
Female	15	10.8	138.8	(77.6-228.9)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	35	29.2	119.9	(83.5-166.8)
Male	84	69.9	120.2	(95.9-148.8)	Female	21	19.0	110.4	(68.3-168.8)
Female	55	43.7	125.8	(94.8-163.8)	<u>Testis</u>				
<u>Larynx</u>					Male	12	22.6	53.0	(27.4-92.6)
Male	17	18.3	92.9	(54.1-148.7)	<u>Thyroid</u>				
Female	10	6.0	166.5	(79.7-306.3)	Male	15	34.2	43.9	(24.5-72.4)
<u>Leukemia</u>					Female	78	114.0	68.4	(54.1-85.4)
Male	49	52.5	93.3	(69.0-123.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	39	41.7	93.6	(66.6-128.0)	Female	115	123.1	93.5	(77.2-112.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	61	43.2	141.3	(108.1-181.5)	Male	1530	1599.2	95.7	(90.9-100.6)
Female	14	16.0	87.6	(47.8-146.9)	Female	1763	1851.6	95.2	(90.8-99.8)
<u>Lung and Bronchus</u>									
Male	240	212.5	112.9	(99.1-128.2)					
Female	252	250.3	100.7	(88.6-113.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sterling

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	7.2	152.7	(76.1-273.2)	Male	8	5.0	161.0	(69.3-317.2)
Female	4	2.8	nc	(nc-nc)	Female	2	4.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	4	1.6	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	8	4.5	176.0	(75.8-346.8)
Female	41	35.4	115.8	(83.1-157.1)	Female	1	4.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.2	nc	(nc-nc)	Male	1	4.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.8	nc	(nc-nc)
Male	8	8.8	90.9	(39.2-179.2)	<u>Ovary</u>				
Female	2	8.9	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.1	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	4	3.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	42	27.8	150.9	(108.7-204.0)
Female	2	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.8	nc	(nc-nc)
Male	8	4.9	164.6	(70.9-324.3)	Female	2	1.2	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.1	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	7	6.7	104.1	(41.7-214.4)
Male	6	3.2	189.9	(69.3-413.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.4	nc	(nc-nc)	Female	10	7.6	130.8	(62.6-240.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.9	nc	(nc-nc)	Male	130	104.8	124.0	(103.6-147.2)
Female	0	0.9	nc	(nc-nc)	Female	112	114.0	98.3	(80.9-118.3)
<u>Lung and Bronchus</u>									
Male	10	13.2	75.9	(36.4-139.7)					
Female	18	14.6	123.1	(72.9-194.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	3.6	nc	(nc-nc)	Male	7	2.1	327.5	(131.2-674.8)
Female	1	1.5	nc	(nc-nc)	Female	6	1.6	372.7	(136.1-811.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	10	12.9	77.3	(37.0-142.2)	Female	2	1.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.8	nc	(nc-nc)
Male	4	3.6	nc	(nc-nc)	<u>Ovary</u>				
Female	7	4.1	170.7	(68.4-351.6)	Female	2	1.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	0.9	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	12	10.2	118.0	(60.9-206.2)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.8	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.8	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.1	nc	(nc-nc)	Female	7	2.9	243.7	(97.6-502.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.1	nc	(nc-nc)	Male	40	43.2	92.5	(66.1-126.0)
Female	0	0.4	nc	(nc-nc)	Female	48	47.6	100.8	(74.3-133.7)
<u>Lung and Bronchus</u>									
Male	1	6.5	nc	(nc-nc)					
Female	2	7.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stoneham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	28.7	83.7	(53.6-124.6)	Male	12	17.4	68.8	(35.5-120.2)
Female	10	10.1	98.7	(47.2-181.5)	Female	10	13.5	73.9	(35.4-135.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	4.9	122.3	(44.7-266.2)	Male	7	5.7	122.9	(49.3-253.3)
Female	4	4.3	nc	(nc-nc)	Female	9	4.6	196.4	(89.6-372.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.0	nc	(nc-nc)	Male	17	15.6	109.0	(63.5-174.5)
Female	137	108.9	125.9	(105.7-148.8)	Female	13	14.0	92.9	(49.4-158.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	3.5	nc	(nc-nc)	Male	17	12.7	133.6	(77.8-213.9)
<u>Colon / Rectum</u>					Female	6	5.9	101.6	(37.1-221.1)
Male	36	30.0	120.2	(84.2-166.4)	<u>Ovary</u>				
Female	28	29.4	95.3	(63.3-137.7)	Female	14	9.5	148.1	(80.9-248.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	7.2	69.6	(22.4-162.3)	Male	6	10.0	60.3	(22.0-131.2)
Female	0	2.0	nc	(nc-nc)	Female	14	10.4	135.1	(73.8-226.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.8	nc	(nc-nc)	Male	51	86.3	59.1	(44.0-77.7)
Female	2	1.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	6.7	148.5	(71.1-273.0)
Male	13	15.0	86.7	(46.1-148.3)	Female	5	4.0	124.0	(40.0-289.4)
Female	9	8.7	103.4	(47.2-196.3)	<u>Testis</u>				
<u>Larynx</u>					Male	5	3.0	167.2	(53.9-390.3)
Male	3	4.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	4	1.2	nc	(nc-nc)	Male	10	6.4	157.1	(75.2-288.9)
<u>Leukemia</u>					Female	26	19.1	136.0	(88.8-199.3)
Male	17	11.0	154.9	(90.2-248.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	8.0	124.3	(59.5-228.5)	Female	36	24.7	145.5	(101.9-201.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	9.4	74.5	(29.9-153.6)	Male	332	355.8	93.3	(83.5-103.9)
Female	9	3.3	270.4	(123.4-513.4)	Female	427	369.6	115.5	(104.8-127.0)
<u>Lung and Bronchus</u>									
Male	41	50.2	81.6	(58.6-110.8)					
Female	54	52.4	103.1	(77.4-134.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stoughton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	31	32.7	94.9	(64.5-134.7)	Male	16	20.4	78.5	(44.8-127.5)
Female	17	13.1	130.2	(75.8-208.4)	Female	23	17.2	133.5	(84.6-200.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	6.0	nc	(nc-nc)	Male	9	6.7	135.3	(61.7-256.8)
Female	6	5.5	109.9	(40.1-239.2)	Female	7	5.9	118.1	(47.3-243.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.1	nc	(nc-nc)	Male	15	18.3	81.8	(45.7-134.9)
Female	133	139.9	95.1	(79.6-112.7)	Female	26	18.0	144.2	(94.1-211.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	4.5	nc	(nc-nc)	Male	11	15.1	72.9	(36.3-130.4)
<u>Colon / Rectum</u>					Female	3	7.6	nc	(nc-nc)
Male	35	34.5	101.5	(70.7-141.1)	<u>Ovary</u>				
Female	39	37.9	102.9	(73.2-140.7)	Female	14	12.1	115.5	(63.1-193.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	8.4	130.9	(65.3-234.3)	Male	13	11.6	111.9	(59.5-191.4)
Female	5	2.6	195.5	(63.0-456.3)	Female	20	13.4	149.2	(91.1-230.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.3	nc	(nc-nc)	Male	97	103.5	93.7	(76.0-114.3)
Female	6	1.9	316.2	(115.5-688.2)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	9	7.8	115.2	(52.6-218.6)
Male	25	17.8	140.5	(90.9-207.4)	Female	6	5.2	116.2	(42.4-252.8)
Female	17	11.2	151.8	(88.4-243.1)	<u>Testis</u>				
<u>Larynx</u>					Male	6	3.9	152.5	(55.7-332.0)
Male	9	4.9	183.7	(83.8-348.7)	<u>Thyroid</u>				
Female	2	1.6	nc	(nc-nc)	Male	9	7.8	115.9	(52.9-220.0)
<u>Leukemia</u>					Female	27	24.2	111.4	(73.4-162.0)
Male	12	12.9	92.8	(47.9-162.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	10.4	77.2	(33.2-152.1)	Female	22	31.9	69.0	(43.2-104.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	12	11.2	107.0	(55.2-187.0)	Male	429	418.5	102.5	(93.0-112.7)
Female	2	4.3	nc	(nc-nc)	Female	494	475.1	104.0	(95.0-113.6)
<u>Lung and Bronchus</u>									
Male	62	58.2	106.5	(81.7-136.6)					
Female	59	67.5	87.4	(66.6-112.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	8.2	195.3	(111.6-317.3)	Male	4	5.2	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.5	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	4	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	4.7	nc	(nc-nc)
Female	28	30.0	93.3	(62.0-134.9)	Female	4	3.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.0	nc	(nc-nc)	Male	0	3.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.5	nc	(nc-nc)
Male	9	9.0	100.2	(45.7-190.2)	<u>Ovary</u>				
Female	8	6.7	119.7	(51.5-235.9)	Female	5	2.5	200.1	(64.5-466.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.1	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	30	26.0	115.4	(77.8-164.7)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.0	nc	(nc-nc)
Male	4	4.6	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.9	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.3	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
<u>Leukemia</u>					Female	7	5.5	127.1	(50.9-261.8)
Male	2	3.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.9	nc	(nc-nc)	Female	9	7.0	128.9	(58.8-244.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.9	nc	(nc-nc)	Male	96	106.1	90.5	(73.3-110.5)
Female	0	0.8	nc	(nc-nc)	Female	103	94.8	108.7	(88.7-131.8)
<u>Lung and Bronchus</u>									
Male	7	14.5	48.2	(19.3-99.2)					
Female	10	12.8	78.0	(37.4-143.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sturbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	10.6	160.2	(93.3-256.5)	Male	9	6.8	132.3	(60.4-251.2)
Female	5	3.7	134.6	(43.4-314.1)	Female	8	5.2	153.1	(65.9-301.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.0	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	8	6.1	132.0	(56.9-260.2)
Female	38	43.0	88.4	(62.5-121.3)	Female	4	5.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.5	nc	(nc-nc)	Male	5	5.2	95.8	(30.9-223.6)
<u>Colon / Rectum</u>					Female	2	2.3	nc	(nc-nc)
Male	8	11.5	69.5	(29.9-136.9)	<u>Ovary</u>				
Female	10	10.9	91.9	(44.0-169.0)	Female	2	3.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.8	nc	(nc-nc)	Male	4	3.9	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	7	3.8	183.8	(73.6-378.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	0.7	nc	(nc-nc)	Male	39	35.4	110.2	(78.3-150.6)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.6	nc	(nc-nc)
Male	6	6.1	98.6	(36.0-214.6)	Female	1	1.5	nc	(nc-nc)
Female	2	3.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.1	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.5	nc	(nc-nc)	Male	0	2.6	nc	(nc-nc)
<u>Leukemia</u>					Female	5	7.9	63.2	(20.4-147.4)
Male	5	4.3	116.3	(37.5-271.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.0	nc	(nc-nc)	Female	18	9.6	187.0	(110.8-295.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	3.9	nc	(nc-nc)	Male	151	140.1	107.8	(91.3-126.4)
Female	2	1.2	nc	(nc-nc)	Female	135	142.2	95.0	(79.6-112.4)
<u>Lung and Bronchus</u>									
Male	21	19.4	108.3	(67.0-165.5)					
Female	14	19.8	70.8	(38.7-118.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sudbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	19.2	73.0	(39.9-122.5)	Male	17	12.8	133.1	(77.5-213.1)
Female	1	6.3	nc	(nc-nc)	Female	9	9.3	96.6	(44.1-183.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	4.0	175.2	(70.2-361.0)	Male	5	4.2	119.9	(38.6-279.8)
Female	5	3.1	163.8	(52.8-382.2)	Female	3	3.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	7	11.4	61.5	(24.6-126.7)
Female	118	79.4	148.6	(123.0-178.0)	Female	14	9.3	151.2	(82.6-253.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.6	nc	(nc-nc)	Male	4	10.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	5	4.0	124.5	(40.1-290.5)
Male	27	21.5	125.6	(82.7-182.7)	<u>Ovary</u>				
Female	13	19.1	68.1	(36.2-116.5)	Female	9	6.7	135.2	(61.7-256.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	5.4	nc	(nc-nc)	Male	9	7.1	126.0	(57.5-239.2)
Female	2	1.3	nc	(nc-nc)	Female	4	6.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.3	nc	(nc-nc)	Male	67	68.3	98.1	(76.0-124.6)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.8	nc	(nc-nc)
Male	9	11.8	76.1	(34.7-144.4)	Female	3	2.6	nc	(nc-nc)
Female	6	6.0	99.3	(36.3-216.3)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.1	nc	(nc-nc)
Male	2	3.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.9	nc	(nc-nc)	Male	7	5.3	133.0	(53.3-274.1)
<u>Leukemia</u>					Female	19	14.4	132.2	(79.5-206.4)
Male	7	8.0	87.0	(34.8-179.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	5.3	95.0	(30.6-221.7)	Female	18	17.8	101.2	(59.9-160.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	7.4	67.1	(21.6-156.7)	Male	223	264.5	84.3	(73.6-96.1)
Female	1	2.2	nc	(nc-nc)	Female	292	253.8	115.0	(102.2-129.0)
<u>Lung and Bronchus</u>									
Male	13	35.8	36.3	(19.3-62.1)					
Female	29	34.0	85.4	(57.2-122.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sunderland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	3.2	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.7	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	17	10.4	163.1	(95.0-261.2)	Female	0	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.4	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	3	3.5	nc	(nc-nc)	<u>Ovary</u>				
Female	3	2.5	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	8	10.4	77.2	(33.3-152.2)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.8	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.8	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.6	nc	(nc-nc)
Male	2	1.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.8	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.2	nc	(nc-nc)	Male	32	42.8	74.7	(51.1-105.5)
Female	0	0.3	nc	(nc-nc)	Female	34	34.7	97.9	(67.8-136.8)
<u>Lung and Bronchus</u>									
Male	3	5.5	nc	(nc-nc)					
Female	3	4.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sutton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	10.0	130.2	(69.2-222.6)	Male	10	6.5	152.8	(73.1-281.0)
Female	5	2.5	196.8	(63.4-459.2)	Female	7	4.3	161.6	(64.7-333.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.0	nc	(nc-nc)	Male	4	2.1	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	9	5.9	152.3	(69.5-289.2)
Female	38	36.6	103.7	(73.4-142.4)	Female	3	4.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.3	nc	(nc-nc)	Male	1	5.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.8	nc	(nc-nc)
Male	6	11.3	53.0	(19.4-115.4)	<u>Ovary</u>				
Female	8	7.8	103.0	(44.3-202.9)	Female	1	3.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	2.7	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	30	34.2	87.7	(59.2-125.3)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.5	nc	(nc-nc)
Male	9	6.1	147.8	(67.5-280.7)	Female	1	1.1	nc	(nc-nc)
Female	5	2.7	187.1	(60.3-436.7)	<u>Testis</u>				
<u>Larynx</u>					Male	4	1.1	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	6	2.7	222.5	(81.2-484.3)
<u>Leukemia</u>					Female	7	7.5	93.8	(37.6-193.3)
Male	8	4.1	193.0	(83.1-380.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	2.2	nc	(nc-nc)	Female	12	8.3	144.3	(74.5-252.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.7	nc	(nc-nc)	Male	141	135.1	104.4	(87.8-123.1)
Female	1	0.9	nc	(nc-nc)	Female	124	113.1	109.6	(91.2-130.7)
<u>Lung and Bronchus</u>									
Male	20	18.1	110.6	(67.5-170.8)					
Female	14	14.2	98.5	(53.8-165.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Swampscott

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	29	16.9	171.4	(114.8-246.2)	Male	14	10.4	134.4	(73.4-225.5)
Female	13	6.2	208.7	(111.0-356.9)	Female	16	8.4	190.0	(108.5-308.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.1	nc	(nc-nc)	Male	1	3.4	nc	(nc-nc)
Female	1	2.7	nc	(nc-nc)	Female	4	2.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	14	9.4	149.5	(81.6-250.8)
Female	76	68.8	110.5	(87.1-138.3)	Female	12	8.7	138.2	(71.3-241.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.2	nc	(nc-nc)	Male	5	7.8	64.0	(20.6-149.4)
<u>Colon / Rectum</u>					Female	4	3.7	nc	(nc-nc)
Male	17	18.2	93.6	(54.5-149.9)	<u>Ovary</u>				
Female	19	18.2	104.2	(62.7-162.8)	Female	4	5.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	4.3	nc	(nc-nc)	Male	6	6.0	100.4	(36.7-218.5)
Female	2	1.2	nc	(nc-nc)	Female	5	6.4	78.6	(25.3-183.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.0	nc	(nc-nc)	Male	56	51.7	108.3	(81.8-140.7)
Female	4	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.0	nc	(nc-nc)
Male	10	9.1	109.8	(52.6-202.0)	Female	2	2.5	nc	(nc-nc)
Female	4	5.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.7	nc	(nc-nc)
Male	1	2.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	5	3.9	129.0	(41.6-301.1)
<u>Leukemia</u>					Female	20	12.1	165.2	(100.9-255.2)
Male	5	6.8	74.0	(23.9-172.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	4.9	222.5	(110.9-398.1)	Female	20	15.4	129.5	(79.1-200.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	5.8	nc	(nc-nc)	Male	225	213.2	105.5	(92.2-120.3)
Female	2	2.0	nc	(nc-nc)	Female	273	230.5	118.4	(104.8-133.3)
<u>Lung and Bronchus</u>									
Male	27	29.4	91.9	(60.5-133.7)					
Female	32	32.4	98.7	(67.5-139.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Swansea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	18.8	111.9	(69.3-171.1)	Male	12	12.1	98.8	(51.0-172.5)
Female	12	7.4	162.7	(83.9-284.1)	Female	6	10.0	60.3	(22.0-131.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	3.6	194.3	(77.8-400.3)	Male	4	3.9	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	Female	4	3.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	14	10.9	129.0	(70.4-216.4)
Female	65	84.2	77.2	(59.6-98.4)	Female	10	10.2	97.6	(46.7-179.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.6	nc	(nc-nc)	Male	6	9.3	64.5	(23.6-140.4)
<u>Colon / Rectum</u>					Female	4	4.4	nc	(nc-nc)
Male	20	20.2	98.8	(60.4-152.7)	<u>Ovary</u>				
Female	18	21.2	84.9	(50.3-134.2)	Female	4	7.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	5.0	nc	(nc-nc)	Male	8	6.8	116.8	(50.3-230.2)
Female	0	1.5	nc	(nc-nc)	Female	8	7.5	106.9	(46.0-210.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	1.3	nc	(nc-nc)	Male	81	64.0	126.6	(100.6-157.4)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	4.6	nc	(nc-nc)
Male	20	10.9	183.0	(111.7-282.6)	Female	5	2.9	174.3	(56.2-406.6)
Female	5	6.6	75.3	(24.3-175.8)	<u>Testis</u>				
<u>Larynx</u>					Male	5	2.3	216.8	(69.9-506.0)
Male	3	3.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.9	nc	(nc-nc)	Male	5	4.8	103.1	(33.2-240.7)
<u>Leukemia</u>					Female	12	14.4	83.2	(43.0-145.4)
Male	4	7.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	5.7	87.2	(28.1-203.4)	Female	14	18.9	74.1	(40.5-124.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	6.8	88.0	(32.2-191.6)	Male	286	250.3	114.3	(101.4-128.3)
Female	2	2.4	nc	(nc-nc)	Female	240	277.2	86.6	(76.0-98.3)
<u>Lung and Bronchus</u>									
Male	33	34.5	95.7	(65.9-134.4)					
Female	37	39.9	92.8	(65.3-127.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Taunton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	52	55.1	94.4	(70.5-123.8)	Male	23	36.6	62.8	(39.8-94.2)
Female	27	21.8	123.8	(81.6-180.2)	Female	25	30.8	81.1	(52.5-119.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	11.5	104.6	(54.0-182.7)	Male	9	11.8	76.5	(34.9-145.2)
Female	9	9.9	91.3	(41.7-173.3)	Female	14	10.0	140.2	(76.6-235.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	5	2.0	252.5	(81.4-589.2)	Male	37	32.8	112.9	(79.5-155.6)
Female	241	246.5	97.8	(85.8-110.9)	Female	41	30.8	133.0	(95.4-180.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	8.5	94.6	(40.7-186.4)	Male	38	28.4	133.8	(94.7-183.7)
<u>Colon / Rectum</u>					Female	11	13.0	84.5	(42.1-151.1)
Male	69	61.1	112.9	(87.8-142.9)	<u>Ovary</u>				
Female	87	65.1	133.7	(107.1-165.0)	Female	15	21.1	71.0	(39.7-117.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	15.0	86.9	(46.2-148.5)	Male	17	20.2	84.0	(48.9-134.6)
Female	1	4.2	nc	(nc-nc)	Female	26	22.4	116.2	(75.9-170.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	8	4.6	172.2	(74.2-339.4)	Male	144	186.9	77.1	(65.0-90.7)
Female	7	3.8	183.8	(73.6-378.8)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	13	13.6	95.5	(50.8-163.3)
Male	36	33.0	109.0	(76.3-150.9)	Female	9	8.8	102.0	(46.6-193.7)
Female	19	19.4	97.8	(58.9-152.8)	<u>Testis</u>				
<u>Larynx</u>					Male	10	8.4	119.0	(57.0-218.8)
Male	15	8.8	170.2	(95.2-280.8)	<u>Thyroid</u>				
Female	6	2.7	224.9	(82.1-489.5)	Male	20	15.3	130.6	(79.7-201.7)
<u>Leukemia</u>					Female	65	46.4	140.0	(108.0-178.4)
Male	16	23.1	69.1	(39.5-112.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	14	18.1	77.3	(42.2-129.6)	Female	47	54.5	86.2	(63.3-114.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	20	20.6	97.0	(59.2-149.8)	Male	759	747.8	101.5	(94.4-109.0)
Female	7	7.2	97.5	(39.1-201.0)	Female	853	825.1	103.4	(96.6-110.6)
<u>Lung and Bronchus</u>									
Male	134	101.0	132.6	(111.1-157.1)					
Female	121	113.0	107.1	(88.8-127.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Templeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	9.9	90.7	(41.4-172.2)	Male	6	6.3	95.1	(34.7-207.0)
Female	3	3.0	nc	(nc-nc)	Female	1	4.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	1.9	270.2	(87.1-630.7)	Male	2	2.1	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	3	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	3	5.7	nc	(nc-nc)
Female	25	37.0	67.6	(43.7-99.8)	Female	4	4.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.2	nc	(nc-nc)	Male	1	5.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.9	nc	(nc-nc)
Male	9	10.9	82.2	(37.5-156.1)	<u>Ovary</u>				
Female	12	8.8	135.7	(70.1-237.1)	Female	5	3.1	160.0	(51.6-373.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.7	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	4	3.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	20	34.9	57.3	(35.0-88.5)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.4	nc	(nc-nc)
Male	9	5.8	154.6	(70.5-293.4)	Female	1	1.2	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.1	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
<u>Leukemia</u>					Female	5	6.7	74.6	(24.1-174.2)
Male	4	4.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.5	nc	(nc-nc)	Female	10	8.3	120.1	(57.5-220.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	3.6	137.1	(44.2-320.0)	Male	108	133.0	81.2	(66.6-98.1)
Female	0	1.0	nc	(nc-nc)	Female	112	119.6	93.6	(77.1-112.6)
<u>Lung and Bronchus</u>									
Male	19	17.7	107.6	(64.7-168.0)					
Female	24	17.0	141.3	(90.5-210.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tewksbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	40	32.1	124.6	(89.0-169.7)	Male	16	21.1	75.8	(43.3-123.2)
Female	13	12.6	103.3	(55.0-176.7)	Female	16	17.1	93.7	(53.5-152.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	6.4	141.1	(64.4-267.8)	Male	3	6.7	nc	(nc-nc)
Female	6	5.4	110.6	(40.4-240.7)	Female	5	5.7	87.9	(28.3-205.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.1	nc	(nc-nc)	Male	18	18.7	96.2	(57.0-152.1)
Female	143	139.8	102.3	(86.2-120.5)	Female	18	17.5	103.0	(61.0-162.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	4.5	176.8	(76.1-348.3)	Male	15	16.3	92.3	(51.6-152.2)
<u>Colon / Rectum</u>					Female	10	7.4	136.0	(65.1-250.1)
Male	34	35.6	95.5	(66.1-133.5)	<u>Ovary</u>				
Female	34	36.7	92.6	(64.2-129.5)	Female	16	12.0	133.7	(76.4-217.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	8.6	151.9	(80.8-259.7)	Male	15	11.7	128.1	(71.7-211.3)
Female	4	2.5	nc	(nc-nc)	Female	11	12.8	86.2	(43.0-154.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	2.5	nc	(nc-nc)	Male	101	106.2	95.1	(77.4-115.5)
Female	4	2.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	7.9	101.3	(43.6-199.7)
Male	29	18.8	154.4	(103.4-221.8)	Female	4	5.0	nc	(nc-nc)
Female	13	11.1	117.2	(62.3-200.4)	<u>Testis</u>				
<u>Larynx</u>					Male	5	4.4	114.5	(36.9-267.3)
Male	5	5.0	99.2	(32.0-231.4)	<u>Thyroid</u>				
Female	0	1.6	nc	(nc-nc)	Male	9	8.6	105.0	(47.9-199.3)
<u>Leukemia</u>					Female	26	25.0	104.1	(68.0-152.5)
Male	23	13.1	175.5	(111.2-263.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	15	10.1	149.1	(83.4-246.0)	Female	26	30.8	84.4	(55.1-123.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	11.8	67.6	(29.1-133.3)	Male	456	428.6	106.4	(96.9-116.6)
Female	1	4.1	nc	(nc-nc)	Female	498	467.7	106.5	(97.3-116.2)
<u>Lung and Bronchus</u>									
Male	70	58.7	119.2	(92.9-150.6)					
Female	81	66.5	121.8	(96.7-151.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	3.4	146.4	(47.2-341.7)	Male	8	2.4	327.8	(141.1-645.9)
Female	0	1.5	nc	(nc-nc)	Female	7	2.2	313.3	(125.5-645.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	27	18.9	143.0	(94.2-208.0)	Female	2	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.0	nc	(nc-nc)
Male	2	4.1	nc	(nc-nc)	<u>Ovary</u>				
Female	4	4.3	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.0	nc	(nc-nc)	Male	5	1.3	384.2	(123.8-896.7)
Female	0	0.3	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	15	12.5	120.3	(67.3-198.5)
Female	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	0.9	nc	(nc-nc)
Male	0	2.2	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.7	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	2	3.5	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.3	nc	(nc-nc)	Female	3	4.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	1.4	nc	(nc-nc)	Male	61	49.3	123.6	(94.5-158.8)
Female	0	0.5	nc	(nc-nc)	Female	74	61.1	121.1	(95.1-152.1)
<u>Lung and Bronchus</u>									
Male	4	6.4	nc	(nc-nc)					
Female	12	8.6	139.8	(72.2-244.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tolland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.8	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	2.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.5	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	10	10.6	94.3	(45.1-173.4)
Female	0	0.1	nc	(nc-nc)	Female	3	7.8	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	1	1.4	nc	(nc-nc)					
Female	1	1.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Topsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	8.6	nc	(nc-nc)	Male	5	5.3	95.1	(30.6-221.8)
Female	4	2.8	nc	(nc-nc)	Female	5	3.7	136.5	(44.0-318.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.5	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	4.7	127.2	(46.4-276.9)
Female	28	30.7	91.2	(60.6-131.8)	Female	4	3.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	1	3.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.6	nc	(nc-nc)
Male	3	9.0	nc	(nc-nc)	<u>Ovary</u>				
Female	4	8.4	nc	(nc-nc)	Female	5	2.6	190.1	(61.3-443.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.2	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	2.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	32	26.7	120.0	(82.1-169.4)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.0	nc	(nc-nc)
Male	5	4.6	108.1	(34.8-252.3)	Female	2	1.1	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.8	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<u>Leukemia</u>					Female	3	5.1	nc	(nc-nc)
Male	2	3.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.2	nc	(nc-nc)	Female	7	6.7	103.8	(41.6-213.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.9	nc	(nc-nc)	Male	93	108.2	86.0	(69.4-105.3)
Female	1	0.9	nc	(nc-nc)	Female	99	103.2	95.9	(78.0-116.8)
<u>Lung and Bronchus</u>									
Male	14	15.4	91.2	(49.8-153.0)					
Female	16	14.6	109.4	(62.5-177.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Townsend

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	7.2	194.5	(106.2-326.3)	Male	4	5.3	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)	Female	9	4.3	208.4	(95.1-395.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.8	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	3	1.4	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	8	4.8	167.3	(72.0-329.7)
Female	35	35.7	98.2	(68.4-136.5)	Female	3	4.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	5	4.7	107.4	(34.6-250.6)
<u>Colon / Rectum</u>					Female	4	1.7	nc	(nc-nc)
Male	14	8.9	158.0	(86.3-265.1)	<u>Ovary</u>				
Female	14	8.0	176.0	(96.1-295.3)	Female	1	3.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	2.3	353.8	(152.3-697.1)	Male	2	2.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.7	nc	(nc-nc)	Male	20	31.0	64.6	(39.4-99.8)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	1.9	nc	(nc-nc)
Male	7	5.3	133.0	(53.3-274.0)	Female	2	1.1	nc	(nc-nc)
Female	5	2.7	188.4	(60.7-439.7)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.4	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
<u>Leukemia</u>					Female	9	7.4	121.7	(55.6-231.1)
Male	1	3.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	2.3	217.4	(70.1-507.4)	Female	2	8.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.3	nc	(nc-nc)	Male	127	112.3	113.1	(94.2-134.5)
Female	0	0.9	nc	(nc-nc)	Female	123	111.5	110.3	(91.6-131.6)
<u>Lung and Bronchus</u>									
Male	15	13.9	107.8	(60.3-177.8)					
Female	16	14.0	114.0	(65.1-185.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Truro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	3.5	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	4	1.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	16	13.2	121.5	(69.4-197.2)	Female	2	1.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	4	1.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.7	nc	(nc-nc)
Male	5	3.6	140.8	(45.4-328.6)	<u>Ovary</u>				
Female	4	3.1	nc	(nc-nc)	Female	3	1.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	0.9	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	2	0.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	8	12.3	65.0	(28.0-128.2)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.8	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.9	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	0.8	nc	(nc-nc)	Female	1	3.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	1.3	nc	(nc-nc)	Male	39	45.4	85.8	(61.0-117.4)
Female	0	0.4	nc	(nc-nc)	Female	48	42.4	113.1	(83.4-150.0)
<u>Lung and Bronchus</u>									
Male	4	6.5	nc	(nc-nc)					
Female	3	6.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tyngsborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	9.8	61.1	(22.3-133.1)	Male	4	7.2	nc	(nc-nc)
Female	6	3.6	169.0	(61.7-367.8)	Female	6	5.8	104.2	(38.0-226.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.3	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	2	6.5	nc	(nc-nc)
Female	42	46.9	89.5	(64.5-121.0)	Female	2	5.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.7	nc	(nc-nc)	Male	3	6.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	2.4	nc	(nc-nc)
Male	10	12.3	81.5	(39.0-149.8)	<u>Ovary</u>				
Female	5	11.2	44.7	(14.4-104.2)	Female	3	4.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	2.9	171.9	(55.4-401.3)	Male	3	3.9	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	3.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.0	nc	(nc-nc)	Male	35	38.0	92.1	(64.2-128.1)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	2.6	nc	(nc-nc)
Male	7	6.8	102.5	(41.1-211.2)	Female	1	1.5	nc	(nc-nc)
Female	2	3.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.8	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	3.4	nc	(nc-nc)
<u>Leukemia</u>					Female	7	9.5	74.0	(29.7-152.5)
Male	6	4.4	136.8	(50.0-297.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.2	nc	(nc-nc)	Female	11	10.4	105.8	(52.8-189.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.3	nc	(nc-nc)	Male	127	147.1	86.3	(72.0-102.7)
Female	2	1.3	nc	(nc-nc)	Female	127	149.5	85.0	(70.8-101.1)
<u>Lung and Bronchus</u>									
Male	22	18.4	119.5	(74.9-181.0)					
Female	20	18.8	106.3	(64.9-164.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tyringham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	4	3.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.9	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	3.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.4	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	3	12.1	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	7	11.4	61.4	(24.6-126.6)
<u>Lung and Bronchus</u>									
Male	1	1.8	nc	(nc-nc)					
Female	0	1.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Upton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	7.1	127.1	(58.0-241.3)	Male	7	5.0	140.8	(56.4-290.2)
Female	1	2.4	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.6	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	5	4.4	112.6	(36.3-262.8)
Female	35	30.9	113.2	(78.8-157.4)	Female	4	3.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.5	nc	(nc-nc)
Male	6	8.4	71.8	(26.2-156.4)	<u>Ovary</u>				
Female	3	7.1	nc	(nc-nc)	Female	4	2.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.1	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	4	2.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	25	26.7	93.7	(60.6-138.3)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.8	nc	(nc-nc)
Male	3	4.7	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.0	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.3	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
<u>Leukemia</u>					Female	6	6.0	99.3	(36.3-216.2)
Male	5	3.1	161.3	(52.0-376.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.0	nc	(nc-nc)	Female	12	6.8	175.5	(90.6-306.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	3.0	233.0	(93.4-480.1)	Male	96	102.4	93.8	(76.0-114.5)
Female	2	0.8	nc	(nc-nc)	Female	106	98.4	107.7	(88.2-130.3)
<u>Lung and Bronchus</u>									
Male	10	13.1	76.1	(36.5-140.0)					
Female	16	13.3	120.7	(68.9-196.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Uxbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	11.1	135.5	(75.8-223.5)	Male	14	7.9	176.1	(96.2-295.5)
Female	2	4.9	nc	(nc-nc)	Female	5	7.1	70.0	(22.5-163.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.6	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	8	7.1	112.1	(48.3-220.9)
Female	61	60.0	101.6	(77.7-130.6)	Female	6	7.1	84.3	(30.8-183.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.0	nc	(nc-nc)	Male	11	6.5	168.7	(84.1-301.8)
<u>Colon / Rectum</u>					Female	1	3.1	nc	(nc-nc)
Male	16	13.2	121.4	(69.4-197.2)	<u>Ovary</u>				
Female	13	14.8	87.6	(46.6-149.7)	Female	6	5.1	118.6	(43.3-258.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	3.2	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	3	5.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.1	nc	(nc-nc)	Male	52	41.6	125.1	(93.4-164.0)
Female	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	2.9	nc	(nc-nc)
Male	13	7.5	174.5	(92.8-298.4)	Female	0	2.0	nc	(nc-nc)
Female	3	4.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.1	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	3.7	nc	(nc-nc)
<u>Leukemia</u>					Female	10	11.1	90.2	(43.2-165.8)
Male	7	4.9	142.3	(57.0-293.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	4.1	122.1	(39.3-284.9)	Female	12	13.2	90.7	(46.8-158.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	4.7	105.7	(34.1-246.6)	Male	212	162.5	130.5	(113.5-149.3)
Female	2	1.7	nc	(nc-nc)	Female	178	194.7	91.4	(78.5-105.9)
<u>Lung and Bronchus</u>									
Male	30	20.8	144.2	(97.3-205.9)					
Female	25	26.5	94.3	(61.0-139.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wakefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	33	30.4	108.7	(74.8-152.6)	Male	22	19.5	113.1	(70.8-171.2)
Female	9	9.3	96.5	(44.0-183.2)	Female	22	13.9	158.7	(99.4-240.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	5.8	155.6	(71.0-295.3)	Male	3	6.3	nc	(nc-nc)
Female	7	4.4	159.7	(64.0-329.0)	Female	3	4.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	11	17.2	63.9	(31.8-114.3)
Female	128	111.9	114.4	(95.4-136.0)	Female	14	13.5	103.6	(56.6-173.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.9	nc	(nc-nc)	Male	13	14.2	91.6	(48.7-156.7)
<u>Colon / Rectum</u>					Female	6	5.8	103.3	(37.7-224.9)
Male	31	32.1	96.6	(65.6-137.1)	<u>Ovary</u>				
Female	27	27.9	96.7	(63.7-140.7)	Female	6	9.6	62.8	(22.9-136.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	7.8	89.5	(35.9-184.4)	Male	7	10.8	64.8	(26.0-133.5)
Female	0	1.9	nc	(nc-nc)	Female	11	9.6	115.1	(57.4-206.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.2	nc	(nc-nc)	Male	61	93.0	65.6	(50.2-84.3)
Female	0	1.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	7.3	68.2	(22.0-159.2)
Male	9	16.8	53.7	(24.5-101.9)	Female	2	3.8	nc	(nc-nc)
Female	12	8.6	138.9	(71.7-242.7)	<u>Testis</u>				
<u>Larynx</u>					Male	2	4.0	nc	(nc-nc)
Male	4	4.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.2	nc	(nc-nc)	Male	5	7.6	65.9	(21.2-153.8)
<u>Leukemia</u>					Female	23	21.5	107.1	(67.9-160.7)
Male	11	12.2	90.2	(45.0-161.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	7.8	76.6	(28.0-166.7)	Female	25	25.1	99.7	(64.5-147.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	10.6	56.8	(20.7-123.5)	Male	309	389.7	79.3	(70.7-88.6)
Female	3	3.2	nc	(nc-nc)	Female	398	367.0	108.5	(98.1-119.6)
<u>Lung and Bronchus</u>									
Male	42	55.0	76.3	(55.0-103.2)					
Female	61	49.3	123.7	(94.6-158.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wales

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	2.7	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.5	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	10	8.9	112.7	(54.0-207.4)	Female	0	1.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	0	2.8	nc	(nc-nc)	<u>Ovary</u>				
Female	7	2.1	325.9	(130.6-671.5)	Female	1	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.7	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	9.4	53.1	(17.1-123.8)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	3	1.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.6	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.6	nc	(nc-nc)	Female	6	2.1	279.3	(102.0-608.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.0	nc	(nc-nc)	Male	22	35.5	62.1	(38.9-94.0)
Female	1	0.3	nc	(nc-nc)	Female	33	28.8	114.7	(78.9-161.1)
<u>Lung and Bronchus</u>									
Male	4	4.9	nc	(nc-nc)					
Female	3	3.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Walpole

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	27.9	71.6	(43.7-110.5)	Male	21	18.0	116.9	(72.3-178.6)
Female	11	10.3	106.3	(53.0-190.3)	Female	12	13.8	86.8	(44.8-151.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	5.3	nc	(nc-nc)	Male	6	5.7	104.6	(38.2-227.7)
Female	7	4.4	157.6	(63.1-324.7)	Female	6	4.7	127.2	(46.4-276.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.0	nc	(nc-nc)	Male	15	16.1	93.2	(52.1-153.7)
Female	136	112.9	120.5	(101.1-142.5)	Female	9	14.5	62.3	(28.4-118.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.7	nc	(nc-nc)	Male	9	13.8	65.2	(29.8-123.8)
<u>Colon / Rectum</u>					Female	6	6.0	99.3	(36.3-216.2)
Male	36	30.8	116.8	(81.8-161.7)	<u>Ovary</u>				
Female	32	30.5	104.9	(71.7-148.1)	Female	13	9.7	133.9	(71.2-229.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	7.3	nc	(nc-nc)	Male	11	10.1	108.6	(54.1-194.3)
Female	3	2.0	nc	(nc-nc)	Female	12	10.5	113.8	(58.7-198.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.0	nc	(nc-nc)	Male	119	90.8	131.0	(108.6-156.8)
Female	1	1.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	6.8	102.8	(41.2-211.9)
Male	17	15.9	106.6	(62.1-170.7)	Female	3	4.1	nc	(nc-nc)
Female	7	9.0	78.2	(31.3-161.0)	<u>Testis</u>				
<u>Larynx</u>					Male	5	3.5	143.3	(46.2-334.4)
Male	5	4.2	117.7	(37.9-274.7)	<u>Thyroid</u>				
Female	2	1.3	nc	(nc-nc)	Male	4	7.2	nc	(nc-nc)
<u>Leukemia</u>					Female	21	19.8	106.3	(65.8-162.5)
Male	9	11.3	79.6	(36.3-151.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	8.3	121.2	(58.0-222.8)	Female	25	25.1	99.5	(64.3-146.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	9	10.1	89.4	(40.8-169.8)	Male	379	366.8	103.3	(93.2-114.3)
Female	3	3.4	nc	(nc-nc)	Female	394	380.4	103.6	(93.6-114.3)
<u>Lung and Bronchus</u>									
Male	41	49.7	82.5	(59.2-111.9)					
Female	45	53.7	83.8	(61.1-112.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Waltham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	62	54.1	114.6	(87.9-147.0)	Male	24	35.9	66.9	(42.9-99.6)
Female	20	20.5	97.6	(59.6-150.7)	Female	13	29.8	43.6	(23.2-74.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	15	11.7	128.4	(71.8-211.7)	Male	11	11.1	99.1	(49.4-177.3)
Female	12	9.6	125.5	(64.8-219.2)	Female	4	9.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.9	nc	(nc-nc)	Male	23	32.2	71.4	(45.2-107.1)
Female	229	223.3	102.6	(89.7-116.7)	Female	34	29.1	117.0	(81.0-163.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	8.1	111.0	(50.6-210.7)	Male	17	26.0	65.3	(38.0-104.6)
<u>Colon / Rectum</u>					Female	8	12.1	66.0	(28.4-130.1)
Male	63	58.9	106.9	(82.1-136.8)	<u>Ovary</u>				
Female	59	60.2	98.1	(74.7-126.5)	Female	19	19.7	96.4	(58.0-150.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	13.9	50.3	(20.2-103.7)	Male	25	19.3	129.3	(83.7-190.9)
Female	5	4.0	125.1	(40.3-292.1)	Female	26	21.0	124.0	(81.0-181.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	5.8	86.7	(27.9-202.3)	Male	140	167.9	83.4	(70.1-98.4)
Female	5	4.8	104.7	(33.7-244.3)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	18	13.2	136.5	(80.9-215.8)
Male	37	30.9	119.7	(84.3-165.0)	Female	10	8.2	122.2	(58.5-224.7)
Female	21	18.0	116.8	(72.3-178.6)	<u>Testis</u>				
<u>Larynx</u>					Male	13	11.6	112.4	(59.8-192.1)
Male	6	8.1	74.1	(27.0-161.2)	<u>Thyroid</u>				
Female	3	2.5	nc	(nc-nc)	Male	17	15.6	109.2	(63.6-174.8)
<u>Leukemia</u>					Female	47	46.8	100.4	(73.8-133.6)
Male	19	23.1	82.3	(49.5-128.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	15	17.4	86.2	(48.2-142.1)	Female	41	49.7	82.5	(59.2-111.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	27	18.8	143.2	(94.4-208.4)	Male	685	714.5	95.9	(88.8-103.3)
Female	4	6.7	nc	(nc-nc)	Female	747	769.9	97.0	(90.2-104.2)
<u>Lung and Bronchus</u>									
Male	103	96.5	106.8	(87.1-129.5)					
Female	100	106.2	94.2	(76.6-114.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ware

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	10.8	65.1	(26.1-134.1)	Male	3	6.9	nc	(nc-nc)
Female	2	3.6	nc	(nc-nc)	Female	4	5.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.2	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	10	6.3	158.6	(75.9-291.8)
Female	34	44.8	75.9	(52.5-106.1)	Female	6	5.2	114.8	(41.9-249.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.5	nc	(nc-nc)	Male	4	5.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	2.3	nc	(nc-nc)
Male	17	11.9	142.9	(83.2-228.8)	<u>Ovary</u>				
Female	14	10.8	130.1	(71.1-218.4)	Female	5	3.8	132.1	(42.6-308.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.9	nc	(nc-nc)	Male	8	3.9	203.0	(87.4-400.1)
Female	1	0.7	nc	(nc-nc)	Female	6	3.7	161.1	(58.8-350.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	26	37.5	69.4	(45.3-101.7)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.6	nc	(nc-nc)
Male	5	6.3	78.8	(25.4-183.8)	Female	1	1.4	nc	(nc-nc)
Female	8	3.5	231.4	(99.6-455.9)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.5	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
<u>Leukemia</u>					Female	4	8.3	nc	(nc-nc)
Male	2	4.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.0	nc	(nc-nc)	Female	9	10.1	89.2	(40.7-169.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	4.0	125.9	(40.6-293.8)	Male	133	145.3	91.6	(76.7-108.5)
Female	2	1.2	nc	(nc-nc)	Female	138	144.8	95.3	(80.1-112.6)
<u>Lung and Bronchus</u>									
Male	20	19.4	103.3	(63.1-159.5)					
Female	20	20.0	99.8	(60.9-154.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wareham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	36	29.0	124.3	(87.0-172.1)	Male	14	17.9	78.3	(42.7-131.3)
Female	16	10.1	158.3	(90.4-257.1)	Female	14	13.6	102.7	(56.1-172.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	5.1	196.3	(94.0-361.0)	Male	11	5.8	188.4	(93.9-337.2)
Female	2	4.3	nc	(nc-nc)	Female	4	4.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	20	15.9	125.5	(76.6-193.8)
Female	93	113.3	82.1	(66.2-100.5)	Female	9	14.1	64.0	(29.2-121.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.6	nc	(nc-nc)	Male	16	12.9	124.0	(70.8-201.4)
<u>Colon / Rectum</u>					Female	6	6.0	100.6	(36.7-218.9)
Male	32	30.4	105.4	(72.1-148.7)	<u>Ovary</u>				
Female	41	29.3	140.2	(100.6-190.1)	Female	7	9.7	72.1	(28.9-148.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	7.2	96.6	(38.7-199.0)	Male	12	10.2	118.1	(61.0-206.4)
Female	2	2.0	nc	(nc-nc)	Female	17	10.2	167.2	(97.3-267.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.9	nc	(nc-nc)	Male	90	85.4	105.3	(84.7-129.5)
Female	3	1.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	6.9	72.5	(23.4-169.2)
Male	16	15.1	105.6	(60.3-171.6)	Female	3	3.9	nc	(nc-nc)
Female	16	9.0	177.1	(101.1-287.6)	<u>Testis</u>				
<u>Larynx</u>					Male	4	3.2	nc	(nc-nc)
Male	5	4.3	117.2	(37.8-273.5)	<u>Thyroid</u>				
Female	4	1.3	nc	(nc-nc)	Male	6	6.5	92.4	(33.7-201.1)
<u>Leukemia</u>					Female	17	19.6	86.6	(50.4-138.7)
Male	12	11.1	107.6	(55.6-188.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	14	8.0	175.5	(95.8-294.4)	Female	21	25.7	81.8	(50.6-125.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	14	9.7	144.3	(78.8-242.2)	Male	420	360.7	116.4	(105.6-128.1)
Female	6	3.4	179.0	(65.4-389.6)	Female	407	377.2	107.9	(97.7-118.9)
<u>Lung and Bronchus</u>									
Male	74	51.7	143.1	(112.4-179.7)					
Female	81	54.1	149.7	(118.8-186.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Warren

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	5.4	110.2	(40.3-239.9)	Male	2	3.5	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.1	nc	(nc-nc)	Male	4	1.1	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.2	nc	(nc-nc)
Female	13	20.7	62.8	(33.4-107.5)	Female	1	2.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.7	nc	(nc-nc)	Male	0	2.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.0	nc	(nc-nc)
Male	7	6.1	114.1	(45.7-235.0)	<u>Ovary</u>				
Female	6	4.7	126.5	(46.2-275.3)	Female	0	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.4	nc	(nc-nc)	Male	7	2.0	353.9	(141.8-729.2)
Female	1	0.3	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	12	18.6	64.7	(33.4-113.0)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.3	nc	(nc-nc)
Male	5	3.2	157.0	(50.6-366.4)	Female	0	0.6	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	0.8	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	3	4.0	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.4	nc	(nc-nc)	Female	5	4.5	110.0	(35.5-256.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.9	nc	(nc-nc)	Male	71	73.0	97.2	(75.9-122.7)
Female	0	0.6	nc	(nc-nc)	Female	47	65.9	71.3	(52.4-94.9)
<u>Lung and Bronchus</u>									
Male	10	9.7	103.2	(49.4-189.8)					
Female	9	9.0	99.9	(45.6-189.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Warwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.3	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	2	4.7	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.3	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.2	nc	(nc-nc)	Female	2	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	6	4.2	143.1	(52.3-311.5)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.7	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	12	16.4	73.2	(37.8-127.8)
Female	0	0.1	nc	(nc-nc)	Female	14	15.6	89.6	(49.0-150.4)
<u>Lung and Bronchus</u>									
Male	3	2.4	nc	(nc-nc)					
Female	3	2.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	4	3.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.7	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.5	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	13.0	38.5	(12.4-89.9)
Female	1	0.1	nc	(nc-nc)	Female	10	10.4	95.8	(45.9-176.3)
<u>Lung and Bronchus</u>									
Male	1	1.7	nc	(nc-nc)					
Female	1	1.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Watertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	30	29.9	100.4	(67.7-143.3)	Male	12	20.2	59.5	(30.7-103.9)
Female	10	12.9	77.4	(37.1-142.3)	Female	22	18.5	118.7	(74.4-179.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	6.4	156.2	(74.8-287.2)	Male	4	6.4	nc	(nc-nc)
Female	8	5.7	141.2	(60.8-278.3)	Female	5	5.9	84.3	(27.2-196.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.1	nc	(nc-nc)	Male	19	18.2	104.7	(63.0-163.5)
Female	140	143.5	97.5	(82.1-115.1)	Female	17	18.3	92.9	(54.1-148.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	10	5.2	191.8	(91.8-352.7)	Male	13	14.9	87.3	(46.4-149.3)
<u>Colon / Rectum</u>					Female	9	7.6	117.9	(53.8-223.9)
Male	39	33.9	114.9	(81.7-157.1)	<u>Ovary</u>				
Female	35	37.3	93.9	(65.4-130.6)	Female	15	12.4	120.6	(67.4-198.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	7.8	90.0	(36.1-185.4)	Male	11	10.8	101.5	(50.6-181.7)
Female	1	2.6	nc	(nc-nc)	Female	19	13.1	145.2	(87.4-226.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	2.8	177.0	(57.0-413.0)	Male	68	93.0	73.2	(56.8-92.7)
Female	3	2.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	9	7.5	120.7	(55.1-229.2)
Male	15	17.7	84.5	(47.3-139.4)	Female	10	5.0	199.3	(95.4-366.5)
Female	2	11.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	6	5.8	102.8	(37.5-223.8)
Male	6	4.6	129.9	(47.4-282.7)	<u>Thyroid</u>				
Female	0	1.6	nc	(nc-nc)	Male	8	8.9	89.9	(38.7-177.1)
<u>Leukemia</u>					Female	29	28.9	100.3	(67.2-144.0)
Male	15	12.7	118.2	(66.1-195.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	12	10.4	115.6	(59.7-202.0)	Female	25	32.1	77.9	(50.4-115.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	10.7	74.7	(32.1-147.1)	Male	369	399.0	92.5	(83.3-102.4)
Female	4	4.2	nc	(nc-nc)	Female	480	486.7	98.6	(90.0-107.9)
<u>Lung and Bronchus</u>									
Male	51	53.4	95.5	(71.1-125.5)					
Female	66	68.9	95.8	(74.1-121.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wayland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	17.6	73.7	(39.2-126.0)	Male	18	10.8	166.3	(98.5-262.9)
Female	5	6.5	76.8	(24.8-179.3)	Female	13	8.3	157.4	(83.7-269.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.1	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	7	9.7	72.0	(28.9-148.4)
Female	81	70.9	114.3	(90.8-142.0)	Female	13	9.0	145.0	(77.2-248.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.1	nc	(nc-nc)	Male	2	8.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	3.7	nc	(nc-nc)
Male	13	18.6	69.8	(37.1-119.4)	<u>Ovary</u>				
Female	8	18.6	43.0	(18.5-84.8)	Female	5	6.0	82.8	(26.7-193.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	4.4	nc	(nc-nc)	Male	4	6.2	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	8	6.5	122.8	(52.9-241.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.0	nc	(nc-nc)	Male	62	53.2	116.5	(89.3-149.3)
Female	2	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	4.2	nc	(nc-nc)
Male	6	9.3	64.3	(23.5-140.1)	Female	0	2.5	nc	(nc-nc)
Female	4	5.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.6	nc	(nc-nc)
Male	0	2.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	5	3.9	126.7	(40.8-295.6)
<u>Leukemia</u>					Female	11	11.2	98.1	(48.9-175.6)
Male	7	6.8	102.3	(41.0-210.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	5.0	nc	(nc-nc)	Female	13	16.0	81.1	(43.2-138.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	5.9	nc	(nc-nc)	Male	185	220.4	83.9	(72.3-96.9)
Female	0	2.1	nc	(nc-nc)	Female	204	236.5	86.3	(74.8-98.9)
<u>Lung and Bronchus</u>									
Male	18	31.1	57.9	(34.3-91.5)					
Female	19	34.8	54.6	(32.8-85.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Webster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	20.4	132.1	(87.0-192.2)	Male	11	12.5	88.2	(44.0-157.8)
Female	6	7.6	78.9	(28.8-171.8)	Female	7	9.8	71.5	(28.6-147.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.6	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
Female	0	3.2	nc	(nc-nc)	Female	7	3.3	209.1	(83.8-430.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	0.7	nc	(nc-nc)	Male	10	11.2	89.5	(42.8-164.6)
Female	83	76.8	108.1	(86.1-134.1)	Female	9	10.3	87.8	(40.0-166.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.6	nc	(nc-nc)	Male	12	9.1	132.5	(68.4-231.4)
<u>Colon / Rectum</u>					Female	5	4.2	118.2	(38.1-275.9)
Male	21	21.6	97.0	(60.0-148.3)	<u>Ovary</u>				
Female	22	22.3	98.6	(61.7-149.2)	Female	12	6.7	179.7	(92.7-313.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	5.0	178.3	(81.3-338.4)	Male	7	7.1	98.7	(39.6-203.4)
Female	2	1.4	nc	(nc-nc)	Female	6	7.8	76.8	(28.0-167.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.4	nc	(nc-nc)	Male	56	60.2	93.0	(70.2-120.7)
Female	1	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.8	nc	(nc-nc)
Male	10	10.7	93.7	(44.9-172.4)	Female	2	3.1	nc	(nc-nc)
Female	11	6.3	175.8	(87.7-314.6)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.5	nc	(nc-nc)
Male	6	2.9	207.0	(75.6-450.6)	<u>Thyroid</u>				
Female	2	0.9	nc	(nc-nc)	Male	6	4.7	128.6	(47.0-280.0)
<u>Leukemia</u>					Female	16	14.0	114.1	(65.2-185.3)
Male	11	7.9	139.2	(69.4-249.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	6.1	82.1	(26.4-191.5)	Female	19	16.5	115.1	(69.2-179.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	9	6.7	134.6	(61.4-255.6)	Male	287	253.5	113.2	(100.5-127.1)
Female	5	2.4	211.3	(68.1-493.0)	Female	302	267.7	112.8	(100.5-126.3)
<u>Lung and Bronchus</u>									
Male	43	35.7	120.3	(87.1-162.1)					
Female	50	38.2	130.8	(97.1-172.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wellesley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	29.5	64.5	(38.8-100.7)	Male	28	18.2	154.0	(102.3-222.5)
Female	6	9.9	60.6	(22.1-131.8)	Female	27	13.7	197.1	(129.9-286.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	5.5	nc	(nc-nc)	Male	5	6.0	84.0	(27.1-195.9)
Female	5	4.9	102.2	(32.9-238.4)	Female	6	4.5	134.0	(48.9-291.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	13	16.5	78.9	(42.0-134.9)
Female	142	110.5	128.5	(108.3-151.5)	Female	10	14.0	71.4	(34.2-131.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.6	nc	(nc-nc)	Male	10	13.6	73.6	(35.2-135.4)
<u>Colon / Rectum</u>					Female	5	5.9	84.9	(27.4-198.2)
Male	22	31.6	69.7	(43.7-105.5)	<u>Ovary</u>				
Female	26	29.4	88.6	(57.8-129.8)	Female	11	9.6	115.0	(57.3-205.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	7.5	nc	(nc-nc)	Male	11	10.4	105.9	(52.8-189.5)
Female	1	1.9	nc	(nc-nc)	Female	11	10.0	109.7	(54.7-196.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.9	nc	(nc-nc)	Male	115	90.2	127.6	(105.3-153.1)
Female	2	2.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	7.0	71.3	(23.0-166.4)
Male	14	16.0	87.7	(47.9-147.1)	Female	1	4.0	nc	(nc-nc)
Female	5	8.8	57.0	(18.4-133.0)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.0	nc	(nc-nc)
Male	3	4.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.2	nc	(nc-nc)	Male	8	6.9	116.6	(50.2-229.7)
<u>Leukemia</u>					Female	20	21.1	94.6	(57.8-146.1)
Male	13	11.9	109.6	(58.3-187.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	13	8.4	154.1	(82.0-263.5)	Female	21	24.0	87.6	(54.2-133.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	9.9	nc	(nc-nc)	Male	313	372.8	83.9	(74.9-93.8)
Female	1	3.3	nc	(nc-nc)	Female	384	373.4	102.8	(92.8-113.7)
<u>Lung and Bronchus</u>									
Male	17	51.7	32.9	(19.1-52.6)					
Female	34	51.8	65.6	(45.4-91.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wellfleet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	7.5	93.0	(37.3-191.7)	Male	4	4.2	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	Female	2	2.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	6	3.7	161.8	(59.1-352.2)
Female	23	25.1	91.8	(58.2-137.7)	Female	1	3.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.4	nc	(nc-nc)
Male	6	7.0	86.1	(31.4-187.3)	<u>Ovary</u>				
Female	5	7.5	66.5	(21.4-155.2)	Female	2	2.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.8	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	5	2.9	171.5	(55.3-400.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	19	22.1	85.9	(51.7-134.1)
Female	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.7	nc	(nc-nc)
Male	2	3.5	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	4	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	1	3.0	nc	(nc-nc)
Male	3	2.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	2.0	nc	(nc-nc)	Female	4	5.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.3	nc	(nc-nc)	Male	66	88.0	75.0	(58.0-95.4)
Female	1	0.9	nc	(nc-nc)	Female	71	90.2	78.7	(61.5-99.3)
<u>Lung and Bronchus</u>									
Male	4	13.8	nc	(nc-nc)					
Female	12	15.1	79.3	(40.9-138.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wendell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.4	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	4.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.9	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	5.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.3	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	2	0.8	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	11	19.4	56.8	(28.3-101.6)
Female	0	0.1	nc	(nc-nc)	Female	9	14.0	64.2	(29.3-122.0)
<u>Lung and Bronchus</u>									
Male	3	2.5	nc	(nc-nc)					
Female	2	1.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wenham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	5.3	133.0	(53.3-274.0)	Male	5	3.1	158.8	(51.2-370.6)
Female	1	1.8	nc	(nc-nc)	Female	7	2.4	296.1	(118.6-610.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
Female	25	18.5	135.2	(87.5-199.6)	Female	2	2.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.0	nc	(nc-nc)
Male	1	5.4	nc	(nc-nc)	<u>Ovary</u>				
Female	9	5.3	170.5	(77.8-323.7)	Female	0	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.3	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	21	14.0	149.9	(92.7-229.1)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.2	nc	(nc-nc)
Male	1	2.6	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.6	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.2	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	4	3.4	nc	(nc-nc)
Male	1	2.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.5	nc	(nc-nc)	Female	8	4.1	195.7	(84.3-385.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.6	nc	(nc-nc)	Male	61	63.0	96.8	(74.0-124.3)
Female	0	0.6	nc	(nc-nc)	Female	80	64.5	123.9	(98.3-154.3)
<u>Lung and Bronchus</u>									
Male	4	9.2	nc	(nc-nc)					
Female	11	9.2	119.5	(59.6-213.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	8.5	223.3	(134.4-348.7)	Male	6	5.7	106.2	(38.8-231.1)
Female	3	3.2	nc	(nc-nc)	Female	2	3.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.8	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	4	5.1	nc	(nc-nc)
Female	26	30.0	86.7	(56.6-127.0)	Female	3	4.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.9	nc	(nc-nc)	Male	4	4.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.7	nc	(nc-nc)
Male	5	9.2	54.1	(17.4-126.2)	<u>Ovary</u>				
Female	5	9.2	54.3	(17.5-126.8)	Female	6	2.7	224.6	(82.0-489.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.2	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	6	3.3	180.6	(65.9-393.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.0	nc	(nc-nc)	Male	28	27.6	101.4	(67.4-146.6)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.1	nc	(nc-nc)
Male	8	4.9	163.0	(70.2-321.1)	Female	2	1.3	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.9	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
<u>Leukemia</u>					Female	11	4.8	231.5	(115.4-414.3)
Male	3	3.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	2.4	205.0	(66.1-478.3)	Female	4	6.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.0	nc	(nc-nc)	Male	133	114.0	116.6	(97.7-138.2)
Female	0	1.0	nc	(nc-nc)	Female	111	107.0	103.7	(85.3-124.9)
<u>Lung and Bronchus</u>									
Male	25	15.1	165.2	(106.9-243.9)					
Female	16	15.8	101.0	(57.7-164.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	8.5	106.4	(48.6-202.0)	Male	10	5.3	189.4	(90.7-348.4)
Female	3	2.7	nc	(nc-nc)	Female	4	3.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	1.6	319.9	(103.1-746.5)	Male	0	1.7	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	8	4.8	167.8	(72.2-330.6)
Female	38	30.8	123.5	(87.4-169.5)	Female	9	3.8	234.5	(107.0-445.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.0	nc	(nc-nc)	Male	6	3.9	152.7	(55.7-332.3)
<u>Colon / Rectum</u>					Female	2	1.6	nc	(nc-nc)
Male	7	9.1	77.2	(30.9-159.1)	<u>Ovary</u>				
Female	17	8.0	212.6	(123.8-340.4)	Female	1	2.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	2.2	229.9	(74.1-536.5)	Male	1	3.0	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	4	2.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	21	26.6	79.0	(48.9-120.8)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.0	nc	(nc-nc)
Male	4	4.6	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.0	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<u>Leukemia</u>					Female	11	5.5	201.1	(100.2-359.8)
Male	0	3.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.2	nc	(nc-nc)	Female	4	7.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.9	nc	(nc-nc)	Male	111	108.3	102.5	(84.3-123.4)
Female	0	0.9	nc	(nc-nc)	Female	129	102.5	125.9	(105.1-149.5)
<u>Lung and Bronchus</u>									
Male	18	15.0	120.1	(71.1-189.8)					
Female	19	14.2	134.1	(80.7-209.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	5.3	nc	(nc-nc)	Male	5	3.2	154.7	(49.8-361.0)
Female	0	1.6	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.9	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	15	16.7	89.6	(50.1-147.8)	Female	3	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	0.9	nc	(nc-nc)
Male	3	5.5	nc	(nc-nc)	<u>Ovary</u>				
Female	2	4.6	nc	(nc-nc)	Female	4	1.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.3	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	13	16.0	81.1	(43.1-138.6)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.3	nc	(nc-nc)
Male	3	2.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.6	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.9	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.3	nc	(nc-nc)	Female	6	3.9	153.7	(56.1-334.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	1.8	nc	(nc-nc)	Male	50	66.1	75.7	(56.2-99.8)
Female	0	0.5	nc	(nc-nc)	Female	58	58.2	99.7	(75.7-128.9)
<u>Lung and Bronchus</u>									
Male	7	9.2	75.9	(30.4-156.3)					
Female	14	8.4	166.1	(90.7-278.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	4.4	159.8	(64.0-329.3)	Male	2	3.0	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.0	nc	(nc-nc)	Male	3	1.0	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
Female	23	18.6	123.8	(78.4-185.7)	Female	0	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.9	nc	(nc-nc)
Male	4	5.1	nc	(nc-nc)	<u>Ovary</u>				
Female	1	4.4	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.2	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	21	16.0	131.5	(81.4-201.0)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.1	nc	(nc-nc)
Male	6	2.7	218.4	(79.7-475.3)	Female	0	0.6	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.6	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	1	3.4	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.2	nc	(nc-nc)	Female	3	4.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.8	nc	(nc-nc)	Male	59	61.5	95.9	(73.0-123.7)
Female	0	0.5	nc	(nc-nc)	Female	47	59.3	79.3	(58.2-105.4)
<u>Lung and Bronchus</u>									
Male	1	7.9	nc	(nc-nc)					
Female	4	7.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	36	30.2	119.1	(83.4-164.9)	Male	14	19.2	73.0	(39.9-122.5)
Female	8	11.9	67.2	(28.9-132.4)	Female	11	15.9	69.2	(34.5-123.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	6.0	116.8	(46.8-240.7)	Male	2	6.2	nc	(nc-nc)
Female	6	5.1	118.3	(43.2-257.4)	Female	4	5.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	20	17.2	116.2	(70.9-179.4)
Female	105	126.1	83.3	(68.1-100.8)	Female	13	16.3	79.6	(42.3-136.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	4.2	215.1	(98.2-408.4)	Male	16	14.2	112.6	(64.3-182.9)
<u>Colon / Rectum</u>					Female	6	6.8	88.5	(32.3-192.6)
Male	43	32.0	134.4	(97.3-181.1)	<u>Ovary</u>				
Female	42	34.5	121.9	(87.8-164.8)	Female	7	10.9	64.1	(25.7-132.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	7.8	153.3	(79.1-267.8)	Male	12	10.8	111.6	(57.6-194.9)
Female	1	2.3	nc	(nc-nc)	Female	8	12.1	66.3	(28.6-130.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.4	nc	(nc-nc)	Male	79	95.4	82.8	(65.6-103.2)
Female	2	2.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	7.3	69.0	(22.2-160.9)
Male	16	16.8	95.5	(54.6-155.1)	Female	5	4.7	107.1	(34.5-250.0)
Female	10	10.2	97.9	(46.9-180.1)	<u>Testis</u>				
<u>Larynx</u>					Male	6	4.3	139.1	(50.8-302.7)
Male	4	4.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.4	nc	(nc-nc)	Male	12	7.5	160.1	(82.6-279.7)
<u>Leukemia</u>					Female	25	23.1	108.2	(70.0-159.7)
Male	11	12.4	88.4	(44.1-158.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	9.6	115.1	(57.4-206.0)	Female	24	27.9	86.1	(55.1-128.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	12	10.6	113.2	(58.4-197.7)	Male	386	391.5	98.6	(89.0-108.9)
Female	4	3.8	nc	(nc-nc)	Female	423	431.5	98.0	(88.9-107.8)
<u>Lung and Bronchus</u>									
Male	49	54.2	90.4	(66.9-119.6)					
Female	81	61.7	131.2	(104.2-163.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.8	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	1.1	nc	(nc-nc)
Female	5	7.4	67.2	(21.6-156.8)	Female	2	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.4	nc	(nc-nc)
Male	0	2.0	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.7	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.5	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	9	6.7	134.0	(61.1-254.3)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.5	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.2	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	0.5	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.7	nc	(nc-nc)	Male	34	25.1	135.4	(93.8-189.3)
Female	0	0.2	nc	(nc-nc)	Female	17	24.3	70.0	(40.8-112.1)
<u>Lung and Bronchus</u>									
Male	7	3.5	201.6	(80.8-415.4)					
Female	0	3.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	2.0	349.8	(140.1-720.8)	Male	4	1.3	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.5	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.2	nc	(nc-nc)
Female	23	14.9	154.1	(97.6-231.2)	Female	4	1.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.8	nc	(nc-nc)
Male	3	2.3	nc	(nc-nc)	<u>Ovary</u>				
Female	4	3.8	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	14	8.5	164.3	(89.8-275.7)
Female	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	4	1.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.3	nc	(nc-nc)
Male	2	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	0	2.7	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.0	nc	(nc-nc)	Female	4	3.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.8	nc	(nc-nc)	Male	47	29.6	158.7	(116.6-211.0)
Female	0	0.4	nc	(nc-nc)	Female	55	48.7	112.9	(85.0-146.9)
<u>Lung and Bronchus</u>									
Male	1	3.9	nc	(nc-nc)					
Female	6	6.1	98.2	(35.8-213.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	17.8	73.1	(38.9-124.9)	Male	12	11.9	101.2	(52.2-176.8)
Female	8	6.9	115.7	(49.8-228.0)	Female	6	9.8	61.4	(22.4-133.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.7	nc	(nc-nc)	Male	6	3.8	158.8	(58.0-345.6)
Female	6	3.2	190.4	(69.5-414.5)	Female	3	3.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	9	10.6	84.5	(38.6-160.4)
Female	79	78.1	101.2	(80.1-126.1)	Female	6	9.8	61.4	(22.4-133.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.6	nc	(nc-nc)	Male	9	9.1	99.2	(45.3-188.4)
<u>Colon / Rectum</u>					Female	3	4.2	nc	(nc-nc)
Male	19	20.4	93.1	(56.0-145.4)	<u>Ovary</u>				
Female	19	21.0	90.4	(54.4-141.2)	Female	5	6.7	74.3	(24.0-173.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	4.7	nc	(nc-nc)	Male	6	6.5	92.8	(33.9-202.0)
Female	3	1.3	nc	(nc-nc)	Female	10	7.2	138.9	(66.5-255.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.5	nc	(nc-nc)	Male	51	55.8	91.4	(68.1-120.2)
Female	2	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	4.4	113.3	(36.5-264.3)
Male	4	10.5	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
Female	1	6.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.9	nc	(nc-nc)
Male	1	2.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	7	5.1	137.0	(54.9-282.3)
<u>Leukemia</u>					Female	13	14.6	88.8	(47.2-151.9)
Male	11	7.5	147.0	(73.3-263.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	5.8	155.6	(71.0-295.4)	Female	20	17.0	117.6	(71.8-181.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	6.5	77.4	(24.9-180.6)	Male	213	236.5	90.1	(78.4-103.0)
Female	2	2.3	nc	(nc-nc)	Female	245	261.4	93.7	(82.3-106.2)
<u>Lung and Bronchus</u>									
Male	20	31.4	63.7	(38.9-98.5)					
Female	28	35.1	79.7	(53.0-115.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	43	43.1	99.8	(72.2-134.4)	Male	20	27.1	73.7	(45.0-113.8)
Female	14	14.5	96.4	(52.7-161.8)	Female	20	20.5	97.4	(59.5-150.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	8.5	nc	(nc-nc)	Male	10	8.8	114.1	(54.6-209.8)
Female	6	6.8	88.4	(32.3-192.5)	Female	3	6.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.5	nc	(nc-nc)	Male	22	24.6	89.4	(56.0-135.3)
Female	198	164.0	120.7	(104.5-138.8)	Female	21	20.6	101.7	(62.9-155.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	5.4	148.8	(64.1-293.3)	Male	17	20.4	83.5	(48.6-133.8)
<u>Colon / Rectum</u>					Female	9	8.7	103.2	(47.1-195.8)
Male	63	46.2	136.3	(104.7-174.4)	<u>Ovary</u>				
Female	51	42.4	120.2	(89.5-158.1)	Female	19	14.3	133.3	(80.2-208.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	14	11.1	126.0	(68.8-211.3)	Male	13	15.3	84.8	(45.1-145.1)
Female	3	2.9	nc	(nc-nc)	Female	10	14.7	67.9	(32.5-124.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	3.5	170.5	(62.3-371.1)	Male	122	136.5	89.3	(74.2-106.7)
Female	0	3.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	11	10.3	106.6	(53.1-190.7)
Male	21	23.8	88.1	(54.5-134.7)	Female	8	5.8	138.2	(59.5-272.3)
Female	8	13.0	61.5	(26.5-121.2)	<u>Testis</u>				
<u>Larynx</u>					Male	7	6.1	114.5	(45.9-236.0)
Male	4	6.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	4	1.8	nc	(nc-nc)	Male	6	10.7	56.0	(20.5-122.0)
<u>Leukemia</u>					Female	22	30.9	71.2	(44.6-107.7)
Male	19	17.7	107.3	(64.6-167.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	12.1	74.5	(34.0-141.5)	Female	37	37.0	99.9	(70.3-137.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	13	15.0	86.8	(46.2-148.5)	Male	549	557.9	98.4	(90.3-107.0)
Female	4	4.9	nc	(nc-nc)	Female	566	551.0	102.7	(94.4-111.5)
<u>Lung and Bronchus</u>									
Male	82	76.2	107.6	(85.5-133.5)					
Female	80	76.8	104.1	(82.6-129.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	20.1	74.5	(41.7-122.9)	Male	13	14.2	91.6	(48.7-156.7)
Female	4	6.4	nc	(nc-nc)	Female	12	10.7	112.2	(57.9-196.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	4.6	151.5	(60.7-312.3)	Male	8	4.6	173.9	(74.9-342.6)
Female	5	3.6	140.3	(45.2-327.4)	Female	3	3.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	13	12.8	102.0	(54.2-174.4)
Female	105	90.9	115.5	(94.4-139.8)	Female	8	10.0	80.3	(34.6-158.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.2	nc	(nc-nc)	Male	6	11.8	50.6	(18.5-110.2)
<u>Colon / Rectum</u>					Female	3	4.4	nc	(nc-nc)
Male	25	24.0	104.1	(67.3-153.6)	<u>Ovary</u>				
Female	25	19.9	125.6	(81.2-185.4)	Female	6	7.5	79.5	(29.0-173.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	5.9	nc	(nc-nc)	Male	9	7.8	116.0	(52.9-220.3)
Female	2	1.3	nc	(nc-nc)	Female	5	6.5	77.1	(24.8-179.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.7	nc	(nc-nc)	Male	83	76.7	108.2	(86.2-134.1)
Female	3	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	5.2	134.9	(54.0-277.9)
Male	10	13.5	73.8	(35.3-135.7)	Female	1	2.7	nc	(nc-nc)
Female	3	6.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.9	nc	(nc-nc)
Male	4	3.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.0	nc	(nc-nc)	Male	10	6.4	155.4	(74.4-285.7)
<u>Leukemia</u>					Female	17	18.0	94.4	(55.0-151.2)
Male	10	8.8	113.0	(54.1-207.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	5.7	157.2	(71.7-298.5)	Female	34	20.4	166.8	(115.5-233.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	8.3	72.3	(26.4-157.4)	Male	289	293.4	98.5	(87.5-110.5)
Female	0	2.3	nc	(nc-nc)	Female	292	282.2	103.5	(91.9-116.0)
<u>Lung and Bronchus</u>									
Male	32	38.1	84.1	(57.5-118.7)					
Female	25	36.0	69.4	(44.9-102.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westhampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.0	nc	(nc-nc)	Male	6	1.3	458.1	(167.3-997.1)
Female	0	0.6	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	10	7.8	128.8	(61.7-236.9)	Female	0	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.4	nc	(nc-nc)
Male	1	2.2	nc	(nc-nc)	<u>Ovary</u>				
Female	2	1.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	10	7.3	137.9	(66.0-253.5)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.4	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.8	nc	(nc-nc)	Male	26	27.4	94.9	(62.0-139.1)
Female	0	0.2	nc	(nc-nc)	Female	14	24.4	57.4	(31.3-96.2)
<u>Lung and Bronchus</u>									
Male	1	3.7	nc	(nc-nc)					
Female	0	3.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westminster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	7.9	76.0	(27.7-165.4)	Male	8	5.3	151.1	(65.0-297.6)
Female	3	2.3	nc	(nc-nc)	Female	6	3.7	160.9	(58.8-350.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.6	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	4.8	126.2	(46.1-274.8)
Female	43	31.0	138.5	(100.2-186.6)	Female	2	3.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	5	4.3	116.8	(37.6-272.5)
<u>Colon / Rectum</u>					Female	3	1.6	nc	(nc-nc)
Male	7	9.2	76.3	(30.6-157.1)	<u>Ovary</u>				
Female	7	7.0	99.3	(39.8-204.7)	Female	3	2.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.2	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	23	27.2	84.5	(53.6-126.8)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.0	nc	(nc-nc)
Male	3	4.8	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.1	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	7	6.0	116.6	(46.7-240.2)
Male	4	3.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.0	nc	(nc-nc)	Female	8	7.3	109.7	(47.2-216.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.1	nc	(nc-nc)	Male	98	108.2	90.6	(73.5-110.4)
Female	0	0.8	nc	(nc-nc)	Female	107	97.8	109.4	(89.7-132.2)
<u>Lung and Bronchus</u>									
Male	10	13.9	71.8	(34.4-132.1)					
Female	14	12.3	113.7	(62.1-190.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Weston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	15.3	117.8	(69.8-186.2)	Male	11	9.2	119.9	(59.8-214.6)
Female	1	5.0	nc	(nc-nc)	Female	9	6.5	138.8	(63.3-263.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.7	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	Female	4	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	10	8.2	122.0	(58.4-224.3)
Female	52	53.8	96.7	(72.2-126.8)	Female	3	6.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.6	nc	(nc-nc)	Male	7	6.7	104.5	(41.9-215.3)
<u>Colon / Rectum</u>					Female	0	2.9	nc	(nc-nc)
Male	12	15.6	76.8	(39.6-134.1)	<u>Ovary</u>				
Female	10	14.6	68.6	(32.9-126.2)	Female	2	4.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	3.8	nc	(nc-nc)	Male	6	5.3	112.6	(41.1-245.0)
Female	0	1.0	nc	(nc-nc)	Female	11	5.1	214.5	(106.9-383.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	47	46.4	101.3	(74.5-134.8)
Female	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.6	nc	(nc-nc)
Male	8	7.9	100.9	(43.4-198.8)	Female	0	2.0	nc	(nc-nc)
Female	1	4.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.2	nc	(nc-nc)
Male	1	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	7	3.2	218.6	(87.6-450.4)
<u>Leukemia</u>					Female	7	9.0	77.9	(31.2-160.5)
Male	6	5.9	101.0	(36.9-219.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	4.1	147.2	(53.7-320.3)	Female	9	12.1	74.2	(33.8-140.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	5.0	119.8	(43.7-260.7)	Male	188	189.2	99.3	(85.7-114.6)
Female	0	1.7	nc	(nc-nc)	Female	146	182.7	79.9	(67.5-94.0)
<u>Lung and Bronchus</u>									
Male	15	27.3	54.9	(30.7-90.5)					
Female	17	26.3	64.8	(37.7-103.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	25	23.8	104.9	(67.8-154.8)	Male	14	14.3	97.9	(53.5-164.2)
Female	7	7.1	98.1	(39.3-202.0)	Female	6	9.5	62.9	(23.0-136.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	4.0	nc	(nc-nc)	Male	5	4.8	104.4	(33.6-243.7)
Female	2	3.0	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	16	12.8	124.8	(71.3-202.6)
Female	69	80.8	85.4	(66.4-108.0)	Female	15	10.0	149.9	(83.8-247.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.5	nc	(nc-nc)	Male	8	10.3	77.6	(33.4-153.0)
<u>Colon / Rectum</u>					Female	4	4.3	nc	(nc-nc)
Male	22	24.0	91.6	(57.4-138.7)	<u>Ovary</u>				
Female	19	20.4	93.0	(56.0-145.2)	Female	5	6.9	72.5	(23.4-169.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	6.0	132.4	(57.0-260.8)	Male	13	8.3	157.0	(83.5-268.5)
Female	1	1.4	nc	(nc-nc)	Female	9	7.3	122.5	(55.9-232.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.3	nc	(nc-nc)	Male	74	73.9	100.1	(78.6-125.7)
Female	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	5.6	89.8	(28.9-209.5)
Male	8	12.4	64.7	(27.9-127.5)	Female	3	2.7	nc	(nc-nc)
Female	6	6.3	94.6	(34.6-206.0)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.1	nc	(nc-nc)
Male	3	3.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	6	5.0	119.0	(43.5-259.0)
<u>Leukemia</u>					Female	18	13.7	131.2	(77.7-207.4)
Male	7	9.0	77.8	(31.2-160.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	5.5	nc	(nc-nc)	Female	11	18.8	58.4	(29.1-104.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	7.7	64.6	(20.8-150.7)	Male	272	295.9	91.9	(81.3-103.5)
Female	1	2.4	nc	(nc-nc)	Female	250	267.7	93.4	(82.2-105.7)
<u>Lung and Bronchus</u>									
Male	36	42.6	84.4	(59.1-116.9)					
Female	41	38.4	106.7	(76.6-144.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	21.3	98.8	(61.1-151.0)	Male	26	12.5	208.1	(135.9-305.0)
Female	7	7.0	99.4	(39.8-204.8)	Female	20	8.7	230.3	(140.6-355.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.5	nc	(nc-nc)	Male	7	4.1	171.9	(68.9-354.2)
Female	5	2.8	177.3	(57.1-413.7)	Female	4	3.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.7	nc	(nc-nc)	Male	9	11.3	79.5	(36.3-150.9)
Female	98	70.5	139.0	(112.8-169.4)	Female	6	9.5	63.5	(23.2-138.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.2	nc	(nc-nc)	Male	7	8.9	78.9	(31.6-162.6)
<u>Colon / Rectum</u>					Female	5	3.9	127.6	(41.1-297.9)
Male	22	22.1	99.5	(62.3-150.7)	<u>Ovary</u>				
Female	22	20.8	105.6	(66.1-159.8)	Female	10	6.1	163.2	(78.1-300.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	5.1	nc	(nc-nc)	Male	9	7.3	122.9	(56.1-233.3)
Female	1	1.3	nc	(nc-nc)	Female	2	7.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	1.1	nc	(nc-nc)	Male	61	59.0	103.5	(79.1-132.9)
Female	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	4.9	nc	(nc-nc)
Male	11	10.5	105.2	(52.4-188.3)	Female	2	2.9	nc	(nc-nc)
Female	6	5.7	105.7	(38.6-230.0)	<u>Testis</u>				
<u>Larynx</u>					Male	5	1.7	299.8	(96.6-699.6)
Male	3	2.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
<u>Leukemia</u>					Female	18	11.5	156.3	(92.6-247.1)
Male	9	8.1	111.2	(50.7-211.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	5.5	181.1	(86.7-333.0)	Female	20	15.3	130.7	(79.8-201.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	6.6	120.9	(52.1-238.2)	Male	254	253.3	100.3	(88.3-113.4)
Female	4	2.2	nc	(nc-nc)	Female	296	244.4	121.1	(107.7-135.7)
<u>Lung and Bronchus</u>									
Male	24	35.8	67.0	(42.9-99.7)					
Female	32	34.8	91.8	(62.8-129.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Weymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	61	57.1	106.9	(81.8-137.3)	Male	41	37.0	110.7	(79.4-150.1)
Female	42	24.0	175.1	(126.2-236.6)	Female	47	32.6	144.1	(105.9-191.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	11.3	97.1	(48.4-173.7)	Male	10	11.9	83.9	(40.2-154.3)
Female	10	10.3	97.4	(46.6-179.2)	Female	8	11.0	72.6	(31.3-143.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	2.0	nc	(nc-nc)	Male	42	33.2	126.5	(91.1-171.0)
Female	287	265.7	108.0	(95.9-121.3)	Female	30	33.6	89.2	(60.1-127.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	8.7	nc	(nc-nc)	Male	29	27.9	104.0	(69.6-149.3)
<u>Colon / Rectum</u>					Female	20	14.1	141.5	(86.4-218.5)
Male	69	62.6	110.3	(85.8-139.6)	<u>Ovary</u>				
Female	74	69.8	106.1	(83.3-133.2)	Female	22	22.8	96.4	(60.4-146.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	19	14.9	127.3	(76.6-198.8)	Male	17	20.6	82.6	(48.1-132.3)
Female	5	4.7	106.8	(34.4-249.2)	Female	20	24.4	82.0	(50.1-126.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	7	4.5	156.8	(62.8-323.1)	Male	172	181.6	94.7	(81.1-110.0)
Female	2	3.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	16	13.9	114.7	(65.5-186.3)
Male	38	32.7	116.2	(82.2-159.5)	Female	7	9.4	74.1	(29.7-152.7)
Female	31	21.0	147.6	(100.2-209.5)	<u>Testis</u>				
<u>Larynx</u>					Male	9	8.2	110.2	(50.3-209.2)
Male	14	8.8	159.7	(87.2-268.0)	<u>Thyroid</u>				
Female	4	3.0	nc	(nc-nc)	Male	14	15.0	93.1	(50.8-156.2)
<u>Leukemia</u>					Female	44	47.6	92.5	(67.2-124.2)
Male	19	23.5	81.0	(48.8-126.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	14	19.1	73.5	(40.1-123.3)	Female	64	60.0	106.7	(82.2-136.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	22	20.4	107.6	(67.4-162.9)	Male	799	749.6	106.6	(99.3-114.2)
Female	9	7.9	114.0	(52.0-216.5)	Female	971	891.5	108.9	(102.2-116.0)
<u>Lung and Bronchus</u>									
Male	117	102.6	114.1	(94.3-136.7)					
Female	163	126.2	129.2	(110.1-150.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Whately

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.6	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	4	7.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	4	1.8	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.9	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.5	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	7	6.5	106.9	(42.8-220.2)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.2	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	4	1.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.7	nc	(nc-nc)	Male	24	23.3	103.0	(66.0-153.3)
Female	0	0.2	nc	(nc-nc)	Female	13	23.6	55.0	(29.3-94.1)
<u>Lung and Bronchus</u>									
Male	1	3.0	nc	(nc-nc)					
Female	2	3.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Whitman

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	12.5	192.0	(123.0-285.6)	Male	8	8.7	91.9	(39.5-181.0)
Female	8	4.5	176.7	(76.1-348.2)	Female	14	7.1	195.9	(107.0-328.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.9	nc	(nc-nc)	Male	0	2.8	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	2	7.8	nc	(nc-nc)
Female	58	57.7	100.5	(76.3-129.9)	Female	5	6.8	73.7	(23.8-172.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	2.1	240.3	(77.5-560.9)	Male	7	7.0	100.3	(40.2-206.7)
<u>Colon / Rectum</u>					Female	6	2.9	205.3	(75.0-446.8)
Male	16	14.5	110.2	(62.9-178.9)	<u>Ovary</u>				
Female	14	13.6	102.6	(56.0-172.1)	Female	3	4.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	3.5	169.7	(62.0-369.5)	Male	2	4.7	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	7	4.6	152.7	(61.2-314.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.2	nc	(nc-nc)	Male	45	45.0	100.0	(72.9-133.8)
Female	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	3.2	nc	(nc-nc)
Male	17	8.1	210.2	(122.4-336.5)	Female	1	1.8	nc	(nc-nc)
Female	4	4.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.3	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
<u>Leukemia</u>					Female	9	11.7	76.7	(35.0-145.6)
Male	9	5.5	162.7	(74.3-308.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	4.0	nc	(nc-nc)	Female	7	13.0	53.9	(21.6-111.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	4.9	nc	(nc-nc)	Male	193	177.8	108.6	(93.8-125.0)
Female	0	1.6	nc	(nc-nc)	Female	205	186.5	109.9	(95.4-126.0)
<u>Lung and Bronchus</u>									
Male	32	23.1	138.3	(94.6-195.3)					
Female	43	24.6	174.6	(126.3-235.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wilbraham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	21.3	84.6	(50.1-133.7)	Male	16	12.7	125.9	(71.9-204.5)
Female	10	7.0	142.2	(68.1-261.5)	Female	9	8.9	101.1	(46.2-192.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.5	nc	(nc-nc)	Male	4	4.2	nc	(nc-nc)
Female	7	2.8	247.5	(99.2-510.0)	Female	2	3.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	9	11.5	78.4	(35.8-148.8)
Female	80	74.0	108.1	(85.7-134.6)	Female	11	9.5	115.4	(57.5-206.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.2	nc	(nc-nc)	Male	8	9.3	85.6	(36.9-168.7)
<u>Colon / Rectum</u>					Female	2	4.0	nc	(nc-nc)
Male	21	22.1	95.0	(58.8-145.3)	<u>Ovary</u>				
Female	15	20.7	72.4	(40.5-119.5)	Female	8	6.4	125.1	(53.9-246.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	5.3	nc	(nc-nc)	Male	3	7.5	nc	(nc-nc)
Female	4	1.4	nc	(nc-nc)	Female	10	7.3	136.4	(65.3-250.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.2	nc	(nc-nc)	Male	45	65.1	69.2	(50.4-92.5)
Female	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	5.0	100.2	(32.3-233.9)
Male	10	11.0	91.2	(43.6-167.7)	Female	3	2.8	nc	(nc-nc)
Female	4	5.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.8	nc	(nc-nc)
Male	2	3.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	4	4.5	nc	(nc-nc)
<u>Leukemia</u>					Female	10	11.8	84.8	(40.6-156.0)
Male	3	8.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	5.5	128.0	(51.3-263.8)	Female	12	16.5	72.8	(37.5-127.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	6.9	100.8	(40.4-207.7)	Male	207	263.2	78.7	(68.3-90.1)
Female	2	2.2	nc	(nc-nc)	Female	241	250.8	96.1	(84.3-109.0)
<u>Lung and Bronchus</u>									
Male	25	37.2	67.1	(43.4-99.1)					
Female	24	35.7	67.2	(43.0-100.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Williamsburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	3.3	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	18	13.6	132.7	(78.6-209.8)	Female	1	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.7	nc	(nc-nc)
Male	3	3.6	nc	(nc-nc)	<u>Ovary</u>				
Female	4	3.5	nc	(nc-nc)	Female	4	1.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.9	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	6	11.6	51.6	(18.8-112.4)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.8	nc	(nc-nc)
Male	4	1.9	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.4	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.3	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.9	nc	(nc-nc)	Female	2	3.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.3	nc	(nc-nc)	Male	30	44.2	67.8	(45.7-96.8)
Female	0	0.4	nc	(nc-nc)	Female	43	44.8	96.0	(69.5-129.4)
<u>Lung and Bronchus</u>									
Male	5	6.1	82.4	(26.5-192.3)					
Female	4	6.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Williamstown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	10.6	94.7	(45.3-174.2)	Male	4	5.8	nc	(nc-nc)
Female	4	3.9	nc	(nc-nc)	Female	3	4.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.6	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	8	5.3	150.8	(64.9-297.1)
Female	25	33.8	74.0	(47.9-109.3)	Female	4	5.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	2.1	nc	(nc-nc)
Male	7	10.2	68.7	(27.5-141.6)	<u>Ovary</u>				
Female	8	11.1	71.9	(31.0-141.7)	Female	4	3.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.4	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	3	4.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	25	27.6	90.5	(58.5-133.5)
Female	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.3	nc	(nc-nc)
Male	4	4.6	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.9	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<u>Leukemia</u>					Female	5	5.3	93.9	(30.2-219.0)
Male	2	3.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.0	nc	(nc-nc)	Female	4	7.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	3.0	nc	(nc-nc)	Male	84	119.5	70.3	(56.1-87.1)
Female	2	1.2	nc	(nc-nc)	Female	94	126.1	74.6	(60.2-91.2)
<u>Lung and Bronchus</u>									
Male	5	17.4	28.7	(9.2-66.9)					
Female	15	19.1	78.6	(44.0-129.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wilmington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	22.7	92.3	(57.1-141.1)	Male	12	14.8	81.0	(41.8-141.5)
Female	9	8.4	107.6	(49.1-204.2)	Female	11	11.9	92.1	(45.9-164.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	4.7	nc	(nc-nc)	Male	4	4.7	nc	(nc-nc)
Female	4	3.8	nc	(nc-nc)	Female	6	3.8	155.8	(56.9-339.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	6	13.4	44.7	(16.3-97.3)
Female	127	96.4	131.7	(109.8-156.7)	Female	16	11.9	134.2	(76.7-218.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.3	nc	(nc-nc)	Male	13	11.4	114.1	(60.7-195.2)
<u>Colon / Rectum</u>					Female	3	5.1	nc	(nc-nc)
Male	22	25.5	86.2	(54.0-130.5)	<u>Ovary</u>				
Female	28	25.1	111.3	(74.0-160.9)	Female	5	8.3	60.5	(19.5-141.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	5.9	nc	(nc-nc)	Male	6	8.3	72.7	(26.5-158.2)
Female	0	1.6	nc	(nc-nc)	Female	6	8.5	70.2	(25.6-152.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	1.9	nc	(nc-nc)	Male	49	72.3	67.8	(50.2-89.6)
Female	1	1.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	5.6	nc	(nc-nc)
Male	21	13.2	159.0	(98.4-243.1)	Female	5	3.4	146.3	(47.1-341.4)
Female	7	7.5	92.9	(37.2-191.3)	<u>Testis</u>				
<u>Larynx</u>					Male	2	3.3	nc	(nc-nc)
Male	3	3.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.1	nc	(nc-nc)	Male	7	6.2	112.9	(45.2-232.6)
<u>Leukemia</u>					Female	13	18.1	72.0	(38.3-123.2)
Male	14	9.6	145.1	(79.3-243.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	6.9	72.1	(23.2-168.1)	Female	21	21.2	99.0	(61.2-151.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	8.1	74.4	(27.2-162.0)	Male	270	299.9	90.0	(79.6-101.4)
Female	2	2.8	nc	(nc-nc)	Female	343	320.2	107.1	(96.1-119.1)
<u>Lung and Bronchus</u>									
Male	46	39.7	115.9	(84.9-154.6)					
Female	43	43.7	98.4	(71.2-132.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Winchendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	11.7	93.7	(46.7-167.6)	Male	1	7.7	nc	(nc-nc)
Female	3	3.9	nc	(nc-nc)	Female	4	5.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.3	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	4	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	4	6.8	nc	(nc-nc)
Female	35	47.4	73.8	(51.4-102.6)	Female	4	5.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	1.5	nc	(nc-nc)	Male	7	5.9	119.0	(47.7-245.2)
<u>Colon / Rectum</u>					Female	1	2.4	nc	(nc-nc)
Male	10	13.1	76.5	(36.6-140.8)	<u>Ovary</u>				
Female	16	11.6	138.3	(79.0-224.6)	Female	5	4.0	124.4	(40.1-290.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.1	nc	(nc-nc)	Male	9	4.3	211.8	(96.6-402.0)
Female	1	0.8	nc	(nc-nc)	Female	5	3.9	127.3	(41.0-297.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.9	nc	(nc-nc)	Male	26	37.2	69.8	(45.6-102.3)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.9	nc	(nc-nc)
Male	8	6.8	118.1	(50.9-232.8)	Female	2	1.5	nc	(nc-nc)
Female	5	3.7	136.5	(44.0-318.6)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.5	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.5	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
<u>Leukemia</u>					Female	7	8.5	82.4	(33.0-169.8)
Male	6	4.9	123.5	(45.1-268.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	3.1	nc	(nc-nc)	Female	9	10.6	84.9	(38.7-161.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	4.3	nc	(nc-nc)	Male	120	154.6	77.6	(64.3-92.8)
Female	0	1.3	nc	(nc-nc)	Female	136	153.6	88.6	(74.3-104.8)
<u>Lung and Bronchus</u>									
Male	14	21.1	66.5	(36.3-111.6)					
Female	19	21.5	88.2	(53.1-137.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Winchester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	23.6	93.4	(58.5-141.4)	Male	16	15.0	106.5	(60.8-172.9)
Female	6	9.1	66.2	(24.2-144.1)	Female	13	12.1	107.8	(57.3-184.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	4.6	nc	(nc-nc)	Male	5	4.9	102.0	(32.9-238.1)
Female	7	4.0	175.3	(70.2-361.2)	Female	3	4.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	17	13.5	125.6	(73.1-201.1)
Female	116	100.8	115.0	(95.1-138.0)	Female	15	12.6	119.3	(66.7-196.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.3	nc	(nc-nc)	Male	5	11.2	44.6	(14.4-104.1)
<u>Colon / Rectum</u>					Female	5	5.3	94.1	(30.3-219.6)
Male	28	25.7	108.9	(72.4-157.5)	<u>Ovary</u>				
Female	27	27.0	99.8	(65.8-145.3)	Female	8	8.5	93.8	(40.4-184.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	6.1	nc	(nc-nc)	Male	5	8.4	59.2	(19.1-138.1)
Female	0	1.8	nc	(nc-nc)	Female	10	9.4	106.6	(51.0-196.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.6	nc	(nc-nc)	Male	70	72.7	96.3	(75.1-121.7)
Female	1	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	5.7	nc	(nc-nc)
Male	5	13.3	37.7	(12.1-87.9)	Female	3	3.7	nc	(nc-nc)
Female	12	7.9	151.8	(78.4-265.2)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.6	nc	(nc-nc)
Male	0	3.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.1	nc	(nc-nc)	Male	5	5.9	84.4	(27.2-196.9)
<u>Leukemia</u>					Female	24	17.7	136.0	(87.1-202.3)
Male	15	9.6	156.5	(87.5-258.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	7.4	95.2	(38.1-196.1)	Female	24	21.8	110.1	(70.5-163.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	8.1	73.8	(26.9-160.6)	Male	266	303.8	87.6	(77.4-98.8)
Female	2	2.9	nc	(nc-nc)	Female	353	336.4	104.9	(94.3-116.5)
<u>Lung and Bronchus</u>									
Male	22	42.3	52.0	(32.6-78.7)					
Female	43	47.0	91.5	(66.2-123.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Windsor

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	4	4.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	5	1.5	334.4	(107.8-780.4)	<u>Ovary</u>				
Female	3	1.0	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	4.7	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.7	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	11	18.0	61.2	(30.5-109.5)
Female	0	0.1	nc	(nc-nc)	Female	20	13.4	149.6	(91.3-231.0)
<u>Lung and Bronchus</u>									
Male	1	2.4	nc	(nc-nc)					
Female	4	1.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Winthrop

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	22.1	95.1	(58.8-145.3)	Male	28	14.2	197.6	(131.3-285.6)
Female	9	6.9	129.6	(59.1-246.0)	Female	19	10.0	189.6	(114.1-296.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	4.2	nc	(nc-nc)	Male	5	4.6	108.0	(34.8-252.1)
Female	2	3.1	nc	(nc-nc)	Female	6	3.2	186.2	(68.0-405.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	6	12.6	47.6	(17.4-103.7)
Female	83	81.5	101.9	(81.1-126.3)	Female	8	10.0	80.2	(34.5-158.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.7	nc	(nc-nc)	Male	10	10.8	93.0	(44.5-171.0)
<u>Colon / Rectum</u>					Female	2	4.2	nc	(nc-nc)
Male	25	23.5	106.3	(68.8-157.0)	<u>Ovary</u>				
Female	28	20.2	138.9	(92.3-200.7)	Female	6	7.0	86.1	(31.4-187.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	5.9	118.4	(47.4-243.9)	Male	15	8.0	188.0	(105.1-310.0)
Female	1	1.4	nc	(nc-nc)	Female	5	7.0	71.8	(23.1-167.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.6	nc	(nc-nc)	Male	69	74.5	92.6	(72.1-117.2)
Female	1	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	5.4	93.2	(30.0-217.6)
Male	25	12.7	197.5	(127.7-291.5)	Female	3	2.7	nc	(nc-nc)
Female	12	6.4	187.2	(96.6-327.0)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.7	nc	(nc-nc)
Male	4	3.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	7	5.5	127.1	(50.9-261.9)
<u>Leukemia</u>					Female	14	15.2	91.9	(50.2-154.2)
Male	5	8.8	56.7	(18.3-132.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	5.6	106.6	(38.9-232.1)	Female	19	18.4	103.1	(62.1-161.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	9	8.0	112.3	(51.3-213.3)	Male	325	292.5	111.1	(99.4-123.9)
Female	1	2.3	nc	(nc-nc)	Female	292	268.7	108.7	(96.6-121.9)
<u>Lung and Bronchus</u>									
Male	53	40.9	129.7	(97.2-169.7)					
Female	43	37.9	113.5	(82.2-152.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Woburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	52	41.0	126.8	(94.7-166.3)	Male	29	26.4	109.9	(73.6-157.9)
Female	21	16.3	129.0	(79.8-197.2)	Female	17	22.0	77.3	(45.0-123.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	8.1	61.6	(19.9-143.8)	Male	10	8.2	121.2	(58.0-223.0)
Female	11	6.9	160.5	(80.0-287.2)	Female	8	7.3	109.3	(47.0-215.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.4	nc	(nc-nc)	Male	34	23.6	144.1	(99.8-201.4)
Female	214	171.8	124.6	(108.5-142.4)	Female	30	22.5	133.2	(89.9-190.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	5.8	138.6	(59.7-273.0)	Male	17	19.3	88.2	(51.4-141.3)
<u>Colon / Rectum</u>					Female	6	9.3	64.2	(23.5-139.8)
Male	60	44.5	134.9	(102.9-173.6)	<u>Ovary</u>				
Female	53	48.0	110.4	(82.7-144.3)	Female	15	15.0	100.0	(55.9-165.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	10.4	115.9	(59.8-202.5)	Male	12	14.6	82.0	(42.3-143.3)
Female	1	3.1	nc	(nc-nc)	Female	19	16.7	114.1	(68.6-178.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	3.4	nc	(nc-nc)	Male	120	124.7	96.2	(79.8-115.1)
Female	1	2.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	9.9	80.7	(34.7-158.9)
Male	24	22.7	105.7	(67.7-157.3)	Female	6	6.6	91.4	(33.4-199.0)
Female	16	13.8	115.9	(66.2-188.2)	<u>Testis</u>				
<u>Larynx</u>					Male	6	6.5	91.7	(33.5-199.6)
Male	4	6.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	6	1.9	311.3	(113.7-677.6)	Male	14	10.7	130.6	(71.3-219.1)
<u>Leukemia</u>					Female	37	31.7	116.8	(82.2-161.0)
Male	21	16.9	124.5	(77.0-190.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	13.1	83.7	(41.7-149.8)	Female	35	37.8	92.5	(64.4-128.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	16	14.1	113.7	(65.0-184.7)	Male	607	527.9	115.0	(106.0-124.5)
Female	3	5.2	nc	(nc-nc)	Female	664	590.1	112.5	(104.1-121.4)
<u>Lung and Bronchus</u>									
Male	98	72.2	135.7	(110.2-165.4)					
Female	82	83.0	98.7	(78.5-122.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Worcester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	169	150.9	112.0	(95.8-130.2)	Male	72	99.2	72.6	(56.8-91.4)
Female	60	62.0	96.8	(73.9-124.6)	Female	61	88.7	68.7	(52.6-88.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	32	33.0	97.0	(66.3-136.9)	Male	24	31.0	77.4	(49.6-115.2)
Female	23	29.2	78.7	(49.9-118.2)	Female	27	28.1	96.1	(63.3-139.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	5.2	nc	(nc-nc)	Male	105	89.8	116.9	(95.6-141.5)
Female	617	676.9	91.1	(84.1-98.6)	Female	72	87.4	82.4	(64.5-103.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	30	24.2	124.2	(83.8-177.3)	Male	72	74.0	97.3	(76.1-122.5)
<u>Colon / Rectum</u>					Female	37	36.7	100.9	(71.0-139.1)
Male	156	167.6	93.1	(79.0-108.9)	<u>Ovary</u>				
Female	177	185.0	95.7	(82.1-110.9)	Female	47	59.4	79.1	(58.1-105.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	53	38.9	136.3	(102.1-178.3)	Male	52	54.3	95.8	(71.5-125.6)
Female	18	11.9	151.3	(89.6-239.1)	Female	63	63.5	99.2	(76.2-126.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	14	15.1	92.9	(50.8-155.9)	Male	476	470.6	101.2	(92.3-110.7)
Female	18	13.4	134.5	(79.6-212.5)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	35	36.9	94.9	(66.1-132.0)
Male	93	86.4	107.6	(86.9-131.8)	Female	22	25.1	87.6	(54.9-132.6)
Female	64	54.3	117.9	(90.8-150.5)	<u>Testis</u>				
<u>Larynx</u>					Male	23	29.0	79.3	(50.2-119.0)
Male	19	22.6	84.2	(50.7-131.6)	<u>Thyroid</u>				
Female	12	7.5	159.8	(82.5-279.2)	Male	44	42.6	103.4	(75.1-138.8)
<u>Leukemia</u>					Female	131	137.9	95.0	(79.4-112.7)
Male	74	65.5	113.0	(88.7-141.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	52	53.1	97.8	(73.1-128.3)	Female	167	148.2	112.7	(96.2-131.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	82	53.9	152.2	(121.1-188.9)	Male	2080	1994.9	104.3	(99.8-108.8)
Female	26	20.1	129.1	(84.3-189.2)	Female	2274	2324.2	97.8	(93.9-101.9)
<u>Lung and Bronchus</u>									
Male	325	264.2	123.0	(110.0-137.2)					
Female	350	318.6	109.8	(98.6-122.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Worthington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.0	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
Female	5	6.3	78.8	(25.4-183.8)	Female	1	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<u>Ovary</u>				
Female	3	1.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	6.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.1	nc	(nc-nc)
Male	2	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	Female	5	1.6	318.7	(102.7-743.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.7	nc	(nc-nc)	Male	26	25.0	103.8	(67.8-152.1)
Female	0	0.2	nc	(nc-nc)	Female	21	20.4	102.7	(63.6-157.1)
<u>Lung and Bronchus</u>									
Male	7	3.5	200.4	(80.3-413.0)					
Female	0	2.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wrentham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	9.7	103.5	(49.6-190.4)	Male	9	6.8	132.7	(60.6-252.0)
Female	4	4.4	nc	(nc-nc)	Female	10	6.2	160.1	(76.6-294.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.2	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	14	6.1	229.1	(125.2-384.5)
Female	64	51.4	124.5	(95.9-159.0)	Female	5	6.3	78.9	(25.4-184.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.7	nc	(nc-nc)	Male	3	5.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	2.7	nc	(nc-nc)
Male	19	11.8	160.6	(96.6-250.8)	<u>Ovary</u>				
Female	12	13.6	88.2	(45.5-154.1)	Female	6	4.4	136.6	(49.9-297.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	2.7	186.8	(60.2-435.9)	Male	5	3.7	135.4	(43.6-316.0)
Female	0	0.8	nc	(nc-nc)	Female	5	4.5	111.8	(36.0-260.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.9	nc	(nc-nc)	Male	56	33.0	169.8	(128.3-220.5)
Female	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.5	nc	(nc-nc)
Male	6	6.2	96.3	(35.2-209.5)	Female	1	1.8	nc	(nc-nc)
Female	4	4.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.5	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
<u>Leukemia</u>					Female	8	9.2	87.1	(37.5-171.6)
Male	4	4.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	3.6	nc	(nc-nc)	Female	6	11.2	53.4	(19.5-116.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.0	nc	(nc-nc)	Male	179	136.0	131.6	(113.0-152.3)
Female	3	1.5	nc	(nc-nc)	Female	165	169.3	97.4	(83.1-113.5)
<u>Lung and Bronchus</u>									
Male	19	17.4	109.0	(65.6-170.2)					
Female	15	22.8	65.7	(36.7-108.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Yarmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	54	46.2	116.9	(87.8-152.6)	Male	42	25.3	166.0	(119.6-224.4)
Female	21	17.2	122.1	(75.6-186.7)	Female	43	18.6	230.8	(167.0-310.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	6.4	125.8	(54.2-247.9)	Male	7	8.4	83.6	(33.5-172.3)
Female	8	5.9	136.7	(58.9-269.4)	Female	8	7.4	108.4	(46.7-213.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.4	nc	(nc-nc)	Male	25	22.8	109.9	(71.1-162.2)
Female	179	154.9	115.5	(99.2-133.8)	Female	24	21.8	109.9	(70.4-163.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	4.2	nc	(nc-nc)	Male	19	16.1	118.1	(71.1-184.5)
<u>Colon / Rectum</u>					Female	14	8.8	159.6	(87.2-267.7)
Male	40	44.2	90.5	(64.6-123.2)	<u>Ovary</u>				
Female	37	47.1	78.5	(55.3-108.2)	Female	9	13.6	66.4	(30.3-126.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	17	10.2	167.0	(97.3-267.5)	Male	18	15.1	119.4	(70.7-188.8)
Female	6	3.3	184.1	(67.2-400.8)	Female	19	17.3	109.5	(65.9-171.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	2.0	nc	(nc-nc)	Male	140	110.7	126.4	(106.4-149.2)
Female	3	1.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	10.3	58.4	(21.3-127.0)
Male	15	19.6	76.5	(42.8-126.2)	Female	7	6.4	108.5	(43.5-223.6)
Female	12	13.2	91.2	(47.1-159.3)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.9	nc	(nc-nc)
Male	4	5.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.9	nc	(nc-nc)	Male	9	7.3	123.0	(56.1-233.4)
<u>Leukemia</u>					Female	11	21.7	50.7	(25.3-90.7)
Male	35	16.3	214.5	(149.4-298.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	21	12.3	170.7	(105.6-260.9)	Female	29	34.2	84.7	(56.7-121.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	19	12.6	150.2	(90.4-234.6)	Male	581	505.6	114.9	(105.8-124.6)
Female	9	5.2	174.8	(79.7-331.8)	Female	611	553.9	110.3	(101.7-119.4)
<u>Lung and Bronchus</u>									
Male	78	76.5	101.9	(80.5-127.2)					
Female	99	88.6	111.8	(90.9-136.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

APPENDICES

APPENDIX I: INTERNATIONAL CLASSIFICATION OF DISEASES FOR ONCOLOGY (THIRD EDITION)

CODES USED FOR THIS REPORT ¹

Cancer Site/Type²

ICD-O-3

**Brain & Other
Nervous System**

C70.0-C72.9
except 9050-9055, 9140,
9590-9992

**Breast
(includes *in situ*)**

C50.0 – C50.9
except 9050-9055, 9140,
9590-9992

Bronchus & Lung

C34.0 – C34.9
except 9050-9055, 9140,
9590-9992

Cervix Uteri

C53.0 – C53.9
except 9050-9055, 9140,
9590-9992

Colon/ Rectum

C18.0-C18.9,
C19.9, C20.9,
C26.0
except 9050-9055, 9140,
9590-9992

**Corpus Uteri
& Uterus, NOS**

C54.0 – C54.9,
C55.9
except 9050-9055, 9140,
9590-9992

Esophagus

C15.0-C15.9
except 9050-9055, 9140,
9590-9992

Hodgkin Lymphoma

C00.00 – C80.9
(includes 9650-9667)

**Kidney &
Renal Pelvis³**

C64.9, C65.9
except 9050-9055, 9140,
9590-9992

Larynx

C32.0 – C32.9
except 9050-9055, 9140,
9590-9992

Leukemia

C00.0 – C80.9
(includes 9733, 9742,
9800-9801, 9805-9809, 9820, 9826, 9831-9836, 9840, 9860-9861,
9863, 9865-9867, 9869-9876, 9891, 9895-9898, 9910-9911, 9920,
9930-9931, 9940, 9945-9946, 9948, 9963-9964)

C42.0, C42.1, C42.4
(includes 9811-9818, 9823, 9827, 9837)

**Liver and Intrahepatic
Bile Ducts**

C22.0, C22.1
except 9050-9055, 9140,
9590-9992

Melanoma of Skin

C44.0 – C44.9
(includes 8720-8790)

Multiple Myeloma

C00.0-C80.9
(includes 9731, 9732,
9734)

**Non – Hodgkin
Lymphoma**

C02.4, C098, C099, C111, C142, C379, C422, C770-C779
(includes 9590-9597, 9670-9671, 9673, 9675, 9678-9680,
9684, 9687-9691, 9695, 9698-9702, 9705, 9708-9709, 9712,
9714-9719, 9724-9729, 9735, 9737-9738, 9811-9818, 9823,
9827, 9837)

All sites except C02.4, C90.8-C09.9, C11.1, C14.2, C37.9,
C42.2, C77.0-C77.9 (includes 9590-9597, 9670-9671, 9673,
9675, 9678-9680, 9684, 9687, 9688, 9689-9691, 9695, 9698-
9702, 9705, 9708-9709, 9712, 9714-9719, 9724-9729, 9735,
9737, 9738)

All sites except C02.4, c09.8-C09.9, C11.1, C14.2, C37.9,
C42.0-C42.2, c42.4, C77.0-C77.9 (includes 9811-9818,
9823, 9827, 9837)

**Oral Cavity
& Pharynx**

C00.0 – C14.8
except 9050-9055, 9140,
9590-9992

Ovary

C56.9
except 9050-9055, 9140,
9590-9992

Pancreas

C25.0 – C25.9
except 9050-9055, 9140,
9590-9992

Prostate

C61.9
except 9050-9055, 9140,
9590-9992

Stomach	C16.0 – C16.9 except 9050-9055, 9140, 9590-9992
Testis	C62.0 – C62.9 except 9050-9055, 9140, 9590-9992
Thyroid	C73.9 except 9050-9055, 9140, 9590-9992
Urinary Bladder (includes <i>in situ</i>)	C67.0 – C67.9 except 9050-9055, 9140, 9590-9992

¹*International Classification of Diseases for Oncology, 3d Ed.* (includes codes added since publication)

²Only invasive cancers (those with invasive behaviors) are included in this publication except Bladder, Urinary, which includes invasive and *in situ* behaviors. Non-invasive (*in situ*) cancers are not included.

³Massachusetts hospital coding conventions may have assigned some cases to a “not otherwise specified” site category that is not included in this cancer type.

APPENDIX II: SELECTED RESOURCES FOR INFORMATION ON CANCER

This Appendix contains a listing of selected resources for additional information on cancer. Cancers are complex diseases, many of which have multiple factors that may contribute to their development.

For information on cancer risk factors or prevention, you may wish to contact the following:

Cancer Information Service (National Cancer Institute): 1-800-4-CANCER (1-800-422-6237)

Cancer Response Line (American Cancer Society): 1-800-ACS-2345 (1-800-227-2345)

In addition, the following selected Internet websites provide information on cancer. Many of these also provide links to other sites (not listed) which may be of interest.

Massachusetts Department of Public Health: <http://www.mass.gov/dph>

American Cancer Society: <http://www.cancer.org>

Centers for Disease Control and Prevention

Home Page: <http://www.cdc.gov>

Cancer Prevention and Control Program: <http://www.cdc.gov/cancer>

Fruits and Veggies More Matters™ Campaign (nutrition – formerly 5-A-Day Program):
<http://www.fruitsandveggiesmorematters.org/>

National Cancer Institute

Information: <http://www.cancer.gov>

Cancer Literature in PubMed:

[https://www.ncbi.nlm.nih.gov/pubmed?cmd_current=Limits&pmfilter_Subsets=Cancer](https://www.ncbi.nlm.nih.gov/pubmed?cmd=current=Limits&pmfilter_Subsets=Cancer)

Surveillance, Epidemiology, and End Results (SEER) Program data: <http://seer.cancer.gov>

Your Cancer Risk (Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; formerly at Harvard Center for Cancer Prevention):
<http://www.yourdiseaserisk.wustl.edu>

Oncolink (Abramson Cancer Center of the University of Pennsylvania):
<http://www.oncolink.org>

Cancerquest (Emory University – Winship Cancer Institute): www.cancerquest.org

National Coalition for Cancer Survivorship: <http://www.canceradvocacy.org>

APPENDIX III: MDPH CANCER PREVENTION AND CONTROL INITIATIVES

The Massachusetts Department of Public Health is working to reduce the incidence and mortality of cancer in the Commonwealth. Partnerships between MDPH programs, researchers, healthcare providers and nonprofit organizations collect information about cancer, lead quality improvement projects, coordinate evidenced-based workshops for managing living with chronic disease (including cancer), provide education for health professionals and bring shared messages to the public. Our collaborated efforts focus on reducing cancer risk, incidence and mortality through healthy lifestyles, early diagnosis, and increased access to care. The Department's programs address the impact of tobacco, alcohol, nutrition, and physical activity on cancer prevention, along with environmental and occupational hazards for cancer. Throughout all of our efforts there is an emphasis on reducing disparate health outcomes and unequal access to cancer care.

MDPH Bureaus and Programs:

Bureau of Environmental Health, www.mass.gov/dph/environmental_health

Bureau of Substance Abuse Services, www.mass.gov/dph/bsas

Comprehensive Cancer Prevention and Control Program, www.mass.gov/compcancer

Men's Health/Women's Health/Care Coordination Program

Tobacco Cessation and Prevention Program, www.mass.gov/dph/mtcp

Occupational Health Surveillance Program, www.mass.gov/dph/ohsp

Office of Elder Affairs www.mass.gov/elders/

Oral Health Program, www.mass.gov/dph/oralhealth

Division of Prevention and Wellness www.mass.gov/dph/healthpromotion

MDPH publications on cancer prevention and screening are available at the Massachusetts Health Promotion Clearinghouse, www.maclearinghouse.com.

Massachusetts Cancer Registry Publications are available through the Massachusetts Cancer Registry, telephone: 617-624-5642 and on the web at www.mass.gov/dph/mcr.

REFERENCES

1. Fritz A, Percy C, Jack A, et al. (eds). *International Classification of Diseases for Oncology*, 3rd Ed. Geneva: World Health Organization, 2000.
2. United States Census Bureau, American Community Survey, accessed June 15, 2018:
<https://www.census.gov/library/publications/2009/acs/state-and-local.html>